



2025 ASCO[®] ANNUAL MEETING

PROGRAM

Driving Knowledge to Action: Building a Better Future

May 30–June 3, 2025

McCormick Place | Chicago, IL & Online

meetings.asco.org | #ASCO25

Wi-Fi Network: ASCO25 | No Password Required

ASCO[®]

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Contents

Scientific Sessions	2
Annual Meeting Program Information and Access	4
Continuing Education	6
Conflict of Interest Disclosure	6
Policies	6
Ancillary Events Directory	6
Onsite Details	7
Planning Committees	8
Awards	12
Industry Expert Theater Schedule	14
Program by Day	17

Scientific Sessions

Breast Cancer—Local/Regional/Adjuvant

Oral Abstract Session	178
Rapid Oral Abstract Session	82
Poster Session	125

Breast Cancer—Metastatic

Oral Abstract Session	52
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?	113
Rapid Oral Abstract Session	20
Poster Session	130

Care Delivery/Models of Care

Oral Abstract Session	179
Clinical Science Symposium: Global Cancer Care Delivery: Resiliency in the Face of Conflict and Resource Constraints	122
Rapid Oral Abstract Session	26
Poster Session	84

Central Nervous System Tumors

Oral Abstract Session	20
Clinical Science Symposium: Refining Local Therapies in Central Nervous System Oncology: Hitting the Bullseye	107
Rapid Oral Abstract Session	75
Poster Session	27

Developmental Therapeutics—Immunotherapy

Oral Abstract Session	75
Clinical Science Symposium: Real-World Immunotherapy: Bridging the Gap Between Trials and Treatment	181
Rapid Oral Abstract Session	109
Poster Session	156

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Oral Abstract Session	21
Rapid Oral Abstract Session	122
Poster Session	163

Gastrointestinal Cancer—Colorectal and Anal

Oral Abstract Session	21
Clinical Science Symposium: Adjunctive Therapies in Colon Cancer—As Good As a Drug?	113
Rapid Oral Abstract Session	110
Poster Session	31

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Oral Abstract Session	76
Clinical Science Symposium: Innovative Biomarkers and Vaccines in Pancreatic Cancer	122
Rapid Oral Abstract Session	153
Poster Session	36

Genitourinary Cancer—Kidney and Bladder

Oral Abstract Session	107
Clinical Science Symposium: Biomarkers in Kidney Cancer: Are We There Yet?	77
Rapid Oral Abstract Session	51
Poster Session	135

Genitourinary Cancer—Prostate, Testicular, and Penile

Oral Abstract Session	186
Clinical Science Symposium: New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy	178
Rapid Oral Abstract Session	114
Poster Session	140

Gynecologic Cancer

Oral Abstract Session	124
Rapid Oral Abstract Session	185
Poster Session	89

Head and Neck Cancer

Oral Abstract Session	53
Clinical Science Symposium: Biomarker-Driven Adaptive Therapy: New Horizons in Head and Neck Cancer	177
Rapid Oral Abstract Session	111
Poster Session	145

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Oral Abstract Session	180
Rapid Oral Abstract Session	18
Poster Session	94

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	
Oral Abstract Session	22
Rapid Oral Abstract Session	27
Poster Session	97
Hematologic Malignancies—Plasma Cell Dyscrasia	
Oral Abstract Session	187
Rapid Oral Abstract Session	123
Poster Session	100
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	
Oral Abstract Session	180
Rapid Oral Abstract Session	114
Poster Session	59
Lung Cancer—Non–Small Cell Metastatic	
Oral Abstract Session	83
Clinical Science Symposium: Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies	186
Rapid Oral Abstract Session	124
Poster Session	53
Medical Education and Professional Development	
Clinical Science Symposium: The Future Is Now: Innovations in Medical Education	51
Rapid Oral Abstract Session	151
Poster Session	170
Melanoma/Skin Cancers	
Oral Abstract Session	188
Rapid Oral Abstract Session	151
Poster Session	102
Pediatric Oncology	
Oral Abstract Session I	77
Oral Abstract Session II	125
Rapid Oral Abstract Session	178
Poster Session	45
Prevention, Risk Reduction, and Genetics	
Oral Abstract Session	154
Clinical Science Symposium: Diving Deeper to Inform Hereditary Cancer Risk and Outcomes	122
Rapid Oral Abstract Session	27
Poster Session	64
Quality Care/Health Services Research	
Oral Abstract Session	19
Rapid Oral Abstract Session	115
Poster Session	68
Sarcoma	
Oral Abstract Session	108
Rapid Oral Abstract Session	154
Poster Session	47
Symptom Science and Palliative Care	
Oral Abstract Session	109
Rapid Oral Abstract Session	152
Poster Session	172
Cross-Cutting Theme Sessions	
Highlights of the Day Session I	84
Highlights of the Day Session II	125
Highlights of the Day Session III	185
Plenary Session	111
Special Clinical Science Symposium: The Future of Cancer Detection Is Coming	26
Special Clinical Science Symposium: Turning “Cold” Tumors “Hot”	107
Special Clinical Science Symposium: ADC 2.0: Discovering the Targets That Will Change the Game	151

Annual Meeting Program Information and Access

Stay up to date with the online Annual Meeting program, accessible by website or app, which offers the latest session and speaker information.

Meetings App: Download the ASCO Meetings Mobile App for Apple or Android devices. Scan the appropriate QR code below to access your device's app store:

Apple



Android



Program Guide: Visit meetings.asco.org for the comprehensive online Program Guide.



Both the Meetings App and the Program Guide provide access to:

- Livestream sessions
- Interactive session tools
- On-demand session videos and downloadable slide decks (available within 12 hours of the session)
- Downloadable abstracts and posters

Make sure you don't miss a minute of presentations—you will need to log in to view or interact with session content. If you require assistance with your login credentials, please visit the Customer Services Desks located in ASCO Central.

Abstract Key

Abstract numbers may include the following prefixes:

LBA: Late-Breaking Abstract

TPS: Trials in Progress Abstract

Cross-Cutting Tracks

The topics of artificial intelligence, clinical trials, geriatric oncology, global health, immunotherapy, survivorship, and value are important for all oncology professionals and cut across disease- and topic-based tracks. These cross-cutting themes have been incorporated into sessions of every track throughout the Meeting. For sessions that feature a cross-cutting track, search by track in the Program Guide.

Session Types

Scientific Program

Plenary Session

Abstract presentations in this session showcase scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field serve as discussants placing clinical research findings into perspective and sharing implications for future research.

Highlights of the Day Sessions

Expert discussants provide an overview of the most impactful and practice-changing abstracts presented within a specific disease track. Presentations focus on key findings and placing abstracts into clinical context.

Oral Abstract Sessions

Presenters summarize their novel research findings and provide background on their methodologies. Discussants analyze the significance of each abstract within the context of current knowledge, highlighting clinical application and implications for future research and practice. Abstract presenters and discussants answer questions during a moderated panel discussion.

Clinical Science Symposia

Presenters summarize research findings, while discussants place the abstracts in the appropriate context with a focus on how the findings apply to clinical practice. Abstracts in these sessions may span disease sites or disciplines, but they are unified by their focus on a key scientific topic.

Rapid Oral Abstract Sessions

Presenters give an overview of their novel research and answer questions during a moderated panel discussion.

Poster Sessions

Presenters outline their research via posters displayed throughout their assigned session(s). Authors are available to answer questions from attendees regarding the data presented. Electronic posters and supplemental materials are available online beginning on the day of their assigned Poster Session(s).

Educational Program

Education Sessions

Education Sessions offer interdisciplinary or multidisciplinary explorations of focused areas of clinical oncology. ASCO's Annual Meeting Education Committee determines the topics and format for these sessions that will best serve the educational needs of Annual Meeting attendees. Particular care is taken to ensure that these sessions address multidisciplinary issues, symptom management, health services research, international perspectives, and pathology, as appropriate.

Case-Based Panels

The Case-Based Panels will center on a case-based discussion and utilize interactive technology to poll the audience throughout the duration of the session.

Award Lectures

The Award Lectures will center on an exciting topic or research area related to the achievement of special award recipients.

Opening Session

The Opening Session includes the President's Address, presentations by guest speakers, recognition of top donors, David Karnofsky Science of Oncology Award lecture, and recognition of special award recipients and the Fellows of the American Society of Clinical Oncology (FASCO).

Workshops

Limited-attendance, in-person-only sessions designed for interactive discussion and small group exercises. Please note: Workshops are not available on-demand.

Annual Business Meeting (ASCO Members Only)

The ASCO Annual Business Meeting is for ASCO Members to hear updates on the state of the Society. Members are encouraged to preregister online to attend this event.

Continuing Education

Sessions at the ASCO Annual Meeting will provide Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points for physicians.

Participants should use the online Program Guide or the ASCO Meeting mobile app to:

- Claim CME credit for sessions
- Request ABIM, ABP, and/or ABS MOC points
- Provide feedback on sessions

Download your Certificate of Attendance at profile.asco.org.

Please visit am.asco.org/continuing-education for more information about how to claim credit and request MOC points for ASCO Annual Meeting sessions.

CME claims and MOC requests are due by September 4, 2025.

For questions or assistance, contact customerservice@asco.org or visit ASCO Central onsite.

Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I=Immediate family member; Inst=My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

Please email coi@asco.org with specific questions or concerns.

Policies

Important policies for this Meeting, including the Attendee Code of Conduct, are available at am.asco.org.

Ancillary Educational Events

Ancillary educational events are hosted independently by other CME-accredited providers and are held adjunct to the 2025 ASCO Annual Meeting. These events are not official events of the 2025 ASCO Annual Meeting and are not sponsored, endorsed, or accredited by ASCO, Association for Clinical Oncology, or Conquer Cancer, the ASCO Foundation.

For an up-to-date listing of events, please scan the QR code below.



The 2025 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors:

Meeting Sponsorship Platinum Level Donors: Daiichi Sankyo, Inc.; Novartis Oncology

Meeting Sponsorship Gold Level Donors: AbbVie, Inc.; Bristol Myers Squibb

ASCO and Conquer Cancer gratefully acknowledge the following major 2025 ASCO Annual Meeting Track donors:

Annual Meeting Track Donors (Champion): Merck & Co., Inc.

Annual Meeting Track Donors (Trailblazer): AbbVie, Inc.; AstraZeneca; Daiichi Sankyo, Inc.

Onsite Details

ASCO Headquarters Office

Badge reprints and assistance is available in N427bc.

Emergency Response for Visitors

If an alarm sounds in McCormick Place:

- Horns and strobes will turn on
- Visitors will be directed over the public announcement system to exit through the closest “Emergency Exit”
- Doors marked as “Stairs” also serve as emergency exits

In the event of a power failure, all emergency systems will run on emergency power. Temporary safe areas are available in open parking lots, roadways, and grass areas adjacent to McCormick Place.

Faculty Registration and Ready Room

All faculty will check in at the Faculty Registration and Ready Room, located in the North Building, Room N426, to receive their badges and Meeting materials. Additionally, faculty and oral abstract presenters should report to N426 to review and submit their presentations at least 4 hours before their scheduled session.

Exhibit Hall

Located in the South Building, Level 3, Hall A, the Exhibit Hall hosts exhibits, posters, the Industry Expert Theaters, Innovation Hub, a Food Court, and ASCO Bistro. The exhibits highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet representatives from pharmaceutical companies, scientific publishers, and advocacy groups. Posters are located on the far-right side of the Exhibit Hall and can be accessed from the Grand Concourse entrance or from the S101 lobby. The Poster Pickup desk is in the S101 lobby.

A print copy of the Exhibitor Directory is available at materials pick up locations and the entrances to the Exhibit Hall.

Exhibits are open Saturday through Monday, 9:00 AM–5:00 PM. Poster Sessions are open during the times listed in the program. Poster presenters can access their posters 30 minutes prior to their Poster Session.

Industry Expert Theater

The Industry Expert Theater, located in the back of the Exhibit Hall, to the left of the Food Court, brings together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies. If the IET company chooses to post their in-person session recording online, the session audio and slides will be available for on-demand viewing after the Meeting at am.asco.org. Review the Theater schedule in this program or at am.asco.org.

Career Fair

Located in Hall C (North Building, Level 2), this area allows you to meet face to face with recruiters and engage in additional networking opportunities. The career fair is open Friday through Sunday.

Communities of Practice

ASCO Communities of Practice provide an opportunity for individuals to come together and build community, fellowship, networking, and goals collaboration, both onsite at the Annual Meeting and virtually throughout the year. Interested attendees are welcome to join.

- **Adolescent and Young Adult (AYA):** Saturday, May 31, 7:30-9:30 AM; E253cd
- **Alliance for the Support and Prevention of Immune-Related Events (ASPIRE):** Friday, May 30, 4:00-6:00 PM; E253cd
- **Artificial Intelligence:** Sunday, June 1, 4:00-6:00 PM; S501
- **Cancer Care for Veterans:** Saturday, May 31, 10:00 AM-12:00 PM; S103
- **Ethics:** Sunday, June 1, 4:00-6:00 PM; E253cd
- **Geriatric Oncology:** Saturday, May 31, 4:00-6:00 PM; E253cd
- **Global Oncology:** Friday, May 30, 1:00-3:00 PM; S103
- **Health Policy:** Saturday, May 31, 4:00-6:00 PM; S103
- **International Medical Graduates (IMG):** Friday, May 30, 4:00-6:00 PM; S103
- **LGBTQ+:** Monday, June 2, 7:30-9:30 AM; S501
- **Medical Education:** Saturday, May 31, 7:30-9:30 AM; S103
- **Palliative Care:** Monday, June 2, 7:30-9:30 AM; E253cd
- **Survivorship:** Friday, May 30, 1:00-3:00 PM; E253cd

Services Available at McCormick Place

- **ASCO Store:** North Building, Level 3, ASCO Central
- **Customer Service, Technical Assistance, Continuing Education:** North Building, Level 3, ASCO Central
- **First Aid Stations:** South Building, Level 2.5 near Business Center; East Building, Level 1, near Arie Crown Theater
- **Headshots:** North Building, Level 3, outside Hall B1
- **Hotel Assistance Desk:** North Building, Level 3, ASCO Central
- **Interpreter Language Assistance:** North Building, Level 3, ASCO Central
- **Internet Stations With Printers:** North Building, Level 2.5
- **Member Services Desk:** Registration; ASCO Central
- **Nursing Room:** North Building, Room N227a
- **Prayer/Meditation Room:** North Building, Level 3, ASCO Central
- **Registration:** North Building, Level 2, Hall C
- **Wellness Zone:** South Building, Level 1, S103 lobby

Shuttle Bus Service

Complimentary shuttle service is provided between McCormick Place and all official ASCO hotels, except those within walking distance. The shuttle schedule is available at am.asco.org. Please be sure to check the ASCO Shuttle sign in your hotel for any changes. Service will be approximately every 20 minutes. McCormick Place is the transfer point for all routes.

Hours of Operation

Friday	8:00 AM–7:00 PM*
Saturday-Monday	6:45 AM–7:00 PM*
Tuesday	6:45 AM–1:30 PM*

*Last shuttle departs McCormick Place at this time, and last shuttle departs hotels coming to McCormick Place approximately 90 minutes prior to this time.

If you have any questions regarding the shuttle or would like to make a reservation for a wheelchair-accessible ASCO Shuttle, please see the ASCO Shuttle supervisor at McCormick Place during shuttle hours or call Kushner & Associates at 312-808-2000.

Airport Shuttle

Shuttle service will be available from McCormick Place to O'Hare International Airport on Monday and Tuesday. Tickets can be purchased at the Airport Shuttle Desk at Gate 3 from Sunday to Tuesday.

Planning Committees

2024–2025 ASCO Board of Directors

Officers

Chair of the Board

Lynn M. Schuchter, MD, FASCO

President

Robin T. Zon, MD, FACP, FASCO

President-Elect

Eric J. Small, MD, FASCO

Past President

Eric P. Winer, MD, FASCO

Treasurer

Taofeek K. Owonikoko, MD, PhD, FASCO

Treasurer-Elect

Carolyn B. Hendricks, MD, FASCO

Directors

Fredrick Chite Asirwa, MD, MBChB, FASCO

Mariana Chavez Mac Gregor, MD, MSc, FASCO

Toni K. Choueiri, MD, FASCO

Jhanelle E. Gray, MD

Clarissa Mathias, MD, PhD, FASCO

Kathleen N. Moore, MD, MS, FASCO

Ann H. Partridge, MD, MPH, FASCO

Debra A. Patt, MD, PhD, MBA, FASCO

Gladys I. Rodriguez, MD, FASCO

Abby R. Rosenberg, MD, MS, MA, FAAP

Jennifer S. Temel, MD, FASCO

Karen M. Winkfield, MD, PhD, FASCO

Ex-Officio Members

Clifford A. Hudis, MD, FACP, FASCO, ASCO Chief Executive Officer

Howard A. Burris III MD, FACP, FASCO, Chair of the Conquer Cancer Board

2025 Conquer Cancer, the ASCO Foundation Board of Directors

Chair

Howard A. Burris III, MD, FACP, FASCO

Treasurer

Alexander Casdin, FASCO

Secretary

Amy C. Peterson, MD, FASCO

Chief Executive Officer

Nancy R. Daly, MS, MPH, ex-officio

Executive Vice Chair and ASCO Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO, ex-officio

ASCO President

Robin T. Zon, MD, FACP, FASCO, ex-officio

Directors

M. Teresa Alonso Thompson

Kathryn Beal, MD

Bill Behnke

Riccardo Braglia

Otis Webb Brawley, MD, MACP, FASCO

Lawrence H. Einhorn, MD, FASCO

Jasmine V. Ferrer, PhD, MPH

Raj Mantena, RPh, FASCO

Thomas A. Marsland, MD, FASCO

Robert J. Mayer, MD, FASCO

Gerald J. McDougall, FASCO

Steven T. Rosen, MD, FACP, FAIMBE, FASCO

Alexandra E.F. Shapiro

Sandra M. Swain, MD, FACP, FASCO

Margaret Tempero, MD, FASCO

Deanna B. van Gestel

Cancer Communications Committee

David R. Spigel, MD, FASCO—Chair

Jane Lowe Meisel, MD—Chair-Elect

Charu Aggarwal, MD, MPH, FASCO—Past Chair

Lisa A. Carey MD, ScM, FASCO

Julie R. Gralow, MD, FACP, FASCO

Jyoti D. Patel, MD, FASCO

Steven Z. Merlin, BS

Dawood Findakly, MD

Pamela L. Kunz, MD

Curtiland Deville, MD

Bradley Alexander McGregor, MD

Oreofe O. Odejide, MD, MPH

Glenn Hanna, MD

Jennifer Tseng, MD

Heather Symons, MD

Eleonora Teplinsky, MD

David Schiff, MD

Toby Christopher Campbell, MD, MS

Manmeet Singh Ahluwalia, MD, MBA, FASCO

Fumiko Chino, MD

April K.S. Salama, MD

William Kevin Kelly, DO

Brian I. Rini, MD, FASCO

Jason Westin, MD, MS, FACP

Olatoyosi Odenike, MD, FASCO

Joel N. Saltzman, MD, FASCO

Julian C. Hong, MD, MS

Krish Patel, MD

Laura Vater, MD, MPH

Tara Michelle Graff, MS, DO

Rebecca Alexandra Dent, MD

Vishwanath Sathyanarayanan, MD

Annual Meeting Education Committee

Cardinale Smith, MD, PhD—Chair
Erika Ruiz-Garcia, MD, MS—Chair-Elect
Thomas LeBlanc, MD—Immediate Past Chair

Breast Cancer

Nadia Harbeck, MD, PhD—Track Leader
Bethany Anderson, MD
David Cescon, MD, PhD, FRCPC
Alexandru Eniu, MD, PhD
Cheryl Ewing, MD
Eleni Nackos, MD
Daniel O'Neil, MD, MPH
Sonya Reid, MD, MPH
Jennifer Shin, MD, MPH

Care Delivery and Regulatory Policy

Kerin Adelson, MD, MS, FASCO—Track Leader
Lisa Kottschade, APRN, MSN, CNP
Peter Marks, MD, PhD
Jackson Orem, PhD, MBChB
Estelamari Rodriguez, MD, MPH
Kathryn Ruddy, MD, MPH
Dan Zuckerman, MD, FASCO

Central Nervous System Tumors

Katherine Peters, MD, PhD, FAAN—Track Leader
James Balogun, MBBS
Annick Desjardins, MD, FRCPC
Mark Korpics, MD
Kathryn Nevel, MD

Developmental Therapeutics—Immunotherapy

Kristen Spencer, DO, MPH—Track Leader
Matteo Carlino, PhD, MBBS, FRACP
Saar Gill, MD, PhD
Raghav Sundar, PhD, MBBS
Naoko Takebe, MD, PhD

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Janice Lu, MD, PhD—Track Leader
Ki Chung, MD
Allen Cohn, MD
Giuseppe Curigliano, MD, PhD
Lola Fashoyin-Aje, MD, MPH

Gastrointestinal Cancer—Colorectal and Anal

Priyadarshini Pathak, MD—Track Leader
Jennifer Eads, MD
Sebastian Mondaca, MD
Aaron Scott, MD
Benjamin Weinberg, MD

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Ryan Nipp, MD—Track Leader
Daniel Chang, MD
Andrew Epstein, MD
Pallavi Kumar, MD, MPH
Do-Youn Oh, MD, PhD
Haeseong Park, MD, MPH

Genitourinary Cancer—Kidney and Bladder

Rana McKay, MD, FASCO—Track Leader
Chunkit Fung, MD, MSCE
Félix Guerrero-Ramos, MD, PhD
Naomi Haas, MD
Adam Olson, MD

Genitourinary Cancer—Prostate, Testicular, and Penile

Marie Carlo, MD—Track Leader
Nabil Adra, MD
Curtiland Deville, MD
Silke Gillesen, MD
Gustavo Villoldo, MD

Gynecologic Cancer

Michael Carney, MD—Track Leader
Shari Damast, MD
Brittany Davidson, MD
Linda Mileshekin, MD, MBBS, FRACP

Head and Neck Cancer

Christine Chung, MD—Track Leader
Jessica Bauman, MD
Aditya Juloori, MD
Cesar Perez, MD

Hematologic Malignancies

Catherine Lai, MD, MPH—Track Leader
Kavita Dharmarajan, MD
Areej El-Jawahri, MD
Olaekan Oluwale, MBBS
Manju Sengar, MD
Catherine Smith, MD

Lung Cancer

Toby Campbell, MD, MS—Track Leader
Benjamin Besse, MD, PhD
Kevin Chua, MBBS, FRCR
Kavitha Ramchandran, MD
Julia Rotow, MD
Navneet Singh, MD, FRCP, DM, FASCO

Medical Education and Professional Development

Joseph McCollom, DO—Track Leader
Tyler Johnson, MD
Alfred Lee, MD, PhD
Bismarck Odei, MD
Erika Ruiz-Garcia, MD, MS
Jennifer Schwartz, MD, FRCPC, FASCO

Melanoma/Skin Cancers

Giorgos Karakousis, MD—Track Leader
Allison Betof Warner, MD, PhD
Marlana Orloff, MD
Suthee Rapisuwon, MD
Susan Swetter, MD

Pediatric Oncology

Kavita Dhodapkar, MD—Track Leader
Prasanna Ananth, MD, MPH
Adam Esbenschade, MD, MSCI
Sumit Gupta, MD, PhD
Lorna Renner, MD

Prevention, Risk Reduction, and Hereditary Cancer

Suzette Delaloge, MD, MSc—Track Leader
Foluso Ademuyiwa, MD, MPH
Philip Castle, PhD, MPH
Judith Balmana Gelpi, MD, PhD
Elena Stoffel, MD, MPH

Sarcoma

Najat Daw, MD—Track Leader
Rashmi Chugh, MD
Birgit Geoerger, MD, PhD
Jason Sicklick, MD

Symptoms and Survivorship

Nicole Stout, DPT—Track Leader
Michael Fisch, MD, MPH, FACP, FAAHPM, FASCO
Judith Paice, PhD, RN, FASCO
Jennifer Snaman, MD
Mazie Tsang, MD, MS
Melisa Wong, MD

Scientific Program Committee

Erika Hamilton, MD—Chair
Amy Jo Chien, MD—Chair-Elect
Angela DeMichele, MD, MSCE, FASCO—Immediate Past Chair

Biostatistics

Dominik Hlauschek, MSc—Track Leader
Megan Othus, PhD
Saskia Litiere, PhD
Fengmin Zhao, PhD
Tian Zhang, MD, MHS
Hao Wang, PhD
Fang-Shu Ou, PhD

Breast Cancer—Metastatic

Gregory Vidal, MD, PhD—Track Leader
Daniel Stover, MD, FASCO
William Gradishar, MD, FACP, FASCO
Jose Bazan, MD
Sharon Giordano, MD
Amy Jo Chien, MD
Amy Clark, MD, MSCE
Maryam Lustberg, MD

Breast Cancer—Local/Regional/Adjuvant

Kevin Kalinsky, MD, MS—Track Leader
Jennifer Bellon, MD
Mediget Teshome, MD, MPH, FACS
Kari Wisinski, MD
Matteo Lambertini, MD
Alastair Thompson, MD, FRCS, FACS, MBChB
Oluwadamilola Fayanju, MD, FACS

Care Delivery/Models of Care

Ravi Parikh, MD, MPP—Track Leader
Erin Gillespie, MD, MPH
Rebecca DeBoer, MD, MA
Dawn Hershman, MD, MS, FASCO
Samilia Obeng-Gyasi, MPH
Alejandro Recio, MD, FACP
Nathan Handley, MD, MBA

Central Nervous System Tumors

Karisa Schreck, MD, PhD—Track Leader
Priya Kumthekar, MD
Philipp Karschnia, MD
Matthias Holdhoff, MD, PhD
Iris Gibbs, MD

Developmental Therapeutics—Immunotherapy

Jarushka Naidoo, MD—Track Leader
Dung Le, MD
Elena Elez, MD, PhD
Daniel Olson, MD
Claire Friedman, MD
Sarah Nikiforow, MD, PhD
Hatem Soliman, MD

Developmental Therapeutics—Molecularly Targeted Agents

Christos Veklavas, MD—Track Leader
Emil Lou, MD, PhD, FACP
Jason Henry, MD
Carlos Ferreira, MD, PhD
Timothy Yap, MD, PhD
Vivek Subbiah, MD
Komal Jhaveri, MD, FACP
Jayesh Desai, MBBS, FRACP

Gastrointestinal Cancer—Colorectal and Anal

Wells Messersmith, MD, FACP, FASCO—Track Leader
Najjia Mahmoud, MD
Sorbarikor Piawah, MD, MPH
Takayuki Yoshino, MD, PhD
Myriam Chalabi, MD, PhD
Kyle Cuneo, MD
Kristen Ciombor, MD, MS
Y. Nancy You, MD, MHSc
Elisa Fontana, MD, PhD

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Nataliya Ubaha, MD, PhD—Track Leader
Samuel Klempner, MD, FASCO
Kelsey Klute, MD
Peter Hosein, MD
Sepideh Gholami, MD, FACS
Kohei Shitara, MD
Kim Reiss, MD
Rohan Katipally, MD
Harshabad Singh, MBBS
Namrata Vijayvergia, MD

Genitourinary Cancer—Kidney and Bladder

Peter Black, MD—Track Leader
Manuela Schmidinger, MD
Thomas Powles, MD, PhD, FCRP
Elizabeth Henry, MD
Ronac Mamtani, MD, MSCE
David Braun, MD, PhD

Genitourinary Cancer—Prostate, Testicular, and Penile

Fatima Karzai, MD
Karen Hoffman, MD, MHSc, MPH
Rahul Aggarwal, MD
Jorge Garcia, MD, FACP
Shahneen Sandhu, MD, MBBS, FRACP

Gynecologic Cancer

Cornelia Kolberg-Liedtke, MD, PhD—Track Leader
Stephanie Lheureux, MD, PhD
Gini Fleming, MD, FASCO
Jimmy Billod, MD, MHA, MT
Carolyn Muller, MD
Anuja Jhingran, MD

Head and Neck Cancer

Sharon Spencer, MD—Track Leader
Patrick Ha, MD
Aarti Bhatia, MD, MPH
Renata Ferrarotto, MD
Anil D'Cruz, MBBS, DNB, MS
Kevin Harrington, PhD, MBBS

Hematologic Malignancies—Leukemia, MDS, and Allotransplant

Eunice Wang, MD—Track Leader
Christine McMahon, MD
Rita Assi, MD
Amer Zeidan, MBBS
Richard Lin, MD, PhD

Hematologic Malignancies—Lymphoma and CLL

Martin Hutchings, MD, PhD—Track Leader
Ann LaCasce, MD
Hetty Carraway, MD, MBA
Ian Flinn, MD, PhD
Nathalie Johnson, MD

Hematologic Malignancies—Plasma Cell Dyscrasia

Rafat Abonour, MD—Track Leader
Amandeep Godara, MD
Maria-Victoria Mateos, PhD
Suzanne Lentzsch, MD, PhD
Amrita Krishnan, MD
Brandon Blue, MD

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Abdul Naqash, MD—Track Leader
Misty Shields, MD, PhD
Patrick Forde, MD
Melina Marmarelis, MD
C. S. Pramesh, MBBS, MS, FRCS
Lecia Sequist, MD, MPH
Mariano Provencio, MD, PhD
Shankar Siva, PhD

Lung Cancer—Non–Small Cell Metastatic

Natalie Vokes, MD, MPhil—Track Leader
Sarah Goldberg, MD
Ana Velazquez Manana, MD, MSc, MS
Nasser Hanna, MD
Bruna Pellini, MD
Adrian Sacher, MD, MMedSc, FRCP
Ticiana Leal, MD
Marjorie Zauderer, MD, MS, FACP

Medical Education and Professional Development

Nishin Bhadkamkar, MD—Track Leader
Richard Riedel, MD
Maria Baggstrom, MD, FACP, FASCO
Niki Tank, MD

Melanoma/Skin Cancers

Elizabeth Buchbinder, MD—Track Leader
Alexander Menzies, PhD, FRACP, MBBS
Michael Postow, MD
Ravi Amaravadi, MD

Pediatric Oncology

Raya Sabb, MD—Track Leader
Mark Applebaum, MD
Sarah Tasian, MD
Anuradha Banerjee, MD

Prevention, Risk Reduction, and Genetics

Andrea De Censi, MD—Track Leader
Payal Shah, MD
Abenaa Brewster, MD, MHS, FASCO
Heather Hampel, MS
Lisa Newman, MD, MPH, FASCO

Quality Care/Health Services Research

Sheetal Kircher, MD—Track Leader
Evangelia Razis, MD, PhD
Stephen Schleicher, MD, MBA
Stephanie Wheeler, PhD, MPH
Winson Cheung, MD, MPH
Monika Krzyzanowska, MD, MPH, FRCPC, FASCO
Mina Sedrak, MD, MS
Caroline Chung, MD, FRCPC

Sarcoma

Alberto Pappo, MD—Track Leader
Kristen Ganjoo, MD
Abhijeet Kumar, MBBS
Priscilla Merriam, MD

Symptom Science and Palliative Care

Eric Roeland, MD, FAAHPM, FASCO—Track Leader
Ramy Sedhom, MD
Peter Angelos, MD, PhD, FACS
Christopher Friese, PhD, RN, AOCN
Carolyn Presley, MD, MHS
Nicholas Zdenkowski, PhD, MBBS, FRACP
June McKoy, MD, MPH, JD, MBA
Marilyn Hammer, PhD, FAAN, RN

Awards

ASCO 2025 SPECIAL AWARDS

Award recipients will be recognized during the Opening Session, Saturday, May 31, 9:45 AM, Hall B1

Allen Lichter Visionary Leader Award

Karen E. Knudsen, PhD, MBA

ASCO-American Cancer Society Cancer Prevention Award

Susan M. Domchek, MD, FASCO

Lecture: The Long Road to Breast Cancer Risk and Genetics-Informed Precision Prevention

Presented on Monday, June 2, 9:45 AM, S100bc

This award is generously supported by the American Cancer Society.

B.J. Kennedy Geriatric Oncology Award, Endowed by Dr. Tony and Mrs. Carrie Cheung

Heidi D. Klepin, MD, MS, FASCO

Lecture: Improving Care for Older Adults With Cancer: Research to Practice

Presented on Saturday, May 31, 3:00 PM, E450a

This award is generously endowed by Dr. Tony and Mrs. Carrie Cheung.

David Karnofsky Science of Oncology Award

Dawn L. Hershman, MD, MS, FASCO

Excellence in Equity Award, Endowed by the American Cancer Society

Don S. Dizon, MD, FACP, FASCO

This award is generously endowed by the American Cancer Society.

Gianni Bonadonna Breast Cancer Award

Ian E. Krop, MD, PhD

Lecture: Redefining the Role of Chemotherapy in the Era of Targeted Therapies in Breast Cancer

Presented on Saturday, May 31, 4:45 PM, Hall B1

This award is generously supported by GlaxoSmithKline Oncology.

Humanitarian Award

Barbara L. McAneny, MD, MACP, FASCO

Jamie Von Roenn Excellence in Teaching and Mentorship Award

Christopher Flowers, MD, MS, FASCO

Patient Advocate Award

Karen E. Jackson

Pediatric Oncology Award

Melissa Hudson, MD, FASCO

Lecture: Accomplishments and Next Challenges in Childhood Cancer Survivorship

Presented on Saturday, May 31, 1:45 PM, S100bc

Walther Cancer Foundation Supportive Oncology Award

Karen M. Mustian, PhD

Lecture: Transformative Approaches in Supportive Oncology: Leadership, Innovation, and Research Presented on Saturday, May 31, 2:00 PM, S402

This award is generously endowed by the Walther Cancer Foundation.

Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO

This award is generously supported by Hologic, Inc

International Women Who Conquer Cancer Mentorship Award

Nazik Hammad, MD, MSc, MEHP, FACP

This award is generously supported by Eisai Inc. and Bristol Myers Squibb.

Fellows of the American Society of Clinical Oncology (FASCO)

Presented during the Opening Session, Saturday, May 31, 9:45 AM, Hall B1

Ghassan K. Abou-Alfa, MD, MBA, FASCO

Janet Abraham, MD, FAAHPM, FACP, FASCO

Jeanny B. Aragon-Ching, MD, FACP, FASCO

Fredrick Chite Asirwa, MD, MBChB, FASCO

Himisha Beltran, MD, FASCO

Erik Bernicker, MD, FASCO

Nishin Bhadkamkar, MD, FASCO

Kathleen E. Bickel, MD, FACP, MPhil, FASCO

Maria T. Boulton, MD, MSc, FASCO

Riccardo C. Braglia, MBA, FASCO

Sam Brondfield, MD, MA, FASCO

Barbara Burtneiss, MD, FASCO

John C. Byrd, MD, FASCO

Timothy L. Cannon, MD, FASCO

Higinia Rosa Cardenas Perera, MD, PhD, FASCO

Jamie E. Chaff, MD, FASCO

Susan M. Chang, MD, FASCO

George J. Chang, MD, MS, MHCM, FASCO

Yanin Chavarri Guerra, MD, MSc, FASCO

Fumiko Chino, MD, FASCO

Melvin L.K. Chua, MBBS, PhD, FRCP, FASCO

Julia L. Close, MD, FASCO

Mehmet Copur, MD, FACP, FASCO

Suzanne E. Dahlberg, PhD, FASCO

Robert M. Daly, MD, MBA, FASCO

Rebecca Dent, MD, FASCO

Aakash Desai, MD, MPH, FASCO

Michael Diaz, MD, FASCO

Maximilian Diehn, MD, PhD, FASCO

Martin J. Edelman, MD, FASCO

Shirish M. Gadgil, MD, FASCO

Sanjay Goel, MD, MS, FASCO

Michael S. Gordon, MD, FASCO

Mary K. Gospodarowicz, MD, FRCPC, FASCO

Sharad Goyal, MD, MS, FASTRO, FASCO

Stacy W. Gray, MD, FASCO

Petros Grivas, MD, PhD, FASCO

Arjun Gupta, MD, FASCO

Shilpi Gupta, MD, FASCO

Bishal Gyawali, MD, PhD, FASCO

Robert I. Haddad, MD, FASCO

Nasser H. Hanna, MD, FASCO

Jack Hensold, MD, FASCO

Alexia Iasonos, PhD, FASCO

Richard M. Ingram, MD, FASCO

Claudine Isaacs, MD, FRCPC, FASCO

Abdul-Rahman Jazieh, MD, MPH, FASCO

Michael Jefford, MBBS, PhD, MPH, FRACP, FASCO

Melissa L. Johnson, MD, FASCO

Kevin Kalinsky, MD, MS, FASCO

Tricia L. Kalwar, MD, MPH, FASCO

Jasmine Kamboj, MD, FASCO

Gretchen G. Kimmick, MD, MS, FASCO

Primo N. Lara, MD, FASCO

Christopher S. Lathan, MD, MS, MPH, FASCO

Steve Lee, MD, FACP, FASCO

Inga T. Lennes, MD, MPH, MBA, FASCO

Mark A. Lewis, MD, FASCO

A. Craig Lockhart, MD, FASCO

Kah Poh Loh, MBCh, MS, FASCO

Sagar Lonial, MD, FACP, FASCO

Herbert H. Loong, MBBS, FRCP, FASCO

Ana Maria Lopez, MD, MPH, FASCO

Alison W. Loren, MD, MSCE, MS, FACP, FASCO

Maryam B. Lustberg, MD, FASCO
 Laurie J. Lyckholm, MD, FASCO
 Allison Magnuson, DO, MS, FASCO
 Issam Makhoul, MD, FASCO
 Monica Malik, MD, DNB, FASCO
 S. Eric Martin, MD, FASCO
 Heather L. McArthur, MD, MPH, FASCO
 Jane Lowe Meisel, MD, FASCO
 Funda Meric-Bernstam, MD, FASCO
 Joseph Mikhael, MD, MEd, FASCO
 Kathleen N. Moore, MD, MS, FASCO
 Michael J. Morris, MD, FASCO
 Rita Nanda, MD, FASCO
 Paul L. Nguyen, MD, MBA, FASCO
 Ryan D. Nipp, MD, FASCO
 Ian N. Olver, MD, PhD, FRACP, FASCO
 Eileen M. O'Reilly, MD, FASCO
 Aparna R. Parikh, MD, FASCO
 Sandip Patel, MD, FASCO
 Mark D. Pegram, MD, FASCO
 Brian E. Persing, MD, FASCO
 Amy C. Peterson, MD, FASCO
 Tycel J. Phillips, MD, FASCO
 Deepa Rangachari, MD, FASCO
 Karen L. Reckamp, MD, FASCO
 Jennie Robertson Crews, MD, FASCO
 Lorna Rodriguez-Rodriguez, MD, PhD, FASCO
 Trevor J. Royce, MD, MPH, MS, FASCO

Kathryn J. Ruddy, MD, MPH, FASCO
 Anne F. Schott, MD, FASCO
 Ramy Sedhom, MD, FASCO
 Mina S. Sedrak, MD, MS, FASCO
 Lecia V. Sequist, MD, MPH, FASCO
 Lesley K. Seymour, MD, PhD, FASCO
 Surendranath S. Shastri, MD, DPH, FASCO
 Davendra Sohal, MD, MPH, FASCO
 Joseph A. Sparano, MD, FACP, FASCO
 Tom Stinchcombe, MD, FASCO
 Erica M. Stringer-Reasor, MD, FASCO
 James A. Talcott, MD, FASCO
 Laura L. Tenner, MD, MPH, FASCO
 Alexandra Thomas, MD, FACP, FASCO
 Sara M. Tolaney, MD, MPH, FASCO
 Anne S. Tsao, MD, FASCO
 Ulka N. Vaishampayan, MD, FASCO
 Ana I. Velazquez Manana, MD, MSc, MS, FASCO
 Vamsidhar Velcheti, MD, FACP, FCCP, FASCO
 Gina M. Villani, MD, MPH, FASCO
 Howard J. West, MD, FASCO
 Jason Westin, MD, MS, FACP, FASCO
 Grant R. Williams, MD, MPH, FASCO
 Laura Williams Goff, MD, FASCO
 Stephanie Williams, MD, FACP, FASCO
 Robert A. Wolff, MD, FASCO
 Yun Yen, MD, PhD, FACP, FASCO

Conquer Cancer®, the ASCO Foundation, has a mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Through our Grants & Awards Program, we are building a pipeline of future leaders and are supporting and encouraging excellence in clinical and translational research in the field of oncology. Please visit [ASCO.org/grants-awards](https://www.asco.org/grants-awards) for a list of 2025 awards and recipients.

Industry Expert Theater Schedule

The Industry Expert Theaters (IETs), located in the back of the Exhibit Hall, to the left of the Food Court, bring together industry leaders and attendees for hour-long, nonaccredited educational presentations on the latest in oncology practices, products, services, and technologies.

If the IET company chooses to post their in-person session recording online, the session audio and slides will be available for on-demand viewing after the Meeting at am.asco.org.

Industry Expert Theater sessions are not official presentations of the 2025 ASCO Annual Meeting and are not sponsored, endorsed, or accredited by ASCO, Association for Clinical Oncology, or Conquer Cancer, the ASCO Foundation. These sessions are not CME-accredited.

This schedule is subject to change. Information listed is current as of March 14, 2025. For the most up-to-date information, please visit am.asco.org.

Saturday, May 31

Time: 9:30 AM-10:30 AM

Title: Advancing Treatment in mCRPC: What Medical Oncologists Should Know About the First and Only PSMA-Targeted Therapy NOW APPROVED Prior to Chemotherapy

Description: A discussion of the clinical data and safety profile of a prescription treatment for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Company: Novartis

Presenter: Tom Boike, MD, MMM, FASTR, US Clinical Program Lead RLT, Novartis

Location: Theater 2

Time: 9:30 AM-10:30 AM

Title: Subcutaneous Delivery in Immunotherapy: Transforming Administration in Oncology

Description: Join us for a conversation about the integration of subcutaneous therapies in oncology and the potential impact on practice and patient. This session will be a panel discussion highlighting a multi-disciplinary perspective.

Company: Bristol Myers Squibb

Presenters:

Daniel Adamczyk, PharmD, Associate Director, US Oncology Medical, Bristol Myers Squibb
Neeta Venepalli, MD, MBA, FACP, Director, US Oncology Medical Engagement Lead, Bristol Myers Squibb
Deborah Jackson, RN, MSN, AOCNS, Senior Director, US Oncology Clinical Nurse Consultants, Bristol Myers Squibb

Location: Theater 1

Time: 12:30 PM-1:30 PM

Title: Evolving Strategies for HR+/HER2- (IHC 0, IHC 1+, IHC 2+/ISH-) mBC

Description: Join Daiichi Sankyo, Inc. and AstraZeneca for a discussion on the latest therapy for adult patients with unresectable or metastatic HR+/HER2- (IHC 0, 1+ or 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy. This program is for US healthcare professionals.

Company: Daiichi Sankyo, Inc. and AstraZeneca

Presenter: Tomasz Szczudlo, MD, VP Global Oncology Medical Affairs, Daiichi Sankyo, Inc.

Location: Theater 2

Time: 12:30 PM-1:30 PM

Title: Use of a Targeted Agent for CLL and MCL

Description: This program discusses treatment patterns, disease management options, and evolving landscapes for chronic lymphocytic leukemia and mantle cell lymphoma. It will also present new clinical efficacy and safety data from multiple clinical trials of a selective Bruton Tyrosine Kinase inhibitor (BTKi).

Company: AstraZeneca

Presenter: Anthony Mato, MD, Global Head of CLL Clinical Development and Strategy, AstraZeneca

Location: Theater 1

Time: 3:00 PM-4:00 PM

Title: New Treatment Option in HER2-Expressing mBC

Description: A discussion around a new treatment option in HER2-Expressing mBC presented by Daiichi Sankyo, Inc. and AstraZeneca.

Company: Daiichi Sankyo, Inc. and AstraZeneca

Presenter: Eleanor C. Faherty, MD, FACS, Director, Medical Affairs, Daiichi Sankyo, Inc.

Location: Theater 2

Time: 3:00 PM-4:00 PM

Title: Powering Today's Insights for a Smarter Tomorrow: Intelligent Diagnostics and AI Solutions Across the Cancer Continuum

Description: At Tempus, AI is infused into everything we do to optimize insights, efficiencies and tailor patient care. Discover how we're redefining precision oncology at scale – where our tests fuel smarter decisions and patient data advances care. Learn how AI, real world data and diagnostics drive innovation.

Company: Tempus

Presenters:

Kate Sasser, PhD, Chief Scientific Officer, Tempus
Halla Nimeiri, MD, Chief Development Officer, Tempus
Ezra Cohen, MD, FASCO, Chief Medical Officer, Tempus

Location: Theater 1

Sunday, June 1

Time: 9:30 AM-10:30 AM

Title: Molecular Residual Disease Testing with Exact Sciences' Oncodetect™ Test: Product and Clinical Data Overview

Description: Get introduced to Exact Sciences' Oncodetect MRD Test. Learn about the test, its approach to detecting residual disease in solid tumors, and its clinical validation results in colorectal cancer (CRC).

Company: Exact Sciences

Presenters:

Rick Baehner, MD, Chief Medical Officer of Precision Oncology, Exact Sciences
Somasundaram Subramaniam, MD, MS, Medical Development Director, Exact Sciences

Location: Theater 2

Time: 9:30 AM-10:30 AM

Title: Practice Changing Advancements in MIBC: A New Treatment Option

Description: Review unmet needs in patients with MIBC. Discussion about a Perioperative Regimen to treat Cisplatin -eligible MIBC Patients.

Company: AstraZeneca

Presenter: Sushant Hardikar, Medical Head GU, AstraZeneca

Location: Theater 1

Time: 11:30 AM-12:30 PM

Title: GOMEKLI - FDA-Approved Treatment For Adult and Pediatric Patients Aged ≥ 2 Years With NF1 Who Have Symptomatic PN Not Amenable to Complete Resection

Description: Learn more about now approved GOMEKLI, the first and only treatment for both adult and pediatric patients aged ≥ 2 years with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

Company: SpringWorks Therapeutics

Presenter: Abraham J. Langseth, PhD, Senior Medical Director, SpringWorks Therapeutics

Location: Theater 2

Time: 11:30 AM-12:30 PM

Title: Transforming Science Within the Community: How Gilead's Legacy has Paved the Way to an Innovative Approach for Patient-Centered Oncology Care

Description: At Gilead and Kite, our commitment lies in pioneering innovative treatments across oncology and virology. We also understand that tackling the challenges community providers face demands more than just medicine. Discover Gilead and Kite's revolutionizing approach to patient-centered oncology care!

Company: Gilead and Kite Oncology

Presenter: Darren Tayama, MD, Vice President, US Medical Affairs, Gilead

Location: Theater 1

Time: 4:15 PM-5:15 PM

Title: Applying Real-World Evidence in Advanced Prostate Cancer

Description: An overview of the evolution of RWE and the rigor needed to enhance treatment effectiveness and patient outcomes.

Company: Johnson & Johnson

Presenter: Charles Drake, Vice President, Prostate Disease Area Stronghold (DAS), Johnson & Johnson

Location: Theater 2

Monday, June 2

Time: 9:30 AM-10:30 AM

Title: Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI in eBC and mBC

Description: Addressing the Needs of Patients With HR+/HER2-: How an innovative medication from Novartis delivers on an unmet patient need, detailing the efficacy, safety, and management of patients.

Company: Novartis

Presenter: Kara Trlica, FNP-BC, AOCNP, Oncology Senior Specialist, Novartis

Location: Theater 1

Time: 9:30 AM-10:30 AM

Title: The Next Era for EGFR+ mNSCLC First-Line Treatment

Description: Join us to discover the latest data about an innovative first-line treatment approach designed to target key mechanisms driving disease progression, helping to address critical unmet needs in EGFR+ locally advanced or metastatic NSCLC

Company: Johnson & Johnson

Presenter: Joshua Bauml, MD, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, Johnson & Johnson

Location: Theater 2

Time: 11:30 AM-12:30 PM

Title: An Innovative Perspective on Advanced NSCLC Treatment

Description: This presentation will explore the evolving strategies in locally advanced/metastatic NSCLC treatment, highlighting an innovative approach to patient care.

Company: AbbVie

Presenter: Pallavi Mhaske, MD, Associate Medical Director, US Medical Affairs - Solid Tumor, AbbVie

Location: Theater 1

Time: 11:30 AM-12:30 PM

Title: What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?

Description: At Johnson & Johnson, we're creating a future where disease is a thing of the past by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. In partnership with Legend Biotech, join us as we share latest data on 2L+ Relapsed/Refractory Multiple Myeloma.

Company: Johnson & Johnson and Legend Biotech

Presenter: Victoria Alegria, APRN, MSN, Medical Director, Johnson & Johnson

Location: Theater 2

Time: 3:00 PM-4:00 PM

Title: Immunize to Optimize: Enhancing Cancer Care Through Vaccinations

Description: Join us to explore the vital role of immunizations in cancer care. Through case studies, we'll highlight the benefits of immunization, review the guidelines for recommended vaccines, and discuss how oncologists and healthcare teams can collaborate to protect patients from preventable infections.

Company: GSK

Presenters:

Len Friedland, MD, VP and Director, US Scientific Affairs and Public Health, Vaccines, GSK
Jean A. Hurteau, MD, Senior Medical Director, US Medical Affairs - Gynecologic Oncology Portfolio; Synthetic Lethality, Immunoncology and Antibody Drug Conjugates, GSK
Noha S. Eltoukhy, PharmD, MPH, BCPS, BCIDP, Director, US Medical Affairs- Adult Immunization and Health Equity, GSK

Location: Theater 1

Time: 3:00 PM-4:00 PM

Title: Two First-in-Class Treatments for Patients with Relapsed or Refractory Multiple Myeloma

Description: Please join Johnson & Johnson to explore and learn more about two exciting first-in-class medications for adult patients with RRMM who have received at least four prior lines of therapy.

Company: Johnson & Johnson Innovative Medicine

Presenters:

Saurabh Patel, MD, Medical Director, Multiple Myeloma, Johnson & Johnson

Agne Paner-Straseviciute, MD, Medical Director, MM Portfolio Strategy, US MAF, Johnson & Johnson

Location: Theater 2

1:00 PM-2:00 PM Education Session

ASCO Voices

Location: S100a

Cardinale B. Smith, MD, PhD, FASCO—Chair

Memorial Sloan Kettering Cancer Center

Welcome and Introduction

Erica Campbell

Pinky Swear Foundation

A Rising Tide Lifts All Boats: Advancing Equity in the Childhood Cancer Journey

Steven Clark Cunningham, MD, MLA, FACS

Saint Agnes Hospital Cancer Institute

Spiritual Care and Religious Literacy in Cancer Care

Naga Koteswari Cheedella, MD

Texas Technical University Health Sciences Center

Cancer Care Choices: What Patients Want and What Oncologists Wish

Ashton Davidson

Umbrella Support Network

Breast Cancer Doesn't Care About Gender

Katie Coleman

Chromophobe and Oncocytic Tumor Alliance

Too Young for Cancer

1:00 PM-2:00 PM Case-Based Panel

ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?

Location: Arie Crown Theater

Priyadarshini Pathak, MBBS—Chair

Massachusetts General Hospital

Moderator

Noelia Tarazona, MD, PhD

University of Valencia

Translational Researcher Perspective

Chloe E. Atreya, MD, PhD

University of California San Francisco

Medical Oncologist Perspective

Midhun Malla, MD, MS

University of Alabama

Hematologist-Oncologist Perspective

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Addressing Financial Toxicity in Breast Cancer Care: Strategies for Mitigation and Support

Location: Hall D2

Alexandru E. Eniu, MD, PhD—Chair

Hôpital Riviera-Chablais

Financial Toxicity of Breast Cancer Care: What It Is, Who Is Impacted, and Should I Care About It?

Christopher M. Booth, MD

Queen's University

When the Health System Bears the Financial Toxicity: Cost, Value, and Solutions!

Fumiko Chino, MD, FASCO

The University of Texas MD Anderson Cancer Center

When the Patient Has to Take the Burden: Communication and Mitigation Strategies and Support Resources

Molly MacDonald

The Pink Fund

Bearing the Burden of Financial Toxicity: What Can a Patient Do?

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Artificial Intelligence in Cancer Care: The Evolving Role of Decision Support in Care Delivery and Practical Application in Your Practice

Location: S100bc

Debra A. Patt, MD, PhD, MBA, FASCO—Chair

Texas Oncology, The US Oncology Network

Artificial Intelligence in Cancer Care: How ASCO Is Influencing Artificial Intelligence in the Cancer Community

Ravi Bharat Parikh, MD, MPP

Winship Cancer Institute, Emory University

Practical Applications of Artificial Intelligence in the Practice Setting

To be determined

The NCI's Prioritization of the Use of Data Science to Improve the Cancer Journey

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Connecting the Dots: Strategies for Academic and Community Synergy in Immunotherapy Toxicity Care

Location: E350

Kerry Lynn Reynolds, MD

Massachusetts General Hospital Cancer Center

Who, What, How: Best Practices for the Development of the Multidisciplinary Immunotherapy Toxicity Service

Kathryn Blount Bollin, MD

Scripps Clinic Medical Group

Getting Practical About Care Transitions: The Community Oncology Experience in Managing Immune-Related Adverse Events and Transitions of Care

Kriti Mittal, MBBS, MSc, FACP

UMass Chan Medical School

Aspire and Stories: Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events

Mazie Tsang, MD, MS—Chair

Mayo Clinic

Framing the Dichotomies of Immunotherapy-Related Adverse Event Management

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Incorporating Targeted Therapy Into Neuro-Oncology Practice

Location: S102

Antonio Iavarone, MD—Chair

Sylvester Comprehensive Cancer Center, University of Miami

Miller School of Medicine

Emerging Therapeutics for Patients With Brain Tumors and Rare Oncogenic Drivers

Marjolein Geurts, MD

Erasmus MC

Targeted Therapy for Patients With IDH-Mutant Glioma

David Olayinka Kamson, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Selection of Blood-Brain Barrier Penetrant Inhibitors for Brain Metastases and Primary Central Nervous System Malignancies

Panel Question and Answer

1:00 PM-2:15 PM Education Session

One Step Ahead: Preventing Tumor Adaptation to Immunotherapy

Location: E451

Judith A. Varner, PhD—Chair

University of California San Diego

Transforming the Battlefield: Targeting the Tumor Microenvironment

Andy J. Minn, MD, PhD

University of Pennsylvania

Deciphering and Disrupting Immunotherapy Resistance Pathways

Dario Vignali, PhD

University of Pittsburgh

Pushing the Boundaries: Next-Generation Immunotherapy Combinations

Panel Question and Answer

1:00 PM-2:15 PM Education Session

Ultra-Rare Sarcomas: How Do We Move Forward?

Location: S402

Silvia Stacchiotti, MD—Chair

Fondazione IRCCS Istituto Nazionale dei Tumori

Ignorance Is Not Bliss: Challenges and Opportunities in Ultrarare Sarcomas

Kevin B. Jones, MD

The University of Utah

Back to Basic (Science): The Power of Preclinical Modeling to Identify Vulnerabilities in Ultrarare Sarcomas

Mrinal M. Gounder, MD

Memorial Sloan Kettering Cancer Center

From Dreams to Reality: New Therapies for Ultrarare Sarcomas

Panel Question and Answer

1:00 PM-2:30 PM Rapid Oral Abstract Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant

Location: E450a

Catherine Lai, MD, MPH—Chair

University of Pennsylvania

Pamela Jeannette Sung, MD, PhD—Chair

Roswell Park Cancer Center

1:00 PM **Abstract 6509:** A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults.
First Author: Marlise R. Luskin, MD

1:06 PM **Abstract 6510:** MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.
First Author: Ibrahim Aldoss

1:12 PM **Abstract 6511:** Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.
First Author: Nihar Desai, MD, DM

1:18 PM Panel Question and Answer

1:30 PM **Abstract 6512:** Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)—naïve patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.
First Author: Guillermo Garcia-Manero, MD

1:36 PM **Abstract 6513:** Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
First Author: Naval Guastad Daver, MD

1:42 PM **Abstract 6514:** Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.
First Author: Bradley Rockwell, MD

1:48 PM Panel Question and Answer

2:00 PM **Abstract 6515:** IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).
First Author: John Mascarenhas, MD

2:06 PM **Abstract 6516:** Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.
First Author: David Jacob Andorsky, MD

2:12 PM **Abstract 6517:** Age-related macular degeneration in individuals with clonal hematopoiesis.
First Author: Keishla Marie Arce-Ruiz, BS

2:18 PM Panel Question and Answer

1:00 PM-2:30 PM Education Session

New Drugs in Oncology: Incorporation Into Practice

Location: Hall D1

Ingo K. Mellinghoff, MD, FACP—Chair

Memorial Sloan Kettering Cancer Center

Mark D. Pegram, MD, FASCO—Chair

Stanford University School of Medicine

Luis G. Paz-Ares, MD, PhD

Hospital Universitario 12 de Octubre

Tarlatamab for Extensive-Stage Small Cell Lung Cancer

Julie Vose, MD, MBA

University of Nebraska Medical Center

Epcoritamab for Relapsed or Refractory Follicular Lymphoma

Panel Question and Answer

Barbara Pistilli, MD

Gustave Roussy

Datopotamab Deruxtecan for Metastatic Hormone Receptor-Positive HER2-Low or HER2-Negative Breast Cancer

Timothy Francis Cloughesy, MD
 Ronald Reagan UCLA Medical Center
Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma With a Susceptible IDH1 or IDH2 Mutation
 Panel Question and Answer

1:00 PM-3:00 PM Workshop

Genomics 101 for Oncologists (Limited Attendance; First-Come, First-Served)
 Location: S501

Richard L. Haspel, MD—Chair
 Beth Israel Deaconess Medical Center

Ramaswamy Govindan, MD—Chair
 Washington University School of Medicine in St. Louis

Phillip Michaels, MD
 Brigham and Women's Hospital
Molecular Pathologist Perspective

Alix D'Angelo, LCGC
 LSU Health School of Medicine
Genetic Counselor Perspective

Deepa Rangachari, MD, FASCO
 Beth Israel Deaconess Medical Center
Medical Oncologist Perspective

1:00 PM-4:00 PM Oral Abstract Session

Quality Care/Health Services Research
 Location: S504

Stephen Matthew Schleicher, MD, MBA—Chair
 Tennessee Oncology

Veena Shankaran, MD, MS—Chair
 Fred Hutchinson Cancer Research Center, University of Washington

1:00 PM Abstract 11000: Psychosocial digital application for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT): A randomized controlled trial.
 First Author: Jamie M. Jacobs, PhD

1:12 PM Abstract 11001: Outcomes of an electronic patient-reported outcomes (ePRO)-based symptom management program (eSyM): A cluster randomized trial.
 First Author: Michael J. Hassett, MD, MPH, FASCO

1:24 PM Abstract 11002: Improving care of older adults with cancer: A randomized trial.
 First Author: Manali I. Patel, MD, MPH, MS, FASCO

1:36 PM Abstract 11003: Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment.
 First Author: Ryan David Nipp, MD, FASCO

1:48 PM Robert Michael Daly, MD, MBA, FASCO
 Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 11000-11003: Try This, Not That: Interventions to Boost How Patients Feel, Where They're At

2:00 PM Panel Question and Answer

2:12 PM Abstract 11004: Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing.
 First Author: Julie B. Moskowitz, MS

2:24 PM Abstract 11005: Real-world social determinants of health (SDOH) and outcomes of early-onset colorectal cancer (EO-CRC): An analysis of a large, nationally representative US community oncology network.
 First Author: Lisa Herms

2:36 PM Michael J. Raphael, FRCP, MSc
 Sunnybrook Health Sciences Centre, Odette Cancer Centre
Discussion of Abstract(s) 11004-11005: Too Soon, Too Fast: Let's Tackle Early-Onset Colorectal Cancer at Last

2:48 PM Panel Question and Answer

3:00 PM Abstract 11006: Association of Medicaid expansion with five-year survival after cancer diagnosis.
 First Author: Elizabeth Schafer, MPH

3:12 PM Abstract 11008: A randomized controlled trial comparing pragmatic interventions to improve mammogram uptake in a non-compliant population.
 First Author: Sasidharan Swarnalatha Lucky, PhD

3:24 PM Mya Roberson, PhD
 The University of North Carolina at Chapel Hill
Discussion of Abstract(s) 11006-11008: Too Many Rules, Too Many Traps: Can Policy Help Close the Gaps?

3:36 PM Panel Question and Answer

2:45 PM-4:00 PM Education Session

Navigating Early Career as an Oncologist: Thriving in Diverse Paths
 Location: E350

Marjorie C. Green, MD
 Merck & Co., Inc.
Breaking the Mold: Why I Went Into Industry and What I've Learned

Gita Suneja, MD
 The University of Utah
How I Navigated the Early Days of My Academic Career: Opportunities, Pitfalls, and the Fellow-to-Attending Transition

Joseph William McCollom, DO—Chair
 Parkview Cancer Institute
How I Became a Community Practice Oncologist and the Surprises I Faced Early On
 Panel Question and Answer

2:45 PM-4:00 PM Education Session

Redefining Success and Survivorship in Pediatric Oncology
 Location: S402

Smita Bhatia, MD, MPH, FASCO—Chair
 University of Alabama at Birmingham Heersink School of Medicine
Molecular Underpinnings of Treatment-Related Complications in Cancer Survivors

Friday, May 30, 2025

Saro Armenian, DO, MPH

City of Hope

Role of Personalized Interventions Among High-Risk Cancer Survivors to Reduce Morbidity

Leontien C.M. Kremer

Princess Maxima Center for Pediatric Oncology

Does Early Detection of Late Effects Reduce Mortality in Childhood Cancer Survivors?

Emily S. Tonorezos, MD, MPH

National Institutes of Health, National Cancer Institute

Care Delivery Models for Adolescent and Young Adult Cancer and Adult Survivors of Childhood Cancer

Panel Question and Answer

2:45 PM-4:15 PM Rapid Oral Abstract Session

Breast Cancer—Metastatic

Location: Hall D2

Jose G. Bazan, MD—Chair

City of Hope Comprehensive Cancer Center

Yara Abdou, MD—Chair

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill

2:45 PM Abstract 1036: Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates: A TriNetX real-world evidence study. First Author: Zunairah Shah, MD

2:51 PM Abstract 1014: Use of artificial intelligence—assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for HER2-targeted treatment. First Author: David Mulder, MSc

2:57 PM Abstract 1015: Treatment rechallenge after trastuzumab-deruxtecan-related interstitial lung disease: A multi-institution cohort study. First Author: Kelsey H. Natsuhara, MD

3:03 PM Panel Question and Answer

3:15 PM Abstract 1016: Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. First Author: Joohyuk Sohn, MD, PhD

3:21 PM Abstract 1017: HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial. First Author: Min Yan, MD

3:27 PM Abstract 1018: A phase II clinical study of adabrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases. First Author: Ting Li, MD

3:33 PM Panel Question and Answer

3:45 PM Abstract 1019: Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. First Author: Yongmei Yin, MD, PhD

3:51 PM Abstract 1020: Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2– metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D). First Author: Patricia LoRusso, PhD, DO, FASCO

3:57 PM Abstract 1021: Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13). First Author: Ju Won Kim, MD, PhD

4:03 PM Panel Question and Answer

2:45 PM-5:45 PM Oral Abstract Session

Central Nervous System Tumors

Location: S100bc

Katherine B. Peters, MD, PhD, FAAN—Chair

Duke University Medical Center

Nazanin Majd, MD—Chair

The University of Texas MD Anderson Cancer Center

2:45 PM Abstract LBA2000: Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trial. First Author: Yuanyuan Chen, MD

2:57 PM Abstract 2001: A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: A report by the RANO resect group. First Author: Philipp Karschnia, MD, MS

3:09 PM Abstract 2002: Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990. First Author: Martin J. Van Den Bent, MD, PhD

3:21 PM Abstract 2003: A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209. First Author: Enrico Franceschi, MD

3:33 PM Eudocia Quant Lee, MD, MPH
Dana-Farber Cancer Institute
Discussion of Abstract(s) LBA2000-2003: Trial Design in Gliomas: Following a Moving Target

3:45 PM Panel Question and Answer

3:57 PM Abstract 2004: A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases. First Author: Pu-Yuan Xing

4:09 PM Abstract 2005: Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non-small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial. First Author: Matthias Preusser, MD

- 4:21 PM Solmaz Sahebjam, MD, FRCPC**
National Cancer Institute
Discussion of Abstract(s) 2004-2005: Mapping the Course in Patients With Central Nervous System Metastases
- 4:33 PM** Panel Question and Answer
- 4:45 PM Abstract 2006:** A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.
First Author: Antoine Carpentier, MD, PhD
- 4:57 PM Abstract 2007:** INB-200: Phase 1 study of gene-modified autologous gamma-delta ($\gamma\delta$) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).
First Author: Mina Lobbous, MD, MSPH, MBChB
- 5:09 PM Abstract 2008:** Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (GBM): INCIPIENT trial.
First Author: Bryan D. Choi
- 5:21 PM Zev A. Binder, MD, PhD**
University of Pennsylvania
Discussion of Abstract(s) 2006-2008: Keeping the Bench at Bedside: Innovative Immunotherapy Approaches in Glioblastoma
- 5:33 PM** Panel Question and Answer

2:45 PM-5:45 PM Oral Abstract Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: Hall D1

Timothy A. Yap, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

Jason Timothy Henry, MD—Chair

Sarah Cannon Research Institute at HealthONE

- 2:45 PM Abstract 3000:** DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
First Author: Aaron Elliott Lisberg, MD
- 2:57 PM Abstract 3001:** Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
First Author: Yunpeng Yang
- 3:09 PM Abstract 3002:** Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
First Author: Yan Huang
- 3:21 PM Abstract 3003:** Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody-drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.
First Author: Rui-Hua Xu, MD, PhD

- 3:33 PM Lillian L. Siu, MD, FRCPC, FASCO**
Princess Margaret Cancer Centre
Discussion of Abstract(s) 3000-3003: Is HER3 the Neu HER2 or Is It Too Soon?
- 3:45 PM** Panel Question and Answer
- 3:57 PM Abstract 3004:** Efficacy and safety of the DLL3/CD3 T-cell engager obixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
First Author: Jaume Capdevila, MD, PhD
- 4:09 PM Abstract 3005:** [^{212}Pb]VMT- α -NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
First Author: Thorvardur Ragnar Halfdanarson, MD
- 4:21 PM Heloisa P. Soares, MD**
Huntsman Cancer Hospital, University of Utah
Discussion of Abstract(s) 3004-3005: To BITE or to Go Nuclear? New Hope for Neuroendocrine Tumors
- 4:33 PM** Panel Question and Answer
- 4:45 PM Abstract 3006:** Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
First Author: Biswajit Das, PhD
- 4:57 PM Abstract 3007:** Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.
First Author: Tadayoshi Hashimoto, MD, PhD
- 5:09 PM Abstract 3008:** Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
First Author: Silver Alkhafaji, BS
- 5:21 PM Emil Lou, MD, PhD, FACP**
University of Minnesota
Discussion of Abstract(s) 3006-3008: I-SPY a MONSTAR MATCH: Is It Written in Blood?
- 5:33 PM** Panel Question and Answer

2:45 PM-5:45 PM Oral Abstract Session

Gastrointestinal Cancer—Colorectal and Anal

Location: Arie Crown Theater

Kristen Keon Ciombor, MD, MS—Chair

Vanderbilt University

Robert William Lentz, MD—Chair

University of Colorado Anschutz School of Medicine

- 2:45 PM Abstract LBA3500:** First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses.
First Author: Elena Elez, MD, PhD

- 2:57 PM Abstract 3501:** Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.
First Author: Heinz-Josef Lenz, MD
- 3:09 PM Abstract LBA3502:** Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).
First Author: Ke-Feng Ding, MD, PhD
- 3:21 PM Andrea Sartore-Bianchi, MD**
Università degli Studi di Milano and Niguarda Cancer Center
Discussion of Abstract(s) LBA3500-LBA3502: Precision Oncology in the First-Line Setting of Colorectal Cancer
- 3:33 PM** Panel Question and Answer
- 3:45 PM Abstract 3503:** ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).
First Author: Jeanne Tie, MD, FRACP, MBChB
- 3:57 PM Abstract 3504:** Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).
First Author: Frank A. Sinicrope, MD
- 4:09 PM Abstract 3505:** Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).
First Author: Koen Rovers, MD, PhD
- 4:21 PM Julien Taieb, MD, PhD**
Institut du Cancer Paris CARPEM, AP-HP Centre, Hôpital Européen Georges Pompidou
Discussion of Abstract(s) 3503-3505: Refining Perioperative Selection and Treatment
- 4:33 PM** Panel Question and Answer
- 4:45 PM Abstract 3506:** Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 101 (phase 1b).
First Author: John H. Strickler, MD
- 4:57 PM Abstract 3507:** Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.
First Author: Antoine Hollebecque, MD
- 5:09 PM Abstract 3508:** The KRAS G12C inhibitor MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
First Author: Iwona A. Lugowska, MD, PhD
- 5:21 PM Elisa Fontana, MD, PhD**
Sarah Cannon Research Institute UK
Discussion of Abstract(s) 3506-3508: KRAS G12C: From First to Next Generation
- 5:33 PM** Panel Question and Answer

2:45 PM-5:45 PM Oral Abstract Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: S100a

Hetty E. Carraway, MD, MBA—Chair

Taussig Cancer Institute, Cleveland Clinic

Reem Karmali, MD—Chair

Northwestern University Feinberg School of Medicine

- 2:45 PM Abstract 7000:** Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
First Author: Steven Wang
- 2:57 PM Abstract 7001:** Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.
First Author: Tongyu Lin, PhD
- 3:09 PM Abstract 7002:** Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses.
First Author: Cong Sun
- 3:21 PM Mark J. Roschewski, MD**
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Discussion of Abstract(s) 7000-7002: Moving the Needle: Improving Clinical and Molecular Risk Stratification in Lymphoma
- 3:33 PM** Panel Question and Answer
- 3:45 PM Abstract 7003:** A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Saurabh Dahiya, MD, FACP
- 3:57 PM Abstract 7004:** Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma.
First Author: Akiva Diamond, MD
- 4:09 PM Abstract 7005:** WaveLINE-003: Phase 2/3 of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.
First Author: Philippe Armand, MD, PhD
- 4:21 PM Paolo Fabrizio Caimi, MD**
Cleveland Clinic
Discussion of Abstract(s) 7003-7005: Strengthening the Strike: Novel Treatment Approaches in Relapsed-Refractory Large B-Cell Lymphoma
- 4:33 PM** Panel Question and Answer
- 4:45 PM Abstract 7006:** Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).
First Author: Huiqiang Huang, MD, PhD
- 4:57 PM Abstract 7007:** Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).
First Author: Peng Liu

- 5:09 PM** **Abstract 7008:** Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).
First Author: Joseph E. Maakaron, MD
- 5:21 PM** **Sarah C. Rutherford, MD**
Weill Cornell Medicine
Discussion of Abstract(s) 7006-7008: Reinventing Immunotherapy in Hodgkin Lymphoma and Extranodal NK/T-Cell Lymphoma
- 5:33 PM** Panel Question and Answer

3:45 PM-5:45 PM Workshop

Communication in Late-Stage Cancer: Discussing Prognosis and Matching Care to Patients' Goals (Limited Attendance; First-Come, First-Served)

Location: S501

Robert Arnold, MD—Chair
University of Pittsburgh Medical Center

James A. Tulskey, MD—Chair
Dana-Farber Cancer Institute

Gordon J. Wood, MD
Northwestern Medicine

Jillian Gustin, MD
The Ohio State University Wexner Medical Center and Comprehensive Cancer Center

Elise Carey, MD
Mayo Clinic

4:30 PM-5:30 PM Case-Based Panel

Pelvic Sarcomas: Treatment Challenges and Outcomes

Location: S402

Najat C. Daw, MD—Chair
The University of Texas MD Anderson Cancer Center
Moderator

Uta Dirksen, MD
Essen University Hospital
Oncologist Perspective

Francis Hornicek, MD, PhD
University of Miami
Oncologic Surgeon Perspective

Siddhartha Laskar, MD, DMRT, DNB
Tata Memorial Centre
Radiation Oncologist Perspective

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Accelerating Cancer Clinical Trials With Artificial Intelligence

Location: S102

Sandip Pravin Patel, MD, FASCO—Chair
UC San Diego Moores Cancer Center
Machine Learning Innovations to Improve Design and Diversity of Phase 2–3 Oncology Trials

Mark Stewart, PhD
Friends of Cancer Research
Matching the Right Trials to the Right Patients Using Artificial Intelligence

Donna Rivera, MSc, PharmD
U.S. Food and Drug Administration
Artificial Intelligence Approaches Across the Drug Development Continuum in Oncology: A Regulatory Perspective

Panel Question and Answer

4:30 PM-5:45 PM Education Session

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer

Location: Hall D2

Seth Andrew Wander, MD, PhD
Massachusetts General Hospital Cancer Center, Harvard Medical School
Optimizing Targeted Therapies and Endocrine Combinations With Molecular Markers

Komal L. Jhaveri, MD, FACP—Chair
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
What's on the Horizon: Emerging Agents for Second Line and Beyond in Hormone Receptor-Positive Disease

Ricki Fairley, MBA
TOUCH, The Black Breast Cancer Alliance
Weighing Priorities: A Patient Advocate's Perspective on Individualized Treatment Approaches

Rena Desai Callahan, MD
UCLA David Geffen School of Medicine
Cytotoxic Therapy in Metastatic Hormone-Receptor Breast Cancer: Antibody-Drug Conjugates and Chemotherapy in Focus

Panel Question and Answer

7:30 AM-9:30 AM Education Session

Oncology Division Chiefs and Department Chairs' Breakfast

Location: S501

Jordan Berlin, MD, FASCO—Chair

Vanderbilt-Ingram Cancer Center

Welcome and Opening Remarks

Table Talk

Alexander T. Pearson, MD, PhD

University of Chicago

Presenter Share: Implications of Artificial Intelligence in Oncology—Training and Education of Current Faculty

Table Talk and Large Group Discussion

Sonali M. Smith, MD, FASCO

University of Chicago

Presenter Share: Network Integration and Preservation of the Academic Mission

Table Talk and Large Group Discussion

Jordan Berlin, MD, FASCO

Vanderbilt-Ingram Cancer Center

Closing Remarks and Feedback

8:00 AM-9:00 AM Case-Based Panel

Therapeutics Options for Patients With Leptomeningeal Disease

Location: S504

Priya Kumthekar, MD—Chair

Northwestern Memorial Hospital

Moderator

Jonathan T. Yang, MD, PhD

New York University

Radiation Oncologist Perspective

Raymond U. Osarogiagbon, MBBS, FACP, FASCO

Baptist Cancer Center

Medical Oncologist Perspective

Dieta Brandsma, MD, PhD

Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital

Neuro-Oncologist Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

“What About Cannabis?”: Incorporating Evidence to Facilitate Informed Discussions With Patients and Caregivers

Location: S100a

Eric Roeland, MD, FAAHPM, FASCO—Chair

Knight Cancer Institute, Oregon Health & Science University

Moderator

Ilana Monica Braun, MD

Dana-Farber Cancer Institute

Psycho-Oncologist Perspective

Ishwaria M. Subbiah, MD, MS, FASCO

Medical Oncology and Palliative Care

Medical Oncologist Perspective

Stacey Blansky

Harlem Lacrosse

Patient Representative

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Advancements and Challenges to Bringing Cell Therapy to Solid Tumors

Location: S102

Lola A. Fashoyin-Aje, MD, MPH—Chair

U.S. Food and Drug Administration

Regulatory Perspectives for T-Cell Therapy

John Haanen, MD, PhD

Netherlands Cancer Institute

CAR T-Cell Therapy and T-Cell Receptor Therapy for Solid Tumors

Sandra P. D'Angelo, MD

Memorial Sloan Kettering Cancer Center

Development of Afami-Cel—Engineered Cell Therapy for Advanced Synovial Sarcoma

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Follow-Up Care After Treatment for Primary Breast Cancer

Location: S100bc

Ines Luis, MD, PhD—Chair

Gustave Roussy

Potential of eHealth Solutions for Therapy Management and Follow-Up Care

Wolfgang Janni, MD, PhD

University Hospital Ulm

Alleviating Gynecologic Symptoms

Jessica Erdmann-Sager, MD

Brigham and Women's Hospital

Potential Complications After Primary Breast Reconstruction

Cristina Kline-Quiroz, MD, DO

Vanderbilt University Medical Center

How to Manage Lymphedema

Panel Question and Answer

8:00 AM-9:15 AM Education Session

State of the Science: Advancing Frontiers—Novel Diagnostics and Therapeutics in Renal Cell Carcinoma and Urothelial Carcinoma

Location: Hall D2

Michael S. Hofman, MBBS, FRACP

Peter MacCallum Cancer Centre

Functional Imaging in Renal Cell Carcinoma: Enhancing Diagnosis and Treatment Strategies

Rana R. McKay, MD, FASCO—Chair

University of California San Diego

Targeting HIF2α: A New Frontier in Renal Cell Cancer Therapy

Elizabeth Marie Wulff-Burchfield, MD

University of Kansas Medical Center

Antibody-Drug Conjugates in Urothelial Carcinoma: Bridging Innovation and Community Practice

Panel Question and Answer

8:00 AM-9:15 AM Education Session

State-of-the-Art Technologies to Advance Outcomes for Patients With Head and Neck Squamous Cell Carcinoma

Location: E450b

Chiaojung Jillian Tsai, MD, PhD

University of Toronto

Novel Radiotherapy Techniques and Approaches for Head and Neck Cancer

Benjamin Harris Kann, MD—Chair

Dana-Farber Cancer Institute

Strategies to Broad Implementation of Artificial Intelligence-/Machine Learning-Based Radiomics for Management of Head and Neck Cancer

Anant Madabhushi, PhD

Emory University

Outcome Prediction Based on Pathomics for Practical Use

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer

Location: Arie Crown Theater

Jessica R. Bauman, MD—Chair

Fox Chase Cancer Center

Let's Talk Toxicity: The Role of Shared Decision-Making in Front-Line Treatment Selection for Patients With Metastatic EGFR+ Non–Small Cell Lung Cancer

Julia K. Rotow, MD

Lowe Center for Thoracic Oncology

Debate: Osimertinib Alone as Front-Line Therapy for a Patient With Metastatic EGFR Non–Small Cell Lung Cancer

Alessio Cortellini, MD, PhD

Campus Bio-Medico University of Rome

Debate: Combination Approaches as Front-Line Therapy for a Patient With Metastatic EGFR Non–Small Cell Lung Cancer

Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

The Future of Cancer Detection Is Coming

Location: Hall D1

Erika Ruiz-Garcia, MD, MS—Chair

Instituto Nacional de Cancerologia

8:00 AM Scott David Ramsey, MD, PhD

Fred Hutchinson Cancer Center

Is It as Easy as a Blood Test? Cancer Detection

8:12 AM Jane Perlmutter, PhD, MBA, FASCO

Gemini Group

Promise and Pitfalls: A Patient's View on Blood-Based Cancer Tests

8:24 AM Abstract 100: Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity.
First Author: Dax Kurbegov, MD, FASCO

8:36 AM Abstract 101: Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis.
First Author: Robert Charles Swanton, MD, PhD, FCRP

8:48 AM Maximilian Diehn, MD, PhD, FASCO

Stanford University

Discussion of Abstract(s) 100-101: Assay Showdown: Comparing Cutting-Edge Blood Tests for Cancer Detection

9:00 AM Marie Wood, MD, FACP, FASCO

University of Colorado

Discussion of Abstract(s) 100-101: From Promise to Practice: The Clinical Future of Blood-Based Cancer Assays

9:12 AM Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Care Delivery/Models of Care

Location: S402

Rebecca Jane DeBoer, MD, MA—Chair

University of California San Francisco

Samilia Obeng-Gyasi, MD, MPH—Chair

The Ohio State University Wexner Medical Center

8:00 AM Abstract LBA1512: Anesthesia type during surgery for treatment of biologically aggressive cancers: Results of the GA-CARES randomized, multicenter trial.
First Author: Elliott Bennett Guerrero, MD

8:06 AM Abstract 1513: General practitioner-led vs surgeon-led colon cancer survivorship care: A randomized clinical trial.
First Author: Julien Vos, PhD

8:12 AM Abstract 1514: Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial.
First Author: Robert Michael Daly, MD, MBA, FASCO

8:18 AM Panel Question and Answer

8:30 AM Abstract 1515: SNF-CLIMEDIN: A HECOG prospective randomized trial of digital support and intervention in patients with advanced non-small cell lung cancer (NSCLC)—Final results.
First Author: Paris A. Kosmidis, MD

8:36 AM Abstract 1516: Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
First Author: Chandler Scott Cortina, MD, MS, FACS

8:42 AM Abstract 1517: Inclusion of people living with HIV in Food and Drug Administration (FDA) oncology pivotal registration trials from 2020 to 2024.
First Author: Alberto Giovanni Leone, MD

8:48 AM Panel Question and Answer

9:00 AM Abstract 1518: Economic modelling to inform pricing for LMICs of immune checkpoint inhibitors in advanced PD-L1-high non-small cell lung cancer.
First Author: Giulia Segafredo, PhD

9:06 AM Abstract 1519: Association of court-documented major adverse financial events before cancer diagnosis and mortality risk in the US.
First Author: Robin Yabroff, MBA, FASCO

9:12 AM Abstract 1520: Effect of broad-based genomic sequencing on survival outcomes in advanced non-small cell lung cancer: A national cohort study, 2011-2023.
First Author: Patricia Mae Garcia Santos, MD, MS

9:18 AM Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: E450a

Ann S. LaCasce, MD—Chair

Dana-Farber Cancer Institute

Catherine Callaghan Coombs, MD—Chair

University of California, Irvine

- 8:00 AM Abstract 7009:** Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naïve (TN) CLL/SLL: Results in SEQUOIA arm D.
First Author: Mazyar Shadman, MD, MPH
- 8:06 AM Abstract 7010:** Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders.
First Author: Jianyong Li, MD, PhD
- 8:12 AM Abstract 7011:** SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
First Author: Constantine Si Lun Tam, MD, FRCPA, FRACP, MBBS
- 8:18 AM** Panel Question and Answer
- 8:30 AM Abstract 7012:** A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.
First Author: Lugui Qiu, PhD
- 8:36 AM Abstract 7013:** CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study.
First Author: Yajun Li
- 8:42 AM Abstract 7014:** Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study.
First Author: Ian W. Flinn, MD, PhD
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 7015:** Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.
First Author: Jeremy S. Abramson, MD
- 9:06 AM Abstract 7016:** Worldwide experience of chronic active EBV infection: Retrospective cohort study.
First Author: Xinran Wang
- 9:12 AM Abstract 7017:** Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.
First Author: Michael Wang, MD
- 9:18 AM** Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Prevention, Risk Reduction, and Genetics

Location: E350

Eduardo Vilar Sanchez, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

Sacha Jon Howell, MD, PhD—Chair

The University of Manchester and The Christie NHS Foundation Trust

- 8:00 AM Abstract 10512:** Interactions between polygenic variants and clinical factors as predictors of breast cancer risk in the UK Biobank.
First Author: Timothy Simmons
- 8:06 AM Abstract 10513:** Association of an ancestry-specific variant near the ESR1 gene with cancer risk and breast density in women of self-reported Hispanic ancestry.
First Author: Elisha Hughes, PhD
- 8:12 AM Abstract 10514:** Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
First Author: Sara Wallam, MD
- 8:18 AM** Panel Question and Answer
- 8:30 AM Abstract 10515:** Disparities in cancer screening and preventive care access among LGBTQ+ populations: A cross-sectional analysis.
First Author: Manas Pustake, MD
- 8:36 AM Abstract 10516:** Risk patterns for second primary malignancies among human papillomavirus (HPV)–associated first primary cancer survivors in the United States.
First Author: Pragati Gole Advani, MD, DrPH, MPH
- 8:42 AM Abstract 10517:** The development and validation of a simulation model–based calculation engine to support individualized physical activity prescriptions for breast cancer survivors.
First Author: Jinani C. Jayasekera, PhD, MS
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 10518:** Dietary polyphenols and the risk of prostate cancer in the prospective Southern Community Cohort Study.
First Author: Grace Xu, BS
- 9:06 AM Abstract 10519:** Escalating impact of alcohol-related cancer mortality in the US: A call for action.
First Author: Chinmay Jani, MBBS
- 9:12 AM Abstract 10520:** Association between wildfire-dominated PM_{2.5} exposure and non-small cell lung cancer survival in California.
First Author: Surbhi Singhal, MD
- 9:18 AM** Panel Question and Answer

9:00 AM-12:00 PM Poster Session

Central Nervous System Tumors

Location: Hall A - Posters and Exhibits

Posters by Topic

Brain Metastases: Board(s) 67-87, 134a-135a

Primary CNS Tumors–Glioma: Board(s) 88-128, 135b-140b

Primary CNS Tumors–Non-Glioma: Board(s) 129-133, 141a

- Board 67 **Abstract 2021:** Brain metastasis: Incidence, trend analysis, and impact on survival using SEER database (2010-2020).
First Author: Shaimaa Fadel, MD
- Board 68 **Abstract 2022:** A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
First Author: Rupesh Kotecha, MD
- Board 69 **Abstract 2023:** Efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with central nervous system (CNS) metastases (mets) from solid tumors: A systematic review and meta-analysis.
First Author: Soraia Lobo Martins, MSc
- Board 70 **Abstract 2024:** Irradiated tumor volume as a predictor of local recurrence and radionecrosis in lung cancer with brain metastases treated with stereotactic radiosurgery.
First Author: Andreas Koulouris, MD
- Board 71 **Abstract 2025:** Efficacy of systemic therapy in breast cancer with CNS metastases: "Real-world" experience.
First Author: Bipin Ghimire, MBBS
- Board 73 **Abstract 2027:** Whole brain radiotherapy and intrathecal injection of thiopeta, combined with systemic treatment for the primary tumor, to treat solid tumor leptomeningeal metastasis: A prospective, single center, single arm, phase II clinical study.
First Author: Siyu Guo
- Board 74 **Abstract 2028:** Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases of NSCLC.
First Author: Yang-Si Li
- Board 75 **Abstract 2029:** IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study.
First Author: Emilie Le Rhun, MD, PhD
- Board 76 **Abstract 2030:** Evaluating the utility of DNA methylation signatures in tissue and biofluids for lung adenocarcinoma brain metastasis prediction and non-invasive detection.
First Author: Jeffrey Zuccato
- Board 77 **Abstract 2031:** Effect of early integrated neuropsychological care in patients with brain metastases: A phase 2 randomized controlled trial (ATHENA trial).
First Author: Haley Kopp Perlow, MD
- Board 78 **Abstract 2032:** Intrathecal deferoxamine in patients with leptomeningeal metastases: Phase 1a analysis.
First Author: Jessica Wilcox, MD
- Board 79 **Abstract 2033:** Improving adherence to cancer care for socioeconomically disadvantaged patients with central nervous system tumors.
First Author: Joshua Amit Budhu, MD, MS, MPH

- Board 80 **Abstract 2034:** Risk of intracranial hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases.
First Author: Ali Mushtaq, MD
- Board 81 **Abstract 2035:** Risk factors (RF) for brain metastases (BM) in patients (pts) with metastatic breast cancer (MBC): An analysis of US electronic health records (EHRs).
First Author: Jose Pablo Leone, MD
- Board 82 **Abstract 2036:** Memantine in radiation-induced cognitive dysfunction in brain metastases: A double-blinded, randomized, placebo-controlled trial (CTRI/2022/01/039599).
First Author: Haripriya Parapparambil Surendran, PhD, PharmD
- Board 83 **Abstract 2037:** Predictors of overall survival in patients with brain metastases from HER2+ breast cancer.
First Author: Qinmei Xu, PhD
- Board 84 **Abstract 2038:** Hippocampal-avoidance whole-brain radiotherapy with dose escalation on metastases: A prospective randomized trial (HIPPORAD).
First Author: Anca-Ligia Grosu, MD
- Board 85 **Abstract 2039:** Initial report of memory avoidance whole brain radiotherapy to treat brain metastases: A prospective phase 2 trial.
First Author: Joshua David Palmer, MD
- Board 86 **Abstract 2040:** Genomic predictors of brain metastases in breast cancer.
First Author: Anton Safonov, MD
- Board 87 **Abstract 2041:** Characterizing functional connectivity in brain tumor patients.
First Author: Alexander B. Remsik, PhD, MSc
- Board 88 **Abstract 2042:** AI-driven transcriptomic classification of glioblastoma: Associations with survival and tumor microenvironment.
First Author: Juan Manuel Fernandez-Muñoz, PhD
- Board 89 **Abstract 2043:** Impact of neuroradiologists' input on peer review meetings for CNS radiotherapy treatment planning.
First Author: Abhishek Mahajan, MD
- Board 90 **Abstract 2044:** Identification and validation of potential diagnostic plasma biomarkers for diffuse gliomas by multiplex immunoassays.
First Author: Miyo K. Chatanaka, BSc
- Board 91 **Abstract 2045:** Association of plasma biomarkers with diagnostic molecular markers for potential diagnosis and prognosis of diffuse gliomas.
First Author: Leonardo Macedo Filho, MD
- Board 92 **Abstract 2046:** A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab: JCOG1308C.
First Author: Motoo Nagane, MD, PhD
- Board 93 **Abstract 2047:** Use of brain protein I3 (BRI3) to predict disease fate in glioblastoma.
First Author: Ifeanyichukwu Ogobuiro, MD, MHS

Board 94	Abstract 2048: Effect of armed oncolytic adenovirus on immunotherapy for primary and metastatic brain tumors. First Author: Jiasen He, MD	Board 108	Abstract 2062: Relationship between aperiodic dynamics and transcriptomic alterations and a neural signature of glioma-induced excitation-inhibition dysregulation. First Author: Youssef Sibih, BA
Board 95	Abstract 2049: A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI). First Author: Iris Dirven, MD	Board 109	Abstract 2063: Comparing ERK signaling and tumor microenvironment in BRAF-altered gliomas. First Author: Lucy Chen
Board 96	Abstract 2050: Effect of 18F-DOPA-PET and advanced MRI on treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors. First Author: Diego Martín Prost, MD, MSc	Board 110	Abstract 2064: Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024). First Author: George Shenouda
Board 97	Abstract 2051: Phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma. First Author: Yoshitaka Narita, MD, PhD	Board 111	Abstract 2065: Association of MGMT status with survival in low and high-grade IDH-mutant astrocytomas. First Author: Katherine E. Schweteye, MD, PhD
Board 98	Abstract 2052: Modification of the novel RANO clinical risk score for low- and middle-income countries without access to MGMT methylation testing. First Author: Imdat Eroglu, MD	Board 112	Abstract 2066: Prognostic impact of DDR mutations (mt) in IDH mutant high-grade gliomas (HGG). First Author: John L. Villano, MD, PhD
Board 99	Abstract 2053: The impact of IDH mutation and 1p/19q codeletion on immune-checkpoint inhibitor efficacy in recurrent gliomas. First Author: Shameel Shafqat, MBBS	Board 113	Abstract 2067: Prognostic value of inflammatory markers in glioblastoma: A meta-analysis of NLR and PLR stratified by cutoff values. First Author: Abril Carrillo, MD
Board 100	Abstract 2054: Factors influencing clinical trial enrollment in glioblastoma patients: A retrospective study at the University of Vermont Medical Center. First Author: Leena Ziane, BS	Board 114	Abstract 2068: A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial. First Author: Marta Padovan, MD
Board 101	Abstract 2055: Safety and tolerability of olaparib, temozolomide, and pembrolizumab in a phase 2 trial in patients with progressive glioblastoma. First Author: Luis Nicolas Gonzalez Castro, MD, PhD	Board 115	Abstract 2069: Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial. First Author: José Manuel Sepulveda
Board 103	Abstract 2057: Efficacy and safety of bevacizumab in combination with radiotherapy and temozolomide in patients with glioblastoma: A meta-analysis and meta-regression of randomized controlled trials. First Author: Ibrahim Khalil, MBBS	Board 116	Abstract 2070: From retrospective analysis to real-world impact: Mismatch repair deficiency detection in gliomas by tissue and liquid ctDNA NGS in glioma management. First Author: Suman Suryanarayana Karanth, MD, DNB
Board 104	Abstract 2058: Assessment of age in the clinical risk stratification of patients with IDH-mutant gliomas. First Author: Michal Nisnboym Ziv, MD	Board 117	Abstract 2071: Immunohistochemical and gene expression profiles as predictors of survival in recurrent high-grade glioma treated with intracranial nivolumab, ipilimumab, and autologous CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells (myDC). First Author: Cleo Bertels, MD
Board 105	Abstract 2059: The tumoral molecular landscape of long-term survivors with isocitrate dehydrogenase wildtype glioblastoma: Lessons from ETERNITY (EORTC 1419). First Author: Michael Weller, MD	Board 118	Abstract 2072: Development and validation of a droplet digital PCR (ddPCR) assay to detect MGMT promoter methylation in FFPE tumors of glioblastoma (GBM) patients. First Author: Mahrukh M. Syeda, MS
Board 106	Abstract 2060: Efficacy and safety of depatuxizumab mafodotin (ABT-414) in EGFR-amplified glioblastoma: A systematic review and Bayesian network meta-analysis. First Author: Sunjida Amin Promi		
Board 107	Abstract 2061: A pilot survey into the landscape of neuro oncology care in the community. First Author: Christine Lu-Emerson, MD		

- Board 119 **Abstract 2073:** Combining abemaciclib, temozolomide, and radiation in DIPG PDOX models: Insights from single-cell RNA-seq on cellular subtypes and genes critical for responsiveness and resistance.
First Author: Zilu Huang, MD
- Board 120 **Abstract 2074:** MRI-based radiomics for prediction of isocitrate dehydrogenase subtype in glioblastoma multiforme through artificial intelligence models: A systematic review and meta analysis.
First Author: Sonali Belankar
- Board 121 **Abstract 2075:** Correlative and spatial transcriptomic analysis of olaparib and durvalumab in patients with recurrent/refractory IDH-mutant gliomas.
First Author: Xin Wang, MD, PhD
- Board 122 **Abstract 2076:** The utilization of palliative care services by patients with glioblastoma: A cross-sectional study with care partners of patients with GBM recruited from Facebook support groups.
First Author: Lauren Robbins
- Board 123 **Abstract 2077:** Identification of novel electrophysiologic biomarkers of cognition in glioma-infiltrated cortex.
First Author: Vardhaan Ambati, MS
- Board 124 **Abstract 2078:** A single-institution retrospective study of multicentric gliomas stratified by IDH mutational status.
First Author: Chuyin Yang, BS
- Board 125 **Abstract 2079:** Diagnostic accuracy of machine learning models in glioma classification: A meta-analysis.
First Author: Maya Gowda
- Board 126 **Abstract 2080:** Identifying key molecular drivers of survival and therapeutic targets in glioblastoma through integrated transcriptomic analysis.
First Author: Mohammad Kashkooli, MD
- Board 127 **Abstract 2081:** Effect of ivosidenib and vorasidenib on 2-hydroxyglutarate levels in low grade glioma: An in vivo MR spectroscopy study.
First Author: Max Saint-Germain
- Board 128 **Abstract 2082:** Vault proteins as prognostic biomarkers and therapeutic targets in lower-grade gliomas.
First Author: Sebawe Syaj, MD
- Board 129 **Abstract 2083:** Accelerator-based boron neutron capture therapy, a randomized controlled trial for refractory recurrent high-grade meningiomas.
First Author: Shin-Ichi Miyatake, MD, PhD
- Board 130 **Abstract 2084:** Phase 2 study of nivolumab for patients with meningiomas refractory to surgery and radiotherapy with immune-related response criteria.
First Author: Hikaru Sasaki, MD
- Board 131 **Abstract 2085:** Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.
First Author: Christian Grommes, MD
- Board 132 **Abstract 2086:** Unraveling survival disparities in primary central nervous system (CNS) lymphoma: An analysis of race, socioeconomic factors, and treatment outcomes using the Surveillance, Epidemiology, and End Results program (2000–2021).
First Author: Imran Khan, MD
- Board 133 **Abstract 2087:** Predicting survival in malignant meningiomas: A machine learning approach.
First Author: Mustafa Alshwayyat
- Board 134a **Abstract TPS2088:** Phase IIa study of aDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from breast cancer.
First Author: Shipra Gandhi, MD, MS
- Board 134b **Abstract TPS2089:** A multicenter, randomized, controlled, pivotal trial of microbubble-enhanced transcranial focused ultrasound for patients with NSCLC brain metastases (LIMITLESS).
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 135a **Abstract TPS2090:** Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE).
First Author: Joshua David Palmer, MD
- Board 135b **Abstract TPS2091:** FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.
First Author: Karisa C. Schreck, MD, PhD
- Board 136a **Abstract TPS2092:** Retifanlimab with bevacizumab and hypofractionated radiotherapy to treat recurrent glioblastoma.
First Author: Nishika Karbhari, MD
- Board 136b **Abstract TPS2093:** PEAR-GLIO: Clinical evaluation of an AI-driven functional precision medicine platform for therapeutic efficacy in gliomas.
First Author: Matthew Williams, FRCR
- Board 137a **Abstract TPS2094:** A multicenter, pivotal trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) for plasma-based liquid biopsy in patients with glioblastoma (LIBERATE).
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 137b **Abstract TPS2095:** Liposomal curcumin and standard radiation and temozolomide for newly diagnosed high-grade gliomas: A phase 1/2 study.
First Author: Matthias Holdhoff, MD, PhD
- Board 138a **Abstract TPS2096:** A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.
First Author: Nader Sanai, MD
- Board 138b **Abstract TPS2097:** Personalized targeted glioblastoma therapies by ex vivo drug screening: Advanced brain tumor therapy clinical trial (ATTRACT).
First Author: Anna Sophie Berghoff, MD

- Board 139a **Abstract TPS2098:** Trial in progress: Feasibility of CSF and plasma ctDNA in BRAF-altered glioma during treatment with plixorafenib.
First Author: Karisa C. Schreck, MD, PhD
- Board 139b **Abstract TPS2099:** Neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy—Clinical trial in progress.
First Author: Ugur Sener, MD
- Board 140a **Abstract TPS2100:** Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
First Author: Emma Maria Viktoria Hyddmark, PhD
- Board 140b **Abstract TPS2101:** Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.
First Author: Anuj Dilip Patel, MD
- Board 141a **Abstract TPS2102:** Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial.
First Author: Alberto Bosio

9:00 AM-12:00 PM Poster Session

Gastrointestinal Cancer—Colorectal and Anal

Location: Hall A - Posters and Exhibits

Posters by Topic

Anal Cancer: Board(s) 190-195, 302a

Colorectal Cancer—Advanced Disease: Board(s) 196-255, 302b-307a

Colorectal Cancer—Local-Regional Disease: Board(s) 256-285, 307b-310b

Epidemiology/Outcomes: Board(s) 286-297

Other Colorectal and Anal Cancer: Board(s) 298-301

- Board 190 **Abstract 3521:** Experience of patients with HIV and squamous cell carcinoma of the anal canal (SCAC) treated with retifanlimab.
First Author: Jean-Philippe Spano Sr
- Board 191 **Abstract 3522:** Investigating the immunogenomic profile of anal HPV driven disease for novel therapeutic discovery.
First Author: Micol Lupi, MBBS
- Board 192 **Abstract 3523:** Immunotherapy combined with hypofractionated radiotherapy and chemotherapy for locally recurrent rectal cancer (TORCH-R): A prospective, single-arm, two-cohort, phase II trial.
First Author: Ruiyan Wu
- Board 193 **Abstract 3524:** Harnessing transcriptome signatures and CD103+CD8+ immune infiltration for prognosis and treatment outcomes in anal squamous cell carcinoma.
First Author: Ilma Soledad Iseas, MD, PhD
- Board 194 **Abstract 3525:** POD1UM-303/INTERACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).
First Author: Marwan Fakih, MD

- Board 195 **Abstract 3526:** Genomic characterization of anal canal squamous cell carcinoma (ASCC) and outcomes on matched targeted therapy.
First Author: Maliha Nusrat, MD, MS
- Board 196 **Abstract 3527:** Monitoring botensilimab- and balstilimab-induced T-cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer.
First Author: Gertjan Rasschaert, MD
- Board 197 **Abstract 3528:** Predictive role of circulating tumor DNA in pMMR locally advanced rectal cancer patients receiving neoadjuvant chemoradiotherapy combined with sintilimab.
First Author: Xiao-bin Zheng
- Board 198 **Abstract 3529:** Risk factors associated with de novo metastatic colorectal cancer in early onset colorectal cancer.
First Author: Emma Schatoff, MD, PhD
- Board 199 **Abstract 3530:** Survival impact of NeoRAS wild-type metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy.
First Author: Hiroki Osumi, MD, PhD
- Board 200 **Abstract 3531:** Revisiting the relevance of sidedness in colonic tumor molecular profiling.
First Author: Ashok K. Vaid, DM
- Board 201 **Abstract 3532:** Predicting pathologic complete response in colorectal cancer patients after immunotherapy based on endoscopic biopsy and deep learning approach.
First Author: Chaoyuan Xiao, BSc
- Board 202 **Abstract 3533:** Metastatic site pattern as predictor of outcome of first-line alternating oxaliplatin-based chemotherapy and nivolumab for patients with microsatellite-stable (MSS) colorectal cancer (CRC).
First Author: Anne Hansen Ree, MD, PhD
- Board 203 **Abstract 3534:** Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).
First Author: Guglielmo Vetere, MD
- Board 204 **Abstract 3535:** COPEC trial: Early determination of pathological tumor response to neoadjuvant chemotherapy in low/intermediate risk stage II/III rectal cancer—A multicenter, non-inferiority phase III randomized trial.
First Author: Mingtian Wei
- Board 205 **Abstract 3536:** Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N).
First Author: Arvind Dasari, MD, MS
- Board 206 **Abstract 3537:** The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials.
First Author: Marco Maria Germani, MD

- Board 207 **Abstract 3538:** Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials.
First Author: Marco Maria Germani, MD
- Board 208 **Abstract 3539:** Drug-eluting beads loaded with irinotecan-transarterial chemoembolization (DEBIRI-TACE) combined with hepatic artery infusion chemotherapy and regorafenib in colorectal liver metastases refractory to second-line and above standard systemic therapy: A single-center, phase II clinical trial (DREAM).
First Author: Wenzhe Fan
- Board 209 **Abstract 3540:** Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreak 300 study.
First Author: Lisa Salvatore, MD
- Board 210 **Abstract 3541:** Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection.
First Author: Wei Zhang
- Board 211 **Abstract 3542:** Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
First Author: Elisa Fontana, MD, PhD
- Board 212 **Abstract 3543:** Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAF^{V600E} mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
First Author: Lena Weiss, MD
- Board 213 **Abstract 3544:** Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment.
First Author: Vittorio Studiale, MD
- Board 214 **Abstract 3545:** Tumour microbiome and immune dysregulation in early-onset colorectal cancer.
First Author: Rachel Violet Purcell, PhD, MSc
- Board 215 **Abstract 3546:** Prognostic and predictive impact of the baseline systemic proteome in patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial.
First Author: Alexej Ballhausen, MD
- Board 216 **Abstract 3547:** Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI/bev ± atezolizumab in the AtezoTRIBE study.
First Author: Daniele Rossini, MD, PhD
- Board 217 **Abstract 3548:** Impact of Medicare Advantage (MA) on timely initiation of pembrolizumab among dMMR/MSI-h metastatic colorectal cancer patients.
First Author: Baqir Jafry, MD
- Board 218 **Abstract 3549:** Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies.
First Author: Daniel Aaron Fox, MD
- Board 219 **Abstract 3550:** Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study.
First Author: Cathy Eng, MD, FACP, FASCO
- Board 220 **Abstract 3551:** Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutant metastatic colorectal cancer (mCRC).
First Author: Jeanne Tie, MD, FRACP, MBChB
- Board 221 **Abstract 3552:** Low-pass whole methylome sequencing-based liquid biopsy for metastatic colorectal cancer monitoring in the VALENTINO trial.
First Author: Paolo Manca, MD
- Board 222 **Abstract 3553:** Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.
First Author: Marwan Fakih, MD
- Board 223 **Abstract 3554:** mFOLFIRINOX efficacy as rescue regimen for patients with metastatic refractory colorectal cancer: The RE-PLAY trial.
First Author: Paulo Marcelo Hoff, MD, PhD, FACP, FASCO
- Board 224 **Abstract LBA3555:** Safety and efficacy of reduced-port laparoscopic surgery for patients with colon and upper rectal cancer.
First Author: Jun Huang, MD
- Board 225 **Abstract 3556:** Analysis of mutational profiles and their correlation with organ-specific metastases in MSS and BRAFwt colorectal cancer (mCRC).
First Author: Francesc Salva, MD
- Board 226 **Abstract 3557:** Patterns of immunotherapy use in dMMR/MSI-H metastatic CRC.
First Author: Hayley Lemisch, BS
- Board 227 **Abstract 3558:** Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit.
First Author: Camila Braganca Xavier, MD
- Board 228 **Abstract 3559:** The efficacy of watch and wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR/MSI-H guided by ctDNA dynamic monitoring (WINDOW): A single-center, open-label, prospective, phase II study.
First Author: Xuan Zhang
- Board 229 **Abstract 3560:** Laparoscopic versus open liver resection for colorectal liver metastasis: An individual participant data meta-analysis of randomized controlled trials.
First Author: Åsmund Avdem Fretland, MD, PhD

- Board 230 **Abstract 3561:** Prognostic factors of survival and recurrence after liver transplantation for unresectable colorectal liver metastases: Results from the TransMet trial.
First Author: Rene Adam, MD, PhD
- Board 231 **Abstract 3562:** Impact of inflammatory bowel disease on outcomes of colorectal cancer patients undergoing open resection.
First Author: Abhinav Malik, MBBS
- Board 232 **Abstract 3563:** A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study.
First Author: Yuwen Zhou
- Board 233 **Abstract 3564:** A medically tailored meal (MTM) delivery program to reduce nutritional decline and improve treatment tolerance in patients with colorectal cancer (CRC): A pilot study.
First Author: Kara Stromberg, RD
- Board 235 **Abstract 3566:** Relapse patterns, risk factors, re-resectability and survival after curative treatment for metastatic colorectal cancer (mCRC): A RAXO substudy.
First Author: Pia J. Osterlund, MD, PhD
- Board 236 **Abstract 3567:** Single-slide histology-based deep learning model for mismatch repair deficiency prediction in colorectal cancer.
First Author: Masoud Tafavvoghi, MSc
- Board 237 **Abstract 3568:** Time to treatment initiation (TTI) in patients with colorectal cancer and liver metastases.
First Author: Kamran Steppe, BS
- Board 238 **Abstract 3569:** Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.
First Author: Léa Mercier
- Board 239 **Abstract 3570:** Comparison of MET genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA).
First Author: Faiza Yasin, MD, MHS
- Board 240 **Abstract 3571:** The role of gut microbiome composition in the IBD-CRC pathway: A retrospective study of 428 patients.
First Author: Sabina Sayeed, MD
- Board 241 **Abstract 3572:** Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants.
First Author: Faran Polani, MD
- Board 242 **Abstract 3573:** Clinicopathologic features of complement activation signatures in colorectal cancer.
First Author: Mir Lim, MD
- Board 243 **Abstract 3574:** Impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on survival outcomes in metastatic colorectal cancer patients treated with bevacizumab-based therapy.
First Author: Coskun Yazgan
- Board 244 **Abstract 3575:** Effect of race/ethnicity on clinical outcomes for metastatic colorectal cancer (mCRC) patients in phase 1 trials: A dual institution experience.
First Author: Hasan Musanna Zaidi, MD
- Board 245 **Abstract 3576:** Understanding and addressing unmet needs in colorectal cancer: Findings from the Colorectal Cancer Alliance's Patient and Survivor survey.
First Author: Kimberley Lynn Newcomer, BS
- Board 246 **Abstract 3577:** Drivers of homologous recombination deficiency (HRD) in metastatic colorectal cancer (mCRC).
First Author: Paula Romero Lozano, MSc
- Board 247 **Abstract 3578:** Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study.
First Author: Nieves Martinez Lago, MD, PhD
- Board 248 **Abstract 3579:** Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC.
First Author: Daneng Li, MD
- Board 249 **Abstract 3580:** Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer.
First Author: Donald A. Richards, MD, PhD
- Board 250 **Abstract 3581:** A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States.
First Author: Benjamin L. Schlechter, MD
- Board 251 **Abstract 3582:** Impact of obesity and lifestyle-associated risk factors on outcomes of early-onset colorectal cancer in patients younger than 50 years old: A propensity-matched analysis.
First Author: Syeda Ashna Fatima Kamal, MD, MBBS
- Board 252 **Abstract 3583:** Colorectal cancer mortality dynamics: Uncovering critical disparities in U.S. population health (2018–2023).
First Author: Pranav Chalasani, MD, MPH
- Board 253 **Abstract 3584:** Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA.
First Author: Andrew Gross
- Board 254 **Abstract 3585:** Cell-free DNA 5-hydroxymethylcytosine profiling for the assessment of colorectal cancer biology and treatment response in blood.
First Author: Ceyda Coruh, PhD
- Board 255 **Abstract 3586:** Sintilimab plus bevacizumab, oxaliplatin, and capecitabine as perioperative therapy in microsatellite-stable, resectable colorectal cancer liver metastases: An open-label, single-arm, phase II trial.
First Author: Yu-hong Li

- Board 256 **Abstract 3587:** Safety and efficacy evaluation of neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab for treating MSS/pMMR locally advanced rectal cancer.
First Author: Zhengyang Yang, PhD
- Board 257 **Abstract 3588:** Neoadjuvant ONO-4578, an EP4 antagonist, in combination with nivolumab after chemoradiation therapy in locally advanced resectable rectal cancer.
First Author: Yusuke Takahashi, MD
- Board 258 **Abstract 3589:** Single-incision laparoscopic surgery vs conventional laparoscopic surgery for colorectal cancer: Short-term outcomes of a multi-center, randomized, controlled trial.
First Author: Yaqi Zhang, MD
- Board 259 **Abstract 3590:** The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: The □-CORRECT study.
First Author: Tadayoshi Hashimoto, MD, PhD
- Board 260 **Abstract 3591:** Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study.
First Author: Emerik Osterlund, MD, PhD
- Board 261 **Abstract 3592:** Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study.
First Author: Martina Carullo, MD
- Board 262 **Abstract 3593:** Digital spatial profiling: Mapping tumor responses to radiotherapy in rectal cancer.
First Author: Rachel Violet Purcell, PhD, MSc
- Board 263 **Abstract 3594:** Clinical and immunopathological evaluation and its comparison with consensus molecular subtypes of colorectal cancer.
First Author: Eduardo Feliciangeli, MD
- Board 264 **Abstract 3595:** Neoadjuvant chemotherapy and surgery for rectal cancer: Omission of radiation in clinical practice.
First Author: Matthew B. Hill, MD
- Board 265 **Abstract 3596:** Performance of a targeted enzymatic methylation-based early detection test by different colorectal cancer subgroups.
First Author: Xiaojian Wu
- Board 266 **Abstract 3597:** ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer.
First Author: Midhun Malla, MD, MS
- Board 267 **Abstract 3598:** Oncologic outcomes of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: A single-center study.
First Author: Mariem Galuia, MD
- Board 268 **Abstract 3599:** Neoadjuvant mFOLFOXIRI chemotherapy with or without cadonilimab versus mFOLFOX6 alone in locally advanced colorectal cancer: A randomized phase II study (OPTICAL2).
First Author: Jianwei Zhang
- Board 269 **Abstract 3600:** Impact of perioperative complications on ctDNA-based MRD detection and prognosis: Insights from the GALAXY study.
First Author: Eiji Oki, MD, PhD, FACS

- Board 270 **Abstract 3601:** Long-term survival and treatment efficacy in dMMR/MSI-H rectal cancer: A real-world cohort from seven large medical college-affiliated hospitals.
First Author: Siyuan Mi, MMedSc
- Board 271 **Abstract 3602:** Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: Initial results of the FIERCE study.
First Author: Emerson Yu-sheng Chen, MD
- Board 272 **Abstract 3603:** Enhancing colorectal cancer precision medicine through multi-omics and clinical data integration with artificial intelligence.
First Author: Enrique Velazquez Villarreal, MD, PhD, MPH, MS
- Board 273 **Abstract 3604:** Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy.
First Author: Ingrid Franken, MD, MSc
- Board 274 **Abstract 3605:** A novel active chromatin cell-free DNA (cfDNAac) assay for early detection of colorectal cancer.
First Author: Yue Wendy Zhang
- Board 275 **Abstract 3606:** Analysis of early onset colorectal cancer: Implications for research and clinical practice.
First Author: Heather Halperin
- Board 276 **Abstract 3607:** Changes in demographics and patterns of colon cancer in the United States: A comprehensive SEER analysis 2010–2021.
First Author: Guy Loic Nguefang Tchoukeu, MD
- Board 277 **Abstract 3608:** Time-weighted ctDNA dynamics for precision monitoring of relapse risk in colon cancer.
First Author: Alessandro Leal, MD, PhD
- Board 278 **Abstract 3609:** Exploring transcriptomic regulation of the tissue-associated microbiome in oncogenic progression of colorectal cancer.
First Author: Amanda Stafford, PhD, MSc
- Board 279 **Abstract 3610:** Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG).
First Author: Sebastian Stasik
- Board 281 **Abstract 3612:** Multicentric evaluation of an artificial intelligence model to stratify stage II colon cancer patients from whole slide images.
First Author: Abdelhakim Khellaf, MDCM
- Board 282 **Abstract 3613:** Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer: Data from 30 health systems in the United States.
First Author: Wilson Lau, PhD
- Board 284 **Abstract 3615:** Use and benefit of adjuvant chemotherapy in early- vs average-onset colorectal cancer.
First Author: Carolina Bernabe, MD
- Board 285 **Abstract 3616:** Detection of early-stage colorectal cancer using multiplexed extracellular vesicle proteomic biomarkers.
First Author: Todd A. Hembrough, PhD

- Board 286 **Abstract 3617:** An early colorectal cancer screening programme based on bisulfite-free sequencing of methylated circulating tumor DNA. First Author: Rushan Fei
- Board 287 **Abstract 3618:** The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients. First Author: Alina Zatsepina, MD
- Board 288 **Abstract 3619:** Risk of pre-cancerous advanced adenomas of the colon in long distance runners. First Author: Timothy Lewis Cannon, MD, FASCO
- Board 289 **Abstract 3620:** Reassessing colorectal cancer recurrence in solid organ transplant recipients: Implications for revised management guidelines. First Author: David Bradley Meyer
- Board 290 **Abstract 3621:** Impact of COVID-19 on the stage at diagnosis and mortality of colorectal cancer. First Author: Soyun Lim, MD
- Board 291 **Abstract 3622:** Leveraging EHRs and a phenome-wide association study to identify pre-diagnostic clinical markers in early-onset colorectal cancer. First Author: Sachleen Kaur Tuteja
- Board 292 **Abstract 3623:** Colorectal cancer screening and detection following USPSTF recommendations for ages 45-49: Insights from a large EHR cohort. First Author: Patricia Jane Rodriguez, PhD, MPH
- Board 293 **Abstract 3624:** Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance). First Author: En Cheng, MD, PhD, MSPH
- Board 294 **Abstract 3625:** Comprehensive analysis of outcomes of patients with colorectal cancer in a racially diverse cohort. First Author: Manasawee Tanariyakul, MD
- Board 295 **Abstract 3626:** Dietary risk factors associated with colorectal polyp risk and potential for progression to malignancy. First Author: Melissa Rachel Goldin, BA
- Board 296 **Abstract 3627:** Characterizing clinical outcomes and DNA co-alterations of ERBB2-amplified colorectal cancer. First Author: Mohamed Nuh, MD, MBA
- Board 297 **Abstract 3628:** Effects of marital status on survival in patients with colorectal cancer. First Author: Lisa Liu, MD
- Board 298 **Abstract 3629:** Clinicopathological features of colorectal cancer in adolescents and young adults (AYA) at a tertiary referral centre in Nigeria. First Author: Sharif Adeniyi Folorunso, MBBCh, MSc
- Board 299 **Abstract 3630:** Adherence to repeat screening for colorectal cancer using the multi-target stool DNA test: Real-world analysis of patients from federally qualified health centers. First Author: Mallik Greene, PhD
- Board 300 **Abstract 3631:** Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability-high (MSI-H)/ mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial. First Author: Elena Elez, MD, PhD
- Board 301 **Abstract 3632:** Association between fine particulate matter exposure and colorectal cancer mortality by age at diagnosis: Insights from county-level analysis in the United States. First Author: Sara F. Haddad, MD
- Board 302a **Abstract TPS3633:** A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium G122-588. First Author: Anita Turk, MD
- Board 302b **Abstract TPS3634:** Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur). First Author: Eric David Miller, MD, PhD
- Board 303a **Abstract TPS3635:** Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial. First Author: John H. Strickler, MD
- Board 303b **Abstract TPS3636:** OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer. First Author: Dirk Arnold, MD, PhD
- Board 304a **Abstract TPS3637:** An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19). First Author: Yu Sunakawa, MD, PhD
- Board 304b **Abstract TPS3638:** OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer. First Author: Joel R. Hecht, MD
- Board 305a **Abstract TPS3639:** Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase II study (SPARKLE-L). First Author: Fang He, MD
- Board 305b **Abstract TPS3640:** Neoadjuvant cetuximab plus tislelizumab combined with chemotherapy in pMMR RAS/BRAF wild-type (wt) locally advanced rectal cancer (LARC): A prospective, multicenter, phase II study. First Author: Gang Liu, MD

- Board 306a **Abstract TPS3641:** Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.
First Author: Zhangfa Song
- Board 306b **Abstract TPS3642:** A phase II study of encorafenib and cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E-mutated metastatic colorectal cancer (mCRC).
First Author: Maria Alessandra Calegari, MD
- Board 307a **Abstract TPS3643:** Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
First Author: Ibrahim Halil Sahin, MD
- Board 307b **Abstract TPS3644:** Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
First Author: Arvind Dasari, MD, MS
- Board 308a **Abstract TPS3645:** Platform study of circulating tumor DNA-directed adjuvant chemotherapy in colon cancer (CLAUDIA Colon Cancer, KCSG CO22-12).
First Author: Yongjun Cha, MD
- Board 308b **Abstract TPS3646:** mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody vs. mFOLFOX6 in locally advanced pMMR/MSS CRC: A multicenter, randomized controlled phase III study (BASKETIII).
First Author: Jun Huang, MD
- Board 309a **Abstract TPS3647:** A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS trial.
First Author: Clara O. Montagut, MD
- Board 309b **Abstract TPS3648:** Phase II study of epacadostat (INCB024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer.
First Author: Moh'd M. Khushman, MD
- Board 310a **Abstract TPS3649:** AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer.
First Author: Gertjan Rasschaert, MD
- Board 310b **Abstract TPS3650:** Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial).
First Author: Caleah Simone Kitchens, MD

9:00 AM-12:00 PM Poster Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall A - Posters and Exhibits

Posters by Topic

Esophageal or Gastric Cancer—Advanced/Metastatic Disease: Board(s) 311-353, 491a-495b

Esophageal or Gastric Cancer—Local-Regional Disease: Board(s) 356-367, 496b-497a

Hepatobiliary Cancer—Advanced/Metastatic Disease: Board(s) 368-415, 497b-500a

Neuroendocrine/Carcinoid: Board(s) 434-438, 502b-503b

Pancreatic Cancer—Advanced/Metastatic Disease: Board(s) 439-478, 504a-507b

Pancreatic Cancer—Local-Regional Disease: Board(s) 479-486, 508a

Other GI Cancer: Board(s) 487-490, 508b

- Board 311 **Abstract 4021:** Claudin-18.2 expression in gastro-oesophageal adenocarcinoma in a Western population: Overlap with other biomarkers and prognostic value.
First Author: Filip Van Herpe, MD
- Board 312 **Abstract 4022:** Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma.
First Author: David Bing Zhen, MD
- Board 314 **Abstract 4024:** Genomic landscape and biomarker analyses utilizing circulating-tumor DNA in advanced esophageal squamous cell carcinoma: Sub-analysis of SCRUM-MONSTAR GOZILA.
First Author: Yuqing Duan, MD, PhD
- Board 315 **Abstract 4025:** HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
First Author: Min Lai
- Board 317 **Abstract 4027:** Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)-guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.
First Author: Longqi Chen
- Board 318 **Abstract 4028:** Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial.
First Author: Xiuying Xiao, PhD
- Board 319 **Abstract 4029:** A multicenter randomized phase II study of trastuzumab biosimilar (CT-P6) and chemotherapy (SOX or CapeOX) in HER2-positive advanced/recurrent gastric cancer (KSCC: TROX study).
First Author: Teppei Yamada
- Board 320 **Abstract 4030:** Neoadjuvant serplulimab in combination with chemotherapy for locally advanced gastric or gastro-esophageal junction cancer.
First Author: Hongjie Zhan

- Board 321 **Abstract 4031:** Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer.
First Author: Tianshu Liu, MD, PhD
- Board 322 **Abstract 4032:** First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102): Updated results of cohort G from a phase I/IIa study.
First Author: Jifang Gong, MD
- Board 323 **Abstract 4033:** Real-world analyses to evaluate the role of TIGIT as a target in first-line (1L) gastric, gastroesophageal junction, and esophageal adenocarcinomas (GC/GEJC/EAC).
First Author: Linda Su-Feher, PhD
- Board 324 **Abstract 4034:** Distinct microenvironment phenotypes across tumor, vascular, and immune compartments from ramucirumab plus pembrolizumab in refractory gastric cancer: A phase II trial.
First Author: Sung Hee Lim, MD
- Board 325 **Abstract 4035:** GABRP as a biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer (WJOG10417GTR study).
First Author: Naoki Takahashi, MD, PhD
- Board 326 **Abstract 4036:** KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
First Author: Sun Young Rha, PhD
- Board 327 **Abstract 4037:** Co-expressing pattern of multiple biomarkers and dynamic change of Claudin18.2 expression after systemic chemotherapy in advanced gastric cancer.
First Author: Sun Young Rha, PhD
- Board 328 **Abstract 4038:** Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial.
First Author: Xinfang Hou
- Board 329 **Abstract 4039:** Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.
First Author: Haiping Jiang
- Board 330 **Abstract 4040:** Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.
First Author: Meili Sun, MD, PhD
- Board 332 **Abstract 4042:** Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.
First Author: Yanhong Gu, MD, PhD
- Board 333 **Abstract 4043:** Immune checkpoint inhibition in EBV-associated gastric cancer: A multi-center international retrospective analysis.
First Author: Darren Cowzer, MSc, MBBCh, MRCP
- Board 334 **Abstract 4044:** Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I/II study.
First Author: Miao Zhang
- Board 335 **Abstract 4045:** Efficacy of venadaparib plus irinotecan in homologous recombination deficiency (HRD) gene mutations as 3+ line treatment in patients with metastatic gastric cancer (mGC).
First Author: Won Sik Lee, MD, PhD
- Board 336 **Abstract 4046:** Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.
First Author: Chenchen Wang, MD
- Board 337 **Abstract 4047:** Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype to guide treatment decisions in patients with gastric cancer.
First Author: Hyung-Don Kim, MD, PhD
- Board 338 **Abstract 4048:** Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer.
First Author: Yuna Lee, MD
- Board 339 **Abstract 4049:** Clinical outcomes of first-line immune checkpoint inhibitors with chemotherapy in advanced EBV-associated gastric cancer.
First Author: Dongwoo Cho, MD
- Board 340 **Abstract 4050:** Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.
First Author: Wei Song
- Board 341 **Abstract 4051:** Improving evidence-based treatment selection and patient-centered care in upper GI cancers: A Project ECHO initiative.
First Author: Elena Elimova, MD
- Board 342 **Abstract 4052:** Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial.
First Author: Yizhou Huang, MBBS
- Board 343 **Abstract 4053:** Combined PD-L1 expression and PD-1+ CD8 T cells to predict immunotherapy outcomes in esophageal squamous cell carcinoma.
First Author: Qian Zhao
- Board 344 **Abstract 4054:** Temporal and spatial expression of CLDN18.2 in gastric cancer and gastroesophageal junction cancer.
First Author: Qiaoqi Li, MD

- Board 345 **Abstract 4055:** Safety and efficacy of endoscopic treatment with mucosal resection, radiofrequency ablation, and cryotherapy in the curative treatment of early esophageal squamous cell cancer and dysplasia.
First Author: Sidra Naz, MD
- Board 347 **Abstract 4057:** Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial.
First Author: Yizhou Huang, MBBS
- Board 348 **Abstract 4058:** A real-world, propensity-matched analysis of second-line (2L) FOLFIRI-Ram versus Ram-Pac in advanced upper gastrointestinal cancers.
First Author: Jonathan Hyak, MD
- Board 349 **Abstract 4059:** Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.
First Author: Lian Liu
- Board 350 **Abstract 4060:** Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.
First Author: Eleonora Cristarella, RN
- Board 351 **Abstract 4061:** Feasibility of circulating tumor DNA-based minimal residual disease (ctDNA-MRD)-guided adjuvant chemotherapy in patients with stage II-III gastric cancer (GC): An adaptive trial (MRD-GATE).
First Author: Lian Liu
- Board 352 **Abstract 4062:** Development and validation of the gastric risk immuno-progression score (GRIPS) in advanced gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy plus nivolumab: Results from the ORACLE study.
First Author: Dario Spanu, MD
- Board 353 **Abstract 4063:** Multicenter phase I/II study of abemaciclib and ramucirumab in metastatic gastroesophageal adenocarcinoma (GEA): CDK4/6 and cyclin D1 alterations as a predictor of response and survival.
First Author: Ronan Joseph Kelly, MD, MBA, FASCO
- Board 356 **Abstract 4066:** Sequential chemo-immunotherapy as a novel bridging strategy for non-complete responders after neoadjuvant chemoradiotherapy in esophageal cancer: First prospective phase 2 trial challenging the immediate-surgery paradigm.
First Author: Lin Peng
- Board 357 **Abstract 4067:** Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: The LIQUID study.
First Author: Michele Prisciandaro, MD, PhD

- Board 358 **Abstract 4068:** Recurrence-free survival as a surrogate endpoint for overall survival in resectable esophageal cancer: An individual patient data analysis of phase III RCTs.
First Author: Jun Okui, MD, MPH
- Board 359 **Abstract 4069:** Neoadjuvant toripalimab plus CapeOX in patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the phase II NICE trial.
First Author: Liying Zhao
- Board 360 **Abstract 4070:** Early detection and neoadjuvant efficacy prediction for esophageal cancer using cfDNA methylation-based liquid-biopsy assay.
First Author: Zhigang Li, MD, PhD
- Board 361 **Abstract 4071:** Effectiveness of a multidomain mHealth-based intervention in enhancing recovery and quality of life for esophageal cancer patients undergoing esophagectomy.
First Author: Xiaodong Su, MD, PhD
- Board 363 **Abstract 4073:** Exome analysis of over 5000 esophagogastric cancers.
First Author: Reetu Mukherji, MD
- Board 364 **Abstract 4074:** The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.
First Author: Yin Li
- Board 366 **Abstract 4076:** An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
First Author: Yan Zheng, MD
- Board 367 **Abstract 4077:** Circulating tumor DNA (ctDNA) analysis for improved treatment response assessment and prediction of clinical outcomes in patients with esophageal cancer.
First Author: Zexi Allan
- Board 368 **Abstract 4078:** Clinical implication of MDM2 amplification in advanced biliary tract cancer (BTC): A propensity score-matched, retrospective cohort study of 813 patients.
First Author: Hyunseok Yoon
- Board 369 **Abstract 4079:** Real-world outcomes of first-line therapies for unresectable hepatocellular carcinoma in the United States.
First Author: Masafumi Ikeda, MD, PhD
- Board 370 **Abstract 4080:** First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.
First Author: Jian Zhou, PhD
- Board 371 **Abstract 4081:** Combined treatment of durvalumab, bevacizumab and tremelimumab in subjects with hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC).
First Author: Joy Awosika, MD

- Board 373 **Abstract 4083:** Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).
First Author: Joseph Patrick Erinjeri, MD, PhD
- Board 374 **Abstract 4084:** Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
First Author: Jia Fan
- Board 375 **Abstract 4085:** Modifiable risk-factors, genetic characteristics, and survival in early-onset cholangiocarcinoma.
First Author: Jordan Nunnelee, MD
- Board 376 **Abstract 4086:** Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma.
First Author: Katherine Ismei Zhou, MD, PhD
- Board 377 **Abstract 4087:** HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: The REACH-01 trial.
First Author: Kangshuai Li
- Board 378 **Abstract 4088:** Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study.
First Author: Weihong Ma
- Board 379 **Abstract 4089:** Characterization of CLDN18 expression in a Western biliary tract cancer population.
First Author: Alexander Bray, MD, PhD
- Board 380 **Abstract 4090:** TACE-HAIC combined with donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): A retrospective IPTW adjusted cohort study.
First Author: Linan Yin, MD
- Board 381 **Abstract 4091:** Multimodal evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD)–related biliary tract cancer (BTC) and immunotherapy outcomes.
First Author: Nakul Manish Shah, MD
- Board 382 **Abstract 4092:** Phase 1 expansion study of FF-10832 (liposomal gemcitabine) antitumor activity in patients with advanced biliary carcinomas.
First Author: Gerald Steven Falchook, MD
- Board 383 **Abstract 4093:** SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.
First Author: Lianxin Liu, PhD
- Board 384 **Abstract 4094:** Hepatic arterial infusion chemotherapy combined with donafenib and tislelizumab versus transcatheter chemoembolization alone for hepatocellular carcinoma: A propensity score matching study.
First Author: Zhongguo Zhou, MD, PhD
- Board 385 **Abstract 4095:** LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
First Author: Richard S. Finn, MD
- Board 387 **Abstract 4097:** Membrane-specific HER2 expression by artificial intelligence-based quantitative scoring for prediction of efficacy of trastuzumab deruxtecan in biliary tract cancer (HERB trial): Exploratory analysis of a multicenter, single arm, phase II trial.
First Author: Mitsuho Imai, MD, PhD
- Board 388 **Abstract 4098:** A prospective, observational phase II clinical study evaluating hepatic artery infusion chemotherapy in combination with HLX10 and HLX04 as first-line treatment for patients with advanced hepatocellular carcinoma.
First Author: Huikai Li, PhD
- Board 389 **Abstract 4099:** Cobolimab and dostarlimab in the first-line treatment of unresectable hepatoma: A multi-center, single arm, phase 2 trial.
First Author: Jared David Acoba, MD
- Board 390 **Abstract 4100:** Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.
First Author: Zefeng Du, MD
- Board 391 **Abstract 4101:** Survival outcomes for zanidatamab-hr1 compared to chemotherapy in previously treated HER2-positive (IHC3+) biliary tract cancer (BTC): HERIZON-BTC-01 vs a real-world (RW) external control arm (ECA).
First Author: Richard D. Kim, MD
- Board 392 **Abstract 4102:** Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract cancer (BTC): An exploratory analysis from the phase 2 HERIZON-BTC-01 trial.
First Author: James J. Harding, MD
- Board 393 **Abstract 4103:** The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes: Histological assessment of CD8+ T cell spatial features as predictive biomarkers.
First Author: Hiroaki Kanzaki, MD, PhD
- Board 394 **Abstract 4104:** Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study.
First Author: Hui-Chuan Sun, MD, PhD
- Board 395 **Abstract 4105:** Efficacy and safety of atezolizumab and bevacizumab with or without transarterial chemoembolization as first-line therapy for advanced hepatocellular carcinoma: An international multicenter real-world study.
First Author: Ningning Zhang, MD, PhD
- Board 396 **Abstract 4106:** Factors associated with immunotherapy response for hepatocellular carcinoma.
First Author: Shing Hin Chung

- Board 397 **Abstract 4107:** Evolutionary divergence of the HLA-B genotype as a predictor of immune checkpoint inhibitor (ICI) therapy efficacy in hepatobiliary cancers.
First Author: Nan Zhang
- Board 398 **Abstract 4108:** Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.
First Author: Jiaxi Liu
- Board 399 **Abstract 4109:** Molecular characteristics, treatment patterns, and survival outcomes in biliary tract cancers: A retrospective analysis from a high-prevalence region.
First Author: Ashish Joshi
- Board 400 **Abstract 4110:** Comparison of outcomes between open and minimally invasive hepatic resections for hepatocellular carcinoma: A retrospective analysis.
First Author: Harjeevan Kalra
- Board 401 **Abstract 4111:** Association of gut microbiota with therapy efficacy and prognosis in biliary tract cancer.
First Author: Fen Saj, MD, DM
- Board 402 **Abstract 4112:** CTC landscape during HCC immunotherapy.
First Author: Marcos Santiago Figueroa, MS
- Board 403 **Abstract 4113:** Deep learning-based contouring of Couinaud segments on CT: Utility for volumetric analysis of future liver remnant.
First Author: Tejas Mathai
- Board 404 **Abstract 4114:** AI-driven prediction of post-transplant survival and stratification of HCC recurrence risk.
First Author: Junho Song, MD
- Board 405 **Abstract 4115:** A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187.
First Author: Anita Turk, MD
- Board 406 **Abstract 4116:** Whole-genome sequencing of biliary tract cancer: Uncovering the genomic origins of evolutionary trajectories.
First Author: Felix Beaudry
- Board 407 **Abstract 4117:** Real-world validation of the risk estimation of tumor recurrence after transplant (RETREAT) score: Insights from UNOS data on hepatocellular carcinoma recurrence after liver transplant.
First Author: Donghoon Shin, MD
- Board 408 **Abstract 4118:** Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study.
First Author: Xinhao Xiong, MD
- Board 409 **Abstract 4119:** Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.
First Author: Taro Shibuki, MD
- Board 410 **Abstract 4120:** Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.
First Author: Frank Po-Yen Lin, PhD, FRACP, MBChB, FAIDH
- Board 411 **Abstract 4121:** First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma.
First Author: Linde Kehmann, PhD
- Board 412 **Abstract 4122:** Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (AIO-MONTBLANC): Safety interim analysis.
First Author: Najib Ben Khaled, MD
- Board 413 **Abstract 4123:** Comparative efficacy of cabozantinib or lenvatinib following atezolizumab plus bevacizumab in patients with advanced hepatocellular cancer.
First Author: Sepideh Mehravar, MD
- Board 414 **Abstract 4124:** Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?
First Author: Jay Parekh, MBBS
- Board 415 **Abstract 4125:** Development and validation of a prognostic risk score for hepatocellular carcinoma recurrence post-liver transplant: Insights from the UNOS database.
First Author: Donghoon Shin, MD
- Board 416 **Abstract 4126:** Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis.
First Author: Bin-Yan Zhong, PhD
- Board 417 **Abstract 4127:** Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.
First Author: Zhicheng Lai
- Board 418 **Abstract 4128:** Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma.
First Author: Jianan Feng
- Board 420 **Abstract 4130:** Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer.
First Author: Maen Abdelrahim, MD, PhD
- Board 421 **Abstract 4131:** Integration of cfDNA fragmentomics for early biliary tract cancer detection.
First Author: Jiwen Wang

- Board 422 **Abstract 4132:** ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer—The IKF/AIO-ADJUBIL trial.
First Author: Thorsten Oliver Goetze
- Board 423 **Abstract 4133:** Novel early-detection model based on cfDNA methylation and fragmentation features for liver cancer.
First Author: Xiaobo Wang
- Board 424 **Abstract 4134:** The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.
First Author: Jianhua Rao
- Board 425 **Abstract 4135:** Effect of the combination of systemic and locoregional therapy on tumor recurrence and survival after liver transplantation for hepatocellular carcinoma (HCC).
First Author: Khadyoth Nanneboyina, MD
- Board 426 **Abstract 4136:** Ultra-sensitive detection of hepatocellular carcinoma (HCC) with methylation signal enrichment of ctDNA and hepatitis B virus (HBV).
First Author: Nan Lin
- Board 427 **Abstract 4137:** Use of artificial intelligence-powered spatial analysis of tumor microenvironment to predict the prognosis in resected gallbladder cancer.
First Author: Young Hoon Choi, MD
- Board 428 **Abstract 4138:** Unveiling the role of sodium glucose cotransporter-2 inhibitors in hepatocellular carcinoma patients with cirrhosis: A comparative global cohort study.
First Author: Asfand Yar Cheema, MD, MBBS
- Board 429 **Abstract 4139:** Neoadjuvant transhepatic arterial infusion chemotherapy (HAIC) with FOLFOX regime plus cadonilimab (PD-1/CTLA-4 bispecific antibody) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (CAR_Hero study).
First Author: Yongguang Wei
- Board 430 **Abstract 4140:** Prognostic significance of pathological response in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based conversion therapy.
First Author: Wen-Jing Zheng
- Board 431 **Abstract 4141:** Comparison outcome of transarterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma.
First Author: Ningning Zhang
- Board 432 **Abstract 4142:** Association of differential expression of genes with survival and relapse in patients treated on the BILCAP clinical trial: Gene expression identification and response to adjuvant chemotherapy in early-stage biliary tract cancer.
First Author: Valerie Elizabeth Crolley, PhD, MBBS
- Board 433 **Abstract 4143:** Comparative analysis of stereotactic body radiotherapy (SBRT) vs. SBRT with bridge therapies for hepatocellular carcinoma patients awaiting liver transplantation: A multi-center study (2010-2020).
First Author: Teja Sureddi, MBBS
- Board 434 **Abstract 4144:** Impact of radionuclide therapy on survival outcomes for de novo metastatic gastroenteropancreatic neuroendocrine tumors: A population-based cohort study.
First Author: Zhiqiao Liu, MD
- Board 435 **Abstract 4145:** A phase II study of lenvatinib plus everolimus in advanced extra-pancreatic neuroendocrine tumors (epNETs): Updated results and real-world comparison.
First Author: Guglielmo Vetere, MD
- Board 436 **Abstract 4146:** Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).
First Author: Rohit Thummalapalli, MD
- Board 437 **Abstract 4147:** Surgical debulking versus non-surgical management for the control of carcinoid syndrome in metastatic small bowel neuroendocrine tumors.
First Author: Rushabh Gujarathi, MBBS
- Board 438 **Abstract 4148:** TROP2 expression in the gastroenteropancreatic neuroendocrine tumors: An analysis of 179 patients.
First Author: Junaid Arshad, MD, MS
- Board 439 **Abstract 4149:** Development of a cfDNA-based protein-informed epigenetic signature (PEp-sig) to enable biomarker-based risk stratification for pancreatic ductal adenocarcinoma (PDA).
First Author: Ashish Manne, MD, MBBS
- Board 440 **Abstract 4150:** Development of a comprehensive cfDNA methylation signature for prognostic, predictive, and diagnostic applications in pancreatic ductal adenocarcinoma (PDA).
First Author: Deepak Sherpally, MD
- Board 441 **Abstract 4151:** DNA methylation signatures as predictive biomarkers for chemotherapy (CT) resistance and survival in pancreatic ductal adenocarcinoma (PDA).
First Author: Deepak Sherpally, MD
- Board 442 **Abstract 4152:** A phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer.
First Author: Saurav Daniel Haldar, MD
- Board 443 **Abstract 4153:** Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study.
First Author: Saurav Daniel Haldar, MD
- Board 444 **Abstract 4154:** Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma.
First Author: Heidi C. Ko, DO
- Board 445 **Abstract 4155:** Functional role of GLI2 in cancer-associated fibroblasts for modulation of the fibrotic tumor microenvironment within pancreatic cancer.
First Author: John Y. Kwon, MD

- Board 446 **Abstract 4156:** Use of an ultra-sensitive sequencing platform to detect mutant KRAS in the whole blood of pancreatic cancer patients.
First Author: Ryne Ramaker, MD
- Board 447 **Abstract 4157:** Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.
First Author: Wen-Quan Wang
- Board 448 **Abstract 4158:** Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: A prospective, observational pilot study.
First Author: James Lee, BA
- Board 449 **Abstract 4159:** TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.
First Author: Si Shi, MD, PhD
- Board 450 **Abstract 4160:** Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.
First Author: Ke Cheng
- Board 451 **Abstract 4161:** First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.
First Author: Guang-Hai Dai, MD
- Board 452 **Abstract 4162:** First-line serplulimab and bevacizumab combined with nab-paclitaxel/ gemcitabine followed by mFOLFFOX in advanced pancreatic cancer: A phase II trial.
First Author: Jieer Ying, MD
- Board 453 **Abstract 4163:** AI-based predictive tool for detection of ctDNA in pancreatic adenocarcinoma using nationwide comprehensive genomic profiling data.
First Author: Hiroaki Ikushima, MD, PhD
- Board 454 **Abstract 4164:** Using live true single-circulating tumor cell comprehensive genomics to show clonal evolution and tumor heterogeneity in pancreatic cancer management.
First Author: Mandana Kamgar, MD, MPH
- Board 455 **Abstract 4165:** Homologous recombination deficiency (HRD) profiling in Chinese pancreatic ductal adenocarcinoma: Implications for platinum-based chemotherapy.
First Author: Yanxia Wang, PhD
- Board 456 **Abstract 4166:** The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/ cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).
First Author: Himil Mahadevia, MBBS

- Board 457 **Abstract 4167:** CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.
First Author: Gulam Abbas Manji, MD, PhD
- Board 458 **Abstract 4168:** Phase 1/2 study of nivolumab and ipilimumab combined with gemcitabine, nab-paclitaxel, and adaptive stereotactic body radiotherapy in borderline resectable, locally advanced or metastatic pancreatic cancer (LAPTOP).
First Author: Inna Markovna Chen, MD
- Board 459 **Abstract 4169:** Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.
First Author: Jonathan W. Lee, MD, MSC
- Board 460 **Abstract 4170:** Prognostic and predictive impact of next-generation sequencing in metastatic pancreatic ductal adenocarcinoma.
First Author: Christopher Schumacher
- Board 461 **Abstract 4171:** Interpretable artificial intelligence-driven selection of doublet chemotherapy regimens as second-line treatment in patients with advanced pancreatic cancer.
First Author: Letizia Procaccio, MD, PhD
- Board 462 **Abstract 4172:** First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
First Author: Dirk Waldschmidt, MD
- Board 463 **Abstract 4173:** Circulated T-cell exhausted subtypes to predict response in PDAC patients.
First Author: Anastasia Xagara, PhD
- Board 464 **Abstract 4174:** USP22 as promoter of Treg cell infiltration and modulator of immunotherapy efficacy through the PIAS1/P65/CCL22 pathway in pancreatic cancer.
First Author: Aman Wang, MD
- Board 465 **Abstract LBA4175:** NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.
First Author: Vincent Chung, MD
- Board 466 **Abstract 4176:** Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).
First Author: Clara J. Oh, MD
- Board 467 **Abstract 4177:** Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.
First Author: Anup Kasi, MD, MPH

- Board 468 **Abstract 4178:** Concurrent mutations in DNA damage repair genes BRCA1, POLE, ATM and FANCA to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial. First Author: Daniel John Renouf, MD
- Board 469 **Abstract 4179:** Clinical outcomes and molecular characteristics of patients with metastatic pancreatic ductal adenocarcinoma according to involved metastatic sites. First Author: Mahmoud M.G. Yousef, MD
- Board 470 **Abstract 4180:** Pancreatic cancer mortality trends (2018-2023): Exposing racial inequities in Michigan's cancer burden. First Author: Mekdes Asfaw
- Board 471 **Abstract 4181:** Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial. First Author: Wei Quan
- Board 472 **Abstract 4182:** Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies. First Author: Catia Gaspar, MD
- Board 473 **Abstract 4183:** BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC). First Author: Kim Anna Reiss, MD
- Board 474 **Abstract 4184:** 5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61). First Author: Julien Taieb, MD, PhD
- Board 475 **Abstract 4185:** Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglisib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward patient enrichment. First Author: Taylor Weiskittel
- Board 476 **Abstract 4186:** Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework. First Author: Akanksha Dua
- Board 477 **Abstract 4187:** A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216). First Author: Anton Lahusen
- Board 478 **Abstract 4188:** Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer. First Author: Funan Liu, MD, PhD
- Board 479 **Abstract 4189:** Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial. First Author: Lorraine A. Chantrill, PhD, MBBS, FRACP
- Board 480 **Abstract 4190:** NeoOPTIMIZE: Phase II trial of adaptive switching of neoadjuvant FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (GA) resectable/borderline resectable (BR)/locally advanced (LA) pancreatic adenocarcinoma (PDAC). First Author: Lyndsey Sandow, MD
- Board 481 **Abstract 4191:** Development and prospective validation of a novel cfDNA-based diagnostic model for the early detection of pancreatic cancer. First Author: Xiuchao Wang
- Board 482 **Abstract 4192:** Prognostic value of postoperative circulating tumor DNA and tumor markers in resected pancreatic adenocarcinoma (PAAD): An interim analysis of a prospective observational study. First Author: Qian Zhan, PhD
- Board 483 **Abstract 4193:** Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group. First Author: Thomas Jens Ettrich, MD
- Board 484 **Abstract 4194:** Perioperative pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Asia versus non-Asia subgroup analysis of KEYNOTE-585. First Author: Takashi Oshima, MD, PhD
- Board 486 **Abstract 4196:** Association of neighborhood-level factors with access to genetic testing in patients with resectable pancreatic ductal adenocarcinoma. First Author: Muhammad Maisam Ali
- Board 487 **Abstract 4197:** Constructing genetic-immune prognostic subtypes of primary duodenal adenocarcinoma through whole exome sequencing and AI-assisted immune microenvironment analysis. First Author: Ting Han
- Board 488 **Abstract 4198:** Uncovering the tumor microenvironment (TME): Exploring survival and immunotherapy (IO) response in cancer of unknown primary (CUP). First Author: Joelle Allam, MD
- Board 489 **Abstract 4199:** Identification of differential epigenetic landscapes in subtypes of appendiceal cancer. First Author: Luisa Ladel, MD
- Board 490 **Abstract 4200:** Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP). First Author: Keelia Clemens, PhD, MS
- Board 491a **Abstract TPS4201:** A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress. First Author: Lin Shen

- Board 491b **Abstract TPS4202:** Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (a/m GEA).
First Author: Kohei Shitara, MD
- Board 492a **Abstract TPS4203:** Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
First Author: Huifang Lv
- Board 492b **Abstract TPS4204:** ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC).
First Author: Rui-Hua Xu, MD, PhD
- Board 493a **Abstract TPS4205:** A randomized controlled trial comparing conversion surgery with palliative chemotherapy in patients with initially unresectable cStage IVB/pStage IV advanced gastric cancer who presented remarkable response to chemotherapy: JCOG2301 (Conversion study).
First Author: Itaru Yasufuku, MD, PhD
- Board 493b **Abstract TPS4206:** A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJ cancer.
First Author: Jaffer A. Ajani, MD
- Board 494a **Abstract TPS4207:** An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
First Author: Kohei Shitara, MD
- Board 494b **Abstract TPS4208:** A phase II study of sacituzumab govitecan for advanced esophageal squamous cell carcinoma patients (SG-ESCC).
First Author: Jhe-Cyuan Guo, MD, PhD
- Board 495a **Abstract TPS4209:** KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).
First Author: Ken Kato, MD, PhD
- Board 495b **Abstract TPS4210:** A phase II study of perioperative intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.
First Author: Brian D. Badgwell, MD

- Board 496b **Abstract TPS4212:** Repurposing itraconazole for secondary prevention of metaplasia and primary prevention of cancer in patients with high-risk Barrett's esophagus in combination with ablation.
First Author: Ajay Bansal, MD
- Board 497a **Abstract TPS4213:** Total neoadjuvant therapy with induction immunochemotherapy and chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma (TNT-ESCC).
First Author: Chien Huai Chuang, MD
- Board 497b **Abstract TPS4214:** PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor α (PPAR α) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.
First Author: Mark Yarchoan, MD
- Board 498a **Abstract TPS4215:** RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC).
First Author: Stephane Champiat, MD, PhD
- Board 498b **Abstract TPS4216:** Phase II trial of zanzalitinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).
First Author: Meghana Singh, MD
- Board 499a **Abstract TPS4217:** A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and/or locally advanced or metastatic hepatocellular carcinoma.
First Author: Daneng Li, MD
- Board 499b **Abstract TPS4218:** A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma.
First Author: Timothy Guy Humphries, MBBS, FRACP
- Board 500a **Abstract TPS4219:** A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: James J. Harding, MD
- Board 500b **Abstract TPS4220:** A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.
First Author: Xiangcheng Li
- Board 501a **Abstract TPS4221:** EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.
First Author: Riad Salem, MD

- Board 501b **Abstract TPS4222:** Trial in progress: A phase Ib/II study to evaluate the safety and efficacy of atezolizumab plus bevacizumab as adjuvant therapy following carbon ion radiotherapy in hepatocellular carcinoma (VANGUARD trial).
First Author: Keisuke Koroki
- Board 502a **Abstract TPS4223:** Donafenib combined with capecitabine for postoperative adjuvant therapy of biliary malignant tumors with high risk of recurrence: A multi-center, randomized controlled, phase II study.
First Author: Jianhua Rao
- Board 502b **Abstract TPS4224:** Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours.
First Author: Matthew E. Burge, MBBS
- Board 503a **Abstract TPS4225:** A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with ¹⁷⁷Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
First Author: Andreja Frilling
- Board 503b **Abstract TPS4226:** NCI 10479: A phase I dose escalation-expansion trial of sunitinib malate plus lutetium (¹⁷⁷Lu-177) dotatate in somatostatin receptor positive pancreatic neuroendocrine tumors.
First Author: Nikolaos Trikalinos, MD, MS
- Board 504a **Abstract TPS4227:** An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/ TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.
First Author: Do-Youn Oh, MD, PhD
- Board 504b **Abstract TPS4228:** ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.
First Author: Jiujiu Cui
- Board 505a **Abstract TPS4229:** A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).
First Author: Anup Kasi, MD, MPH
- Board 505b **Abstract TPS4230:** Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Brian M. Wolpin, MD, MPH
- Board 506a **Abstract TPS4231:** A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.
First Author: Bruno Bockorny, MD

- Board 506b **Abstract TPS4232:** Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): A phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Ronan Andrew McLaughlin, MRCPATH, MBBCh
- Board 507a **Abstract TPS4233:** Phase I trial of MK2 inhibitor in combination with mFOLFIRINOX for untreated metastatic pancreatic ductal adenocarcinoma.
First Author: Moh'd M. Khushman, MD
- Board 507b **Abstract TPS4234:** An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer.
First Author: Erkut H. Borazanci, MD, MS
- Board 508a **Abstract TPS4235:** A supervised prehabilitation program for patients with pancreatic cancer.
First Author: Philip Chang
- Board 508b **Abstract TPS4236:** IMMUNORARE⁵: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimumab combination in patients with advanced rare cancers—The Peritoneal Mesotheliomas Cohort.
First Author: Julien Peron Sr

9:00 AM-12:00 PM Poster Session

Pediatric Oncology

Location: Hall A - Posters and Exhibits

Posters by Topic

Leukemia/Lymphoma: Board(s) 142-146, 189a

Pediatric Solid Tumors: Board(s) 147-169, 189b

Survivorship: Board(s) 170-187

Symptom Management/Supportive Care/Palliative Care: Board(s) 188

- Board 142 **Abstract 10027:** New pediatric formulation of asciminib in children with chronic myeloid leukemia in chronic phase: Second interim analysis of pharmacokinetics and safety from the ASC4Kids study.
First Author: Nobuko Hijiya, MD
- Board 143 **Abstract 10028:** Financial toxicity and association with treatment outcomes during pediatric CAR T therapy.
First Author: Daniel J. Zheng, MD, MHS
- Board 144 **Abstract 10029:** Growth recovery in patients with BRAF altered pediatric low-grade gliomas (LGG) after discontinuation of tovorafenib.
First Author: Cassie Kline, MD, MSc
- Board 145 **Abstract 10030:** Cerebrospinal fluid proteome during chemotherapy for childhood leukemia: Identifying pathways associated with treatment and system toxicity.
First Author: Justin Tanner, PhD

- Board 146 **Abstract 10031:** Unraveling gut gram-negative antibiotic-resistant colonization dynamics in hematologic cancers: Insights from bioinformatics and immune signatures.
First Author: Mahdi Malekpour
- Board 147 **Abstract 10032:** Association of baseline clinical factors with outcomes in patients with localized Ewing sarcoma treated on frontline trials with interval compressed chemotherapy (ICC): A report from the Children's Oncology Group.
First Author: Ajay Gupta, MD
- Board 148 **Abstract 10033:** Demographic characteristics and survival outcomes of pediatric clear cell sarcoma of the kidney: A National Cancer Database retrospective study.
First Author: Assal Sadighian
- Board 149 **Abstract 10034:** Late effects in high-risk neuroblastoma survivors who received MIBG therapy.
First Author: Perna Kumar, MD
- Board 150 **Abstract 10035:** Survival and prognostic factors of patients with Ewing sarcoma at first recurrence following modern era multimodal therapy: A report from the Children's Oncology Group (COG).
First Author: Sarah Cohen-Gogo, MD, PhD
- Board 151 **Abstract 10036:** Neurocognitive outcomes following 30.6-Gy whole-ventricular radiotherapy with 54-Gy total dose focal tumor bed boost for CNS non-germinomatous germ cell tumors: A Children's Oncology Group study (ACNS1123).
First Author: Sunita K. Patel, PhD
- Board 152 **Abstract 10037:** Post hoc analysis of rashes reported in patients (pts) with BRAF-altered relapsed/refractory (r/r) pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1.
First Author: Olaf Witt, MD
- Board 153 **Abstract 10038:** Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the neoadjuvant treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study.
First Author: Yi Que
- Board 154 **Abstract 10039:** Irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) and naxitamab plus GM-CSF and ifosfamide, carboplatin, etoposide (NICE) for patients with relapsed or refractory high-risk neuroblastoma: A single center, open-label phase 2 clinical trial.
First Author: Jaume Mora, MD, PhD
- Board 155 **Abstract 10040:** Pembrolizumab in pediatric participants with relapsed or refractory microsatellite instability-high solid tumors: Results from the phase 1/2 KEYNOTE-051 trial.
First Author: Alberto S. Pappo, MD
- Board 156 **Abstract 10041:** Socioeconomic disparities in survival outcomes among children with non-metastatic Ewing sarcoma treated on upfront Children's Oncology Group clinical trials.
First Author: Rahela Aziz-Bose, MD, MPH
- Board 157 **Abstract 10042:** HLA allele, TCR V- and J-gene segment usage combinations and their association with survival in neuroblastoma.
First Author: Eddie Fung
- Board 158 **Abstract 10043:** MYC amplification and protein expression as prognostic markers in pediatric and young adult osteosarcoma.
First Author: Matthew Nagy, MD, MPH
- Board 159 **Abstract 10044:** Updated data of efficacy and safety of luvometinib (FCN-159) in pediatric participants with neurofibromatosis type 1 from a multi-center, open-label, single-arm phase 2 study.
First Author: JinHu Wang
- Board 160 **Abstract 10045:** MYC amplification as a prognostic biomarker in osteosarcoma: A report from the Children's Oncology Group.
First Author: Sarah Whittle, MD
- Board 161 **Abstract 10046:** A phase I dose-escalation study to assess the oncolytic virus VCN-01 safety and efficacy in refractory retinoblastoma patients.
First Author: Jaume Català-Mora, MD
- Board 162 **Abstract 10047:** Multi-omics evaluation of relapsed pediatric cancers: What information do these sequential analyses yield?
First Author: Caroline Bellavance
- Board 163 **Abstract 10048:** Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients (pts) with NTRK fusion-positive (NTRK+) solid tumors.
First Author: Yizhuo Zhang, MD
- Board 164 **Abstract 10049:** Phase I study of mitoxantrone hydrochloride liposome in relapsed and refractory pediatric tumors.
First Author: Junting Huang
- Board 165 **Abstract 10050:** Updated efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring ROS1 fusions.
First Author: Ami V. Desai, MD, MSCE
- Board 166 **Abstract 10051:** A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children's Oncology Group study PEPN2111.
First Author: David Simon Ziegler, MD, MBBS, FRACP
- Board 167 **Abstract 10052:** Factors associated with survival following relapse of high-risk neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Data Commons.
First Author: Daniel A. Morgenstern, PhD, MBBChir
- Board 168 **Abstract 10053:** Whole genome-based circulating tumor DNA analysis as an ultrasensitive biomarker in pediatric sarcomas.
First Author: Claire Johns, MD
- Board 169 **Abstract 10054:** A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.
First Author: Kathryn S. Sutton, MD

Board 170	Abstract 10055: Association of neurocognitive impairment and financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). First Author: Daniel J. Zheng, MD, MHS	Board 184	Abstract 10069: Assessment of smartwatch-based electrocardiogram (ECG) abnormality detection among childhood cancer survivors. First Author: Ibrahim Karabayir, PhD
Board 171	Abstract 10056: Psychologic distress amongst adolescent and young adult cancer survivors' and parents. First Author: Kaille Meguiar, DO	Board 185	Abstract 10070: Predicting valvular heart disease in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE). First Author: Daniel A. Mulrooney, MD, MS
Board 172	Abstract 10057: Longitudinal associations between chronic health condition burden and financial hardship among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor study (CCSS). First Author: Tara Suntum, MD, MS	Board 186	Abstract 10071: Characteristics and concomitant congenital abnormalities among newborns with cancer: A population level analysis. First Author: Sergio Hernandez-Llamas, MD
Board 173	Abstract 10058: Treatment and lifestyle profiles of healthy aging survivors: A report from the Childhood Cancer Survivor Study. First Author: Timothy James Daeun Ohlsen, MD, MS	Board 187	Abstract 10072: Evaluating survivorship-related communication gaps to develop a community health worker-led intervention for Hispanic/Latino young adult childhood cancer survivors and their families. First Author: Stephanie M. Smith, MD, MPH
Board 174	Abstract 10059: US population-level costs and cost-savings associated with long-term follow-up (LTFU) screening for survivors of childhood cancer. First Author: Matthew J. Ehrhardt, MD, MS	Board 188	Abstract 10073: Development of a pediatric oncology financial toxicity outcome measure with content and face validity: The Parent-Reported Instrument of Costs and Experiences with financial toxicity (PRICE) measure. First Author: Timothy James Daeun Ohlsen, MD, MS
Board 175	Abstract 10060: Food insecurity, dietary quality, and cardiovascular risk in early childhood cancer survivors. First Author: Rahela Aziz-Bose, MD, MPH	Board 189a	Abstract TPS10074: A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children < 12 years of age with CBFA2T3::GLIS2 acute myeloid leukemia. First Author: Sarah K. Tasian, MD
Board 176	Abstract 10061: Risk assessment and development of a machine learning-based prediction model for survival in patients with medulloblastoma. First Author: Yu Su	Board 189b	Abstract TPS10075: Phase 1/2 study of zilovetamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A). First Author: Hyoung Jin Kang
Board 177	Abstract 10062: Retinoblastoma patient outcomes in the contemporary era: The RIVERBOAT Consortium. First Author: Murali M. Chintagumpala, MD	<hr/>	
Board 178	Abstract 10063: Genome-wide association study of neurocognitive outcomes among childhood cancer survivors. First Author: Jennifer N. French, PhD, MPH	9:00 AM-12:00 PM Poster Session	
Board 179	Abstract 10064: Accelerated aging among long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). First Author: AnnaLynn Williams, PhD	Sarcoma	
Board 180	Abstract 10065: Cardiovascular risk factor control and risk of future cardiovascular events in survivors of childhood cancer: A report from the St. Jude Lifetime cohort. First Author: Stephanie B. Dixon, MD, MPH	Location: Hall A - Posters and Exhibits	
Board 181	Abstract 10066: Breast cancer recurrence and mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). First Author: Lucie Marie Turcotte, MD, MS, MPH	Posters by Topic	
Board 183	Abstract 10068: Financial hardship and non-adherence to lifestyle and surveillance recommendations in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). First Author: Neel S. Bhatt, MBBS, MPH	Bone Tumors: Board(s) 1-3	
		Gastrointestinal Stromal Tumors (GIST): Board(s) 4-10, 61a-62a	
		Molecular Targets/Biomarkers/Tumor Biology: Board(s) 12-26, 62b-63b	
		Soft Tissue Tumors: Board(s) 27-60, 64a-66b	
		Board 1	Abstract 11518: Liposomal irinotecan together with vincristine and temozolomide (NALIRI-VT) for patients with relapsed or refractory Ewing sarcoma: A two-cohort, phase 1a/1b study. First Author: Jie Xu, MD
		Board 2	Abstract 11519: MRI-based machine learning model for predicting early relapse in osteosarcoma following neoadjuvant chemotherapy. First Author: Yucheng Fu, MD, PhD
		Board 3	Abstract 11520: The preoperative management of patients with giant cell tumors in limb bones using denosumab therapy. First Author: Saidrasul Nasirov

Board 4	Abstract 11521: Feasibility and clinical outcomes of imatinib personalized dosing in gastrointestinal stromal tumor patients. First Author: Maud Berendina Annelies van der Kleij, MD	Board 20	Abstract 11537: Early on-treatment ctDNA dynamics and response by imaging in patients with sarcoma. First Author: Adrienne I. Victor, MD, MS
Board 5	Abstract 11522: Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk locally advanced stage gastrointestinal stromal tumor. First Author: Zhidong Gao, MD	Board 21	Abstract 11538: MicroRNA-based biomarkers of outcome in soft tissue sarcoma treated with hypofractionated preoperative radiation therapy. First Author: Joanne B. Weidhaas, MD, PhD
Board 6	Abstract 11523: The benefit of cytoreductive surgery during imatinib (IM) therapy in patients with metastatic gastrointestinal stromal tumors (mGISTs): Retrospective analysis from several cancer centers. First Author: Daria Filonenko, MD	Board 22	Abstract 11539: Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma. First Author: Carlos Diego Holanda Lopes, MD
Board 7	Abstract 11524: In vitro profiling of IDRX-42 against secondary and tertiary mutations (AP/AL) found in TKI-resistant GIST. First Author: Michael C. Heinrich, MD, FACP	Board 23	Abstract 11540: Predictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study. First Author: David Silva Moura, PhD
Board 8	Abstract 11525: 15-year survivorship in patients with metastatic gastrointestinal stromal tumors. First Author: Julia A. Levy, MD	Board 24	Abstract 11541: RNA-based fusion NGS panel testing for the improved classification of soft tissue sarcomas: A retrospective analysis. First Author: Suruchi Aggarwal, PhD, MSc
Board 9	Abstract 11526: Second-line treatment patterns and outcomes of advanced gastrointestinal stromal tumor: A real-world study. First Author: Xinhua Zhang	Board 25	Abstract 11542: Comprehensive molecular analysis of phase II trial of nivolumab in patients with recurrent or metastatic carcinosarcomas. First Author: Kum-Hee Yun, PhD
Board 10	Abstract 11527: Long-term outcomes in GIST Trial 13-162: Phase II study of imatinib in combination with binimetinib in untreated patients with advanced gastrointestinal stromal tumor (GIST). First Author: Yudi Bao, MD	Board 26	Abstract 11543: Neutrophil-to-lymphocyte ratio as a clinical biomarker for immune checkpoint inhibitor response in advanced sarcoma. First Author: Gabriel Tinoco, MD
Board 12	Abstract 11529: Predicting transposable element-derived neoantigens in ATRX-mutated sarcoma. First Author: Simon Cao, MPH	Board 27	Abstract 11544: Pediatric patients with tenosynovial giant cell tumor: Real-world results from an observational registry. First Author: Sydney Stern, PhD, MS
Board 13	Abstract 11530: Spatial and bulk transcriptomic analysis of skin Kaposi sarcoma lesions: Differences by disease characteristics. First Author: Quashawn Rakeem Chadwick, MA	Board 28	Abstract 11545: IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study. First Author: Haiyan Hu
Board 14	Abstract 11531: Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma. First Author: Maggie Yuxi Zhou, MD	Board 29	Abstract 11546: A pilot study of Janus kinase 1 (JAK1) inhibitor itacitinib for treatment-refractory sarcomas: Leiomyosarcoma cohort. First Author: Michael J. Wagner, MD
Board 15	Abstract 11532: Kaposi sarcoma herpesvirus (KSHV) subtypes and impact on survival in 107 patients with Kaposi sarcoma and other KSHV-associated diseases. First Author: Jose Mercado-Matos, MD	Board 30	Abstract 11547: Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and CTNNB1/APC mutated soft tissue tumors. First Author: Steven Christopher Smith, MD, PhD
Board 16	Abstract 11533: Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. First Author: Anqi Wang	Board 31	Abstract 11548: The global, regional, and national burden of soft tissue sarcomas and other extraosseous sarcomas, 1990-2021: A systematic analysis for the Global Burden of Disease study 2021. First Author: Venkatraman Radhakrishnan, MD, MSc, DM, MBBS
Board 17	Abstract 11534: Advancing precision oncology in soft tissue sarcomas: The role of iTRAC in metastatic risk stratification and treatment personalization. First Author: Fred Chibon, PhD	Board 32	Abstract 11549: Clinicopathologic features and outcomes of follicular dendritic cell sarcoma with or without Castleman disease: A large retrospective cohort analysis. First Author: Yoshito Nishimura, MD, PhD, MPH
Board 19	Abstract 11536: Molecular subtyping and insights into sarcoma biology and prognosis. First Author: Aleksei Shevkoopias		

Board 33	Abstract 11550: Molecular-genetic characteristics of soft tissue sarcomas associated with the development of chemotherapy resistance. First Author: Anastasia Alekseevna Tararykova, MD	Board 47	Abstract 11564: Doxorubicin-based chemotherapy vs gemcitabine/docetaxel in uterine leiomyosarcoma (ULMS). First Author: Stephanie Soewito, MPH, DO
Board 35	Abstract 11552: Overall survival from the open label phase 2 trial of palbociclib in patients with advanced well differentiated/dedifferentiated liposarcoma. First Author: Olayode Babatunde, MD	Board 48	Abstract 11565: Heterogeneity in epithelioid hemangioendothelioma (EHE): Insights into common and organ-specific tumor pathways. First Author: Tom Wei-Wu Chen, MD, PhD
Board 36	Abstract 11553: Clinical activity of immune checkpoint blockade in advanced perivascular epithelioid cell neoplasms (PEComas): A retrospective single center study. First Author: Daniel Reinhorn, MD	Board 49	Abstract 11566: Molecular profiling and prognosis of spindle cell/sclerosing rhabdomyosarcoma: A report from the Chinese PPOG trial. First Author: Suying Lu
Board 37	Abstract 11554: An update on the results of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma. First Author: Zhichao Tan, MD	Board 50	Abstract 11567: Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSarCC study. First Author: Haydée Williams Sanchez, MD
Board 38	Abstract 11555: Comprehensive molecular analysis of phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma. First Author: Hyo Song Kim, MD, PhD	Board 51	Abstract 11568: A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for localized high-risk limbs and trunk soft tissue sarcomas. First Author: Yan Wang, MD, PhD
Board 39	Abstract 11556: Multicenter phase II study of anlotinib and toripalimab in patients with advanced soft tissue sarcoma (STS) and bone sarcoma (BS). First Author: Xing Zhang, MD, PhD	Board 52	Abstract 11569: Self-assembled patient-derived tumor-like cell clusters for personalized drug testing in diverse sarcomas. First Author: Tian Gao, PhD
Board 40	Abstract 11557: Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumors. First Author: Mrinal M. Gounder, MD	Board 53	Abstract 11570: Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria. First Author: Wendy Kohlmann, MS
Board 41	Abstract 11558: Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial. First Author: Vivek A. Bhadri, PhD, FRACP, MA, MBBS	Board 54	Abstract 11571: A propensity-score matched analysis for time to trabectedin-failure in advanced myxoid liposarcoma patients. First Author: Roberta Sanfilippo, MD
Board 42	Abstract 11559: Daily low-dose oral temozolomide as maintenance therapy following doxorubicin plus dacarbazine in advanced leiomyosarcoma patients: An observational study. First Author: Zhichao Tan, MD	Board 55	Abstract 11572: Moving beyond the traditional two-step approach for prognosis prediction: The BayeSarc model. First Author: Gabriele Tine', MSc
Board 43	Abstract 11560: A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: Efficacy updates. First Author: Xing Zhang, MD, PhD	Board 56	Abstract 11573: Clinical and prognostic implications of the TCR repertoire in leiomyosarcoma. First Author: John Seng Wang, MD
Board 44	Abstract 11561: Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing. First Author: Dmitrii Grachev, MSc	Board 57	Abstract 11574: Ramucirumab in pediatric and young adult patients (Pts) with relapsed/refractory (R/R) desmoplastic small round cell tumor (DSRCT) or synovial sarcoma (SS): Results from the CAMPFIRE study. First Author: Emily K. Slotkin, MD
Board 45	Abstract 11562: Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. First Author: Irvin Yi, BA	Board 58	Abstract 11575: Global inequities in sarcoma clinical trials: A comprehensive analysis over the last decade. First Author: Shushan Hovsepyan, MD
Board 46	Abstract 11563: Safety and antitumor activity of ¹⁷⁷ Lu-catelase: A preliminary clinical study in soft tissue sarcoma. First Author: Jiayong Liu, MD	Board 59	Abstract 11576: NF1- and non-NF1-associated malignant peripheral nerve sheath tumors (MPNST): The University of Texas MD Anderson (MDACC) experience. First Author: Reeja Raj
		Board 60	Abstract 11577: Enhancing soft tissue sarcoma surveillance: The role of ctDNA testing in early detection and monitoring beyond traditional imaging. First Author: Amrit Paudel, MD

- Board 61a **Abstract TPS11578:** Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
First Author: Mrinal M. Gounder, MD
- Board 61b **Abstract TPS11579:** SARC044: A phase II trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy.
First Author: Candace L. Haddox, MD
- Board 62a **Abstract TPS11580:** An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor.
First Author: Sreenivasa R. Chandana, MD, PhD
- Board 62b **Abstract TPS11581:** PYNACLE phase 2 clinical trial of rezatopopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.
First Author: Alison M. Schram, MD
- Board 63a **Abstract TPS11582:** Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).
First Author: Andrew J. Wagner, MD, PhD
- Board 63b **Abstract TPS11583:** Phase I/II study to evaluate the feasibility and efficacy of sequential abemaciclib and gemcitabine treatment in patients with retinoblastoma (Rb)-positive leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLPS).
First Author: Elise F. Nassif Haddad, MD, PhD, MS
- Board 64a **Abstract TPS11584:** A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).
First Author: Hans Gelderblom, MD
- Board 64b **Abstract TPS11585:** ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.
First Author: Candace L. Haddox, MD
- Board 65a **Abstract TPS11586:** The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).
First Author: Dai Ogata, MD, PhD
- Board 65b **Abstract TPS11587:** Integrating early palliative care in advanced sarcoma patients for enhanced quality of life: The SARQUALITY study.
First Author: Catherine S. Weadick, MRCP
- Board 66a **Abstract TPS11588:** A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
First Author: Sant P. Chawla, MD

- Board 66b **Abstract TPS11589:** Trial in progress: TAGGED—A phase 2 study using low dose/metronomic trabectedin, gemcitabine, and dacarbazine as 2nd/3rd/4th line therapy for advanced soft tissue sarcoma (NCT04535271).
First Author: Samantha Jeffrey

9:45 AM-12:00 PM Opening Session

Opening Session

Location: Hall B1

Clifford A. Hudis, MD, FACP, FASCO

ASCO

Welcome and Introduction of Dr. Zon

Robin Zon, MD, FACP, FASCO

Cincinnati Cancer Advisors

President's Address

Ruth Porat

Alphabet, President and Chief Investment Officer

Guest Speaker's Address

Doug Abrams

Author, President and Founder of Idea Architects

Guest Speaker

Howard A. Burris III, MD, FACP, FASCO

Sarah Cannon Research Institute

Top Donor Recognition Ceremony

Dawn L. Hershman, MD, MS, FASCO

Herbert Irving Comprehensive Cancer Center, Columbia

University Irving Medical Center

David Karnofsky Science of Oncology Award Lecture

Eric P. Winer, MD, FASCO

Yale Cancer Center

Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)

1:15 PM-2:15 PM Case-Based Panel

Esophageal Cancer: Current Standards in an Ever-Changing Treatment Landscape

Location: Hall D1

Samuel J. Klempner, MD, FASCO—Chair

Massachusetts General Hospital

Moderator

Stephanie G. Worrell, MD

University of Arizona College of Medicine

Surgeon Perspective

Steven H. Lin, MD, PhD

The University of Texas MD Anderson Cancer Center

Radiation Oncologist Perspective

Bryan J. Schneider, MD, FASCO

Michigan Medicine

Medical Oncologist Perspective

Aki Smith, BA

Hope for Stomach Cancer

Patient Perspective

Panel Question and Answer

1:15 PM-2:30 PM Education Session

ASCO/AACR Joint Session: Lessons From Gene Therapy in Practice: Successes, Challenges, and How to Have Access for All

Location: E450a

Robin Zon, MD, FACP, FASCO—Chair

Cincinnati Cancer Advisors

Welcome and Introductory Remarks From ASCO President

Patricia LoRusso, PhD, DO, FASCO—Chair

Yale Cancer Center

Welcome and Introductory Remarks From AACR President

Haydar Frangoul, MD

Sarah Cannon Research Institute

Established Gene Therapy Options in the Clinic

Jimi Olaghere

Resurgence

How Gene Therapy Changed My Life

Anne Muigai, PhD, MSc

National Defence University-Kenya

Making Advances Actionable: How Do We Deliver These Therapies?

Katy Rezvani, MD

The University of Texas MD Anderson Cancer Center

Beyond CAR-T and CRISPR: The Promise of Natural Killer Cells

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Myeloproliferative Neoplasms and Chronic Myelogenous Leukemia: New Directions in Therapies and Sequencing Oral Agents

Location: E450b

Kristen M. Pettit, MD—Chair

University of Michigan

Novel Janus Kinase Inhibitors in Myeloproliferative Neoplasms

Timothy P. Hughes, MD, FRACP, FRCPA

South Australian Health and Medical Research Institute and University of Adelaide

Which Are the Best Tyrosine Kinase Inhibitors for Newly Diagnosed Chronic Myelogenous Leukemia?

Rebecca Klisovic, MD

University Hospitals

Is There a Role for Pegylated Interferons in Myeloproliferative Neoplasms in the Present Era?

Panel Question and Answer

1:15 PM-2:30 PM Education Session

The Microbiome's Influence on Cancer Therapy: Insights and Innovations

Location: Hall D2

Laurence Zitvogel, MD, PhD

Institut Gustave Roussy

Microbiota Signatures in Patients Receiving Immune Checkpoint Inhibitors

Jennifer Leigh McQuade, MD—Chair

The University of Texas MD Anderson Cancer Center

Designing Microbiome-Focused Clinical Trials in Cancer Immunotherapy

Arielle Elkrief, MD

Memorial Sloan Kettering Cancer Center

Strategies for Manipulating the Microbiome

Panel Question and Answer

1:15 PM-2:45 PM Clinical Science Symposium

The Future Is Now: Innovations in Medical Education

Location: E350

Nishin Bhadkamkar, MD, FASCO—Chair

The University of Texas MD Anderson Cancer Center

Sunandana Chandra, MD—Chair

Northwestern University

1:15 PM Simon Hughes, MD, FRCP, MBBS, FRCR

Guy's Cancer, Guy's and St Thomas' NHS Foundation Trust

Modern Learning in Action: Emerging Strategies

1:27 PM Abstract 9000: Implementation of a fellow-led tumor board to enhance learning and support in fellow continuity clinic.

First Author: Neha Hippalgaonkar, MD

1:39 PM Abstract 9001: Integration of a podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized control trial.

First Author: Vivek Patel, MD

1:51 PM Saiama Naheed Waqar, MS, MBBS

Washington University School of Medicine in St. Louis

Discussion of Abstract(s) 9000-9001: Finding the Frequency: Fellow-Driven Learning Initiatives

2:03 PM Abstract 9002: Perception and concerns of the hematology and oncology (HemOnc) workforce about artificial intelligence (AI) in clinical practice (CliPr) and medical education (MedED).

First Author: Guilherme Sacchi de Camargo Correia, MD

2:15 PM Douglas B. Flora, MD

Oncology Hematology Care, Inc

Discussion of Abstract(s) 9002: The Promises and Perils of Artificial Intelligence in Oncology Training

2:27 PM Panel Question and Answer

1:15 PM-2:45 PM Rapid Oral Abstract Session

Genitourinary Cancer—Kidney and Bladder

Location: Arie Crown Theater

David A. Braun, MD, PhD—Chair

Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine

Karie Runcie, MD—Chair

Columbia University Medical Center

1:15 PM Abstract LBA4513: ENLIGHTENED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC).

First Author: Vitaly Margulis, MD

- 1:21 PM** **Abstract 4514:** Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).
First Author: Naomi Balzer Haas, MD
- 1:27 PM** **Abstract 4515:** Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
First Author: Jad Chahoud, MD, MPH, MHA
- 1:33 PM** Panel Question and Answer
- 1:45 PM** **Abstract 4516:** Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis.
First Author: Tian Zhang, MD, MHS
- 1:51 PM** **Abstract 4517:** Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
First Author: Thomas Powles, MD, PhD, FCRP
- 1:57 PM** **Abstract 4518:** First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).
First Author: Andrea Necchi, MD
- 2:03 PM** Panel Question and Answer
- 2:15 PM** **Abstract 4519:** 9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study.
First Author: Shusuan Jiang, PhD
- 2:21 PM** **Abstract 4520:** CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment.
First Author: Bishoy Morris Faltas, MD
- 2:27 PM** **Abstract 4521:** AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.
First Author: Nicholas Cost
- 2:33 PM** Panel Question and Answer

1:15 PM-4:15 PM Oral Abstract Session

Breast Cancer—Metastatic

Location: Hall B1

Gregory A. Vidal, MD, PhD—Chair

West Cancer Center and Research Institute and University of Tennessee Health Sciences Center

Sharon H. Giordano, MD—Chair

The University of Texas MD Anderson Cancer Center

- 1:15 PM** **Abstract LBA1000:** Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
First Author: Erika P. Hamilton, MD
- 1:27 PM** **Abstract 1001:** Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator's choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
First Author: Giuseppe Curigliano, MD, PhD
- 1:39 PM** **William John Gradishar, MD, FACP, FASCO**
Northwestern University Feinberg School of Medicine
Discussion of Abstract(s) LBA1000-1001: New at the Dispensary: Easy Pills to Swallow?
- 1:51 PM** Panel Question and Answer
- 2:07 PM** **Abstract 1003:** INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC).
First Author: Nicholas C. Turner, MD, PhD
- 2:19 PM** **Abstract 1004:** Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2- LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
First Author: Mafalda Oliveira, MD, PhD
- 2:31 PM** **Abstract LBA1005:** A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
First Author: Stephen K.L. Chia, MD, FRCPC
- 2:43 PM** **Amy Sanders Clark, MD, MSCE**
Perelman School of Medicine at the University of Pennsylvania, Penn Medicine's Abramson Cancer Center
Discussion of Abstract(s) 1003-LBA1005: PIK Your Partner Carefully
- 2:55 PM** Panel Question and Answer
- 3:11 PM** **Abstract 1007:** Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
First Author: Sung-Bae Kim, MD

- 3:23 PM Abstract 1013:** Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06).
First Author: Rebecca Alexandra Dent, MD, FASCO
- 3:35 PM Sonya A. Reid, MD, MPH**
Vanderbilt-Ingram Cancer Center
Discussion of Abstract(s) 1007-1013: Evolving Choices in Metastatic Breast Cancer Care
- 3:47 PM** Panel Question and Answer

1:15 PM-4:15 PM Oral Abstract Session

Head and Neck Cancer

Location: S100a

Christine H. Chung, MD—Chair
Moffitt Cancer Centers

Christopher Douglas Willey, MD, PhD—Chair
University of Alabama at Birmingham

- 1:15 PM Abstract 6000:** Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).
First Author: Shlomo A. Koyfman, MD
- 1:27 PM Abstract 6001:** Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin, MD
- 1:39 PM Abstract 6002:** A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).
First Author: Dan Paul Zandberg, MD
- 1:51 PM Kevin Joseph Harrington, PhD, MBBS**
The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust
Discussion of Abstract(s) 6000-6002: Immunotherapy Gets Skin in the Game
- 2:03 PM** Panel Question and Answer
- 2:15 PM Abstract LBA6003:** PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.
First Author: Jun Ma, MD
- 2:27 PM Abstract 6004:** Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
First Author: Yuankai Shi, MD, PhD
- 2:39 PM Abstract LBA6005:** Becotatug Vedotin vs. Chemotherapy in Pre-heavily Treated Advanced Nasopharyngeal Carcinoma: A Randomize-controlled, Multicenter, Open-label Study.
First Author: Fei Han

- 2:51 PM Quynh-Thu Xuan Le, MD**
Stanford University
Discussion of Abstract(s) LBA6003-LBA6005: Sniffing Victory: Further Breakthroughs in Nasopharyngeal Cancer
- 3:03 PM** Panel Question and Answer
- 3:15 PM Abstract 6006:** SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results.
First Author: Guangliang Chen, MD
- 3:27 PM Abstract 6007:** Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVERY).
First Author: Susumu Okano, MD, PhD
- 3:39 PM Abstract 6008:** Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFM-ATC): A multicenter phase 2 trial.
First Author: Mark Zafereo, MD
- 3:51 PM Alan Loh Ho, MD, PhD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 6006-6008: Rare but Real: New Therapeutic Options
- 4:03 PM** Panel Question and Answer

1:30 PM-4:30 PM Poster Session

Lung Cancer—Non-Small Cell Metastatic

Location: Hall A - Posters and Exhibits

Posters by Topic

Biologic Correlates: Board(s) 1-21

Immunotherapies: Board(s) 22-66, 129a-138b

Targeted (Non-Immunotherapy): Board(s) 67-126, 127a-137a

- Board 1 Abstract 8521:** First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/ mNSCLC): Results from TROPION-Lung04 (cohort 5).
First Author: Saiama Naheed Waqar, MS, MBBS
- Board 2 Abstract 8522:** Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).
First Author: Enriqueta Felip, MD, PhD
- Board 3 Abstract 8523:** Whole-genome and transcriptome landscape of actionable driver-negative lung adenocarcinoma.
First Author: Masahiro Torasawa, MD, PhD
- Board 4 Abstract 8524:** Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC.
First Author: Jun Miyakoshi, MD
- Board 5 Abstract 8525:** Effects of immediate elevation of inflammatory cytokines after platinum, pemetrexed, and pembrolizumab on antitumor efficacy in advanced non-squamous, non-small cell lung cancer.
First Author: Yuichi Ozawa, MD, PhD

- Board 6 **Abstract 8526:** Characterization of histology-dependent immunobiological differences in metastatic NSCLC: Implications for treatment with PD-1 and LAG-3 inhibitors.
First Author: Hossein Borghaei, DO, MS
- Board 7 **Abstract 8527:** Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).
First Author: Martin Reck, MD, PhD
- Board 8 **Abstract 8528:** Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer.
First Author: Fatemeh Ardeshtir Larijani, MD
- Board 9 **Abstract 8529:** Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
First Author: Wenfeng Fang, MD, PhD
- Board 10 **Abstract 8530:** Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
First Author: Hibiki Udagawa, MD, PhD
- Board 11 **Abstract 8531:** Tumor-derived ILT5 and suppression of T cell immunity in non-small cell lung cancer.
First Author: Xuebing Fu
- Board 12 **Abstract 8532:** Prognostic value of baseline and dynamic circulating tumor cell monitoring in advanced lung cancer patients receiving immunotherapy.
First Author: Zhihui Wang
- Board 13 **Abstract 8533:** Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 $\geq 50\%$ metastatic NSCLC.
First Author: Vamsidhar Velcheti, MD, FACP, FCCP, FASCO
- Board 14 **Abstract 8534:** Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in KRAS-STK11 NSCLC.
First Author: Joshua Pothan, MD, PhD
- Board 15 **Abstract 8535:** A large validation study of AI-powered PD-L1 analyzer compared to pathologists' assessment of PD-L1 expression in lung cancer.
First Author: Yoshitaka Zenke, MD, PhD
- Board 16 **Abstract 8536:** Artificial intelligence-powered spatial analysis of tumor microenvironment in non-small cell lung cancer patients who acquired resistance after EGFR tyrosine kinase inhibitors.
First Author: Yeong Hak Bang, MD, PhD
- Board 17 **Abstract 8537:** Molecular analysis of lung adenocarcinomas from the SAFIRO2-Lung trial explores metastasis-associated alterations and potential prognostic markers.
First Author: Abderaouf Hamza, MS, PharmD
- Board 18 **Abstract 8538:** Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).
First Author: Nikita Dahake, MD

- Board 19 **Abstract 8539:** Spatial transcriptomic profiling of the tumor microenvironment in EGFR and KRAS mutant non-small cell lung cancer.
First Author: Fabian Johannes Bolte, MD
- Board 20 **Abstract 8540:** Immune landscape of liver metastases in advanced lung cancer.
First Author: Kamy Sankar, MD
- Board 21 **Abstract 8541:** Biomarker testing of lung cancer in North America versus globally.
First Author: Matthew Paul Smeltzer, PhD, MS
- Board 22 **Abstract 8542:** Prediction of site-specific immune-related adverse events of PD-L1 blockade in advanced non-small cell lung cancer through baseline organ-metastatic landscape: Pooled post-hoc analyses of two randomized controlled trials.
First Author: Si-Heng Wang, BM
- Board 23 **Abstract 8543:** A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.
First Author: Lin Wu, MD
- Board 24 **Abstract 8544:** Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
First Author: Yunan Nie, MD
- Board 25 **Abstract 8545:** Breaking barriers for patients with stage IV non-small cell lung cancer with brain metastases: Insight into the impact of immunotherapy on survival and survival disparities.
First Author: Reema Tawfiq, MD
- Board 26 **Abstract 8546:** Association between pretreatment emotional distress and survival outcomes in patients with advanced non-small-cell lung cancer: An individual patient data meta-analysis of 4632 patients in 7 trials.
First Author: Jian-Guo Zhou, MD, PhD
- Board 27 **Abstract 8547:** First-in-human study of CJRB-101, a live biotherapeutic product in combination with pembrolizumab in selected types of advanced or metastatic cancer.
First Author: Jii Bum Lee, MD, PhD
- Board 28 **Abstract 8548:** Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study.
First Author: Hongbing Liu
- Board 29 **Abstract 8549:** Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.
First Author: Sophie Cousin, MD
- Board 30 **Abstract 8550:** Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.
First Author: Tuan Hoang, PhD, MDCM

Board 31	Abstract 8551: A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy. First Author: Zainub Ajmal, MBBS	Board 45	Abstract 8565: Analysis of genomic and immune microenvironment differences in Chinese populations: Revealing potential mechanisms of poor immunotherapy outcomes in patients with EGFR mutation and ALK fusion non-small cell lung cancer. First Author: Junhong Lü
Board 33	Abstract 8553: Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. First Author: Cihui Yan	Board 46	Abstract 8566: A phase II study of durvalumab, doxorubicin, and ifosfamide in recurrent and/or metastatic pulmonary sarcomatoid carcinoma (KCSG LU-19-24). First Author: Bhumsuk Keam, MD, PhD
Board 35	Abstract 8555: T-cell effector cytokine signature as predictor of survival and toxicity in metastatic NSCLC patients treated with immunotherapy. First Author: Varshini Odayar, MS	Board 47	Abstract 8567: Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). First Author: Nirosha D. Perera, MD
Board 36	Abstract 8556: Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated non-small cell lung cancer with brain metastases. First Author: Rafi Aibani, MD	Board 48	Abstract 8568: Predictive implications of immune-related adverse events after exposure to VEGF inhibitors on outcomes in patients with advanced NSCLC treated with prior immune check point inhibitor. First Author: Jinah Kim, MD
Board 37	Abstract 8557: Updated analysis from NEJ045A study: Safety and efficacy of durvalumab plus carboplatin and etoposide for previously untreated extensive-stage small-cell lung cancer patients with a poor performance status. First Author: Tetsuhiko Asao, MD, PhD	Board 49	Abstract 8569: Digital pathology-based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer. First Author: Feyisope Eweje
Board 38	Abstract 8558: Avidity engineered multifunctional antibodies for stimulation and orchestration of innate and adaptive immune cells in tumor tissues. First Author: Robert Friesen, PhD, DPhil, MSc	Board 50	Abstract 8570: SMET12 and toripalimab combined chemotherapy in patients with advanced non-small cell lung cancer who are treatment-naïve or have developed resistance to standard therapy. First Author: Jinghui Lin, BS
Board 39	Abstract 8559: Predictive value of circulating tumor DNA detection for long-term survival in patients with advanced lung cancer undergoing chemoimmunotherapy. First Author: Hui Li	Board 51	Abstract 8571: Exploratory study on the impact of intestinal low-dose radiation on the efficacy and prognosis of immunotherapy in metastatic non-small cell lung cancer. First Author: Baiyang Huang
Board 40	Abstract 8560: Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization. First Author: Yan Xu, MD	Board 52	Abstract 8572: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes and tertiary lymphoid structures in non-small cell lung cancer patients treated with immune-checkpoint inhibitors±chemotherapy. First Author: Yeong Hak Bang, MD, PhD
Board 41	Abstract 8561: A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer. First Author: Yi-Long Wu, FACS	Board 53	Abstract 8573: First-line envafolelimab in combination with recombinant human endostatin and chemotherapy for advanced squamous non-small cell lung cancer: Updated results from a prospective, single-arm, multicenter phase II study. First Author: Lian Liu
Board 42	Abstract 8562: Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC. First Author: Valentina Santo, MD	Board 54	Abstract 8574: First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF ^{V600E} -mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. First Author: Alessandro Di Federico, MD
Board 43	Abstract 8563: Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with oncogene-driver negative NSCLC who have never smoked. First Author: Eleonora Gariazzo, MD	Board 55	Abstract 8575: A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC). First Author: Omar Shukri Yaghi, MD, MPH
Board 44	Abstract 8564: Efficacy and safety of metronomic oral vinorelbine combined with PD-1 inhibitors as first-line therapy in advanced non-small-cell lung cancer in elderly patients. First Author: Lin Li, MD		

Board 56 **Abstract 8576:** Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis.
First Author: Parth Sharma, MD, MBBS

Board 57 **Abstract 8577:** Artificial intelligence for immunotherapy response assessment in lung cancer using PET-CT reports.
First Author: Ozden Altundag, MD

Board 58 **Abstract 8578:** Multimodal AI using host, tumor, and ghost biomarker for predicting immunotherapy efficacy in NSCLC.
First Author: Vanja Miscovic

Board 59 **Abstract 8579:** Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy.
First Author: Yehonatan Elon, PhD

Board 60 **Abstract 8580:** Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: CJLSG1902.
First Author: Hidetoshi Itani

Board 61 **Abstract 8581:** Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction of outcomes across immunotherapy regimens in NSCLC: An external validation study.
First Author: Vamsidhar Velcheti, MD, FACP, FCCP, FASCO

Board 63 **Abstract 8583:** Validation of HistoTME-predicted immune subtypes and immunotherapy outcomes using human interpretable features (HIFs) from H&E images in non-small cell lung cancer.
First Author: Meghdad Sabouri Rad

Board 64 **Abstract 8584:** Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review.
First Author: Toshali Pandey, MBBS

Board 65 **Abstract 8585:** Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor-resistant advanced NSCLC: Evaluation of overall survival (OS).
First Author: Tomasz Jankowski, MD, PhD

Board 66 **Abstract 8586:** Efficacy profile of pembrolizumab for primary pulmonary NUT carcinoma: A systematic review and meta-analysis.
First Author: Amruth Akhil Alluri, BA

Board 67 **Abstract 8587:** Survival after osimertinib dose-reduction, discontinuation in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
First Author: Adam Barsouk, MD

Board 68 **Abstract 8588:** Clinical relevance of starting alectinib at a reduced dose in patients with ALK-positive non-small cell lung cancer.
First Author: Junkyu Kim, MD

Board 69 **Abstract 8589:** Depth of response and progression-free survival in patients with advanced ALK-positive non-small-cell lung cancer treated with lorlatinib.
First Author: Rosario Garcia Campelo, MD

Board 70 **Abstract 8590:** Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.
First Author: Geoffrey Liu, MD

Board 71 **Abstract 8591:** Dynamic changes in target protein expression following treatment in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 expression in paired biopsies.
First Author: Saori Murata, MD

Board 72 **Abstract 8592:** RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial.
First Author: Yu-Tao Liu

Board 73 **Abstract 8593:** Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C-mutated advanced non-small cell lung cancer: A systematic review and meta-analysis.
First Author: Wint Yan Aung, MD, MS

Board 75 **Abstract 8595:** Area deprivation index and EGFR-mutated non-small-cell lung cancer.
First Author: Michael Seth Weinfeld, DO

Board 76 **Abstract 8596:** Final results of afatinib plus chemotherapy with genomic profiling in osimertinib-refractory EGFR-mutant NSCLC: NEJ025B.
First Author: Akihiko Miyana, MD, PhD

Board 78 **Abstract 8598:** Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
First Author: Guzman Alonso, MD

Board 79 **Abstract 8599:** Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
First Author: Niels Reinmuth, MD

Board 80 **Abstract 8600:** A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058).
First Author: Caicun Zhou, MD, PhD, ABFT

Board 81 **Abstract 8601:** First-in-human phase I/II study of BYS10 in patients (pts) with locally advanced or metastatic RET-altered solid tumors: Preliminary dose escalation results.
First Author: Jianchun Duan

Board 82 **Abstract 8602:** Dysregulation of DNA damage repair in lung cancer driven by MTAP loss: Mechanistic insights and target discovery.
First Author: Bo Jiang, PhD

Board 83 **Abstract 8603:** Real-world treatment patterns and time-to-treatment discontinuation among advanced ALK-positive non-small cell lung cancer patients.
First Author: Rahul Mudumba, MHS

Board 84 **Abstract 8604:** Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.
First Author: Andrés Aguilar Hernandez, MD

Board 85	Abstract 8605: MK-1084 for KRAS G12C-mutated (mut) metastatic non-small-cell lung cancer (mNSCLC): Results from KANDLEIT-001. First Author: Adrian G. Sacher, MD, FRCPC, MMedSc	Board 97	Abstract 8617: Patient and caregiver treatment preferences for ALK+ non-small cell lung cancer in the United States. First Author: Christopher Danes, PhD
Board 86	Abstract 8606: Clinicogenomic analysis of EGFR-mutant lung cancers for identification of Rb inactivation as a hallmark of squamous transformation. First Author: Mark Yungjie Jeng, MD, PhD	Board 98	Abstract 8618: LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein-overexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy. First Author: Jonathan W. Goldman, MD
Board 87	Abstract 8607: Shifting landscape of resistance to next-generation ALK inhibitors with evolving treatment paradigm in ALK+ lung cancer. First Author: Sarah Walianny, MD, MS	Board 99	Abstract 8619: EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC). First Author: Sebastian Yves Friedrich Michels, MD
Board 88	Abstract 8608: Real-world comparative outcomes of alectinib and brigatinib in ALK-positive non-small cell lung cancer: A retrospective cohort analysis using HIRA data. First Author: Hyun Woo Lee, MD	Board 100	Abstract 8620: Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): Results from the Beamion LUNG-1 trial. First Author: Joshua K. Sabari, MD
Board 89	Abstract 8609: High-dose furmonertinib combined with bevacizumab and pemetrexed in non-small cell lung cancer patients with EGFR mutations and leptomeningeal metastasis: A prospective real-world study. First Author: Qi Zhao, MD	Board 101	Abstract 8621: Advancing evidence-based NSCLC testing and treatment across academic and community-based settings. First Author: Gilberto Lopes, MD, MBA, FASCO
Board 90	Abstract 8610: Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis. First Author: Daniel Shao-Weng Tan, PhD, MRCP, MBBS	Board 102	Abstract 8622: Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy. First Author: Gauthier Errasti, PhD, MSc
Board 91	Abstract 8611: Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial. First Author: Elisa Fontana, MD, PhD	Board 103	Abstract 8623: Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834). First Author: Kyoji Tsurumi, MD
Board 92	Abstract 8612: Exploring decisional needs of patients considering first line treatment of advanced EGFR+ lung cancer: An interpretive descriptive study. First Author: Rena Seeger, BSc	Board 104	Abstract 8624: Epigenetic and transcriptional consequences of MTAP-loss in lung adenocarcinoma. First Author: Swati Pothukuchi, BSc
Board 93	Abstract 8613: MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study. First Author: Rebecca Heist, MD	Board 105	Abstract 8625: Rare ALK: Clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK. First Author: Felix Carl Saalfeld, MD
Board 94	Abstract 8614: GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. First Author: Hyunjeong Lee, MS	Board 106	Abstract 8626: Clinico-genomic characteristics of clinical trial participation and its impact on clinical outcome in metastatic NSCLC: A nationwide database analysis in Japan. First Author: Kentaro Goshio, MD
Board 95	Abstract 8615: Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study. First Author: Li Zhang, MD	Board 107	Abstract 8627: Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study. First Author: Guanming Jiang
Board 96	Abstract 8616: Phase I/II study of DZD6008, a 4 th -generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC. First Author: Mengzhao Wang, MD, PhD	Board 108	Abstract 8628: Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC). First Author: Amin Nassar, MD

- Board 109 **Abstract 8629:** Safety and efficacy of ifebeamtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).
First Author: Zhengbo Song
- Board 111 **Abstract 8631:** Clinical outcomes of tepotinib and immune checkpoint inhibitor therapy for MET exon 14 skipping NSCLC: A multicentric retrospective analysis.
First Author: Kazuhito Misawa, MD
- Board 112 **Abstract 8632:** Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study.
First Author: Fei Zhou, MD, PhD
- Board 113 **Abstract 8633:** Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations: Heat on Beat randomized phase II study.
First Author: Nobuhiko Seki, MD, PhD
- Board 115 **Abstract 8635:** Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center.
First Author: Jeong Uk Lim, MD, PhD
- Board 116 **Abstract 8636:** Artificial intelligence-powered real-time model for predicting survival in advanced EGFR-mutant NSCLC.
First Author: Hyun Ae Jung, MD
- Board 117 **Abstract 8637:** Efficacy and omics-based insights of TROP2 ADC in non-small cell lung cancer with or without actionable genomic alterations (AGAs).
First Author: Anlin Li, MD
- Board 118 **Abstract 8638:** Real-world data on the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive advanced lung adenocarcinoma patients previously treated with lorlatinib.
First Author: Fen Wang, MD
- Board 119 **Abstract 8639:** Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.
First Author: Raffaele Califano, MD
- Board 120 **Abstract 8640:** Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, phase 2, cohort-1 trial.
First Author: Xiuning Le, MD, PhD
- Board 121 **Abstract 8641:** Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.
First Author: Jill Libles Feldman, MA
- Board 122 **Abstract 8642:** Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC).
First Author: Julie Anna Wiedower, MS
- Board 123 **Abstract 8643:** Comparable efficacy and safety of talrectinib for advanced ROS1+ non-small cell lung cancer across pivotal studies and between races and world regions.
First Author: Maurice Perol, MD
- Board 124 **Abstract 8644:** Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.
First Author: Gilberto Lopes, MD, MBA, FASCO
- Board 125 **Abstract 8645:** Final results of a phase II study of cabozantinib in patients with MET-altered lung cancers.
First Author: Guilherme Harada, MD
- Board 126 **Abstract 8646:** Rechallenge with first-generation RET inhibitors in RET-rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.
First Author: Arianna Marinello, MD
- Board 127a **Abstract TPS8647:** TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).
First Author: Shun Lu, MD, PhD
- Board 127b **Abstract TPS8648:** SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations.
First Author: Xiuning Le, MD, PhD
- Board 128a **Abstract TPS8649:** Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS^{G12C} mutant non-small-cell lung cancer.
First Author: Benjamin J. Solomon, PhD, MBBS
- Board 128b **Abstract TPS8650:** Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer.
First Author: Sun Min Lim, MD
- Board 129a **Abstract TPS8651:** Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
First Author: Stephen V. Liu, MD
- Board 129b **Abstract TPS8652:** KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non-small-cell lung cancer.
First Author: Charu Aggarwal, MD, MPH, FASCO
- Board 130a **Abstract TPS8653:** ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.
First Author: Clarissa Mathias, MD, PhD, FASCO

- Board 131a **Abstract TPS8655:** Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.
First Author: David Ross Camidge, MD, PhD
- Board 131b **Abstract TPS8656:** Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).
First Author: Ferdinandos Skoulidis, MD, PhD
- Board 132a **Abstract TPS8657:** FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
First Author: Dominique Arpin
- Board 132b **Abstract TPS8658:** TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein-overexpressing, locally advanced/metastatic non-squamous EGFR wildtype non-small cell lung cancer.
First Author: Alona Zer, MD
- Board 133a **Abstract TPS8659:** Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
First Author: Ben C. Creelan, MD, MS
- Board 133b **Abstract TPS8660:** NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
First Author: Toon Van Gorp, MD, PhD
- Board 134a **Abstract TPS8661:** A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).
First Author: Wei Zhong, PhD
- Board 134b **Abstract TPS8662:** Phase 2 cohort-2 trial in progress: Vabametakib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation.
First Author: Dae Ho Lee, MD, PhD
- Board 135a **Abstract TPS8663:** A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).
First Author: Xiuning Le, MD, PhD

- Board 135b **Abstract TPS8664:** A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non-small cell lung cancer: HARMONI-3.
First Author: Jianjun Zhang, MD, PhD
- Board 136a **Abstract TPS8665:** NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.
First Author: Xiuning Le, MD, PhD
- Board 136b **Abstract TPS8666:** Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
First Author: Sanjay Popat, PhD, FRCP
- Board 137a **Abstract TPS8667:** A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation.
First Author: Timothy A. Yap, MD, PhD
- Board 137b **Abstract TPS8668:** TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.
First Author: Giuseppe Lo Russo
- Board 138a **Abstract TPS8669:** A biomarker-directed, multicenter phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).
First Author: Valsamo Anagnostou, MD, PhD
- Board 138b **Abstract TPS8670:** A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).
First Author: Solange Peters, MD, PhD

1:30 PM-4:30 PM Poster Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Hall A - Posters and Exhibits

Posters by Topic

Adjuvant Therapy: Board(s) 139-148, 234a

Biologic Correlates: Board(s) 149-163, 234b

Local-Regional Non-Small Cell Lung Cancer: Board(s) 164-201, 235a-238a

Mesothelioma: Board(s) 202-208, 238b-239a

Small Cell Lung Cancer: Board(s) 209-228, 239b-242a

Thymic Malignancies: Board(s) 230-233

- Board 139 **Abstract 8018:** Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer.
First Author: Natasha Venugopal, MD
- Board 140 **Abstract 8019:** Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection.
First Author: Jair Bar, MD, PhD

- Board 142 **Abstract 8021:** Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003).
First Author: Si-Yu Wang, MD
- Board 143 **Abstract 8022:** IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
First Author: Heather A. Wakelee, MD, FASCO
- Board 144 **Abstract 8023:** Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: A retrospective study.
First Author: Jorge Raul Vazquez Urrutia, MD
- Board 145 **Abstract 8024:** Ensartinib as postoperative adjuvant therapy in patients with ALK-positive non-small cell lung cancer (NSCLC): A registered, retrospective, real-world study.
First Author: Lin Wang, MD
- Board 146 **Abstract 8025:** Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.
First Author: Si-Yang Maggie Liu, DM
- Board 147 **Abstract 8026:** Molecular profiling and survival in oncogene-addicted resected stage II/III non-small cell lung cancer (NSCLC): A study from the Lung ART IFCT 0503 trial.
First Author: Victor Albarran-Artahona, MD
- Board 148 **Abstract LBA8027:** An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
First Author: David R. Spigel, MD, FASCO
- Board 149 **Abstract 8028:** A panel of four protein tumor markers for effective and affordable lung cancer early detection by artificial intelligence.
First Author: Mao Mao, MD, PhD
- Board 150 **Abstract 8029:** Genomic characterization of STAS in stage 1 EGFR-mutated NSCLC and prognostic implications.
First Author: Stephanie Pei Li Saw, PhD, MBBS
- Board 151 **Abstract 8030:** Genomic and immunophenotypic landscape of early-stage pulmonary carcinoid tumors.
First Author: Song Xu, PhD
- Board 152 **Abstract 8031:** Association of 8-gene signature with early recurrence in resected non-small cell lung cancer.
First Author: Arsalan A. Khan, MD, MBBS
- Board 153 **Abstract 8032:** Study on optimizing serum-based lung cancer diagnosis using a multi-biomarker approach.
First Author: Hyejin Sung, PhD
- Board 154 **Abstract 8033:** A novel aptamer-based non-invasive test for lung cancer: A proof-of-concept.
First Author: Line Nederby, PhD
- Board 155 **Abstract 8034:** Diagnostic properties of a novel ctDNA assay for lung cancer detection.
First Author: Peter Hjorth-Hansen, MD
- Board 156 **Abstract 8035:** Actionable gene alterations in resected non-small cell lung cancer (AGA-R study).
First Author: Ilaria Attili, MD
- Board 157 **Abstract 8036:** Tumor type prediction via tissue- and liquid-based comprehensive genomic profiling: High-specificity tobacco signature detection to support lung cancer diagnosis.
First Author: Soo-Ryum Yang, MD
- Board 158 **Abstract 8037:** Racial and ethnic disparities in risk of second primary lung cancer among initial lung cancer survivors in the United States.
First Author: Pragati Gole Advani, MD, DrPH, MPH
- Board 159 **Abstract 8038:** Longitudinal EGFR assessment in plasma and tissue samples in early non-small cell lung cancer (NSCLC).
First Author: Sara Torresan, MD
- Board 160 **Abstract 8039:** Clinical utility of pathologist-directed comprehensive comparative molecular profiling for the classification of separate primary lung cancers vs. intrapulmonary metastasis.
First Author: Douglas I. Lin, MD, PhD
- Board 161 **Abstract 8040:** A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial.
First Author: Chang Gon Kim, MD, PhD
- Board 162 **Abstract 8041:** Genomic landscape of NSCLC with no targetable driver mutation among different races: An exploratory analysis of the AACR Project GENIE Database.
First Author: Yazan Hamadneh, MD
- Board 163 **Abstract 8042:** Trends in lung cancer epidemiology and mortality over 12 years: Socioeconomic and demographic disparities.
First Author: Ali Shahbaz Baloch, MBBS
- Board 164 **Abstract 8043:** Safety and efficacy of radiotherapy combined with anlotinib in locally advanced non-small cell lung cancer patients intolerant to concurrent chemoradiotherapy: Preliminary result of a phase II clinical trial.
First Author: Yupei Yuan
- Board 165 **Abstract 8044:** Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma: A multicentre retrospective study.
First Author: Zan Hou, MD
- Board 166 **Abstract 8045:** Neoadjuvant immunotherapy and surgery in patients with stage IIIB-IIIC (N3) non-small cell lung cancer.
First Author: Wen-Yu Zhai
- Board 167 **Abstract 8046:** Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
First Author: Tina Cascone, MD, PhD
- Board 168 **Abstract 8047:** Initial treatment and survival outcomes for early-stage NSCLC in Veterans: Insights from cancer cube data.
First Author: Madison Panell, DO

- Board 169 **Abstract 8048:** Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.
First Author: Nan Bi, MD, PhD
- Board 170 **Abstract 8049:** A prospective, single-arm, phase II study to evaluate the efficacy and safety of perioperative tislelizumab in resectable non-small-cell lung cancer (NSCLC).
First Author: Daqiang Sun
- Board 171 **Abstract 8050:** Characteristics, treatment patterns, and outcomes of HIV-associated lung cancer.
First Author: Tina Roy, MD
- Board 172 **Abstract 8051:** Impact of lymph node characteristics on clinical outcomes in clinical N2 non-small cell lung cancer patients treated with chemoradiotherapy: Single- vs. multiple-stations, bulky vs. non-bulky and discrete vs. infiltrative.
First Author: Yuki Kato, MD
- Board 173 **Abstract 8052:** Outcomes with neoadjuvant chemotherapy and/or osimertinib in patients with EGFR-mutant resectable non-small cell lung cancers.
First Author: Prashasti Agrawal, MD
- Board 174 **Abstract 8053:** Leveraging electronic medical records for early lung cancer diagnosis: An evaluation of the C the Signs AI cancer prediction platform using the Mayo data platform.
First Author: Seema Dadhanania, MBBS
- Board 175 **Abstract 8054:** Survival impact of lymphocytopenia during chemoradiation in locally advanced NSCLC patients treated with adjuvant durvalumab.
First Author: Monika Satoskar, MD, MPH
- Board 176 **Abstract 8055:** Lung cancer screening in high-risk never-smokers with artificial intelligence (LC-SHIELD study).
First Author: Molly S.C. Li, MBBS
- Board 178 **Abstract 8057:** Enhancing early detection of lung cancer: Methylation anchor probe for low-signal enrichment (MAPLE).
First Author: Wenzhao Zhong
- Board 179 **Abstract 8058:** Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase I/II trial.
First Author: Xiao-yang Li
- Board 180 **Abstract 8059:** Clinical outcomes with definitive surgery or radiotherapy after neoadjuvant immunochemotherapy in stage II-III NSCLC: Full cohort pragmatic analysis.
First Author: Jie He, MD PhD
- Board 181 **Abstract 8060:** ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC).
First Author: Jay M. Lee, MD
- Board 182 **Abstract 8061:** Unique mutational landscape and therapeutic implications in non-small cell lung cancer with comorbid fibrotic interstitial lung disease.
First Author: Jacob Michalski, MD
- Board 183 **Abstract 8062:** Differential prognostic significance of distant and locoregional recurrence on survival in surgically resected non-small cell lung cancer post-chemotherapy: Multicenter dynamic prediction with landmark model.
First Author: Zeliang Ma, MD
- Board 184 **Abstract 8063:** Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).
First Author: Min Fang, MD
- Board 185 **Abstract 8064:** Five-year survival outcomes from CRES³T: S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
First Author: Kazuya Takamochi, MD, PhD
- Board 186 **Abstract 8065:** Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.
First Author: Yuki Matsumura
- Board 187 **Abstract 8066:** Are we casting the net wide enough? Applying the proposed lung cancer screening criteria in single centre lung cancer resections.
First Author: Clement Lim
- Board 188 **Abstract 8067:** Commission on Cancer lung cancer surgery quality metric and overall survival in a population-based cohort.
First Author: Sora Ely, MD
- Board 189 **Abstract 8068:** Racial and ethnic disparities in receipt of guideline concordant treatment for early-stage non-small cell lung cancer in Los Angeles County.
First Author: Miriam L. Gorbatov, MPH
- Board 190 **Abstract 8069:** Impact of time to neoadjuvant treatment initiation (TTI) for resectable non-small cell lung cancer (NSCLC) on clinical outcomes.
First Author: Srinidhi Radhakrishnan, MD
- Board 191 **Abstract 8070:** Driving precision oncology in lung cancer: Patient stratification through comprehensive genomic profiling.
First Author: Vidya H. Veldore
- Board 192 **Abstract 8071:** Real-world (rw) study to identify disparities in outcomes for patients (pts) with early-stage resected NSCLC who received biomarker-targeted adjuvant treatment (BTRx).
First Author: Raymond U. Osarogiagbon, MBBS, FACP, FASCO
- Board 193 **Abstract 8072:** Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
First Author: Giorgio Caturegli, MD
- Board 194 **Abstract 8073:** Sequential versus concurrent strategy of immunotherapy and radiotherapy in advanced non-small-cell lung cancer: A territory-wide multicenter study (OCEANUS study).
First Author: Han Zhou

- Board 195 **Abstract 8074:** Evaluating lung cancer clinical characteristics and tumor subtypes using cell-free DNA fragmentomes.
First Author: Milou Schuurbijs, MD
- Board 196 **Abstract 8075:** EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.
First Author: Willdragon Wang, BS
- Board 197 **Abstract 8076:** A retrospective study of induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced non-small cell lung cancer.
First Author: Yuliang Meng
- Board 198 **Abstract 8077:** Association of radiomic features with disease-free survival following neoadjuvant chemoimmunotherapy in resectable NSCLC.
First Author: Bryan Berube, MD
- Board 199 **Abstract 8078:** Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer.
First Author: Jay M. Lee, MD
- Board 200 **Abstract 8079:** Pronounced gender-based and regional disparities in lung cancer mortality in the US: Insights from five decades of nationwide mortality data.
First Author: Muhammad Ahmad
- Board 201 **Abstract 8080:** Radiomic signatures as predictors of pathological response to neoadjuvant chemoimmunotherapy in surgically resected NSCLC.
First Author: Ryan Brown, MD
- Board 202 **Abstract 8081:** Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma.
First Author: Jessica Ross, MD
- Board 203 **Abstract 8082:** Test performance of a DNA methylation-based liquid biopsy biomarker for detection and classification of pleural mesothelioma (PM).
First Author: Sabine Schmid
- Board 204 **Abstract 8083:** Prognostic significance of VISTA expression in patients with malignant pleural mesothelioma treated with nivolumab: Results of a retrospective multi-institutional analysis (HOT1901).
First Author: Hiroshi Yokouchi, MD, PhD
- Board 205 **Abstract 8084:** Digital spatial profiling for identification of prognostic genes and molecular subgroups in pleural mesothelioma.
First Author: Mercedes Herrera, MD, MSc
- Board 207 **Abstract 8086:** Multiomics profiling for prediction of immunotherapy response in advanced pleural mesothelioma: Sub-study of the NIPU trial.
First Author: Mehrdad Rakaee, PhD
- Board 208 **Abstract 8087:** Phase III study on atezolizumab versus placebo in adjuvant therapy of pleural mesothelioma patients after pleurectomy/decortication: Preliminary results of the AtezoMeso study.
First Author: Maria Pagano

- Board 209 **Abstract 8088:** Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.
First Author: Mitchell Parma, MD
- Board 210 **Abstract 8089:** A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
First Author: Qiming Wang, MD
- Board 211 **Abstract 8090:** Efficacy and safety of envafolelimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial.
First Author: Shengjie Sun
- Board 212 **Abstract 8091:** Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer.
First Author: Triparna Sen, PhD
- Board 214 **Abstract 8093:** Serplulimab versus placebo plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study.
First Author: Ying Cheng, MD
- Board 215 **Abstract 8094:** DAREONTM-9, a phase Ib study of obixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results.
First Author: Martin Wermke
- Board 216 **Abstract 8095:** Lung cancer enrollment of demographic subgroups in US clinical trial sites.
First Author: Evon Okidi, ScM, MSc
- Board 217 **Abstract 8096:** Comprehensive longitudinal immune cell monitoring in patients with extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy to predict early relapse.
First Author: Seren Durer, MD
- Board 218 **Abstract 8097:** Efficacy and safety of HTMC0435 combination with temozolomide in relapsed extensive-stage small-cell lung cancer (ES-SCLC): A phase Ib/II study.
First Author: Yun Fan, MD
- Board 219 **Abstract 8098:** Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.
First Author: Valentina Gambardella, MD, PhD
- Board 220 **Abstract 8099:** Does early versus late initiation of immunotherapy in extensive-stage small cell lung cancer affect survival outcomes?
First Author: Paresh Kumar
- Board 221 **Abstract 8100:** Predictive and prognostic impacts of SCLC comprehensive index (SCI) in extensive-stage small-cell lung cancer (ES-SCLC) treated with chemo-immunotherapy.
First Author: Songji Oh, PhD

- Board 222 **Abstract 8101:** Multi-omic analysis and overall survival update of phase II TRIDENT study: Durvalumab plus olaparib in extensive-stage small-cell lung cancer (ES-SCLC).
First Author: Yuanyuan Zhao, PhD
- Board 223 **Abstract 8102:** Impact of immunotherapy on small cell lung cancer survival: A focus on treatment setting, race, and socioeconomics.
First Author: Pranali Santhoshini Pachika, MD
- Board 225 **Abstract 8104:** Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC).
First Author: Jacob Sands, MD
- Board 226 **Abstract 8105:** Association of IFITM3 with the efficacy of anti-PD1/PD-L1 therapy and regulation of immunosensitivity via MHC-I regulation in SCLC.
First Author: Shengxiang Ren, PhD
- Board 227 **Abstract 8106:** Implementation of tarlatamab treatment for small cell lung cancer using an outpatient care program.
First Author: Jennifer W. Carlisle, MD
- Board 228 **Abstract 8107:** Cataloging genomic and transcriptomic features of relapsed SCLC.
First Author: Sid Devarakonda, MD
- Board 230 **Abstract 8109:** A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas.
First Author: Ning Xu
- Board 231 **Abstract 8110:** Combining SBRT with GM-CSF and peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors: A single arm, single center, phase II trial.
First Author: Min Fan
- Board 232 **Abstract 8111:** Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors.
First Author: Harold Nathan C. Tan, MD, MBA
- Board 233 **Abstract 8112:** Pathomics-based prediction of thymic epithelial tumor subtypes within the French RYTHMIC network.
First Author: Lodovica Zullo, MD
- Board 234a **Abstract TPS8113:** Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).
First Author: Raid Aljumaily, MD
- Board 234b **Abstract TPS8114:** GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients.
First Author: Douglas C. Palmer, PhD
- Board 235a **Abstract TPS8115:** KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II-IIIb (N2) non-small-cell lung cancer (NSCLC).
First Author: Konstantin H. Dragnev, MD
- Board 235b **Abstract TPS8116:** A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).
First Author: Ardy Davarifard, MD, PhD
- Board 236a **Abstract TPS8117:** Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).
First Author: Ekaterine Arkanian, MD
- Board 236b **Abstract TPS8118:** Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.
First Author: Eziafa Oduah, MD, PhD, MPH
- Board 237a **Abstract TPS8119:** Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial.
First Author: Hye Ryun Kim, MD, PhD
- Board 237b **Abstract TPS8120:** Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
First Author: Friederike C. Althoff, MD
- Board 238a **Abstract TPS8121:** Efficacy of low-dose nivolumab combined with chemotherapy as neoadjuvant treatment for lung cancer.
First Author: Aline Fusco Fares, MD, MSc
- Board 238b **Abstract TPS8122:** Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study).
First Author: Giulia Pasello, MD, PA
- Board 239a **Abstract TPS8123:** Trial in progress: Sacituzumab govitecan for the treatment of patients with diffuse pleural mesothelioma.
First Author: Michael Offin, MD
- Board 239b **Abstract TPS8124:** TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.
First Author: Melissa Lynne Johnson, MD, FASCO
- Board 240a **Abstract TPS8125:** Radiotherapy integration strategy for small-cell lung cancer in extensive stage (RISE) with up to 10 metastases: A study protocol of a randomized phase II trial.
First Author: Łukasz Kuncman
- Board 240b **Abstract TPS8126:** A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC).
First Author: Bo Wang, MD

- Board 241a **Abstract TPS8127:** The TIGOS trial: A randomized, double-blind phase 3 trial of atigotatug + nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with 1L extensive-stage small cell lung cancer (ES-SCLC).
First Author: Luis G. Paz-Ares, MD, PhD
- Board 241b **Abstract TPS8128:** An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).
First Author: Jacob Sands, MD
- Board 242a **Abstract TPS8129:** A global phase III, double-blind, randomized trial of BNT327/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
First Author: Martin Reck, MD, PhD
- Board 242b **Abstract TPS8130:** IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.
First Author: Michaël Duruisseaux, MD, PhD

1:30 PM-4:30 PM Poster Session

Prevention, Risk Reduction, and Genetics

Location: Hall A - Posters and Exhibits

Posters by Topic

Cancer Prevention: Board(s) 246-275, 348a-350b

Etiology/Epidemiology: Board(s) 276-290

Germline Genetic Testing: Board(s) 292-320

Health Promotion/Behaviors: Board(s) 321-328

Hereditary Cancer Syndromes: Board(s) 329-347

- Board 246 **Abstract 10521:** Large-scale clinical validation of a blood-based, multi-cancer, early detection test across different sample types, platforms, and populations.
First Author: Mao Mao, MD, PhD
- Board 247 **Abstract 10522:** Multi-cancer risk prediction in asymptomatic adults using urinary glycosaminoglycan profiling.
First Author: Francesco Gatto, PhD, MSc
- Board 248 **Abstract 10523:** The effect of metformin exposure on colorectal cancer incidence according to tumor sidedness.
First Author: Yehudit Peerless, MD
- Board 249 **Abstract 10524:** Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer.
First Author: Kelly-Anne Phillips, FRACP, MBBS
- Board 250 **Abstract 10525:** Colonoscopy quality indicators for colorectal cancer precursors: Sessile serrated lesion and adenoma detection rates from a large clinical study of a blood-based test for CRC screening.
First Author: Man Yee Wong, MPH, MBBS

- Board 251 **Abstract 10526:** Machine learning for cancer risk stratification: A bi-directional approach to screening.
First Author: Erez Hasnis
- Board 252 **Abstract 10527:** Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: A real-world study with implications for cancer prevention/interception.
First Author: Martino Oliva, MSc
- Board 253 **Abstract 10528:** Growing burden of cancer and high body mass index in the United States from 1990-2021: A benchmarking cross-state analysis.
First Author: Adit Dharia, MD, MBBS
- Board 254 **Abstract 10529:** Sex-based disparities in HPV-related cancer outcomes: Insights into social determinants of health.
First Author: Xiangren Wang
- Board 255 **Abstract 10530:** Do health care providers offer advice to adolescents about nicotine-containing product use?
First Author: Michael T. Halpern, MD, PhD, MPH, FASCO
- Board 256 **Abstract 10531:** Awareness, knowledge, and attitudes toward breast cancer polygenic risk scores for precision prevention in a multiethnic cohort of high-risk women.
First Author: Jincong Q. Freeman, MPH, MS
- Board 257 **Abstract 10532:** Evaluating the impact of long-term glucocorticoid use on cancer risk in patients with rheumatologic diseases: A retrospective cohort study.
First Author: Farigol Hakem Zadeh, DO
- Board 258 **Abstract 10533:** The Selfie study: Cervical precancer detection using novel human papillomavirus biomarkers.
First Author: Sarah Phillips, MD
- Board 259 **Abstract 10534:** Analyzing trends in multimorbidity-related mortality among patients with cancer and myocardial infarction: A decadal analysis.
First Author: Abdul Ahad, MBBS
- Board 260 **Abstract 10535:** Can we determine the mechanism behind cancer risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1RAs)?
First Author: Junmin Song, MD, MS
- Board 261 **Abstract 10536:** Estimation of population attributable fractions based on integrated global cancer incidence data, 1990-2021.
First Author: Yongjie Xu
- Board 262 **Abstract 10537:** Development and clinical validation of a cell-free DNA methylation sequencing test for multi-cancer early detection.
First Author: Xiaosheng He
- Board 263 **Abstract 10538:** Utilizing cancer community outreach and engagement to explain impact of age, income, residence, knowledge, and survivorship on cancer fatalism in urban and rural/marginalized areas.
First Author: Runcie C.W. Chidebe, MS, MSc
- Board 264 **Abstract 10539:** Machine learning-informed navigation of patients in persistent poverty zip codes to improve colorectal cancer screening: A prospective controlled study.
First Author: Ravi Bharat Parikh, MD, MPP

- Board 265 **Abstract 10540:** Clinical and radiological characteristics of intermediate and high-risk cases in the Brazilian early lung cancer screening trial (BRELT3): Insights into Lung-RADS categories 3 and 4 and biopsy decision-making factors.
First Author: Audrey Cabral Ferreira de Oliveira, MD
- Board 266 **Abstract 10541:** Cost-effectiveness analysis of population-based screening for 6-gene panel testing for hereditary breast and ovarian cancer.
First Author: Giovanni Galvis Rojas
- Board 267 **Abstract 10542:** The potential of multi-cancer early detection screening in reducing cancer incidence and mortality in high-risk groups: A modeling study.
First Author: Jagpreet Chhatwal, PhD
- Board 268 **Abstract 10543:** One-year impact of a large-scale pilot multimodal personalized early cancer detection and prevention program for individuals at high risk of cancers.
First Author: Tarek Ben Ahmed, MD, MSPH
- Board 269 **Abstract 10544:** Clinical impact of integrating polygenic risk scores with breast cancer risk assessment models: Results from the prospective multisite GENRE-2 clinical trial.
First Author: Siddhartha Yadav, MD
- Board 270 **Abstract 10545:** Genetic predictors of 16,000 multi-omic traits and associations with breast cancer survival outcomes in the Pathways Study.
First Author: Arya Mariam Roy, MD
- Board 271 **Abstract 10546:** Impact of 2021 United States cancer screening guideline changes on racial and ethnic differences in patient-reported adherence to age-appropriate colorectal cancer screening.
First Author: Nishwant Swami, MD, MPH
- Board 272 **Abstract 10547:** Bariatric surgery and risk of gastrointestinal and hormone-sensitive cancers in patients with metabolic-associated steatotic liver disease and obesity: A multicenter matched cohort study.
First Author: Diptasree Mukherjee, MD
- Board 273 **Abstract 10548:** Escalating burden and trend of cancer attributable to smoking in Southeast Asia, east Asia and Oceania from 1990-2021: A benchmarking systematic analysis.
First Author: Abdullah Jamal, MD, MBBS
- Board 274 **Abstract 10549:** Global burden and trend of pancreatic cancer in high-income countries: A 30-year analysis of disease dynamics.
First Author: Anmol Singh, MD
- Board 275 **Abstract 10550:** Evaluation of a plasma cell-free DNA methylation-based multi-cancer detection test.
First Author: Yupeng He
- Board 276 **Abstract 10551:** Incidence of viral and non-viral etiologies of hepatocellular carcinoma (HCC) in the US over time by race and ethnicity.
First Author: Mona Cai, PhD
- Board 277 **Abstract 10552:** Early-onset (EO) cancer trends in Brazil: A comprehensive analysis of hospital-based cancer registry data (2000–2019).
First Author: Wesley Rocha Grippa Sr, PhD
- Board 278 **Abstract 10553:** Evaluation of a polygenic risk score for breast cancer in Chinese women: A three-stage case-control study of 13,715 subjects.
First Author: Yuxiang Lin, MD, PhD
- Board 279 **Abstract 10554:** Trends in cancer incidence in Singapore over the last two decades.
First Author: Hui Miao, PhD
- Board 280 **Abstract 10555:** Racial differences in the association between agent orange exposure and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US Veterans.
First Author: Lawrence W. Liu, MD
- Board 281 **Abstract 10556:** Lung cancer combined with interstitial lung disease: Controversial role of preexisting hypertension and emphysema observed in a fully followed 20-year patient cohort.
First Author: Zhichao Wang
- Board 282 **Abstract 10557:** GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.
First Author: Guo Cheng, MD, PhD
- Board 283 **Abstract 10558:** Unmasking the link between sleep apnea and lung cancer risk: A retrospective propensity-matched cohort study.
First Author: Mohammed Al-Nusair, MD
- Board 284 **Abstract 10559:** Exposure to Di-2-ethylhexyl phthalate and hormone receptor-positive breast cancer incidence.
First Author: Lijuan Tang, PhD
- Board 285 **Abstract 10560:** Burden and trend of breast cancer attributable to high red meat consumption in the United States from 1990-2021: An insight from the Global Burden of Disease study 2021.
First Author: Shivani Modi, MD
- Board 286 **Abstract 10561:** Recent trends in cancer distribution and survival outcomes among adolescent and young adult patients: A national data analysis.
First Author: Fatma Nihan Akkoc Mustafayev, MD
- Board 287 **Abstract 10562:** Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database.
First Author: Gregory Sampang Calip, PhD, MPH, PharmD
- Board 288 **Abstract 10563:** Decoding tumour bacterial ecosystems: Topological data analysis of bacterial association with immunogenicity.
First Author: Eva Lymberopoulos, MSc
- Board 289 **Abstract 10564:** Environmental PFAS exposure as an understudied social determinant of health for endometrial cancer disparities: A geospatial study in Florida.
First Author: Ming Sheng Lee, MD
- Board 290 **Abstract 10565:** Nationwide analysis and trend of liver cancer mortality attributable to drug use in United States from 1991 to 2021.
First Author: Adit Patel, MD
- Board 292 **Abstract 10567:** Germline pathogenic variants in BRCA1-, BRCA2-, and PALB2- genes among Ethiopian young women and men diagnosed with breast cancer.
First Author: Tove Ekdahl Hjelm, MD

- Board 293 **Abstract 10568:** Discrepancies between germline and somatic laboratories in the reporting of germline cancer predisposition variants.
First Author: Brittany Cooper, MA
- Board 294 **Abstract 10569:** Implementation of pan-cancer universal germline testing in an ethnically diverse and rural community oncology practice.
First Author: Sarah Nielsen Young, MS, CGC
- Board 295 **Abstract 10570:** Preventative intervention uptake among women with breast cancer and pathogenic germline variants.
First Author: Sarah Nielsen Young, MS, CGC
- Board 296 **Abstract 10571:** Better together: Synergy of germline and somatic testing in HRR pathway-driven cancers.
First Author: Michelle Green, PhD
- Board 297 **Abstract 10572:** Polygenic risk score for breast cancer in the Thai population: Addressing genetic disparities in underrepresented populations.
First Author: Phuwanat Sakornsakolpat, MD
- Board 298 **Abstract 10573:** Histopathologic and demographic features of non-small cell lung cancer in patients with BRCA pathogenic germline variants.
First Author: Benjamin Aaron Bleiberg, MD
- Board 299 **Abstract 10574:** Profiling DNA damage response in ATM/BRCA2 carriers to inform hereditary cancer risk.
First Author: Demitrios Dedousis, MD
- Board 300 **Abstract 10575:** Age-related germline landscape of endometrial cancer: Focus on early-onset cases.
First Author: Judy J. Wang, MD, MS
- Board 301 **Abstract 10576:** Leveraging high variant allele frequencies (VAF) of DNA damage repair (DDR) mutations (mut) in liquid biopsy (LBx) as a surrogate for germline testing: Implications for precision medicine.
First Author: Sagal Pannu, MD
- Board 302 **Abstract 10577:** Estimated prevalence of pathogenic variants in patients with breast, colon, and/or endometrial cancer who do not meet guidelines for genetic testing.
First Author: Ryan Bernhisel
- Board 303 **Abstract 10578:** Performance of previously described polygenic risk scores for prostate cancer in a population with mixed ancestry.
First Author: Vinicius Marques Rocha, MSc
- Board 304 **Abstract 10579:** Frequency and spectrum of BRCA pathogenic/likely pathogenic variants in the Hispanic population of south Florida: A retrospective analysis.
First Author: Srika Amin
- Board 305 **Abstract 10580:** Mainstreaming the diagnosis of Lynch syndrome (LS) in colorectal cancer (CRC) patients: The ItaLynch study.
First Author: Alberto Puccini, MD
- Board 306 **Abstract 10581:** Identification of germline hereditary cancer syndrome variants and associated cancers in a healthcare biobank population.
First Author: Juliann Savatt, MS

- Board 307 **Abstract 10582:** Clinical characteristics of young-onset breast cancer and the role of germline pathogenic variants.
First Author: Nara Tashjian
- Board 308 **Abstract 10583:** NuGenA (Nurse Led Genetic Counselling and Awareness): A proof-of-concept to implementation of genetic counseling for HBOC in LMICs.
First Author: Asima Mukhopadhyay, MD, PhD, MSc, MRCOG
- Board 309 **Abstract 10584:** Concordance of somatic whole exome sequencing and germline genotyping of DPYD to screen for DPD deficiency.
First Author: Aditya Sharma, MD
- Board 310 **Abstract 10585:** Clinical features and occurrence of other cancers in patients with chronic lymphocytic leukemia and their families with POT1 tumor predisposition syndrome.
First Author: Jennifer Croden, MD
- Board 311 **Abstract 10586:** Incidence of concurrent pathogenic variants in BRCA1 breast cancer patients.
First Author: Angel Lok Yiu Lee, MBChB
- Board 312 **Abstract 10587:** Exploring the prevalence of germline mutations in young-onset biliary tract cancer (BTC).
First Author: Osama M. MoSalem, MD, MBChB
- Board 313 **Abstract 10588:** Limited versus expanded multigene germline genetic testing among adolescents and young adults (AYA) with breast cancer.
First Author: Baha' Sharaf, MD
- Board 314 **Abstract 10589:** Sequential EHR interventions to increase genetic testing for breast and ovarian cancer predisposition across diverse patient populations in gynecology practices at Penn Medicine.
First Author: Heather Symecko, MPH
- Board 315 **Abstract 10590:** Clinical utility of germline genetic testing in diverse cancer types.
First Author: Diane Renee Koeller, CGC, MS, MPH
- Board 316 **Abstract 10591:** Clinical significance of germline CFTR mutations in pancreatic cancer.
First Author: Nicholas Liguori, MD
- Board 317 **Abstract 10592:** Germline genetic testing for hereditary cancer syndromes among newly diagnosed patients with solid tumors: A report of 10,000 patients from the Jordanian Exploratory Cancer Genetics study.
First Author: Hikmat Abdel-Razeq, MD
- Board 318 **Abstract 10593:** Results of a program addressing multi-level barriers to completion of hereditary cancer genetic testing (GT) among underserved and minority individuals in Texas.
First Author: Darya Aleksandrovna Kizub, MD
- Board 319 **Abstract 10594:** Germline genetic testing among patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.
First Author: Udhayvir Singh Grewal, MD

Board 320	Abstract 10595: Concordance of parent-of-origin predictions for hereditary cancer variants using proband-only analysis. First Author: Lilian Cordova	Board 336	Abstract 10611: Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: 32-month follow-up from a single-center exploratory study. First Author: Sai Ge, MD, PhD
Board 321	Abstract 10596: Clinical decision support system based on artificial intelligence and the patient's subjective intention treatment model: A randomized controlled clinical trial. First Author: Lu Wang, MD	Board 337	Abstract 10612: A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs). First Author: Bahar Laderian, MD
Board 323	Abstract 10598: Impact of incretin mimetic therapy on weight change in patients with cancer: A pan-cancer analysis from a single institutional cohort. First Author: Yan Leyfman, MD	Board 338	Abstract 10613: Genetics and family history in a diverse cohort of females with early-onset breast cancer. First Author: Tanaya Shroff
Board 324	Abstract 10599: Assessing the association between cycles of fertility treatments with gonadotropins and cancer risk. First Author: Amichay Meirovitz, MD, MBA	Board 339	Abstract 10614: Post-mastectomy surveillance: A patient-reported survey of 110 women with Li-Fraumeni syndrome. First Author: Renata Lazari Sandoval, MD, PhD, MMedSc
Board 325	Abstract 10600: Decoding oncology terminology: Using large language models for patient education. First Author: Yuqing Wang, MD, PhD	Board 340	Abstract 10615: Clinicopathologic and allele-specific analysis of germline ATM alterations in a pan-cancer cohort. First Author: Matteo Repetto, MD
Board 326	Abstract 10601: Recruitment strategies and enrollment for a virtually supervised exercise intervention for Hispanic/Latinx breast cancer survivors. First Author: Christina Marie Dieli-Conwright, PhD, MPH	Board 341	Abstract 10616: Cancer genetics evaluation among individuals at risk for Lynch syndrome across all qualifying indications. First Author: Vinit Singh, MBBS
Board 327	Abstract 10602: Women's breast cancer mortality trends: The impact of lifestyle factors from the 2021 Global Burden of Disease (GBD) study. First Author: Samantha El Warrak, MBBS	Board 342	Abstract 10617: Familial lung cancer: A thirteen-year prospective analysis of participants with germline EGFR T790M pathologic variant. First Author: Elizabeth R. Francis, MD, MPH
Board 328	Abstract 10603: Are indulgent lifestyle practices the driving determinants behind the rising cancer rates in young adult men? First Author: Nathan Tran	Board 343	Abstract 10618: Mammography results in male BRCA carriers. First Author: Maliha Tayeb, BA, BS
Board 329	Abstract 10604: Skewed offspring distribution of TP53 pathogenic variants in Israeli Li-Fraumeni syndrome families. First Author: Naama Halpern, MD, MBA, MPA	Board 344	Abstract 10619: The evolution of breast cancer genetic testing: Comparative outcomes of NCCN, ASCO, and universal guidelines in 6,000+ patients. First Author: Hikmat Abdel-Razeq, MD
Board 330	Abstract 10605: Long-term safety of belzutifan in von Hippel-Lindau syndrome: A single-center experience. First Author: Paulo Siqueira do Amaral, MD	Board 345	Abstract 10620: Rurality and screening colonoscopy participation in patients with Lynch syndrome. First Author: Isabel Thomas
Board 331	Abstract LBA10606: The Genetic Information and Family Testing (GIFT) Trial. First Author: Steven J. Katz, MD, MPH	Board 346	Abstract 10621: Retrospective review of hereditary leiomyomatosis and renal cell cancer at a single institution. First Author: Michael N. Trinh, MD, PhD
Board 332	Abstract 10607: Breast cancer post-ovarian cancer in germline non-BRCA homologous recombination (HR) gene pathogenic variant carriers. First Author: Ariadna Roqué-Lloveras, MD	Board 347	Abstract 10622: Characteristics and outcome of breast cancers diagnosed in patients with germline ATM mutations. First Author: Amanda Lanier, BS
Board 333	Abstract 10608: Codon 167 missense mutations in von Hippel-Lindau syndrome: Genotype-phenotype correlations in a population-based study. First Author: Jianhui Qiu	Board 348a	Abstract TPS10623: A process evaluation trial of a telehealth service intervention to support uptake of breast cancer prevention medications. First Author: Kelly-Anne Phillips, FRACP, MBBS
Board 334	Abstract 10609: Clinical characteristics and cancer spectrum among breast cancer patients with TP53 germline mutation from a single institution. First Author: Ashley Woodson, MS	Board 349a	Abstract TPS10625: A phase II biomarker RCT in women at high risk for breast cancer: Low dose tamoxifen and lifestyle changes for breast cancer prevention (TOLERANT study). First Author: Sara Gandini, PhD
Board 335	Abstract 10610: Characterization of hereditary tumor risk in individuals with SDHA germline variants. First Author: Kelsey Ellis, MS		

- Board 349b **Abstract TPS10626:** The Hercules study: A prospective real-world evaluation of screening whole-body MRI (sWB-MRI) for multi-cancer detection and general preventive healthcare.
First Author: Yosef Chodakiewitz, MD
- Board 350a **Abstract TPS10627:** HERA-TEST: A novel precision oncology tool using breast milk for early detection of postpartum breast cancer.
First Author: Alejandra Díaz
- Board 350b **Abstract TPS10628:** Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.
First Author: Carol J. Fabian, MD, FASCO

1:30 PM-4:30 PM Poster Session

Quality Care/Health Services Research

Location: Hall A - Posters and Exhibits

Posters by Topic

Clinical Research Design: Board(s) 357-362, 525a-525b

Health and Regulatory Policy: Board(s) 363-375, 526a

Health Outcomes: Board(s) 376-409

Health Services Research: Board(s) 410-440

Patient-Reported Outcomes: Board(s) 441-473

Quality Improvement: Board(s) 474-480

Real-World Data/Outcomes: Board(s) 481-524, 526b

- Board 357 **Abstract 11018:** Improving clinical trial interpretability and efficiency: A Bayesian re-analysis of individual patient outcomes from 230 phase III oncology trials.
First Author: Alexander Dean Sherry, MD
- Board 358 **Abstract 11019:** Adherence of published randomized phase 3 cancer trials to principles proposed by common-sense oncology.
First Author: Omar Abdihamid, MD
- Board 359 **Abstract 11020:** Kaleido registry: A multi-center registry platform with site staff and automation to enable accelerated clinical research and drug development at scale in community practices.
First Author: Luis T. Campos, MD
- Board 360 **Abstract 11021:** Are patients satisfied with the information in an informed consent form? Questionnaire-based study examining patients' viewpoints.
First Author: Bhagyashree Pathak, MA
- Board 361 **Abstract 11022:** Why the duration of cancer treatment requires a closer look: An empirical analysis of recent FDA approvals.
First Author: Jeremy Birkmire, BS
- Board 362 **Abstract 11023:** Publication and data sharing of completed NCI cooperative group trials.
First Author: Lauren N. Cueto, MPH
- Board 363 **Abstract 11024:** Predictors of withdrawal for FDA accelerated approvals of anticancer drugs, 1992-2022.
First Author: Alejandra Romano, MD
- Board 364 **Abstract 11025:** Disparities in NIH and federal cancer research funding across different cancer types.
First Author: Suneel Deepak Kamath, MD

- Board 365 **Abstract 11026:** Communication of uncertainties about recent cancer drugs in large language models.
First Author: Avi Cherla
- Board 366 **Abstract 11027:** Achieving equity in genomic testing for breast cancer through partner-led strategies and policies.
First Author: Mary Obasi, MD, MPH
- Board 367 **Abstract 11028:** Pain in cancer survivors in the US after federal and state opioid prescribing guidelines and laws.
First Author: Justin Michael Barnes, MD, MS
- Board 368 **Abstract 11029:** Industry promotion of oncology drugs with accelerated approval that failed confirmatory trials.
First Author: Maryam Mooghali, MD, MSc
- Board 369 **Abstract 11030:** Unpacking the relationship between cancer survival and political environment in the United States (US).
First Author: John E. Dobbs, MD, MPH
- Board 370 **Abstract 11031:** Progression-free survival in control arms of clinical trials: Analysis of FDA cancer drug approvals between 2014 and 2023.
First Author: Angela Viggiano
- Board 371 **Abstract 11032:** Early signals of Inflation Reduction Act impact on small-molecule versus biologic post-approval oncology trials.
First Author: Hanke Zheng, PhD
- Board 372 **Abstract 11033:** Cost-effective cancer care: The role of oncology biosimilars in generating cost savings.
First Author: James W. Gilmore, PharmD
- Board 373 **Abstract 11034:** Access to cancer care for undocumented immigrants in the United States.
First Author: Patricia Mae Garcia Santos, MD, MS
- Board 374 **Abstract 11035:** Likelihood of unplanned readmission among oncology patients with a completed post-discharge follow-up encounter.
First Author: Emma Hannan, MHA
- Board 375 **Abstract 11036:** Molecular testing and targeted therapy use in lung cancer across state Medicaid programs.
First Author: Thomas J. Roberts, MD, MBA
- Board 376 **Abstract 11037:** Comprehensive analysis on reactive cutaneous capillary endothelial proliferation following camrelizumab-based therapy in patients with solid tumors: A large-scale pooled analysis of nine phase 2 or phase 3 registration trials.
First Author: Shukui Qin, MD
- Board 377 **Abstract 11038:** Demographic and clinical factors associated with young-onset rectal cancer: Is the Latinx population at higher risk?
First Author: Antoine Jeri-Yabar, MD
- Board 378 **Abstract 11039:** Pharmacotherapy as an adjunct to behavioral weight loss treatment in survivors of breast cancer.
First Author: Jennifer Y. Sheng, MD

- Board 379 **Abstract 11040:** Association between frailty and clinical outcomes in older adults with early breast cancer: Results from the Hurria Older Patients (HOPE) study.
First Author: Yuliya Zektser, MD, MHS
- Board 380 **Abstract 11041:** The impact of iron deficiency anemia on long-term cardiovascular outcomes in breast cancer patients hospitalized with heart failure preserved ejection fraction: A propensity score-matched retrospective cohort study.
First Author: Colton Jones, MD
- Board 381 **Abstract 11042:** Sex-based differences in clinical outcomes for solid tumours: A pooled IPD meta-analysis of contemporary anticancer drug trials.
First Author: Rakchha Chhetri
- Board 382 **Abstract 11043:** Race/ethnicity reporting and representation in clinical trials presented at the American Society of Clinical Oncology (ASCO) presidential plenaries from 2014 to 2024.
First Author: Bingtao Xiang, MD
- Board 383 **Abstract 11044:** Prognostic value of time-varying patient-reported symptoms and quality of life in cancer patients receiving chemotherapy.
First Author: Roshan Paudel, PhD, MPH
- Board 384 **Abstract 11045:** Treatment patterns and out-of-pocket cost after CAR-T cell therapy in commercially insured patients with hematologic malignancies: A real-world US study.
First Author: Mohammed Zuber, PharmD
- Board 385 **Abstract 11046:** Receiving a cancer diagnosis during hospitalization and associations with care outcomes.
First Author: Saurav Kadamane
- Board 386 **Abstract 11047:** Impact of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) on mortality and kidney function in cancer patients receiving cisplatin.
First Author: Saad Javaid, MD
- Board 387 **Abstract 11048:** Sociodemographic differences in lung cancer mortality trends across the United States (US) rural-urban divide.
First Author: Dena Rhinehart, MD
- Board 388 **Abstract 11049:** Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States.
First Author: Kunal C. Potnis, MD
- Board 389 **Abstract 11050:** Cancer-related mortality of incarcerated populations in the United States.
First Author: Owen Tolbert, BA
- Board 390 **Abstract 11051:** Age acceleration among adolescent and young adult patients with Ewing sarcoma and osteosarcoma.
First Author: Michael J. Robinson, MD
- Board 391 **Abstract 11052:** Evaluating the effectiveness of immersive virtual reality in reducing distress in patients with cancer receiving chemotherapy: A prospective randomized trial.
First Author: Maria Herran, MD
- Board 392 **Abstract 11053:** How cancer impacts adolescents' and young adults' (AYAs) scholastic experiences: Insight on supportive survivorship care needs from AYAs, parents, and clinicians.
First Author: Carla Fisher
- Board 393 **Abstract 11054:** Demographic and genomic landscape of early mortality in patients with stage IV non-small-cell lung cancer.
First Author: Osama Mustafa Younis, MD
- Board 394 **Abstract 11055:** Development of second primary malignancies (SPMs) in head and neck cancer survivors stratified by receipt of radiation therapy (RT) and chemotherapy (CT).
First Author: Kriti Ahuja, MBBS
- Board 395 **Abstract 11056:** A digital intervention to enhance engagement with oral oncolytic treatments and assess patient experiences with novel therapies.
First Author: David Michael Waterhouse, MD, MPH
- Board 396 **Abstract 11057:** From chemotherapy allergy to tolerance: Desensitization as a safe alternative in oncology.
First Author: Magda Arredondo, MD
- Board 397 **Abstract 11058:** Exploring two decades of cancer trends in adolescents and young adults: Insights from a resource-restricted country.
First Author: Sarah Abdel-Razeq, MD
- Board 398 **Abstract 11059:** Treatment patterns, use of healthcare resources, and clinical characteristics of patients with castration-resistant prostate cancer (mCRPC) in Colombia: Preliminary analysis from ProColombia RC study.
First Author: Ray Manneh, MD
- Board 399 **Abstract 11060:** Differential and cumulative impact of metabolic syndrome traits on cardiovascular, renal, and mortality outcomes in cancer patients.
First Author: Arunkumar Krishnan, MD, MS
- Board 400 **Abstract 11061:** Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial.
First Author: Abiola Oladapo, PhD
- Board 401 **Abstract 11062:** Trends and disparities in sepsis-related mortality among patients with malignancies: A 25-year nationwide analysis.
First Author: Malik W.Z. Khan, MD, MBBS
- Board 402 **Abstract 11063:** Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.
First Author: Melissa Taylor, MD, MPH
- Board 403 **Abstract 11064:** Impact of protein-energy malnutrition on inpatient mortality, healthcare cost and clinical outcomes among patients with head and neck cancer.
First Author: Vaishali Deenadayalan, MD
- Board 404 **Abstract 11065:** Efficacy of immune checkpoint inhibitors in smokers vs non-smokers: A large real-world retrospective cohort analysis.
First Author: Nanda Siva, MBA

- Board 405 **Abstract 11066:** Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.
First Author: Jinbing Bai, PhD, MSN, FAAN, RN
- Board 406 **Abstract 11067:** Impact of protein energy malnutrition on hospitalized patients with breast cancer: A United States population-based cohort study.
First Author: Arshi Syal, MD
- Board 407 **Abstract 11068:** Incidence and outcomes of rejection in solid organ transplant recipients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
First Author: Muhammad Awidi, MD
- Board 408 **Abstract 11069:** Evaluating the impact of Medicaid expansion on outcomes for patients with gastric cancer in Louisiana.
First Author: Donnell White III, PhD
- Board 409 **Abstract 11070:** Racial disparities in major adverse cardiovascular and cerebrovascular events outcomes among gastric cancer patients.
First Author: Amanda Lussier, MD
- Board 410 **Abstract 11071:** Patient-reported communication and satisfaction in breast cancer: Does doctor-patient identity concordance matter?
First Author: Kamaria L. Lee, MD
- Board 411 **Abstract 11072:** Patient-reported health experiences among US immigrant patients with cancer.
First Author: Anh B. Lam, DO, MBA
- Board 412 **Abstract 11073:** Factors associated with readmission to index vs. non-index hospitals after major cancer surgery: Does centralization play a role?
First Author: Avanish Madhavaram, BS
- Board 413 **Abstract 11074:** The association between profitability, clinical benefit, and physicians' selection of cancer drugs.
First Author: Aaron Philip Mitchell, MD, MPH
- Board 414 **Abstract 11075:** Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare.
First Author: Aaron Philip Mitchell, MD, MPH
- Board 415 **Abstract 11076:** Longitudinal changes in credit status for newly diagnosed metastatic colorectal cancer patients (SWOG S1417).
First Author: C. Natasha Kwendakwema, MD
- Board 416 **Abstract 11077:** Association of county-level medical debt and timely treatment initiation among individuals newly diagnosed with cancer.
First Author: Jingxuan Zhao, MPH
- Board 417 **Abstract 11078:** Association between cost and insurance on receipt of guideline-concordant mammography.
First Author: Nicole E. Caston, PhD, MPH
- Board 418 **Abstract 11079:** Shifts in Medicare spending for patients with cancer undergoing chemotherapy following implementation of the Maryland Global Budget Revenue program.
First Author: Yu-Li Lin, MS

- Board 419 **Abstract 11080:** Insurance coverage of germline genetic testing for ovarian, pancreatic, and early-onset colorectal, endometrial, and breast cancers, stratified by self-reported race and ethnicity.
First Author: Erica M. Vaccari
- Board 420 **Abstract 11081:** Longitudinal risk of physical functional impairment and health care utilization in cancer survivors within 3 years of diagnosis.
First Author: Ann Marie Flores, PhD, PT, MA, MS
- Board 421 **Abstract 11082:** Addressing disparities by implementing a supportive care program in oncology.
First Author: Emily Meichun Ko, MD
- Board 422 **Abstract 11083:** Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.
First Author: Emily Meichun Ko, MD
- Board 423 **Abstract 11084:** The state of the oncologist workforce in America in areas prone to natural disasters.
First Author: M. Kelsey Kirkwood, MPH
- Board 424 **Abstract 11085:** Influenza and COVID-19 vaccination uptake among cancer survivors in the US.
First Author: Ted Akhiwu, MBBS, MPH
- Board 426 **Abstract 11087:** The implications of using truncated Medicare definitions of avoidable hospital visits.
First Author: Pranathi Pilla
- Board 427 **Abstract 11088:** United States treatment pattern response to carboplatin and cisplatin shortages.
First Author: John Kent Lin, MD
- Board 428 **Abstract 11089:** Medicare plan switching, hospice enrollment, and place of hospice services at the end-of-life among decedent patients diagnosed with distant stage cancers in 2010-2019.
First Author: Xin Hu, PhD
- Board 429 **Abstract 11090:** Disparate recovery of cancer screenings by demographic in traditional Medicare post-pandemic.
First Author: T. Anders Olsen, MD, MPP
- Board 430 **Abstract 11091:** Workforce, economic, and infrastructural barriers to global oncology clinical trial participation: Focus on sub-Saharan Africa.
First Author: Oyepeju Folashade Abioye, MD, MSc
- Board 431 **Abstract 11092:** Financial toxicity for cancer patients: Out-of-pocket costs by cancer diagnosis in traditional Medicare.
First Author: T. Anders Olsen, MD, MPP
- Board 432 **Abstract 11093:** Climate change and cancer: An ecological evaluation of climate risks for cancer survivors.
First Author: Joseph M. Unger, PhD, MS
- Board 433 **Abstract 11094:** Preliminary efficacy of VOICE, a decision support tool for older adults with advanced cancer: A pilot randomized trial.
First Author: Amy C. Cole
- Board 434 **Abstract 11095:** The studies industry neglects: Characteristics of cancer clinical trials conducted by federal versus industry sponsors.
First Author: Joseph M. Unger, PhD, MS

- Board 435 **Abstract 11096:** Early examination of national changes in potentially avoidable hospital visits after chemotherapy, 2018–2022.
First Author: Pranathi Pilla
- Board 436 **Abstract 11097:** Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data.
First Author: Maureen Canavan, PhD, MPH
- Board 437 **Abstract 11098:** Integration of a virtual personalized medicine review board integration into a major community oncology phase 1 unit.
First Author: Marilyn Elaine Hammer, PhD
- Board 438 **Abstract 11099:** Temporal trends in opioid prescription fills following cancer-directed surgery.
First Author: Andrea Catherine Enzinger, MD
- Board 439 **Abstract 11100:** Integrative oncology interest in persons with a cancer diagnosis.
First Author: Julia Witkowski, MPH
- Board 440 **Abstract 11101:** Utilization and timeliness of next-generation sequencing testing for patients with resected or metastatic non-small cell lung cancer: A real-world analysis.
First Author: Raheem D. Bell, MD, MS
- Board 441 **Abstract 11102:** Health-related quality of life and financial toxicity among patients with gynecological cancers in southern Nigeria: A multicenter cross-sectional study.
First Author: Chibuzor Franklin Ogamba, MBBS, MSc
- Board 442 **Abstract 11103:** Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: A discrete choice experiment.
First Author: Baohui Han
- Board 443 **Abstract 11104:** Characterizing unmet supportive care needs in diverse adolescent and young adult cancer survivors.
First Author: Akina Natori, MD, MSPH
- Board 444 **Abstract 11105:** Understanding psychosocial wellbeing and concern for death and dying: Insights from a psycho-oncology clinic.
First Author: Shahrzad A. Zamani, DO
- Board 445 **Abstract 11106:** Self-reported adherence to cancer therapy: Development and validation of a cancer-specific DOSE-Nonadherence measure.
First Author: Yashasvini Sampathkumar, MD
- Board 446 **Abstract 11107:** Employer-sponsored insurance, paid sick leave, and financial toxicity among cancer survivors.
First Author: Michael T. Halpern, MD, PhD, MPH, FASCO
- Board 447 **Abstract 11108:** Ethnic disparities in unmet supportive care needs and outcomes among older ambulatory cancer patients.
First Author: Frank J. Penedo, PhD
- Board 448 **Abstract 11109:** Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study.
First Author: Mitchell Reed Smith, MD, PhD
- Board 449 **Abstract 11110:** Patient-reported pain and emergency department utilization in patients with newly diagnosed ovarian cancer: A retrospective cohort study.
First Author: Esin Christine Namoglu, BS
- Board 450 **Abstract 11111:** Patient experiences of diagnosis and treatment of invasive lobular carcinoma: A qualitative study from a prospective registry.
First Author: Astrid Quirarte, BA
- Board 451 **Abstract 11112:** Disparities in glioblastoma care: Insights from a nationwide survey.
First Author: Jacob Ellen, MS
- Board 452 **Abstract 11113:** A prospective observational study to compare speech and swallowing outcomes in different types of oral tongue defects and reconstructions in patients undergoing treatment for oral tongue squamous cell carcinoma.
First Author: Shivakumar Thiagarajan, DNB, MS
- Board 453 **Abstract 11114:** Association between alcohol intake and health-related quality of life in breast cancer survivors.
First Author: Sanjna Rajput, MD
- Board 454 **Abstract 11115:** Caregiver distress: Caring for those who care for our patients.
First Author: Abigail Smith Zamorano, MD
- Board 455 **Abstract 11116:** Factors associated with patient-reported outcomes in hospitalized patients with cancer.
First Author: Noha Soror, MD, MSc
- Board 456 **Abstract 11117:** Perception of postoperative functional status in gastrointestinal and hepatobiliary cancer patients over 80.
First Author: Sarah Remer, MD
- Board 457 **Abstract 11118:** Prospective assessment of health-related quality of life in early phase clinical trials.
First Author: Udit Nindra, MD
- Board 458 **Abstract 11119:** Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.
First Author: Udit Nindra, MD
- Board 459 **Abstract 11120:** Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.
First Author: Nobuaki Matsubara, MD
- Board 460 **Abstract 11121:** Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.
First Author: Andre P. Fay, MD, PhD
- Board 461 **Abstract 11122:** Beyond survival: Prospective longitudinal insights into quality of life after hepatectomy for colorectal liver metastases.
First Author: Ankur P. Choubey, MD, MPH

- Board 462 **Abstract 11123:** Quality of life in a phase III study of prospective radiation therapy (IMRT) +/- cetuximab for locally advanced resected head and neck cancer: NRG/TOG 0920.
First Author: Clement K. Gwede, PhD, RN, FAAN
- Board 463 **Abstract 11124:** Cancer misinformation and trust in doctors and scientists among cancer survivors.
First Author: Brandon Godinich
- Board 464 **Abstract 11125:** Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).
First Author: Sue-Anne McLachlan, MBBS
- Board 465 **Abstract 11126:** Electronic patient-reported outcomes (ePRO) in patients with advanced melanoma receiving immune checkpoint inhibitors: Insights from the Canopy ePRO system.
First Author: Benjamin Avi Derman, MD
- Board 466 **Abstract 11127:** Evaluating acceptance of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: Lessons from a randomized controlled trial.
First Author: Ka Yu Tse, PhD, MBBS
- Board 467 **Abstract 11128:** Preliminary findings from the ALVA ePRO Platform pilot study: A novel approach to collecting quality of dying and death data among informal caregivers in palliative care.
First Author: Javier Retamales, MD
- Board 468 **Abstract 11129:** A patient-reported outcome measure (PROM) to capture patients' experiences with immuno-oncology therapy (IO)-induced cytokine release syndrome (CRS): The IO-induced CRS patient diary.
First Author: Joyce R. Talavera, MD
- Board 469 **Abstract 11130:** Electronic patient-reported outcomes (ePRO)-based alerts deployed in clinical practice to inform treatment burden and care management in pancreatic cancer.
First Author: Emelly Rusli, MPH
- Board 470 **Abstract 11131:** Evaluation of sleep quality and quality of life among patients newly diagnosed with head and neck cancer.
First Author: Eric Adjei Boakye, PhD
- Board 471 **Abstract 11132:** Financial burden and financial toxicity in cancer patients: A sub-analysis from a Brazilian prospective cohort.
First Author: Mariana Ribeiro Monteiro, MD
- Board 472 **Abstract 11133:** The impact of a second primary cancer diagnosis on health-related quality of life in African American cancer survivors.
First Author: Jennifer Lynn Beebe-Dimmer, PhD, MPH
- Board 473 **Abstract 11134:** The impact of breast cancer treatment on young women's body image and sexual health.
First Author: Shari Beth Goldfarb, MD
- Board 474 **Abstract 11135:** Outpatient infusion sepsis protocol and outcomes for patients with cancer.
First Author: Ashley Miles

- Board 475 **Abstract 11136:** The association of cancer history with markers of cognitive decline in a large US national survey registry.
First Author: Emmanuel Kampanga
- Board 476 **Abstract 11137:** Improving genetic counseling uptake for breast, pancreatic, and prostate cancers at a safety net hospital.
First Author: Jenny Jing Xiang, MD
- Board 477 **Abstract 11138:** OncoPRO: A US national initiative supporting implementation of remote symptom monitoring with electronic patient-reported outcomes (ePROs) in oncology practices.
First Author: Ethan Basch, MD, MSc, FASCO
- Board 478 **Abstract 11139:** Transforming genomic testing in prostate cancer: A comprehensive system-wide initiative.
First Author: Chinmay Jani, MBBS
- Board 479 **Abstract 11140:** Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative.
First Author: Kelley Chan, MD, MS
- Board 480 **Abstract 11141:** Systematic communication model to facilitate conversations about metastatic breast cancer.
First Author: Fernanda Mesa-Chavez, MD, MSc
- Board 481 **Abstract 11142:** Epidemiologic patterns and mortality outcomes in young lung cancer non-smokers: A National Inpatient Sample analysis (2016–2021).
First Author: Simo Du, MD, MHS
- Board 482 **Abstract 11143:** Real-world assessment of breast cancer risk following hormonal therapy in endometriosis: A Global Collaborative Network propensity score matched analysis.
First Author: Caterina Gianni, MD
- Board 483 **Abstract 11144:** Comprehensive genomic profiling in AYA cancer patients.
First Author: Naomi Hayashi, MD, PhD
- Board 485 **Abstract 11146:** Hospice utilization in Veterans with newly diagnosed metastatic prostate cancer.
First Author: Jennifer Mei Lee, BS
- Board 486 **Abstract 11147:** Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.
First Author: Erin Frances Cobain, MD
- Board 487 **Abstract 11148:** Adherence to vaccination recommendations in the adult cancer population.
First Author: Kimberly Feng, MD
- Board 488 **Abstract 11149:** Association between body mass index and overall survival in veterans receiving immune checkpoint inhibitors.
First Author: Abhishek Bhattacharya, MD
- Board 489 **Abstract 11150:** Impact of palliative chemotherapy in hospitalized patients with advanced solid tumors.
First Author: Sydney Roussel, PharmD
- Board 490 **Abstract 11151:** Association of co-administration of a vaccine with immune checkpoint inhibitors with survival.
First Author: Justin Dejia Wang, MD

- Board 491 **Abstract 11152:** Trends in place of death among breast cancer patients in the United States (1999–2023): A 25-year analysis of racial and regional disparities.
First Author: Fatima Ali, MD
- Board 492 **Abstract 11153:** Regional trends in disability adjusted life years (DALYs) and mortality of pancreatic cancer among older adults (70+): A global burden of disease study (1990–2021).
First Author: Nana Sardarova, MD
- Board 493 **Abstract 11154:** Characterizing health related quality of life among individuals living with non-small cell lung in the United States: Findings from the Cancer Experience Registry.
First Author: Erica Fortune
- Board 494 **Abstract 11155:** Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
First Author: Xiao Wang, MD
- Board 495 **Abstract 11156:** Real-world outcomes in patients living with HIV with lung cancer and treated with immune checkpoint inhibitors.
First Author: Melinda Laine Hsu, MD, MS
- Board 496 **Abstract 11157:** ARIMA prediction model for mortality caused by metastatic cancers in the United States population up to the year 2050: A CDC WONDER Database analysis.
First Author: Nisar Ahmed, MBBS
- Board 497 **Abstract 11158:** Determinants of overall survival in the South African Breast Cancer and HIV Outcomes cohort.
First Author: Maureen Joffe
- Board 498 **Abstract 11159:** Implementation and evaluation of multi-cancer early detection testing at the Dana-Farber Cancer Institute: A retrospective analysis of clinical outcomes and diagnostic pathways.
First Author: Elizabeth O'Donnell, MD
- Board 499 **Abstract 11160:** Evaluation of large language model (LLM)-based clinical abstraction of electronic health records (EHRs) for non-small cell lung cancer (NSCLC) patients.
First Author: Kabir Manghnani
- Board 500 **Abstract 11161:** Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC).
First Author: Adam Fox, MD, MS
- Board 501 **Abstract 11162:** Assessing biosimilar entry in the market for biologic cancer drugs.
First Author: Xiaoyu Liu
- Board 502 **Abstract 11163:** A real-world data claims-based review of CAR-T procedures, time to adverse events, patient characteristics and social factors.
First Author: Karina D'Angelo, PhD
- Board 503 **Abstract 11164:** Risk of fracture following androgen receptor pathway inhibitors (ARPIs): A population-based study.
First Author: Grace L. Lu-Yao, PhD, MPH
- Board 505 **Abstract 11166:** Validation of real-world event-free survival (rwEFS) in early-stage triple-negative breast cancer.
First Author: Carole Berini
- Board 506 **Abstract 11167:** Impact of AI medical scribes on physician productivity and satisfaction in medical oncology.
First Author: Nima Toussi, BSc
- Board 507 **Abstract 11168:** Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
First Author: Rebecca Forman, MD
- Board 508 **Abstract 11169:** Early onset cancer in Chile: 27-year mortality rate trends from a nationwide database with focus in gastrointestinal tumors.
First Author: Cristobal Tomas Sanhueza Condell, MD
- Board 509 **Abstract 11170:** Frailty in lung cancer hospitalizations: Identifying critical predictors for improved patient outcomes.
First Author: Davin Turku, MD
- Board 510 **Abstract 11171:** Multicenter study of the impact of trial eligibility criteria on enrollment to KRAS G12C inhibitor trials in patients with non-small cell lung cancer.
First Author: Michael S. May, MD
- Board 511 **Abstract 11172:** Accelerating phase 2 clinical development with real-world data (RWD): An external control arm (ECA) pilot in HER2-positive (HER2+) metastatic breast cancer (mBC).
First Author: Cherrishe Brown-Bickerstaff, PhD, MPH
- Board 512 **Abstract 11173:** Proton pump inhibitors and the risk of adverse renal events and all-cause mortality in cancer patients receiving immune checkpoint inhibitors.
First Author: Arunkumar Krishnan, MD, MS
- Board 513 **Abstract 11174:** Efficacy GLP-1 agonists, SGLT-2 inhibitors and other glucose-lowering medications on cardiorenal outcomes in patients with diabetes and cancer on immune checkpoint therapy.
First Author: Diptasree Mukherjee, MD
- Board 514 **Abstract 11175:** Real-world evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer.
First Author: Reshma L. Mahtani, DO
- Board 515 **Abstract 11176:** Use of large language models to extract cancer diagnosis, histology, grade, and staging from unstructured electronic health records.
First Author: Gayathri Namasivayam
- Board 516 **Abstract 11177:** Immune checkpoint inhibitor-associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort.
First Author: Zhiting Tang, MD
- Board 517 **Abstract 11178:** Leveraging real-world data sources for clinical oncology research: A review of studies published in ASCO publications.
First Author: Thomas Lucido, MD
- Board 518 **Abstract 11179:** Venous thromboembolism among cancer patients receiving chimeric antigen receptor-T cell therapy.
First Author: Rahul Mishra, MBBS

- Board 519 **Abstract 11180:** Clinical outcomes for Medicaid recipients with early-onset breast cancer: An analysis of the National Inpatient Sample.
First Author: Vineet Polineni
- Board 520 **Abstract 11181:** Inpatient outcomes of breast cancer hospitalizations in the northeastern vs western United States.
First Author: Davin Turku, MD
- Board 521 **Abstract 11182:** Trends in early-onset gastrointestinal cancers: A comprehensive analysis of US cancer statistics (2001–2021).
First Author: Abdul Qahar Khan Yasinzai, MBBS
- Board 522 **Abstract 11183:** Clinical outcomes for low-income patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
First Author: Ben Brik
- Board 523 **Abstract 11184:** Clinical outcomes for patients with hyperlipidemia and early-onset breast cancer: An analysis of the National Inpatient Sample.
First Author: Mahija Cheekati, MD
- Board 524 **Abstract 11185:** Clinical outcomes for Black patients with early-onset breast cancer: An analysis of the National Inpatient Sample.
First Author: Mahija Cheekati, MD
- Board 525a **Abstract TPS11186:** A platform to identify patients for cancer vaccine trials: The NHS England Cancer Vaccine Launch Pad (CVLP).
First Author: Victoria Goss, PhD, MCh
- Board 525b **Abstract TPS11187:** Barriers and facilitators of adoption and implementation of a financial navigation program in Nigeria: An analysis of participant data from the COST-FIN trial.
First Author: Adewale Isaiah Oyewole, MSc
- Board 526a **Abstract TPS11188:** Strength of evidence supporting cancer drug approvals in China, 2017–2021.
First Author: Yichen Zhang
- Board 526b **Abstract TPS11189:** Falcon: Exact Sciences' multicancer early detection (MCED) real world evidence (RWE) registry.
First Author: Ronan Joseph Kelly, MD, MBA, FASCO

1:45 PM-2:30 PM Award Lecture

Accomplishments and Next Challenges in Childhood Cancer Survivorship

Location: S100bc

Gregory T. Armstrong, MD, MSCE—Chair

St. Jude Children's Research Hospital

Melissa M. Hudson, MD, FASCO

St. Jude Children's Research Hospital

Award Recipient

Panel Question and Answer

2:00 PM-2:45 PM Award Lecture

Transformative Approaches in Supportive Oncology: Leadership, Innovation, and Research

Location: S402

Supriya Gupta Mohile, MD, MS, FASCO—Chair

University of Rochester Medical Center

Karen Michelle Mustian, PhD

University of Rochester Medical Center

Award Recipient

Panel Question and Answer

3:00 PM-3:45 PM Award Lecture

Improving Care for Older Adults With Cancer: Research to Practice

Location: E450a

Carolyn J. Presley, MD, MHS—Chair

Ohio State University

Heidi D. Klepin, MD, MS, FASCO

Atrium Health Wake Forest Baptist Medical Center

Award Recipient

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward

Location: Arie Crown Theater

Maria Jose Ribal, MD, PhD

Hospital Clinic Barcelona

Integration of Universal Perioperative Immunotherapy

Jonathan E. Rosenberg, MD

Memorial Sloan Kettering Cancer Center

Risk-Adaptive Neoadjuvant Chemotherapy and Adjuvant Immunotherapy

Immunotherapy

Anne K. Schuckman, MD, FACS—Chair

University of Southern California

Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer

Management of Muscle-Invasive Bladder Cancer

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Assess, Advise, Refer, Connect: Strategies That Work to Implement Exercise in Oncology

Location: S402

Kathryn H. Schmitz, PhD, MPH—Chair

UPMC Hillman Cancer Center

Too Strong to Ignore: Getting the Evidence for Exercise Into

Oncology Practice

Mackenzi Pergolotti, PhD

Select Medical

Right Patient, Right Exercise Prescription, Right Time: Supporting

Clinical Screening and Triage for Exercise

Prajakta Adsul, PhD, MBBS, MPH

University of New Mexico Comprehensive Cancer Center

Implementation Science and the Secret Sauce for Integrating

Exercise Screening and Triage Pathways in Oncology

Panel Question and Answer

3:00 PM-4:15 PM Education Session

The Art and Know-How of Oncology Teaching, Learning, and Knowledge Sharing

Location: E350

Rami Manochakian, MD, FASCO—Chair

Mayo Clinic Florida

How I Educate “With Impact” in Oncology

Lori J. Rosenstein, MD

Gundersen Health System

How I “Effectively” Teach Oncology Trainees

Rohit Gosain, MD

Roswell Park Comprehensive Cancer Center

How I Use Social Media to Teach and Learn Oncology Updates for the Community

Panel Question and Answer

3:00 PM-4:15 PM Education Session

When and How Long to Treat Chronic Lymphocytic Leukemia

Location: E450b

Barbara Eichhorst, MD—Chair

University of Cologne

When to Start Treatment in Newly Diagnosed Chronic Lymphocytic Leukemia?

Carsten Niemann

Copenhagen University Hospital

Time-Limited Therapy Versus Indefinite Therapy in Chronic Lymphocytic Leukemia

Talha Munir, PhD, MBChB

National Health Service

Is There a Role for Minimal Residual Disease Testing in Chronic Lymphocytic Leukemia?

Panel Question and Answer

3:00 PM-4:30 PM Rapid Oral Abstract Session

Central Nervous System Tumors

Location: S102

Matthias Holdhoff, MD, PhD—Chair

Johns Hopkins Medical Center

Jennie Webster Taylor, MD, MPH—Chair

University of California San Francisco

3:00 PM Abstract 2012: Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: A prospective, single-arm, phase II trial.
First Author: Yehui Shi, MD, PhD

3:06 PM Abstract 2013: Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.
First Author: Jordi Rodon Ahnert, MD, PhD

3:12 PM Abstract 2014: Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results.
First Author: Joseph Georges, DO, PhD

3:18 PM Panel Question and Answer

3:30 PM Abstract 2015: Results from phase 1 study of mycophenolate mofetil with chemoradiation in newly diagnosed glioblastoma to target de-novo purine metabolism to overcome treatment resistance.
First Author: Yoshie Umemura, MD, MS

3:36 PM Abstract 2016: Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBP β -dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
First Author: Fabio Massaiti Iwamoto, MD

3:42 PM Abstract 2017: Safety and tolerability of intraventricular CARv3-TEAM-E T cells following lymphodepleting chemotherapy in recurrent glioblastoma: INCIPIENT trial.
First Author: Elizabeth R. Gerstner, MD

3:48 PM Panel Question and Answer

4:00 PM Abstract 2018: A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.
First Author: Gordon Li

4:06 PM Abstract 2019: Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
First Author: Lakshmi Nayak, MD

4:12 PM Abstract 2020: Using single-cell transcriptomics to reveal CD226 upregulation and enhancement of CD19-CAR-T function in the inhibitory CNS microenvironment of refractory CNS lymphoma.
First Author: Ulrike Gerdemann, MD

4:18 PM Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Developmental Therapeutics—Immunotherapy

Location: Hall D2

Sarah Nikiforow, MD, PhD—Chair

Dana-Farber Cancer Institute

Meredith Pelster, MD, MSc—Chair

Nashville-Centennial Clinic, Tennessee Oncology

3:00 PM Abstract 2500: Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naïve advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
First Author: Ming Lu

3:12 PM Abstract 2501: First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
First Author: Timothy A. Yap, MD, PhD

3:24 PM Abstract 2502: Efficacy and safety results of a first-in-class PD-1/IL-2 α -bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.
First Author: Bin Lian, MD

- 3:36 PM** **Guillem Argiles, MD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 2500-2502: The Power of Two: Leveraging Bispecifics in Solid Tumors
- 3:48 PM** Panel Question and Answer
- 4:00 PM** **Abstract 2503:** A therapeutic vaccine for fibrolamellar hepatocellular carcinoma.
First Author: Marina Baretti, MD
- 4:12 PM** **Abstract 2504:** Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Charles J. Link Jr, MD
- 4:24 PM** **Abstract 2505:** Phase 1 study of B440, an oral Bifidobacterium-engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer.
First Author: Toshiro Shirakawa, MD, PhD
- 4:36 PM** **Margaret E. Gatti-Mays, MD, MPH, FACP**
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Discussion of Abstract(s) 2503-2505: Moving the Needle: Taking a New Shot at Therapeutic Vaccines
- 4:48 PM** Panel Question and Answer
- 5:00 PM** **Abstract 2506:** Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial.
First Author: Xiaoqian Nie, MS
- 5:12 PM** **Abstract 2507:** Phase 1 clinical trial of EpCAM CAR-T cell therapy in patients with gastrointestinal cancers.
First Author: Tianhang Luo, MD
- 5:24 PM** **Abstract 2508:** Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
First Author: Martin Wermke
- 5:36 PM** **Ben C. Creelan, MD, MS**
Moffitt Cancer Center
Discussion of Abstract(s) 2506-2508: Walking the Tightrope of Targets and Toxicities
- 5:48 PM** Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall D1

Nataliya V. Uboha, MD, PhD—Chair
UW Carbone Cancer Center

Erica S. Tsang, MD, FRCPC, MPH—Chair
Princess Margaret Cancer Centre

- 3:00 PM** **Abstract 4000:** Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
First Author: Ronan Joseph Kelly, MD, MBA, FASCO

- 3:12 PM** **Abstract 4001:** Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.
First Author: Kohei Shitara, MD
- 3:24 PM** **Abstract LBA4002:** Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
First Author: Kohei Shitara, MD
- 3:36 PM** **Abstract 4003:** Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).
First Author: Changsong Qi, MD, PharmD
- 3:48 PM** **Anwaar Saeed, MD**
University of Pittsburgh Medical Center and UPMC Hillman Cancer Center
Discussion of Abstract(s) 4000-4003: Refining Therapeutic Approaches in Gastroesophageal Cancer
- 4:00 PM** Panel Question and Answer
- 4:12 PM** **Abstract LBA4004:** Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.
First Author: Michele Reni, MD
- 4:24 PM** **Abstract LBA4005:** PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
First Author: Vincent J. Picozzi, MD, MMM
- 4:36 PM** **Abstract 4006:** Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Devalingam Mahalingam, MD, PhD
- 4:48 PM** **Brian M. Wolpin, MD, MPH**
Dana-Farber Cancer Institute
Discussion of Abstract(s) LBA4004-4006: Persistence and Progress in Pancreatic Cancer
- 5:00 PM** Panel Question and Answer
- 5:12 PM** **Abstract 4007:** A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).
First Author: Reena Engineer, DNB
- 5:24 PM** **Abstract 4008:** Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.
First Author: Thorsten Oliver Goetze

5:36 PM To be determined
Discussion of Abstract(s) 4007-4008: Don't Stop Believing: Neoadjuvant Therapies in Biliary Tract Cancer

5:48 PM Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Pediatric Oncology I

Location: S100bc

Raya Saab, MD—Chair

Stanford University School of Medicine

Amit J. Sabnis, MD—Chair

UCSF Benioff Children's Hospital San Francisco

3:00 PM Abstract 10000: Association of immunotherapy of high-risk neuroblastoma patients with long term infusion of dinutuximab beta with survival over short term infusion: Results from the HR-NBL1/SIOPEN trial.
 First Author: Ruth Lydia Ladenstein, MD, MBA

3:12 PM Abstract 10001: A phase 2 randomized study of chemoimmunotherapy with or without effornithine (DFMO) in relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) report.
 First Author: Margaret E. Macy, MD

3:24 PM Abstract 10002: Vincristine and topotecan versus carboplatin-, etoposide-, and vincristine-based chemotherapy for ocular salvage in group D and group E intraocular retinoblastoma: A randomized, comparative trial.
 First Author: Prashant Prabhakar, DM

3:36 PM Keri A. Streby, MD
 Ohio State University/Nationwide Children's Hospital
Discussion of Abstract(s) 10000-10002: Advances in Embryonal Tumor Treatment: Old, New, and Evolving Therapies

3:48 PM Panel Question and Answer

4:00 PM Abstract 10003: Safety and efficacy of the EZH1/2 inhibitor valemestostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial.
 First Author: Ayumu Arakawa, MD

4:12 PM Abstract 10004: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.
 First Author: Francois Doz, MD

4:24 PM Abstract 10005: Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.
 First Author: Suzanne J. Forrest, MD

4:36 PM Matteo Maria Trucco, MD
 Cleveland Clinic Children's
Discussion of Abstract(s) 10003-10005: A Target's a Target, No Matter How Small

4:48 PM Panel Question and Answer

5:00 PM Abstract 10006: Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
 First Author: Martin McCabe, PhD, MBChir

5:12 PM Abstract 10007: ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.
 First Author: Sara Michele Federico, MD, MD

5:24 PM Abstract 10008: Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.
 First Author: Pablo Berlanga, MD, PhD

5:36 PM Lisa M. McGregor, MD, PhD
 Penn State Health Milton S. Hershey Medical Center
Discussion of Abstract(s) 10006-10008: Emerging Therapies for Sarcoma: A Focus on Novel Agents

5:48 PM Panel Question and Answer

4:30 PM-6:00 PM Clinical Science Symposium

Biomarkers in Kidney Cancer: Are We There Yet?

Location: Arie Crown Theater

Allison May, MD—Chair

University of Virginia

Rana R. McKay, MD, FASCO—Chair

UC San Diego School of Medicine

4:30 PM W. Kimryn Rathmell, MD, PhD, FASCO
 The Ohio State University Comprehensive Cancer Center
Biomarkers in Kidney Cancer: Are We There Yet?

4:42 PM Abstract 4509: Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy.
 First Author: Axel Bex, MD, PhD

4:54 PM Abstract 4510: Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC).
 First Author: Sumanta Kumar Pal, MD, FASCO

5:06 PM Abstract 4511: An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).
 First Author: David A. Braun, MD, PhD

5:18 PM Abstract 4512: Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
 First Author: Renee Maria Saliby, MD, MSc

5:30 PM **David F. McDermott, MD**
Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center
Discussion of Abstract(s) 4509-4512: Guts, Blood, and Tumor: The Search for Kidney Cancer Biomarkers Continues

5:42 PM Panel Question and Answer

4:45 PM-5:30 PM Award Lecture

Redefining the Role of Chemotherapy in the Era of Targeted Therapies in Breast Cancer

Location: Hall B1

Eric P. Winer, MD, FASCO—Chair

Yale Cancer Center

Ian E. Krop, MD, PhD

Yale Cancer Center

Award Recipient

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Addressing Barriers in Palliative Care for Rural and Underserved Communities

Location: S402

Matthias Weiss, MD, PhD—Chair

ThedaCare

Rural for Real: Symptom Management in Rural Populations—Does Our Current Evidence Apply?

Susan Sabo-Wagner, MSN, OCN, RN

American Oncology Network

Pragmatic Insights From Community Oncology: Designing Care Plans to Address Social Needs

C.S. Pramesh, MBBS, MS, FRCS

Tata Memorial Centre

Global Perspectives on Rural Symptom Management: Care Delivery in Low- and Middle-Income Countries

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Advancing Non–Small Cell Lung Cancer Care: Strategic Integration of Neoadjuvant, Surgical, and Adjuvant Therapies

Location: S100a

Maria Lucia Madariaga, MD

University of Chicago

Surgical Advances and Perioperative Care for Locally Advanced Non–Small Cell Lung Cancer

Benjamin Besse, MD, PhD—Chair

Gustave Roussy

Optimizing Neoadjuvant Therapy in Locally Advanced Non–Small Cell Lung Cancer: Current and Emerging Strategies

Dwight Hall Owen, MD

The Ohio State University Comprehensive Cancer Center

Optimizing Adjuvant Therapy for Locally Advanced Non–Small Cell Lung Cancer: Current and Emerging Strategies

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise?

Location: S102

Katy E. French, MD—Chair

The University of Texas MD Anderson Cancer Center

Can a Robot Write My Notes? Real-World Examples of Ambient Listening Technology

Ming Tai-Seale, PhD

University of California San Diego

Doctor, Is It Really You? Auto-Reply to Patient Messages

Larry Edward Bilbrey

Tennessee Oncology

Scaling Artificial Intelligence to the Community Oncology Clinic

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Joy and Wellness in Oncology: An Oxymoron or a New Reality?

Location: E350

Reshma Jagsi, MD, DPhil, FASTRO, FASCO—Chair

Emory University School of Medicine

Microaggressions and Mitigation Strategies for Patients, Caregivers, and Providers

Shanda H. Blackmon, MD, MPH

Baylor College of Medicine

The Support Group: Connection, Hope, and Healing for Patients and Providers

Erin Price, MSW, LCSW

Smith Center for Healing and the Arts

Health and Happiness: A Survivor's Story

Panel Question and Answer

7:30 AM-9:30 AM Education Session

Training Program Directors' Breakfast

Location: S103

Rami Manochakian, MD, FASCO—Chair

Mayo Clinic Florida

Welcome and Opening Remarks

Rami Manochakian, MD, FASCO

Mayo Clinic Florida

Navigating Effective Program Evaluations: Methods, Impact, and Response

Richard F. Riedel, MD

Duke Cancer Institute

Navigating Effective Program Evaluations: Program Share

Table Talk and Large Group Discussion

Annie P. Im, MD, FASCO

University of Pittsburgh Medical Center

Navigating Effective Program Evaluations: Program Share

Table Talk and Large Group Discussion

Rami Manochakian, MD, FASCO

Mayo Clinic Florida

Closing Remarks and Feedback

8:00 AM-9:00 AM Case-Based Panel

Beyond the Expected: Exploring Rare and Severe Toxicities in Immunotherapy Treatments

Location: S406

Sandrine Aspeslagh, MD, PhD—Chair

Universitair Ziekenhuis Brussel (UZ Brussel)

Moderator

Douglas Buckner Johnson, MD

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Medical Oncologist Perspective

Joe-Elie Salem, MD, PhD

Hôpital La Pitié-Salpêtrière, APHP

Cardio-Oncologist Perspective

John Probasco

Johns Hopkins University

Neuro-Oncologist Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Is Minimal Residual Disease Testing Helpful in Managing Multiple Myeloma?

Location: E450b

Neha Korde, MD—Chair

Memorial Sloan Kettering Cancer Center

Moderator

Benjamin Avi Derman, MD

University of Chicago

Hematologist-Oncologist Perspective

Luciano J. Costa, MD, PhD

University of Alabama at Birmingham

Hematologist Perspective

Rebecca Silberman, MD

Oregon Health & Science University

Physician-Scientist Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Treatment of High-Risk Prostate Cancer and PSMA PET-Positive Regional Lymph Nodes

Location: Hall D2

Curtiland Deville, MD—Chair

Johns Hopkins University

Moderator

Alberto Briganti, MD, PhD

Fred Hutch Cancer Center and University of Washington

Surgical Oncologist Perspective

Alicia K. Morgans, MD, MPH, FASCO

Dana-Farber Cancer Institute

Medical Oncologist Perspective

Amir Iravani, MD, FRACP

Washington University School of Medicine

Nuclear Medicine Perspective

David John Matheson, PhD, MEd

University of Wolverhampton

Patient Perspective

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Emerging Strategies for Drug-Based Cancer Risk Reduction

Location: S100bc

Andrea De Censi, MD

E.O. Ospedali Galliera

Selecting the Right Dose: The Case of Low-Dose Endocrine Breast Cancer Prevention

Darren R. Brenner, PhD, MSc

University of Calgary

Drug Repositioning: GLP1 Inhibition and Cancer Risk Reduction—What Are We Waiting For?

Francesc Balaguer, MD—Chair

University of Barcelona

Preventive Agents for Gastrointestinal Cancers

Ian Murchie Thompson Jr, MD

UT Health San Antonio

Who Should Be Offered Prostate Cancer Drug Prevention and When?

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks

Location: E451

Sepideh Gholami, MD, FACS—Chair

Northwell Health

Hepatic Arterial Infusion Pumps and Metastatectomy for Colorectal Liver Metastases

Riad Salem, MD

Northwestern Feinberg School of Medicine

Ablation, Embolization, and Radiation Approaches to Colorectal Liver Metastases

Kaznuari Sasaki, MD

Stanford University

Role of Liver Transplantation in Unresectable Colorectal Liver Metastases

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Navigating B-Acute Lymphoblastic Leukemia in the Era of Blinatumomab

Location: S402

Rachel Rau, MD—Chair

Seattle Children's Hospital

Who Would and Would Not Benefit From Receiving Blinatumomab in Frontline Treatment of B-Cell Acute Lymphoblastic Leukemia

Sue Zupanec, MN, NP

The Hospital for Sick Children

Barriers to Blinatumomab Administration and Access: How to Overcome Them

David T. Teachey, MD

Children's Hospital of Philadelphia

What Comes Next?

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Proposed Federal and State Policy Changes to Oncology Reimbursement: A Tsunami or Just a Change in Tide?

Location: E350

Kerin B. Adelson, MD, MS, FASCO—Chair

The University of Texas MD Anderson Cancer Center

Site Neutrality: Curbing the Cost of Cancer Care, but at What Risk?

Tufia C. Haddad, MD

Mayo Clinic

Post-Pandemic Digital Health Reimbursement: Impact on Access to Care

Kerstin Vokinger, MD

Universitat Zurich

Will We Live to See Efficacy-Based Pricing for Cancer Drugs?

Learning From International Models

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Rare Uterine Tumors: What to Do?

Location: S102

Martee Leigh Hensley, MD, MSc, FASCO—Chair

Memorial Sloan Kettering Cancer Center

Making Progress in the Treatment of Uterine Leiomyosarcoma

Stephanie Gaillard, MD, PhD

Johns Hopkins School of Medicine

Making Sense Out of Rare and Confusing Uterine Stromal Tumors

Erin Crane, MD

Levine Cancer, Atrium Health

Understanding Rare and Difficult Uterine Cancers: Mesonephric Mess and Serious Serous

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent MASCC-ASCO Standards and Practice Recommendations

Location: E450a

Andrea Smith, PhD, MPH

The Daffodil Centre

Navigating Both Sides: A Researcher and Patient's Experiences and Perspectives on Metastatic Survivorship

Larissa Nekhlyudov, MD, MPH, FASCO

Brigham and Women's Hospital

Survivorship Care for People Affected by Advanced or Metastatic Cancer: Changing the Clinical Care Paradigm

Nicolas H. Hart, PhD

University of Technology

Survivorship Care Standards and Practice Recommendations for People Affected by Advanced or Metastatic Cancer

Michael Jefford, PhD, MBBS, MHM, MPH—Chair

Peter MacCallum Cancer Centre

Clinical Care, Policy, and Research Priorities in Metastatic Cancer Survivorship

Panel Question and Answer

8:00 AM-9:15 AM Education Session

We Have Only GIST Begun: Navigating Ongoing Challenges in Gastrointestinal Stromal Tumors

Location: S100a

Heikki Joensuu

Helsinki University Hospital Comprehensive Cancer Center

Managing Localized KIT-Mutant Gastrointestinal Stromal Tumor: From Prognostication to Adjuvant Therapy

Suzanne George, MD—Chair

Dana-Farber Cancer Institute

Understanding, Diagnosing, and Targeting Tyrosine Kinase Inhibitors' Resistance and Persistence: Lessons Learned Over 25 Years

Jason K. Sicklick, MD

University of California, San Diego

Emerging Strategies for Managing Non-KIT/PDGFRα-Mutant Gastrointestinal Stromal Tumor Subtypes

Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall B1

Matteo Lambertini, MD—Chair

U.O. Clinical Oncology, IRCCS Ospedale Policlinico San Martino, University of Genova

Eileen Connolly, MD, PhD—Chair

Columbia University Irving Medical Center

8:00 AM Abstract LBA509: NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
First Author: Vicente Valero, MD

8:06 AM Abstract 510: Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
First Author: Christian F. Singer, MD, MPH

- 8:12 AM** **Abstract 511:** A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Rachel Occhiogrosso Abelman, MD
- 8:18 AM** Panel Question and Answer
- 8:30 AM** **Abstract 512:** The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ.
First Author: Swati Kulkarni, MD
- 8:36 AM** **Abstract 513:** The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer.
First Author: Lucy Haggstrom, MD
- 8:42 AM** **Abstract 514:** Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes.
First Author: Yazid Belkacemi
- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 515:** Dapiciclib (Dap) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2-early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
First Author: Zhi-Ming Shao
- 9:06 AM** **Abstract 516:** Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.
First Author: Kevin Kalinsky, MD, MS, FASCO
- 9:12 AM** **Abstract 517:** The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
First Author: Erica L. Mayer, MD, MPH, FASCO
- 9:18 AM** Panel Question and Answer

8:00 AM-11:00 AM Oral Abstract Session

Lung Cancer—Non–Small Cell Metastatic

Location: Arie Crown Theater

Natalie I. Vokes, MD—Chair

The University of Texas MD Anderson Cancer Center

Bruna Pellini, MD—Chair

Moffitt Cancer Centers

- 8:00 AM** **Abstract 8500:** First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS^{G12C}-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
First Author: Pasi A. Jänne, MD, PhD, FASCO
- 8:12 AM** **Abstract 8501:** TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).
First Author: Benjamin Philip Levy, MD, FASCO

- 8:24 AM** **Abstract LBA8502:** CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.
First Author: Baohui Han
- 8:36 AM** **Ticiana Leal, MD**
Winship Cancer Institute at Emory University
Discussion of Abstract(s) 8500-LBA8502: Right Out of the Gate: New Directions in Front-Line Therapy in Metastatic Non–Small Cell Lung Cancer
- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 8503:** Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.
First Author: Helena Alexandra Yu, MD
- 9:12 AM** **Abstract 8504:** SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.
First Author: Herbert H. Loong, FRCP, MBBS, FASCO
- 9:24 AM** **Marcelo Corassa, MD**
Hospital A Beneficência Portuguesa de São Paulo
Discussion of Abstract(s) 8503-8504: Targeting HER2 and EGFR Exon 20: Same Zip Code, Different Address
- 9:36 AM** Panel Question and Answer
- 9:48 AM** **Abstract LBA8505:** Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
First Author: Shun Lu, MD, PhD
- 10:00 AM** **Abstract 8506:** Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
First Author: Tony S. K. Mok, MD, FRCPC, FASCO
- 10:12 AM** **Abstract 8507:** Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.
First Author: Li Zhang, MD
- 10:24 AM** **Vanita Noronha, MD**
Tata Memorial Hospital
Discussion of Abstract(s) LBA8505-8507: Breaking Resistance in EGFR-Mutant Non–Small Cell Lung Cancer: What's the Next Move?
- 10:36 AM** Panel Question and Answer

8:15 AM-9:30 AM Highlights of the Day Session

Highlights of the Day I

Location: Hall D1

Kimmie Ng, MD, MPH—Chair

Dana-Farber Cancer Institute

8:15 AM Jane N. Winter, MD
Robert H. Lurie Comprehensive Cancer Center,
Northwestern University
*Hematologic Malignancies—Lymphoma and
Chronic Lymphocytic Leukemia*

8:30 AM Christine Parseghian, MD
The University of Texas MD Anderson Cancer
Center
Gastrointestinal Cancer—Colorectal and Anal

8:45 AM Namrata Vijayvergia, MD
Fox Chase Cancer Center
*Gastrointestinal Cancer—Gastroesophageal,
Pancreatic, and Hepatobiliary*

9:00 AM Barbara Burtness, MD, FASCO
Yale University School of Medicine
Head and Neck Cancer

9:00 AM-12:00 PM Poster Session

Care Delivery/Models of Care

Location: Hall A - Posters and Exhibits

Posters by Topic

Access to Care: Board(s) 274-289

Care Delivery: Board(s) 290-317, 422a-422b

Clinical Informatics/Advanced Algorithms/Machine Learning:
Board(s) 318-338, 423a

Digital Technology: Board(s) 340-345

Disparities in Care: Board(s) 346-388, 423b-424a

Geriatric Models of Care: Board(s) 389-390, 424b

Global Models of Care: Board(s) 391-397

Survivorship Models of Care: Board(s) 398-409, 425a-425b

Telemedicine/Remote Care: Board(s) 410-421

Board 274 **Abstract 1521:** Financial toxicity and drivers of delayed care among cancer survivors across the lifespan.
First Author: Justine Po, BS

Board 275 **Abstract 1522:** Spillover effects of Medicaid expansion on insurance coverage, diagnosis, and survival among low-income elderly patients with cancer.
First Author: Kewei Sylvia Shi, MPH

Board 276 **Abstract 1523:** Bolstering access to clinical trials: Sociodemographic characteristics of patients enrolled in interventional clinical trials within a large, NCORP-designated community oncology practice setting.
First Author: Meera Vimala Ragavan, MD, MPH

Board 277 **Abstract 1524:** Integrating collaborative care in oncology: Improving quality of life and mental health for patients with cancer.
First Author: Kyle Lavin

Board 278 **Abstract 1525:** From food deserts to clinical trial deserts: Challenges in access to breast cancer trials.
First Author: Rachel Sachs

Board 279 **Abstract 1526:** Low-dose anti-PD-(L)1 inhibitor strategies: A systematic review.
First Author: Pablo Jiménez Labaig, MDCM, MSc

Board 280 **Abstract 1527:** Characterizing transportation need and missed visits among patients receiving radiotherapy.
First Author: Kathleen Cui

Board 281 **Abstract 1528:** Disparities in breast cancer screening for the Brazilian Unified Health System (SUS): A warning of the need to change public policies.
First Author: Ruffo Freitas-Junior, MD, PhD

Board 282 **Abstract 1529:** Differences in insurance status among Asian Americans with cancer: A disaggregated analysis by ethnic subgroup.
First Author: Lilac Nguyen

Board 283 **Abstract 1530:** Breast cancer screening mammography among transgender and gender diverse (TGD) individuals: A nationwide study of >10,000 TGD individuals.
First Author: Elizabeth Jane Cathcart-Rake, MD

Board 284 **Abstract 1531:** Implementation of an academic precision oncology service in a community setting.
First Author: Junlone Moy, PharmD, RPh

Board 285 **Abstract 1532:** Development and fairness assessment of machine learning models for predicting 30-day readmission after lung cancer surgery.
First Author: Atulya Aman Khosla, MD

Board 286 **Abstract 1533:** Fall risk assessment by QTUG device in geriatric cancer patients on chemotherapy at a tertiary care hospital.
First Author: Tilak Tvsvvgk, MD

Board 287 **Abstract 1534:** APP-first as a strategy to increase new patient access and treatment of patients with gastrointestinal malignancies within a cancer center.
First Author: Amalia Stefanou, MD, FACS

Board 288 **Abstract 1535:** Gender, place of death, and racial disparities in the reporting odds ratio of cardiovascular disease burden in leukemia across age groups (15–85) in the U.S.: A CDC WONDER disproportionality analysis.
First Author: Tehmasp Mirza

Board 289 **Abstract 1536:** Oncofertility practice patterns in NCCN cancer centers after the overturn of Roe v. Wade.
First Author: Nikita V. Baclig, MD, MPH

Board 290 **Abstract 1537:** Trade-off preferences in older adults with newly diagnosed acute myeloid leukemia.
First Author: Kah Poh Loh, MS, MBBCh, FASCO

Board 291 **Abstract 1538:** OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively?
First Author: Ryan W. Huey, MD, MS

Board 292 **Abstract 1539:** Qualitative findings from providers and patients for planning implementation of screening clinical breast examination in Soweto, South Africa.
First Author: Daniel O'Neil, MD, MPH

Board 293	Abstract 1540: Development of an early sepsis treatment-decision algorithm in children and adolescents with cancer in a middle-income country: Results from a multinational modified Delphi consensus. First Author: Paula Aristizabal, MD, MS	Board 318	Abstract 1552: Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial. First Author: Javier Montalt-Tordera
Board 294	Abstract 1541: Impact of the eSyM symptom monitoring program on nurse telephone encounters across six cancer centers. First Author: Michael J. Hassett, MD, MPH, FASCO	Board 319	Abstract 1553: Real-world side effects of targeted therapies: High-throughput association studies leveraging the CancerLinQ Discovery lung cancer database. First Author: Joseph Vento, MD, MS
Board 295	Abstract 1542: Cost and resource utilisation for liquid biopsy vs tissue biopsy genotyping in advanced NSCLC: A micro-costing model. First Author: David O'Reilly	Board 320	Abstract 1554: Transforming oncology clinical trial matching through multi-agent AI and an oncology-specific knowledge graph: A prospective evaluation in 3,800 patients. First Author: Arturo Loaiza-Bonilla, MD, FACP, MED
Board 296	Abstract 1543: Impact of a collaborative care-based symptom intervention model on chemotherapy adherence in patients with breast cancer. First Author: Michael H. Storandt, MD	Board 321	Abstract 1555: Breath-based VOC analysis leveraging canine olfaction for multi-cancer detection: Insights from a 1000-sample study. First Author: Akash Kulgod, BSc
Board 297	Abstract 1544: Successful accrual of a cluster randomized controlled trial (RCT) comparing an educationally enhanced genomic tumor board (EGTB) intervention to usual practice (S2108CD, NCT# 05455606). First Author: Meghna S. Trivedi, MD, MS	Board 322	Abstract 1556: PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor-positive breast cancer. First Author: Eleftherios P. Mamounas, MD
Board 311	Abstract 1545: Electronic patient-reported outcomes with vital sign monitoring versus usual care during trastuzumab deruxtecan treatment for metastatic breast cancer: Updated results from the PRO-DUCE study. First Author: Yuichiro Kikawa, MD, PhD	Board 323	Abstract 1557: Computational pathology to predict docetaxel benefit for high-risk localized prostate cancer in NRG/RTOG 0521 (NCT00288080). First Author: Sebastian R. Medina, MSc
Board 312	Abstract 1546: Advancing equity and collaboration in a dedicated young onset cancer clinic: A prospective study. First Author: Ilit Turgeman, MD	Board 324	Abstract 1558: Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research. First Author: Ziad Bakouny, MSc
Board 313	Abstract 1547: Automated conversational artificial intelligence (AI) for outpatient malignant bowel obstruction (MBO) symptom monitoring. First Author: Ainhua Madariaga, MD	Board 325	Abstract 1559: Association of deep learning CT response assessment and interpretable components with overall survival in advanced NSCLC: Validation in a trial of sasanlimab and a real-world dataset. First Author: Chiharu Sako, PhD
Board 314	Abstract 1548: Oncologists' perspectives on challenges using chemotherapy, immune checkpoint inhibitors, and targeted kinase inhibitors for metastatic cancer. First Author: Christine M. Veenstra, MD, MS	Board 326	Abstract 1560: Computational pathology to predict docetaxel benefit in patients with metastatic hormone-sensitive prostate cancer from the CHARTED trial (ECOG-ACRIN E3805). First Author: Sebastian R. Medina, MSc
Board 315	Abstract 1549: Improving access to cancer screening through national telehealth-based lung and colorectal cancer screening programs. First Author: Deanna Brockman	Board 327	Abstract 1561: Frailty in motion: How Fitbit data reflects patients with cancers' functional status in the All-of-Us database. First Author: Kenan Najjar
Board 316	Abstract 1550: Current treatment patterns for early breast cancer among healthcare professionals and concordance with expert recommendations: Analysis of an online interactive decision support tool. First Author: Timothy Quill, PhD	Board 328	Abstract 1562: DeepSeal: Empowering clinical researchers to analyze clinicogenomic data with an intuitive chat-based interface. First Author: Gaurav Sharma, MS
Board 317	Abstract LBA1551: Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration. First Author: Roxana Stefania Dronca, MD	Board 329	Abstract 1563: Virtual oncology collaborative tumor board using multiple artificial intelligence agents. First Author: Jiasheng Wang, MD
		Board 330	Abstract 1564: Comparison of artificial intelligence to expert physician assessments of real-world oncology cases. First Author: Olivia Main, MD

Board 331	Abstract 1565: Evaluating fairness and mitigating bias in models predicting financial toxicity among patients with genitourinary cancers. First Author: Atulya Aman Khosla, MD	Board 346	Abstract 1580: Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small cell lung cancer following definitive chemoradiation. First Author: Chaewon Hwang, MD
Board 332	Abstract 1566: Machine learning model to forecast patient availability for oncology clinical trials. First Author: Rajeev Kulkarni	Board 347	Abstract 1581: Food insecurity and disparities in mental health symptoms and severity among breast cancer survivors. First Author: Kent Schechter, BS
Board 333	Abstract 1567: Magnetic resonance imaging (MRI) radiomics as predictor of clinical outcomes to neoadjuvant immunotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy. First Author: Andrea Necchi, MD	Board 348	Abstract 1582: Real world treatment patterns and outcomes in metastatic EGFR mutation - positive NSCLC patients: A retrospective study from a tertiary care cancer center in India. First Author: Jyothis P. Jose
Board 334	Abstract 1568: Acoustic biomarkers and AI: Transforming NSCLC detection and personalized care. First Author: Chiara Giangregorio	Board 349	Abstract 1583: Racial disparities in oncology clinical trials by absolute neutrophil count eligibility criteria: A single center retrospective analysis. First Author: Arvind Suresh, MD
Board 335	Abstract 1569: Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. First Author: Jeeyeon Elizabeth Lee, PhD	Board 350	Abstract 1584: Factors associated with receipt of surveillance breast MRI among racially/ethnically diverse women with a personal history of breast cancer. First Author: Preeti Kakani, MD, MBA
Board 336	Abstract 1570: Cancer patients' messages about radiology/pathology reports: Insights for AI. First Author: Susan Chimonas	Board 351	Abstract 1585: Meeting enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC). First Author: Christopher Cotter, PhD
Board 337	Abstract 1571: Analysis of a large language model-based system versus manual review in clinical data abstraction and deduction from real-world medical records of patients with melanoma for clinical trial eligibility assessment. First Author: Christine Vecchio, BS	Board 352	Abstract 1586: Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401). First Author: Ashley Odai-Afotey, MD
Board 338	Abstract 1572: Leveraging AI to enhance symptom capture and reduced hospitalizations. First Author: Arman Koul, MS	Board 353	Abstract 1587: Breast cancer optimal care timeframes for culturally and linguistically diverse populations and First Nations People: A regional centre experience in Australia. First Author: Matthew Hon, MBBS
Board 340	Abstract 1574: The role of healthcare system distrust in shaping patients' attitudes and beliefs of artificial intelligence (AI) use in oncology. First Author: Marco Santos Teles, BS	Board 354	Abstract 1588: Continuous financial toxicity screening in community oncology. First Author: Thomas Gregory Knight, MD
Board 341	Abstract 1575: Cross-sectional study on the impact of receiving potentially sensitive test results online on the emotional health of patients with breast cancer. First Author: Anezka Carvalho Rubin de Celis Ferrari, MD	Board 355	Abstract 1589: Socioeconomic- and insurance-based inequities in Oncotype DX testing and score-guided treatment. First Author: Courtney Williams, DrPH
Board 342	Abstract 1576: Utilization and impact of a digital care platform on cancer patients in India. First Author: Vamshi Krishna Muddu, MD, MBBS	Board 356	Abstract 1590: Empowering minority patients: A tailored education initiative for clinical trial awareness in thoracic oncology. First Author: Tadana Angelica Vazquez Rothschild, MS
Board 343	Abstract 1577: Biologically interpretable pathomics-driven transformer model with self-supervised training for outcome prediction of immunotherapy in non-small cell lung cancer. First Author: Butuo Li	Board 357	Abstract 1591: Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa). First Author: Christopher Johns
Board 344	Abstract 1578: Artificial intelligence based music therapy intervention in cancer patients undergoing chemotherapy in oncology day care (MUSICC). First Author: Sujith Kumar Mullapally, DM, MBBS, DNB	Board 358	Abstract 1592: Comparative analysis of demographics and outcomes in young versus average onset hospitalized gastrointestinal cancer patients in New York State. First Author: Mrinalini Ramesh, DO
Board 345	Abstract 1579: A randomized, controlled pilot trial of a neuromodulatory digital therapeutic for individuals with breast cancer. First Author: Samantha Adler, PhD		

Board 359	Abstract 1593: Assessing the effects of financial toxicity on quality of life among hematopoietic stem cell transplantation recipients. First Author: Grace Ann Hanvey, PhD	Board 374	Abstract 1608: Implementation of a clinical trial navigation program for cancer patients: Barriers and facilitators identified through stakeholder perspectives. First Author: Milica Paunic, BSc
Board 360	Abstract 1594: Early post-operative opioid fills after cancer-directed surgery among Medicare beneficiaries by race and ethnicity. First Author: Ashley Odai-Afotey, MD	Board 375	Abstract 1609: Association of West African ancestry, reproductive factors, and deprivation with incidence of triple-negative breast cancer among Black women in the U.S. First Author: Neha Hippalgaonkar, MD
Board 361	Abstract 1595: Disaggregating Asian American and Pacific Islander subgroups to evaluate disparities in breast cancer characteristics and outcomes. First Author: Shawn Michael Doss, BA	Board 376	Abstract 1610: Effects of socioeconomic status on access to next generation sequencing in patients with metastatic breast cancer. First Author: Conchita Martin de Bustamante
Board 362	Abstract 1596: The development of the cost of cancer in 31 European countries. First Author: Andrea Manzano, MS	Board 377	Abstract 1611: Trust and communication among sexual and gender minority (SGM) cancer survivors. First Author: Brandon Godinich
Board 363	Abstract 1597: Trends in female breast cancer among adolescent and young adults in Southeast Asia. First Author: Jenny Chen, MD	Board 378	Abstract 1612: Quantifying financial toxicity in oncology: A comprehensive analysis of prescription cost disparities using public data from 2022. First Author: Charishma Bhimineni, DO
Board 364	Abstract 1598: The impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC). First Author: Jacquelyne Janean Gaddy, MD, MS	Board 379	Abstract 1613: Racial differences in cardiovascular outcomes among cancer patients receiving immune checkpoint inhibitors. First Author: Cho Han Chiang, MD, MSCI
Board 365	Abstract 1599: 30 year trends in racial disparities for early stage lung cancer treatment. First Author: Olivia Frances Lynch, MD, MPH	Board 380	Abstract 1614: Impact of sociodemographic factors and Medicaid expansion on postoperative outcomes for glioblastoma, 2004-2021. First Author: Bhav Jain, BS
Board 366	Abstract 1600: At-risk cancer genetic syndrome identification (ARCAGEN-ID): Novel EHR integrated system to overcome disparities in identification and testing for cancer genetic syndromes. First Author: Vinit Singh, MBBS	Board 381	Abstract 1615: Symptom burden, quality of life (QoL), social and behavioral characteristics in young patients (<40 years old) with cancer: A prospective cohort of 7323 patients across 110 sites in France and Belgium. First Author: Kaïssa Ouali, MD
Board 367	Abstract 1601: Clinical implications and prevalence of benign ethnic neutropenia (BEN) in breast cancer patients of Middle Eastern ethnicity. First Author: Shruti Prem Sudha, MD, MRCP	Board 382	Abstract 1616: Prevalence of and factors associated with financial toxicity among gastrointestinal cancer patients in Pakistan. First Author: Sehar Salim Virani, MBBS
Board 368	Abstract 1602: Community-based patient navigation and preventative care among women surviving breast cancer. First Author: Anthony Zisa, BS	Board 383	Abstract 1617: The effect of a vertically integrated health system on the disparity of socioeconomic status seen in cancer stage at presentation. First Author: Robert Michael Cooper, MD
Board 369	Abstract 1603: Mutation rate differences across populations and association with performance disparities in pathology AI diagnostic models. First Author: Po-Jen Lin, MD, MPH	Board 384	Abstract 1618: Dihydropyrimidine dehydrogenase (DPD) deficiency-related variants among Mexican patients with gastrointestinal (GI) malignancies. First Author: Enrique Soto Pérez de Celis, MD, PhD, MSc, FASCO
Board 370	Abstract 1604: Gentian violet compared with methylene blue for sentinel lymph node biopsy in breast cancer: A retrospective analysis from a resource-limited setting. First Author: Mehwish Mooghal, FCPS	Board 385	Abstract 1619: State-level trends and associated disparities in melanoma burden in the United States. First Author: Furkan Bahar, MD
Board 371	Abstract 1605: Comparison of mobile mammography versus urban hospital-based breast cancer screening. First Author: Carla Zeballos Torrez, MD, PhD	Board 386	Abstract 1620: Association of allostatic load (AL) and residential segregation with breast biopsy outcomes after screening mammography. First Author: Braelyn Wekwerth
Board 372	Abstract 1606: Radiotherapy utilization at the fourth most populous province in Indonesia: A single centre study. First Author: Vito Filbert Jayalie, MD	Board 387	Abstract 1621: Racial differences in serious immune-related adverse events among cancer patients receiving immune checkpoint inhibitors. First Author: Cho Han Chiang, MD, MSCI
Board 373	Abstract 1607: Rates and predictors of cancer screening in California (CA) prisons. First Author: Christopher Manz, MD, MS		

- Board 388 **Abstract 1622:** Survival disparities between patients with breast cancer with and without HIV at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH).
First Author: Harriet Fridah Adhiambo, BSN, MSN
- Board 389 **Abstract 1623:** Association between Geriatric 8 frailty, guideline treatment, treatment adherence, and overall survival in older patients with cancer (PROGNOSIS-G8).
First Author: Helena Møgelbjerg Ditzel, MD
- Board 390 **Abstract 1624:** Prognostic awareness in older adults with metastatic cancer: Secondary analysis of a randomized controlled trial.
First Author: Cristiane Decat Bergerot, PhD, MS
- Board 391 **Abstract 1625:** National cancer system characteristics and global pan-cancer outcomes.
First Author: Edward Christopher Dee, MD
- Board 392 **Abstract 1626:** Validating Navya Earthshot: An AI-enabled point-of-care solution for guideline-adherent treatment planning in a decentralized cancer care model.
First Author: Umesh Mahantshetty, MD, DNB
- Board 393 **Abstract 1627:** Advancing global equity in cancer care: Comparative environmental impacts of radiotherapy in Brazil and the U.S.
First Author: Katie Lichter
- Board 394 **Abstract 1628:** Achieving global breast cancer initiative key performance indices for breast cancer patients in Botswana by HIV status.
First Author: Tara Friebe-Klingner, PhD, MPH
- Board 395 **Abstract 1629:** Disparities in exercise referral practices and barriers among oncologists in public and private institutions in Latin America.
First Author: Paulo Gustavo Bergerot, MD
- Board 396 **Abstract 1630:** Investigating gender demographics and equity among hematologists.
First Author: Florence Broussais
- Board 397 **Abstract 1631:** Clinical profiles, patient expectations and outcomes from an integrative oncology clinic in India: A novel integrated model of care in oncology.
First Author: Kanakavalli K. Kundury, PhD
- Board 398 **Abstract 1632:** How do health concerns present in cancer survivors who require interpreters? Database analysis of a structured survivorship clinic for early-stage cancer.
First Author: Lawrence Kasherman, FRACP, MBBS, MMed
- Board 399 **Abstract 1633:** Living beyond cancer: The long-term impact of breast cancer diagnosis on cognitive function.
First Author: Cheng Peng, ScD
- Board 400 **Abstract 1634:** Blended survivorship and palliative care for patients with advanced lung cancer receiving targeted therapy: An open pilot.
First Author: Laura A. Petrillo, MD
- Board 401 **Abstract 1635:** Experiences and preferences of cancer survivors across the immunotherapy journey.
First Author: Shelley Fuld Nasso, MPA
- Board 402 **Abstract 1636:** Health related social needs in an urban academic breast cancer survivorship program.
First Author: Mumtu Lalla, MD
- Board 403 **Abstract 1637:** Feasibility trial of health coaching-based navigation after breast cancer treatment.
First Author: Ruvarashe Rumano, MPH
- Board 404 **Abstract 1638:** Predicting overall survival in adults with cancer in the US using machine learning approaches integrating comprehensive social risk factors.
First Author: Yiwang Zhou
- Board 406 **Abstract 1640:** Pioneering cancer survivorship care in Latin America: Early results from the OC sobre VIVER program in Brazil.
First Author: Luciana Landeiro, MD, PhD
- Board 407 **Abstract 1641:** Oncology primary care clinics for comprehensive care of high-risk adolescent and young adult (AYA) cancer survivors.
First Author: Alique Gabrielle Topalian, PhD, MPH
- Board 408 **Abstract 1642:** Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
First Author: Tendai Kwaramba, MD, MSc
- Board 409 **Abstract 1643:** Subtype-specific trends in lung cancer incidence and survival: A SEER analysis (2004–2021).
First Author: Shubhank Goyal, MBBS
- Board 410 **Abstract 1644:** Telehealth and cancer care delivery: An updated real-world analysis of the impact of telehealth on patient access and treatment utilization at a comprehensive cancer center.
First Author: Kelsey H. Natsuhara, MD
- Board 413 **Abstract 1647:** Pilot study of an enhanced telehealth program for patients with prostate cancer.
First Author: Erin Mary Bange, MD
- Board 414 **Abstract 1648:** Impact of telehealth utilization on adherence to endocrine therapies in privately insured breast cancer patients: A claims-based cohort study.
First Author: Shaimaa Elshafie, PhD, MSc
- Board 415 **Abstract 1649:** Comparative effectiveness of delivering early palliative care via video versus in-person on end-of-life outcomes in patients with advanced lung cancer.
First Author: Jessica R. Bauman, MD
- Board 416 **Abstract 1650:** Assessing circadian rhythms and chemotherapy safety in remote patients with pancreatic ductal adenocarcinoma (PDAC) using a multidimensional digital platform (MultiDom, NCT04263948).
First Author: Francis Albert Lévi, MD, PhD
- Board 417 **Abstract 1651:** Remote physiologic and behavioral monitoring to predict early treatment response in metastatic cancer: High-Definition Oncology study (HDOs) preliminary results.
First Author: Leire Paz-Arbaizar, MS
- Board 418 **Abstract 1652:** Administration of tarlatamab in an outpatient setting utilizing remote patient monitoring: Mayo Clinic experience.
First Author: Ashley Potter, PharmD

- Board 419 **Abstract 1653:** Teledermatology-dermoscopy: Expanding access to skin cancer screening to reduce healthcare disparities.
First Author: Brenda Santellano, MD
- Board 420 **Abstract 1654:** Patient-reported experience with an immunotherapy telehealth platform.
First Author: Robert Michael Daly, MD, MBA, FASCO
- Board 421 **Abstract 1655:** Outcomes of germline expedited point of care (POC) genetic testing through telehealth in the Veterans Health Administration (VA).
First Author: Akiko Chiba, MD
- Board 422a **Abstract TPS1656:** DIPCAN, a multidimensional approach to precision oncology: Harnessing genomic, clinical, pathological and radiographic data to advance personalized cancer treatment.
First Author: Enrique Grande, MD, PhD
- Board 422b **Abstract TPS1657:** A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise) Beyond Walls (CCBW) program.
First Author: Dina Elantably, MD, MSc
- Board 423a **Abstract TPS1658:** Trial in progress: Evaluating the effectiveness of Blue-button—A tool for institution-agnostic, EHR-integrated regional automated clinical trial prescreening and matching.
First Author: Waddah Arafat, MD
- Board 423b **Abstract TPS1659:** DISCO App: A patient intervention to reduce the financial burden of cancer in a diverse patient population.
First Author: Lauren M. Hamel, PhD
- Board 424a **Abstract TPS1660:** RACED (Reduction of Cervical Cancer Disparities): The impact of navigators and racial literacy training.
First Author: Abna Faustina Sousa Vieira, MD
- Board 424b **Abstract TPS1661:** Practical geriatric assessment (PGA) implementation strategies and correlative evaluations (PACE-70): A hybrid implementation-effectiveness study in 3 community practices.
First Author: Gabriel Aleixo, MD
- Board 425a **Abstract TPS1662:** Patient Priorities Care for older breast cancer survivors: A patient-centered approach to improve quality of breast cancer survivorship.
First Author: Dana Elena Giza, MD
- Board 425b **Abstract TPS1663:** Impacting quality of life and pancreatic cancer survivorship through a telehealth intervention.
First Author: Vincent Chung, MD
- Board 298 **Abstract 5518:** A phase II study of tumor microenvironment profiling at single cell level in patients with locally advanced cervical cancer (LACC) treated with immunotherapy combined with concurrent chemoradiotherapy (CICRT).
First Author: Yuhan Sheng, MD
- Board 299 **Abstract 5519:** Impact of pre-treatment counseling on uptake of hormone replacement therapy in patients undergoing chemoradiation for cervical cancer.
First Author: Keizra Mecklai, MD, MBA
- Board 300 **Abstract 5520:** Toripalimab with chemoradiotherapy followed by toripalimab maintenance therapy for newly diagnosed, high-risk, locally advanced cervical cancer (TorCH-CC): A single-arm phase II study.
First Author: Shuangzheng Jia, PhD
- Board 301 **Abstract 5521:** Nimotuzumab with chemoradiotherapy for newly diagnosed, high-risk, locally advanced squamous cervical cancer (CC11): A prospective single-arm phase II study.
First Author: Shuangzheng Jia, PhD
- Board 302 **Abstract 5522:** Enlonstobart in patients with PD-L1 positive recurrent/metastatic cervical cancer: Updated survival results of the phase II study.
First Author: Jing Zuo
- Board 303 **Abstract 5523:** miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot.
First Author: Alyssa Bujnak, MD
- Board 304 **Abstract 5524:** An NCDB study examining disparities in the administration of immunotherapy among advanced cervical cancer patients.
First Author: Alicia Youssef
- Board 305 **Abstract 5525:** Clinicopathological and prognostic characteristics of gastric-type endocervical adenocarcinoma: A single-center retrospective study.
First Author: Yang Liu
- Board 306 **Abstract 5526:** Adjuvant, neoadjuvant and surgical treatment for locally advanced cervical cancer: A network meta-analysis.
First Author: Rafael Lara Nohmi
- Board 307 **Abstract 5527:** A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.
First Author: Dengfeng Wang
- Board 308 **Abstract 5528:** Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, as monotherapy in patients with advanced cervical cancer.
First Author: Hanmei Lou, MS
- Board 309 **Abstract 5529:** Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.
First Author: Hanmei Lou, MS

9:00 AM-12:00 PM Poster Session

Gynecologic Cancer

Location: Hall A - Posters and Exhibits

Posters by Topic

Cervical Cancer: Board(s) 298-310, 429-439, 516a-518a

Ovarian Cancer: Board(s) 440-491, 493, 518b-522b

Uterine Cancer: Board(s) 494-508, 523a-524b

Other Gynecologic Cancer: Board(s) 509-515, 525a-526a

- Board 310 **Abstract 5530:** Induction cadonilimab combined with chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A multicenter, single-arm, phase II trial.
First Author: Lin Ding
- Board 429 **Abstract 5531:** A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab.
First Author: Alberto Farolfi, MD
- Board 430 **Abstract 5532:** A non-invasive metabolomic biomarker for detecting cervical intraepithelial neoplasia and cervical cancer.
First Author: Jihoon Kang, MD, PhD
- Board 431 **Abstract 5533:** GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
First Author: Haifeng Qin, MD
- Board 432 **Abstract 5534:** Management of loop electrosurgical excision procedure with positive margins.
First Author: Christopher M Mayer, MD, MS
- Board 433 **Abstract 5535:** Global cervical cancer outcomes and national cancer system characteristics.
First Author: Erin Jay Garbes Feliciano, MD, MBA
- Board 434 **Abstract 5536:** Atezolizumab and stereotactic body radiation in metastatic, recurrent, or persistent cervical cancer: Results from a phase II multi-institutional study.
First Author: Kamran A. Ahmed, MD
- Board 435 **Abstract 5537:** Real-world efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced, recurrent, and metastatic cervical cancer.
First Author: Dapeng Li
- Board 436 **Abstract 5538:** Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes.
First Author: Kristina Lindemann, MD, PhD
- Board 437 **Abstract 5539:** A meta-analysis of induction chemotherapy (ICT) followed by chemoradiotherapy for locally advanced cervical cancer: The role of ICT type and duration on efficacy outcomes.
First Author: Matheus de Oliveira Andrade, MD
- Board 438 **Abstract 5540:** A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.
First Author: Li Zheng, MD
- Board 439 **Abstract 5541:** Evolving global burden and trend of cervical cancer in G20 countries: Age, sex, regional disparities from 1990-2021.
First Author: Jahn timer Chaudhari, MD
- Board 440 **Abstract 5542:** Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx).
First Author: Rene Lynnette Roux, MBChB

- Board 441 **Abstract 5543:** Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery versus cytoreductive surgery alone for ovarian cancer: An updated meta-analysis.
First Author: Osama Ijaz, MBBS
- Board 442 **Abstract 5544:** Gynecologic oncology referral rates of adnexal masses suspicious for ovarian cancer in an academic health system: A cohort study.
First Author: Anna Jo Bodurtha Smith, MD, MPH
- Board 443 **Abstract 5545:** Progression-free survival as a surrogate outcome for overall survival in ovarian cancer maintenance therapy randomized controlled trials.
First Author: Rachel P. Mojdehakhsh
- Board 444 **Abstract 5546:** Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study.
First Author: Ruomeng Bi, MBBS
- Board 445 **Abstract 5547:** Comparison of predictive models in women with advanced epithelial ovarian cancer triaged to primary debulking or neoadjuvant chemotherapy.
First Author: Shalini Rajaram, MD
- Board 446 **Abstract 5548:** Concordance of circulating tumor DNA and tissue genomic profiling in ovarian cancer: Influencing factors and clinical significance.
First Author: Hao Su
- Board 448 **Abstract 5550:** Validation of the performance of Ovarian Cancer Score for diagnosing ovarian cancer in a multicenter study.
First Author: Haixia Wang
- Board 449 **Abstract 5551:** Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC).
First Author: Mark S. Shahin, MD
- Board 450 **Abstract 5552:** HER2 and HER3 expression in ovarian cancer: Evolution across chemotherapy exposure and implications for targeted therapies.
First Author: Felix Blanc-Durand, MD
- Board 452 **Abstract 5554:** Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvmecitug combined with chemotherapy for platinum-resistant ovarian cancer.
First Author: Guangwen Yuan, MD
- Board 453 **Abstract 5555:** Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
First Author: Victor Cervera, PhD, PharmD
- Board 454 **Abstract 5556:** Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
First Author: Hyun-Woong Cho, PhD

- Board 455 **Abstract 5557:** JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials.
First Author: Xiaohua Wu
- Board 458 **Abstract 5560:** Analyzing the relationship between glutaminase expression and features of the immune tumor microenvironment in epithelial ovarian cancer using imaging mass cytometry.
First Author: Neha Verma, MD
- Board 459 **Abstract 5561:** Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.
First Author: Pamela Soberanis Pina, MD
- Board 460 **Abstract 5562:** Phase I study of sustained and local delivery of intraperitoneal IL-2 using encapsulated cells in patients with platinum-resistant high-grade serous carcinoma.
First Author: Helen D. Clark, MD
- Board 461 **Abstract 5563:** Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
First Author: Jung-Yun Lee, MD, PhD
- Board 462 **Abstract 5564:** Preliminary analysis of disitamab vedotin combined therapy for HER2-expressing platinum-sensitive recurrent ovarian/peritoneal/Fallopian tube cancer (Diversity study): A single-arm, multicenter phase II trial.
First Author: Tong Shu
- Board 463 **Abstract 5565:** IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.
First Author: Jin Shu, PhD
- Board 464 **Abstract 5566:** Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine.
First Author: Annegé Vledder
- Board 465 **Abstract 5567:** Optimizing an NGS low-pass-based method to detect genomic instability as a PARP inhibitor predictive biomarker in high-grade serous ovarian cancer.
First Author: Ignacio Romero, MD
- Board 466 **Abstract 5568:** Real-world analysis of folate receptor alpha (FR α ; FOLR1) expression in pan-tumor samples from over 6000 patients in the US.
First Author: Thomas C. Krivak, MD
- Board 467 **Abstract 5569:** Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients.
First Author: Thanh Hue Dellinger, MD
- Board 468 **Abstract 5570:** Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer (OC): A meta-analysis of randomized trials.
First Author: Riccardo Vida
- Board 469 **Abstract 5571:** Harnessing EHR for goals of care: The role of electronic alerts for care optimization in gynecologic cancer patients at risk of death in 6 months.
First Author: Katherine Fitch, MD
- Board 470 **Abstract 5572:** Safety and effectiveness of fuzuloparib in patients with ovarian cancer: A nationwide, multicenter, prospective real-world study.
First Author: Qinglei Gao, ANP
- Board 471 **Abstract 5573:** EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.
First Author: Ji Son, MD, MS
- Board 472 **Abstract 5574:** Potential of tumor-informed ctDNA as an early predictive indicator for relapse in advanced ovarian cancer.
First Author: Christina Victoria Isabella Tauber, MD
- Board 473 **Abstract 5575:** AI-powered quantification of tumor-infiltrating lymphocytes from H&E stained images in ovarian cancer and its association with PARP inhibitor therapy outcomes.
First Author: Hiroshi Asano, MD, PhD
- Board 474 **Abstract 5576:** Genomic instability score (GIS) and benefit from olaparib (ola) and bevacizumab (bev) maintenance in high-grade ovarian cancer (HGOC): Phase III PAOLA-1 GINECO/ENGOT-ov25 trial exploratory analysis.
First Author: Jose Sandoval, MD, PhD
- Board 475 **Abstract 5577:** Survival outcomes of advanced ovarian cancer treated with neoadjuvant chemotherapy versus primary cytoreductive surgery using a quality-assured decision-making approach.
First Author: Ji Hyun Kim, MD
- Board 476 **Abstract 5578:** Impact of rucaparib on circadian rhythms and adverse events in ovarian cancer: Insights from the MAMOC trial.
First Author: Deeksha Malhan
- Board 477 **Abstract 5579:** Efficacy of third-line and later (3L+) therapies post poly (ADP-ribose) polymerase inhibitor (PARPi) exposure in recurrent platinum-sensitive ovarian cancer (PSOC): A pooled clinical trial database analysis.
First Author: Robert Louis Coleman, MD, FACS, FACOG, FASCO
- Board 479 **Abstract 5581:** A multi-omics approach using lipids and proteins for early detection in individuals with signs and symptoms of ovarian cancer.
First Author: Rachel Culp-Hill, PhD
- Board 480 **Abstract 5582:** Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test.
First Author: Carlos Salomon, PhD, DPhil, MPhil
- Board 481 **Abstract 5583:** Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.
First Author: Gabriela Branquinho Guerra, MS

- Board 482 **Abstract 5584:** Hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer: An updated systematic review and meta-analysis. First Author: Yemesrach Mekonen, MD
- Board 483 **Abstract 5585:** Impact of body mass index, diabetes, and tumor mutational burden in ovarian, fallopian tube, and primary peritoneal carcinoma with BRCA1/2 alteration on poly(ADP-ribose) polymerase inhibitors. First Author: Ryan Tan, MBBS, MRCP
- Board 484 **Abstract 5586:** Survival outcomes for ovarian cancer patients in the post-poly ADP-ribose polymerase inhibitor (PARPi) era in the US. First Author: Henry Becerra, MD
- Board 485 **Abstract 5587:** Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor- and platinum-resistant ovarian cancer: A two-cohort, single-arm phase 2 study (OPERA/KGOG3065/APGOT-OV6). First Author: Junsik Park, MD, PhD
- Board 486 **Abstract 5588:** Platinum or non-platinum therapy in post-olaparib recurrent ovarian cancer: Analysis in matched cohorts. First Author: Alexey Rumyantsev, MD
- Board 487 **Abstract 5589:** A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION). First Author: Bairong Xia
- Board 488 **Abstract 5590:** A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. First Author: Alicia Youssef
- Board 489 **Abstract 5591:** Folate receptor alpha (FR α ; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort. First Author: Elizabeth M. Swisher, MD
- Board 490 **Abstract 5592:** Distinguishing tumor vs. clonal hematopoiesis (CH)-derived TP53 and BRCA1/2 alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making. First Author: Natalie Danziger, BS
- Board 491 **Abstract 5593:** Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial. First Author: Jing Liu
- Board 493 **Abstract 5595:** Characterization of copy number variations (CNV) patterns and pseudotime trajectories in high-grade serous ovarian cancer (HGSOC). First Author: Luca Mastrantonio, MD, MSc
- Board 494 **Abstract 5596:** Analysis of serous carcinoma subgroup in FRUSICA-1: Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with pMMR status. First Author: Xiaohua Wu, MD
- Board 495 **Abstract 5597:** A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers. First Author: Maria M. Rubinstein, MD
- Board 496 **Abstract 5598:** Molecular testing in primary advanced or recurrent endometrial cancer: A cost-effectiveness analysis. First Author: Yilin Chen
- Board 497 **Abstract 5599:** E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO). First Author: Jung-Yun Lee, MD
- Board 498 **Abstract 5600:** Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. First Author: Florian Heitz, MD
- Board 499 **Abstract 5601:** Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. First Author: Cara Amanda Mathews, MD
- Board 500 **Abstract 5602:** A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer. First Author: Judong Li
- Board 501 **Abstract 5603:** Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer. First Author: Domenica Lorusso, MD, PhD
- Board 502 **Abstract 5604:** Clinicopathological features and survival outcomes in women with endometrial neuroendocrine tumors. First Author: Morgan Bou Zerdan, MD
- Board 504 **Abstract 5606:** Quality of life and lifestyle changes during and after therapy in women with endometrial cancer: A global study of 1,066 patients (NOGGO, ENGOT, GCIG, ENGAGe-IMPROVE/EXPRESSION XI). First Author: Lukas Chinczewski
- Board 505 **Abstract 5607:** The landscape of chromosomal instability in uterine leiomyosarcoma. First Author: Sara Moufarrij
- Board 506 **Abstract 5608:** Post-hoc analysis evaluating selinexor maintenance therapy in patients with TP53wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study. First Author: Jalid Sehouli, MD

- Board 507 **Abstract 5609:** The role of platinum-free interval in advanced endometrial cancer treatment: A real-world study of 843 patients.
First Author: John K. Chan, MD
- Board 508 **Abstract 5610:** Adverse effects of immune checkpoint inhibitors in advanced endometrial cancer: A systematic review and meta-analysis.
First Author: Fizza Mohsin, MBBS
- Board 509 **Abstract 5611:** The impact of prior neoadjuvant/adjuvant chemotherapy (NACT/ACT) on fruquintinib plus sintilimab outcomes in advanced endometrial cancer (EMC) patients with pMMR status: A subgroup analysis of FRUSICA-1.
First Author: Jing Wang
- Board 510 **Abstract 5612:** SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study.
First Author: Beihua Kong
- Board 511 **Abstract 5613:** Evaluating the safety and efficacy of CRISPR/Cas9-modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors.
First Author: Pin Wang, PhD
- Board 512 **Abstract 5614:** Feasibility of ChatGPT-4o in management of gynecologic oncologic patients in the emergency department.
First Author: Junhwan Kim, MD
- Board 513 **Abstract 5615:** Clinical and demographic profiles and predictors of survival in epithelioid trophoblastic tumors: A population-based analysis.
First Author: Zhuoran Xiao
- Board 514 **Abstract 5616:** Effects of surgery on the prognosis of patients with locally advanced vulva cancer: A retrospective study of the SEER database and a Chinese multicentre registry.
First Author: Yuqin Wang
- Board 515 **Abstract 5617:** Temporal and regional mortality trends due to pulmonary embolism in female patients with genital cancers in the United States from 1999 to 2020.
First Author: Marcos Alberto Jr, MD
- Board 516a **Abstract TPS5618:** TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer.
First Author: Ritu Salani, MD, MBA
- Board 516b **Abstract TPS5619:** Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for women with locally advanced cervical cancer.
First Author: Henrique Alkalay Helber, MD
- Board 517a **Abstract TPS5620:** A prospective, randomized control trial of concurrent paclitaxel and carboplatin along with radiotherapy versus concurrent cisplatin along with radiotherapy in carcinoma cervix patients at a tertiary care hospital of central India.
First Author: Praghnaya Subhash Tejale, MD
- Board 517b **Abstract TPS5621:** ANA trial: Development of a diagnostic test and dynamic evaluation of ctDNA to optimize follow-up and tailor treatment in patients with HPV-related cervical and anal tumors.
First Author: Renata Colombo Bonadio, MD
- Board 518a **Abstract TPS5622:** A phase II, single-arm, open-label clinical trial to evaluate the combination of cadonilimab injection and gut microbiota modulation in the treatment of persistent, recurrent, or metastatic cervical cancer following second-line therapy.
First Author: Qin Xu, MD
- Board 518b **Abstract TPS5623:** A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.
First Author: Melanie Wain Kier, MD, MBA
- Board 519a **Abstract TPS5624:** Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS).
First Author: Myong Cheol Lim, MD, PhD
- Board 519b **Abstract TPS5625:** A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer.
First Author: Rebecca Kristeleit, MD, PhD
- Board 520a **Abstract TPS5626:** SALVOVAR: A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT-ov78).
First Author: Benoit You, MD, PhD
- Board 520b **Abstract TPS5627:** A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator's choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).
First Author: Angeles Alvarez Secord, MD, MHS
- Board 521a **Abstract TPS5628:** Rationale and study design of the KOV-HIPEC-02R (RECOVER): A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer.
First Author: Myong Cheol Lim, MD, PhD
- Board 522a **Abstract TPS5630:** SynKIR-CAR T cell advanced research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma.
First Author: Janos Laszlo Tanyi, MD, PhD
- Board 522b **Abstract TPS5631:** Evaluating zAvatar test-guided chemotherapy vs. standard of care in relapsed ovarian cancer and metastatic breast cancer: A multicenter randomized clinical trial (zAVATAR-FLUIDS).
First Author: Marcio Debiase, MD, PhD

- Board 523a **Abstract TPS5632:** Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians' choice in advanced/recurrent endometrial carcinoma previously treated with anti-PD-(L)1 immunotherapy.
First Author: Ramez Nassef Eskander, MD
- Board 523b **Abstract TPS5633:** Sapanisertib and serabelisib (PIKTOR) with paclitaxel and a diet substudy in patients with advanced/recurrent endometrial cancer (GOG-3111).
First Author: David Starks, MD
- Board 524a **Abstract TPS5634:** Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study.
First Author: Maria M. Rubinstein, MD
- Board 524b **Abstract TPS5635:** PENELOPE: A randomized phase II trial of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab with or without nesuparib, in patients with newly diagnosed advanced or recurrent MMR-proficient endometrial cancer.
First Author: Se Ik Kim, MD
- Board 525a **Abstract TPS5636:** IMMUNORARE⁵: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Gestational Trophoblastic Tumors Cohort.
First Author: Benoit You, MD, PhD
- Board 525b **Abstract TPS5637:** Stratification of vulvar squamous cell carcinoma (VSCC) by HPV and P53 status to guide excision: CCTG VU.2 STRIVE study (NCT06358469).
First Author: Amy Jamieson
- Board 526a **Abstract TPS5638:** Evaluation of indocyanine green (ICG) and handheld fluorescence imager in the management of early-stage gynecological cancer.
First Author: Shalini Rajaram, MD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Location: Hall A - Posters and Exhibits

Posters by Topic

Acute Leukemia: Board(s) 134-167, 196a-197b

Allogeneic Stem Cell Transplantation: Board(s) 168-179

Chronic Leukemia—CML: Board(s) 180-182

Myelodysplastic Syndromes (MDS): Board(s) 183-186, 198a-199a

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders: Board(s) 187-190, 199b-200b

Other Leukemia, Myelodysplastic Syndromes, and Allotransplant: Board(s) 191-195

- Board 134 **Abstract 6518:** Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.
First Author: Anthony Selwyn Stein, MD
- Board 135 **Abstract 6519:** Decoding immune dysregulation in AML: Insights from integrated genomic and transcriptomic analysis.
First Author: Harsh Goel, MSc
- Board 136 **Abstract 6520:** V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML).
First Author: Thomas William LeBlanc, MD, MHS, MA, FAAHPM, FASCO
- Board 137 **Abstract 6521:** Venetoclax as cytoreductive therapy in high-risk acute promyelocytic leukemia: A potential alternative to anthracyclines.
First Author: Ravi Teja Banda, MD, DM
- Board 139 **Abstract 6523:** Use of BAFFR CAR-T to treat B cell leukemia/lymphoma and auto-immune diseases.
First Author: Min Luo, PhD
- Board 140 **Abstract 6524:** The IRAK4 long isoform as widely upregulated in non-spliceosome mutated acute myeloid leukemia and as altered by hypomethylating agent therapy.
First Author: Eric J. Vick, MD, PhD
- Board 141 **Abstract 6525:** A phase I study of allogeneic anti-CD19 CAR-T therapy for patients with CD19+ relapsed/refractory acute B-lymphoblastic leukemia.
First Author: Sun Guangyu
- Board 142 **Abstract 6526:** TLR9 agonists as a potential therapeutic option for B-ALL patients with low P53 expression.
First Author: Ling Bai, MD, PhD
- Board 143 **Abstract 6527:** Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.
First Author: Ofir Wolach, MD
- Board 144 **Abstract 6528:** Nucleophosmin (NPM1) genomic alterations (GA) in acute myeloid leukemia (AML): A genomic landscape study.
First Author: Osama Batayneh, MD
- Board 145 **Abstract 6529:** Real-world outcomes of inaticabtagene autoleucl in Chinese patients with B-ALL.
First Author: Hongsheng Zhou
- Board 146 **Abstract 6530:** Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes.
First Author: Gaurav Prakash, MD, DM
- Board 147 **Abstract 6531:** Subgroup analysis by fitness criteria of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with first-line (1L) tagraxofusp (TAG).
First Author: Naveen Pemmaraju, MD

- Board 148 **Abstract 6532:** Detection of KMT2A partial tandem duplication (PTD) in AML by whole genome sequencing (WGS): Addressing limitations of traditional techniques in the era of revumenib approval.
First Author: Robert Huether
- Board 149 **Abstract 6533:** Mitoxantrone hydrochloride liposome combined with cytarabine (MA) for patients with newly diagnosed secondary acute myeloid leukemia.
First Author: Stephen Yang Liang
- Board 150 **Abstract 6534:** Co-mutational landscape of Indian core binding AML: An answer to the unfavorable outcome in a favorable AML?
First Author: Rahul Bhargava
- Board 151 **Abstract 6535:** Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies.
First Author: Hamed Rahmani Youshanlouei, MD
- Board 152 **Abstract 6536:** Potential benefits of using a different donor for transplantation consolidation after donor-derived CD7 CAR T.
First Author: Jing Pan, MD, PhD
- Board 153 **Abstract 6537:** Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting.
First Author: João Agostinho Machado-Neto, PhD
- Board 154 **Abstract 6538:** Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
First Author: Talha Badar, MD
- Board 155 **Abstract 6539:** Cytomolecular mechanisms of relapse after frontline FLT3 inhibitor (FLT3i)-based therapy in FLT3-mutated (mut) acute myeloid leukemia (AML).
First Author: Sankalp Arora, MBBS
- Board 156 **Abstract 6540:** Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).
First Author: Noam Edward Kopmar, MD
- Board 157 **Abstract 6541:** Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by body mass index.
First Author: Wendy Stock, MD
- Board 158 **Abstract 6542:** Novel potent and selective inhibitors targeting FLT3 for AML therapy.
First Author: Gauthier Errasti, PhD, MSc
- Board 159 **Abstract 6543:** Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia.
First Author: Niranjana Khair
- Board 160 **Abstract 6544:** Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia.
First Author: Roberta Santos Azevedo
- Board 161 **Abstract 6545:** A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
First Author: Eunice S. Wang, MD
- Board 162 **Abstract 6546:** Matching-adjusted indirect comparison (MAIC) of olutasidenib (OLU) and ivosidenib (IVO) in isocitrate dehydrogenase 1 (IDH1)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).
First Author: Justin M. Watts, MD
- Board 163 **Abstract 6547:** Investigating age of onset and prognosis of p53 mutant myeloid malignancies in African Americans.
First Author: Brendon Fusco, MD
- Board 164 **Abstract 6548:** Socioeconomic and clinical predictors of 30-day readmissions in AML patients undergoing allogeneic stem cell transplantation.
First Author: Aditi Sharma, MD
- Board 165 **Abstract 6549:** Outcomes of therapy-related AML (T-AML) with venetoclax-based therapies.
First Author: Jennifer Croden, MD
- Board 166 **Abstract 6550:** Impact of clinical trial treatment and area deprivation index in the outcomes of adolescent and young adult patients with acute myeloid leukemia.
First Author: James Wesley Hill
- Board 167 **Abstract 6551:** Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia.
First Author: Mehmet Uyanik
- Board 168 **Abstract 6552:** Factors associated with frailty in vulnerable hematopoietic cell transplantation candidates.
First Author: Hyunhae Lee, MS, RN
- Board 169 **Abstract 6553:** Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission.
First Author: Shlomo Elias
- Board 170 **Abstract 6554:** Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT.
First Author: Emily Walsh
- Board 171 **Abstract 6555:** Peripheral blood cell-free DNA testing as a predictor for relapse post-allogeneic stem cell transplant for AML.
First Author: Vanisha Patel, MD
- Board 173 **Abstract 6557:** The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS.
First Author: Yanal Mufeed Alnimer, MD
- Board 174 **Abstract 6558:** Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients.
First Author: Ali Alsugair, MBBS
- Board 175 **Abstract 6559:** Allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia adults in complete remission: A systematic review and meta-analysis.
First Author: Muhammad Umair Mushtaq, MD

- Board 176 **Abstract 6560:** Factors associated with outcomes following reduced intensity conditioning haploidentical hematopoietic cell transplantation in acute myeloid leukemia.
First Author: Muhammad Umair Mushtaq, MD
- Board 177 **Abstract 6561:** Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study.
First Author: Uday R. Popat, MD
- Board 178 **Abstract 6562:** Association between pre-transplant biological aging markers and clinical outcomes in allogeneic hematopoietic cell transplant recipients.
First Author: Kelly Rentscher
- Board 179 **Abstract 6563:** Pre-transplant measures of geriatric assessment domains and outcomes of allogeneic hematopoietic cell transplantation in adults aged 75 and older.
First Author: Amar Harry Kelkar, MD, FACP, MPH
- Board 180 **Abstract 6564:** Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India.
First Author: Akhil Santhosh, MD
- Board 181 **Abstract 6565:** Early predictors of treatment-free remission in chronic myeloid leukemia.
First Author: Aziz Farhat, MD
- Board 182 **Abstract 6566:** Long-term follow-up of treatment-free remission in chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitor therapy.
First Author: Mehmet Uyanik
- Board 183 **Abstract 6567:** Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes.
First Author: Alexandre Bazinet, MD
- Board 184 **Abstract 6568:** Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation.
First Author: Luis E. Aguirre, MD
- Board 185 **Abstract 6569:** Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
First Author: Rami S. Komrokji, MD
- Board 186 **Abstract 6570:** Real-world (RW) outcomes of patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.
First Author: Idoroenyi Usua Amanam, MD
- Board 187 **Abstract 6571:** An exploratory analysis of myelofibrosis (MF) patient subgroups by baseline hemoglobin levels in the gecacitinib phase 3 trial.
First Author: Yi Zhang
- Board 188 **Abstract 6572:** Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model.
First Author: Xiaomei Li, PhD
- Board 189 **Abstract 6573:** Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis.
First Author: Harinder Gill, MD, FRCP, MBBS, FRCPATH
- Board 190 **Abstract 6574:** Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
First Author: Justin M. Watts, MD
- Board 191 **Abstract 6575:** A simplified scoring system to predict in-hospital mortality of leukapheresis in patients with leukemia.
First Author: Barath Prashanth Sivasubramanian, MD
- Board 192 **Abstract 6576:** Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
First Author: Bijal D. Shah, MD, MS
- Board 193 **Abstract 6577:** Updated results of a phase 2 study: Timdarpaccept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
First Author: Hongyan Tong, PhD
- Board 194 **Abstract 6578:** Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia.
First Author: Timothy Edward O'Connor, MD
- Board 195 **Abstract 6579:** Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients.
First Author: Muhammad Yousuf
- Board 196a **Abstract TPS6580:** QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD-negative acute myeloid leukemia (AML).
First Author: Pau Montesinos
- Board 196b **Abstract TPS6581:** First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
First Author: Abhishek Maiti, MD, MBBS
- Board 197a **Abstract TPS6582:** Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory acute myeloid leukemia.
First Author: Woojin Cho, BSc
- Board 197b **Abstract TPS6583:** A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies.
First Author: Jeremy L. Ramdial, MD

- Board 198a **Abstract TPS6584:** Phase 3 study of either ivosidenib monotherapy or azacitidine monotherapy in patients with IDH1-mutant myelodysplastic syndromes who are hypomethylating agent naive (PyramIDH).
First Author: Valeria Santini, MD, PhD
- Board 198b **Abstract TPS6585:** Phase II study evaluating olutasidenib in patients with IDH1-mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia.
First Author: Kelly Sharon Chien, MD
- Board 199a **Abstract TPS6586:** Phase II study evaluating olutasidenib and azacitidine in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.
First Author: Kelly Sharon Chien, MD
- Board 199b **Abstract TPS6587:** Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.
First Author: Kristen M. Pettit, MD
- Board 200a **Abstract TPS6588:** IMPactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi).
First Author: John Mascarenhas, MD
- Board 200b **Abstract TPS6589:** Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1/2 clinical trial.
First Author: Melda S. Dolan, MD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: Hall A - Posters and Exhibits

Posters by Topic

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL: Board(s) 201-217, 266a-268a

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell:

Board(s) 218-222, 268b-269a

Hodgkin Lymphoma: Board(s) 223-224, 269b

Non-Hodgkin Lymphoma: Board(s) 225-259, 270a-272b

Other Lymphoma: Board(s) 260-265, 273a

- Board 201 **Abstract 7018:** Incidence of infections, cardiac events, neurological toxicity and cytokine response syndrome (CRS) in patients treated with chimeric antigen receptor (CAR) T cell therapy: A 3-year nationwide analysis.
First Author: Himil Mahadevia, MBBS
- Board 203 **Abstract 7020:** Association of enrichment of CD7⁺CXCR3⁺ CAR T cells in infusion products with remission in relapsed or refractory diffuse large B-cell lymphoma.
First Author: Michel Obeid, MD, PhD

- Board 204 **Abstract 7021:** Clinical outcomes of cytomegalovirus infection among patients receiving chimeric antigen receptor T cell therapy.
First Author: Muhammad Atif Khan, MD
- Board 205 **Abstract 7022:** Characterization of mechanisms driving CD20 loss in patients with relapsed or refractory large B-cell lymphoma treated with glofitamab.
First Author: Linlin Cao, PhD
- Board 206 **Abstract 7023:** Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
First Author: Fateeha Furqan, MD
- Board 207 **Abstract 7024:** Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL).
First Author: Narendranath Epperla, MD, MS
- Board 208 **Abstract 7025:** Social vulnerability by neighborhood of association correlates with CAR T referrals.
First Author: Clare E. Anderson, MD
- Board 209 **Abstract 7026:** Optimizing post-chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.
First Author: Manali Kirtikumar Kamdar, MD
- Board 210 **Abstract 7027:** Comprehensive precise CAR-T bridging therapy for diffuse large B-cell lymphoma: A multicenter study from the Chinese Southwest Study Group.
First Author: Tongyu Lin, PhD
- Board 211 **Abstract 7028:** Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).
First Author: Matthew Alexander Lunning, DO
- Board 212 **Abstract 7029:** Pregnancy and infant outcomes post-CD19-directed CAR-T therapy: Tisagenlecleucel (tisa-cel) and/or huCAR19 (CTL119).
First Author: Stephan A. Grupp, MD, PhD
- Board 213 **Abstract 7030:** Effect of prophylactic corticosteroids on toxicities and outcomes in CAR T-cell therapy: A cohort study.
First Author: Anuja Vidyadhar Abhyankar, MD
- Board 214 **Abstract 7031:** Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803).
First Author: Junichiro Yuda, MD, PhD
- Board 215 **Abstract 7032:** Impact of pre-lymphodepletion (pre LD) and day 30 (M1) immune cell counts on outcomes of CAR T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
First Author: Suheil Albert Atallah-Yunes, MD

- Board 216 **Abstract 7033:** Influence of pre-existing autoimmune disease on outcomes in patients treated with CD-19 targeting CAR-t cell therapy for lymphoma: A retrospective propensity score matched study utilizing TriNetX.
First Author: Shanawar Ali Waris, MD
- Board 217 **Abstract 7034:** Comparing outcomes of lymphoma-directed CAR T-cell therapy in patients with and without HIV: A retrospective cohort study from a global health research network.
First Author: Cassandra Reimonn, DO
- Board 218 **Abstract 7035:** Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025.
First Author: Raza Aslam, MBBS
- Board 219 **Abstract 7036:** Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.
First Author: Paolo Ghia
- Board 220 **Abstract 7037:** Propensity score (PS) comparison between lisocabtagene maraleucl (liso-cel) plus ibrutinib combination therapy (combo) and liso-cel monotherapy (mono) cohorts from TRANSCEND CLL.
First Author: William G. Wierda, MD, PhD
- Board 221 **Abstract 7038:** Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies.
First Author: Shuhua Yi
- Board 222 **Abstract 7039:** Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts.
First Author: William G. Wierda, MD, PhD
- Board 223 **Abstract 7040:** Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.
First Author: Ryan C. Lynch, MD
- Board 224 **Abstract 7041:** Updated efficacy and safety results from the phase 2 study of timdarpaccept in combination with tislelizumab in patients with classical Hodgkin lymphoma for whom prior anti-PD-1 therapy failed.
First Author: Ke-Shu Zhou
- Board 225 **Abstract 7042:** Longitudinal assessment from liquid biopsy of mutations in CD20: A pilot study using a PETE enrichment strategy.
First Author: Tyler Landrith, PhD, MPH
- Board 226 **Abstract 7043:** Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
First Author: Yasmin Karimi, MD
- Board 227 **Abstract 7044:** Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients.
First Author: Steven Le Gouill, MD, PhD
- Board 228 **Abstract 7045:** Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts.
First Author: Jose Concepcion, MD
- Board 229 **Abstract 7046:** Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.
First Author: Tae Min Kim, MD, PhD
- Board 230 **Abstract 7047:** High HDAC I/Ib selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase Ib study.
First Author: Lijuan Chen, PhD
- Board 231 **Abstract 7048:** Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone (CMOP) for patients with treatment-naïve peripheral T-cell lymphomas (PTCLs): Extended follow-up analysis of a multicenter, open-label, single-arm, phase Ib study.
First Author: Huiqiang Huang, MD, PhD
- Board 232 **Abstract 7049:** Long-term follow-up of the phase 2 ELM-2 study: Odronektamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
First Author: Deepa Jagadeesh, MD, MPH
- Board 233 **Abstract 7050:** Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.
First Author: Peng Liu
- Board 234 **Abstract 7051:** Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.
First Author: Yan Huang, MD
- Board 235 **Abstract 7052:** Impact of cell of origin, gene rearrangements, and frontline treatment on incidence of secondary central nervous system lymphoma in newly diagnosed diffuse large B-cell lymphoma.
First Author: Ayo Samuel Falade, MD, MBA
- Board 236 **Abstract 7053:** A phase I study of the EZH2 inhibitor TR115 in patients with relapsed/refractory non-Hodgkin's lymphomas and advanced solid tumors.
First Author: Jie Jin, PhD
- Board 237 **Abstract 7054:** Lorlatinib therapy in relapsed/refractory ALK+ lymphomas previously treated with tyrosine kinase inhibitors.
First Author: Federica Colombo
- Board 238 **Abstract 7055:** Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: A phase Ib/II study.
First Author: Qingqing Cai, PhD

- Board 239 **Abstract 7056:** Comparative analysis of survival outcomes in infused versus not-infused patients with aggressive B-cell lymphoma referred for CART. First Author: John Seng Wang, MD
- Board 240 **Abstract 7057:** CD58 alterations and their role in regulating antitumor immune responses in diffuse large B-cell lymphoma. First Author: Yidan Zhang
- Board 241 **Abstract 7058:** Assessing the role of cytarabine-based regimens in mantle cell lymphoma: A real world study. First Author: Yanal Mufeed Alnimer, MD
- Board 242 **Abstract 7059:** Total metabolic tumor volume for predicting cytokine release syndrome and treatment response in patients receiving bispecific antibodies for B-cell lymphoma. First Author: Xi Yang, MD
- Board 243 **Abstract 7060:** DLBCL-associated PIM1 mutation and its impact on ANXA2 localization and lymphomagenesis. First Author: Yaxiao Lu
- Board 244 **Abstract 7061:** Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study. First Author: Peiqi Zhao
- Board 245 **Abstract 7062:** Association between progression-free survival and overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era: A surrogate endpoint analysis. First Author: Charles J. Milrod, MD
- Board 246 **Abstract 7063:** Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). First Author: Charles J. Milrod, MD
- Board 247 **Abstract 7064:** Descriptive epidemiology of Waldenström macroglobulinemia (WM): Demographics, outcomes, and predictors of survival in the US community oncology setting. First Author: Alisha Monnette Kimble, PhD, MPH
- Board 248 **Abstract 7065:** PET metabolic response in Lugano: Comparison of qualitative and quantitative outcome by independent central review. First Author: Danielle Phillippi, PhD
- Board 249 **Abstract 7066:** Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. First Author: Deevyashali Parekh, MBBS
- Board 250 **Abstract 7067:** Distinct outcomes with the detection of endemic Burkitt lymphoma, T-cell receptor (TCR) complementarity determining region-3s (CDR3s) matching known anti-HIV TCR CDR3s. First Author: Taha Huda, MD
- Board 251 **Abstract 7068:** Effect of CD73 on immune escape via tryptophan metabolic reprogramming in diffuse large B-cell lymphoma. First Author: Yingfang Feng
- Board 252 **Abstract 7069:** Outcomes of patients treated for monomorphic B-cell post-transplant lymphoproliferative disorder: A single-center experience. First Author: Imran Nizamuddin, MD
- Board 253 **Abstract 7070:** Clinical and biological subtypes of follicular lymphoma revealed by tumor and immune cell states. First Author: Hengqi Liu
- Board 254 **Abstract 7071:** Clinical outcomes of hemophagocytic lymphohistiocytosis in patients with HIV-related lymphomas: A multicentre observational study. First Author: Alessia Dalla Pria, MD, PhD
- Board 255 **Abstract 7072:** Effect of pre-biopsy steroids on diagnostic yield in diffuse large B-cell lymphoma (DLBCL). First Author: Sathwik Madireddy, MD
- Board 256 **Abstract 7073:** The optimized HLH inflammatory index: A novel prognostic tool for newly diagnosed patients with diffuse large B-cell lymphoma—Discovery and validation. First Author: Adi Zoref Lorenz, MD
- Board 257 **Abstract 7074:** The effect of patient self-reported confidence on psychosocial outcomes in the context of lymphoma and chronic lymphocytic leukaemia. First Author: Steve Kalloger
- Board 258 **Abstract 7075:** Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience. First Author: Syeda A. Mina, MBBS
- Board 259 **Abstract 7076:** Influence of HIV on outcomes in patients with diffuse large B cell lymphoma treated with CD19 targeting CAR-T cell therapy. First Author: Shanawar Ali Waris, MD
- Board 260 **Abstract 7077:** Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. First Author: Swaminathan P. Iyer, MD
- Board 261 **Abstract 7078:** ALK-positive anaplastic large cell lymphoma: Statistics and survival trends. First Author: Hassan Ali, MD, MBBS
- Board 262 **Abstract 7079:** Safety and efficacy of chimeric antigen receptor (CAR)—T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients. First Author: Xinfeng Chen, MD
- Board 263 **Abstract 7080:** Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data analysis. First Author: Matthew Alexander Lunning, DO
- Board 264 **Abstract 7081:** A phase I/II trial of high-dose methotrexate (HDMTX) followed by prophylactic glucapridase in patients with impaired renal function and central nervous system lymphoma (CNSL). First Author: Sven Liebig, MD

- Board 265 **Abstract 7082:** Variable response rates across chemotherapy regimens for severe idiopathic multicentric Castelman disease.
First Author: Saishravan Shyamsundar
- Board 266a **Abstract TPS7083:** SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
First Author: Toby Andrew Eyre, MBChB, MRCP
- Board 266b **Abstract TPS7084:** A phase 2 trial to evaluate the efficacy and safety of WZTL-002, a third-generation anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (ENABLE-2).
First Author: Aine Hurley, MBCh
- Board 267a **Abstract TPS7085:** ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
First Author: Jason Westin, MD, MS, FACP, FASCO
- Board 267b **Abstract TPS7086:** A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).
First Author: Swaminathan P. Iyer, MD
- Board 268a **Abstract TPS7087:** CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089).
First Author: Stefan K. Barta, MD, MS, MRCP
- Board 268b **Abstract TPS7088:** Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.
First Author: Thomas Kipps
- Board 269b **Abstract TPS7090:** Phase 2 study of MK-3475A in relapsed or refractory classic Hodgkin lymphoma or primary mediastinal large B-cell lymphoma.
First Author: Alejandro Berkovits
- Board 270a **Abstract TPS7091:** TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
First Author: Mazyar Shadman, MD, MPH
- Board 270b **Abstract TPS7092:** waveLINE-010: Zilovetamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma.
First Author: Russell Patrick Trapletti Gollard, MD
- Board 271a **Abstract TPS7093:** A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
First Author: Dai Maruyama, MD, PhD

- Board 271b **Abstract TPS7094:** Optimizing frontline therapy for diffuse large B cell lymphoma (DLBCL) in older adults: A glofitamab-based, response-adapted, window-style study (GLORY).
First Author: Pallawi Torka, MD
- Board 272a **Abstract TPS7095:** Sequencing-guided chemotherapy optimization using real-time evaluation in newly diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA (NCT06693830).
First Author: Hua-Jay Jeffery Chheng, MD
- Board 272b **Abstract TPS7096:** A phase 1a/1b trial in relapsed/refractory T-cell non-Hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, an intravenous fenretinide phospholipid suspension (12.5 mg/mL).
First Author: Oleg Akilov, MD, PhD
- Board 273a **Abstract TPS7097:** A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas.
First Author: Michael Wang, MD

9:00 AM-12:00 PM Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: Hall A - Posters and Exhibits

Posters by Topic

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders: Board(s) 86-92
Multiple Myeloma: Board(s) 93-129, 131a-133b
Plasma Cell Disorders: Board 130

- Board 86 **Abstract 7518:** Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM).
First Author: Thomas Luo, MD
- Board 87 **Abstract 7519:** Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy (SACT): A comparative study using a real-world database.
First Author: Attaya Suvannasankha, MD
- Board 88 **Abstract 7520:** Utilization and cost implications for collection and storage of excess autologous hematopoietic stem cells in patients with multiple myeloma.
First Author: Liz Thaliath, MD
- Board 89 **Abstract 7521:** Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data.
First Author: Vladimir Otasevic, MD, PhD
- Board 90 **Abstract 7522:** Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.
First Author: Kenneth JC Lim, MBBS
- Board 91 **Abstract 7523:** Risk of second primary hematological malignancy post CAR-T cell therapy in relapsed/refractory multiple myeloma: Propensity-matched analysis using TriNetX database.
First Author: Rushi Shah

Board 92	Abstract 7524: Investigating metabolic connectivity in patients with multiple myeloma receiving BCMA CAR T cell therapy. First Author: Mehrnaz Jenabi, MS	Board 103	Abstract 7535: Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). First Author: Andrzej J. Jakubowiak, MD, PhD
Board 93	Abstract 7525: Machine learning–based sequential analysis for optimal selection between IRD and KRd regimen in multiple myeloma patients. First Author: Taemin Park, BS	Board 104	Abstract 7536: Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data. First Author: Meral Beksac
Board 94	Abstract 7526: Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO. First Author: Gurdeep Parmar, FRACP, FRCPA	Board 106	Abstract 7538: GPRC5D and BCMA bi-specific CAR-T: Ex vivo study to simulate early to late-line multiple myeloma (MM) with elevated soluble BCMA. First Author: Jincai Zhou
Board 95	Abstract 7527: Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). First Author: Muhamed Baljevic, MD	Board 107	Abstract 7539: Ciltacabtagene autoleucl (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. First Author: Surbhi Sidana, MD
Board 96	Abstract 7528: Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up. First Author: Leo Rasche	Board 108	Abstract 7540: Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial. First Author: Shaji Kumar, MD
Board 97	Abstract 7529: Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis. First Author: Nizar J. Bahlis, MD	Board 109	Abstract 7541: Clinical characteristics, cytogenetic associations, and outcomes in multiple myeloma with chromosome 1q abnormalities. First Author: Abdullah Ramzan
Board 98	Abstract 7530: Assessment of normal plasma cell biomarkers after arlocabtagene autoleucl (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM). First Author: Kristina Jordahl	Board 110	Abstract 7542: Real-world comparison of anti-BCMA vs anti-GPRC5D BiTE therapy in relapsed/refractory multiple myeloma without prior CAR-T cell exposure. First Author: Ali Younas Khan, MD
Board 99	Abstract 7531: Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). First Author: Sundar Jagannath, MD, FASCO	Board 111	Abstract 7543: Correlation of a senescence-associated gene signature with prognosis in multiple myeloma. First Author: Andras Lanczky
Board 100	Abstract 7532: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. First Author: Darrell White, MD	Board 112	Abstract 7544: Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). First Author: Meral Beksac
Board 101	Abstract 7533: DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features. First Author: Suzanne Trudel, MD	Board 114	Abstract 7546: DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features. First Author: Maria-Victoria Mateos, PhD
Board 102	Abstract 7534: Immune profiling to identify a functionally high-risk smoldering multiple myeloma patient population. First Author: Ross Firestone, MD, PhD	Board 115	Abstract 7547: Leveraging AI for validating the association between minimal residual disease (MRD) and survival outcomes in multiple myeloma. First Author: Zexin Ren

- Board 116 **Abstract 7548:** Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
First Author: Marcelo Pitombeira de Lacerda, MD, PhD
- Board 117 **Abstract 7549:** Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): A US subgroup analysis from MagnetisMM-3.
First Author: Ajay K. Nooka, MBBS
- Board 118 **Abstract 7550:** Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.
First Author: Hang Quach, MD, FRACP, FRCPA
- Board 119 **Abstract 7551:** Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.
First Author: Elena Zamagni, MD, PhD
- Board 120 **Abstract 7552:** Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.
First Author: Rebecca Albuquerque
- Board 121 **Abstract 7553:** Carfilzomib, iberdomide, and dexamethasone (KID) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated results from phase 1/2 study.
First Author: Noa Biran, MD
- Board 122 **Abstract 7554:** Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma (MM) relapsing on current therapy.
First Author: Noa Biran, MD
- Board 123 **Abstract 7555:** Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl, MD, MSCE
- Board 125 **Abstract 7557:** ASCOmind: Is instant ASCO abstract analysis possible with AI agents?
First Author: Kyeryoung Lee, PhD
- Board 126 **Abstract 7558:** Gene-expression-profiling plus integrated multidisciplinary approach to detect new-generation risk-adapted prognostic index in smoldering myeloma and multiple myeloma (GIMPI).
First Author: Claudio Cerchione, MD, PhD
- Board 127 **Abstract 7559:** The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes.
First Author: Tajana Juranovic, MD
- Board 128 **Abstract 7560:** Role of the combination of 3 T whole-body MRI and 18F-FDG PET/CT in the management of multiple myeloma and smoldering myeloma: The new era of imaging.
First Author: Claudio Cerchione, MD, PhD
- Board 129 **Abstract 7561:** Real-world analysis of thromboembolism in SAVED/IMPEDE risk-stratified newly diagnosed multiple myeloma (NDMM).
First Author: Kian Rahbari, MD

- Board 130 **Abstract 7562:** Teclistamab in relapsed/refractory systemic AL amyloidosis.
First Author: Vasil Mico, MD
- Board 131a **Abstract TPS7563:** QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).
First Author: Krina K. Patel, MD, MSc
- Board 131b **Abstract TPS7564:** QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide.
First Author: Rakesh Popat
- Board 132a **Abstract TPS7565:** Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.
First Author: Rakesh Popat
- Board 132b **Abstract TPS7566:** MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
First Author: Alexander M. Lesokhin, MD
- Board 133a **Abstract TPS7567:** Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
First Author: Sagar Lonial, MD, FACP, FASCO
- Board 133b **Abstract TPS7568:** MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38-directed therapy.
First Author: Steven Robert Schuster, MD

9:00 AM-12:00 PM Poster Session

Melanoma/Skin Cancers

Location: Hall A - Posters and Exhibits

Posters by Topic

Advanced/Metastatic Disease: Board(s) 1-46, 75a-81b

Local-Regional Disease: Board(s) 48-64, 82a-84b

Other Melanoma/Skin Cancers: Board(s) 65-74, 85a-85b

- Board 1 **Abstract 9518:** Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.
First Author: Lyna Haybout, MD
- Board 2 **Abstract 9519:** OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
First Author: Rodabe Navroze Amaria, MD

Board 3	Abstract 9520: Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study. First Author: Nimisha Srivastava, MD	Board 15	Abstract 9532: Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review. First Author: XiangLin Tan, PhD
Board 4	Abstract 9521: Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM). First Author: Afsaneh Amouzegar, MD	Board 16	Abstract 9533: CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. First Author: Soo J. Park, MD
Board 5	Abstract 9522: Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial. First Author: Hildur Helgadóttir	Board 17	Abstract 9534: Biosafety analysis from the skin cancer cohorts in the IGYTE clinical trial of RP1. First Author: Trisha Michel Wise-Draper, MD, PhD
Board 6	Abstract 9523: Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study. First Author: Caroline Burkey, MD	Board 18	Abstract 9535: Clinical and biomarker analyses of first-line nivolumab and relatlimab (nivo-rela) in advanced or resectable melanoma (mel). First Author: Lilit Karapetyan, MD, MSc
Board 7	Abstract 9524: Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients. First Author: Paolo Antonio Ascierto, MD, BC	Board 19	Abstract 9536: Final results of POD1UM-201, a phase 2 study of retifanlimab, a humanized anti-PD-1 antibody, in patients with advanced or metastatic Merkel cell carcinoma (MCC). First Author: Giovanni Grignani, MD
Board 8	Abstract 9525: RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM). First Author: Hussein A. Tawbi, MD, PhD	Board 20	Abstract 9537: Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep/visceral RP1 injection in the registrational cohort of anti-PD-1-failed melanoma patients of the IGYTE trial. First Author: Gino Kim In, MD, MPH
Board 9	Abstract 9526: Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020. First Author: Georgina V. Long, MD, PhD, FRACP	Board 21	Abstract 9538: Long-term outcomes after discontinuation of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) in the POD1UM-201 trial. First Author: Giovanni Grignani, MD
Board 10	Abstract 9527: Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma. First Author: Michael A. Postow, MD	Board 22	Abstract 9539: Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study. First Author: Leila Khoja, PhD, MBChB
Board 11	Abstract 9528: Characteristics and predictors of chronic immune-related adverse events (irAEs) following anti-PD-1 (PD1) treatment for melanoma. First Author: Roma A. Kankaria, BS, BA	Board 23	Abstract 9540: A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (laBCC): The SONIBEC trial. First Author: Carlo Resteghini
Board 12	Abstract 9529: Safety and efficacy analysis of DNV3 plus toripalimab and chemotherapy in advanced melanoma: An open-label investigator-initiated trial. First Author: Jing Lin	Board 24	Abstract 9541: AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma. First Author: Mark Schuiveling, MD
Board 13	Abstract 9530: Prognostic implications of glycemia in non-diabetic patients with metastatic melanoma undergoing immunotherapy. First Author: Domenico Mallardo, PhD, BMedSci, DMSc	Board 25	Abstract 9542: Real-world clinical outcomes of patients with BRAF-mutated melanoma with or without brain metastases receiving frontline immune-checkpoint inhibitors in the US community oncology setting. First Author: Wolfram Samlowski, MD
Board 14	Abstract 9531: Trick-MCC: Final results from the proof-of-concept investigator-initiated study of combination therapy with anti-PD-1, anti-LAG-3, and anti-TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma (NCT06056895). First Author: Natalie J. Miller, MD, PhD	Board 26	Abstract 9543: Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM). First Author: Jürgen C. Becker

Board 28	Abstract 9545: Progression-free survival (PFS) assessment by blinded independent central review (BICR) versus local investigator (LI) in metastatic melanoma (MM) randomized controlled trials (RCT): A systematic review and meta-analysis. First Author: Islam Eljilany, PhD, MS, PharmD	Board 40	Abstract 9557: Outpatient treatment-related toxicity after hospital discharge among patients receiving lifileucel for advanced melanoma. First Author: James William Smithy, MD, MHS
Board 29	Abstract 9546: Efficacy and safety of transcatheter arterial infusion of immune checkpoint inhibitors in locoregional unresectable or in-transit acral melanoma: A multi-center real-world study. First Author: Ziluan Chen	Board 41	Abstract 9558: Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075). First Author: Ilya Pokataev, MD
Board 30	Abstract 9547: The phase 1 clinical trial of anti-PD-1 ab plus intrahepatic injection of oncolytic virus (OH2) combined radiotherapy of liver metastasis in stage IV melanoma. First Author: Xuan Wang, MD	Board 42	Abstract 9559: ctDNA versus 18F-FDG PET-CT in predicting long-term disease control in patients with advanced melanoma undergoing immune checkpoint blockade therapy. First Author: Milton Jose De Barros E. Silva, MD
Board 31	Abstract 9548: Influence of tumor infiltrating lymphocytes (TIL) monotherapy on persistent clinical and immunological responses in Asian metastatic melanoma patients with specific CD8+ TIL proportions: A phase I trial. First Author: Chuanliang Cui, MD	Board 43	Abstract 9560: Electronic health records (EHR)-based machine learning (ML) approach to predict risk of progression to metastatic melanoma after initial diagnosis. First Author: Ryan Pindale, MS
Board 32	Abstract 9549: Intensive surveillance and aggressive multi-modal treatment for liver metastases from uveal melanoma. First Author: Hemant M. Kocher, MD, FRCS	Board 44	Abstract 9561: Delineating the role of the microbiome and tumor microenvironment interactions driving mucosal melanoma (MM) response and resistance to immune checkpoint inhibitor (ICI) treatment. First Author: Florentia Dimitriou, MD, PhD
Board 33	Abstract 9550: High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases. First Author: Carin F. Gonsalves	Board 45	Abstract 9562: Multidimensional, spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade (ICB) therapies. First Author: Zichao Liu, MS
Board 34	Abstract 9551: Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors. First Author: Siwen Hu-Lieskovan, MD, PhD	Board 46	Abstract 9563: Long-term outcomes following melanoma metastasectomy categorized by response to immune checkpoint inhibitor (ICI) therapy. First Author: Aravind Sreeram, BS
Board 35	Abstract 9552: Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM). First Author: Rodabe Navroze Amaria, MD	Board 48	Abstract 9565: Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis. First Author: Anna Constantinescu
Board 36	Abstract 9553: First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: Results from LEAP-003. First Author: Jun Guo, MD	Board 49	Abstract 9566: Anxiety, depression, fear of cancer recurrence (FCR) and health-related quality of life (HRQL) in people with melanoma receiving adjuvant therapies. First Author: Julia Elizabeth Lai-Kwon, MBBS
Board 37	Abstract 9554: Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data. First Author: Dirk Schadendorf, MD	Board 50	Abstract 9567: Identification of patients at high risk for relapse by Merlin assay (CP-GEP) in an independent cohort of melanoma patients (pts) that did not undergo sentinel lymph node biopsy: An H&N subgroup analysis. First Author: Teresa Amaral, MD, PhD
Board 38	Abstract 9555: Phase 2 study of axitinib + nivolumab in mucosal melanoma with pilot addition of stereotactic body radiotherapy or ipilimumab in select progressors. First Author: Sarah E. Lochrin, MBCh	Board 51	Abstract 9568: Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response. First Author: Ines Esteves Domingues Pires da Silva, MD, PhD
Board 39	Abstract 9556: Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors. First Author: Sarina A. Piha-Paul, MD, MS	Board 52	Abstract 9569: Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma. First Author: Tuba Nur Gide, PhD

Board 53	Abstract 9570: Combining machine learning with the immunohistochemical expression of AMBRA1 and loricrin to identify non-ulcerated AJCC stage I/II melanomas at high-risk of metastasis. First Author: Penny Lovat, PhD	Board 66	Abstract 9583: Comparison of the tolerability and safety of hedgehog inhibitors in real-life: A cohort of 330 patients with locally advanced basal cell carcinoma. First Author: Florian Herms, MD
Board 54	Abstract 9571: Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma. First Author: George Ansstas, MD	Board 67	Abstract 9584: Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients. First Author: Vincent The-Luc Ma, MD
Board 55	Abstract 9572: Efficacy of adjuvant anti-PD-1 antibodies and interferon in patients with nail apparatus melanoma: A retrospective, multicenter study (ADJ-NAIL study). First Author: Takaya Komori	Board 68	Abstract 9585: Multiomic analysis of cutaneous squamous cell carcinoma (cSCC) and association with response to anti-PD1 therapy (PD1). First Author: Yu-Ju Kuo, MD
Board 56	Abstract 9573: The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I-III cutaneous melanoma: An NCI-SEER analysis. First Author: Merve Hasanov, MD	Board 69	Abstract 9586: Immunoembolization for patients with uveal melanoma hepatic metastasis: A single-institution real-world data analysis. First Author: Rino S. Seedor, MD
Board 57	Abstract 9574: Comparison of surveillance circulating tumor DNA and Merkel polyomavirus antibody titer for detection of Merkel cell carcinoma recurrence. First Author: Joshua Elbridge Chan, MS	Board 70	Abstract 9587: Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors. First Author: William J Mullally, BSc, MBChB
Board 58	Abstract 9575: Overall survival outcomes in stage III melanoma patients treated with adjuvant immunotherapy vs targeted therapy: A National Cancer Database analysis. First Author: Siavash Bolourani, MD, PhD	Board 72	Abstract 9589: Tobacco smoking as a risk for cutaneous squamous cell carcinoma in skin of color. First Author: Tahira Naqvi, MD
Board 59	Abstract 9576: Survival impact of adjuvant treatment in resected stage III cutaneous melanoma patients: Results from a real-life cohort study (TAMARIS). First Author: Charlee Nardin, MD, PhD	Board 73	Abstract 9590: Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors. First Author: David Alan Reichstein, MD
Board 60	Abstract 9577: Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies. First Author: Julia Elizabeth Lai-Kwon, MBBS	Board 74	Abstract 9591: PD-1-directed intratumoral immunotherapy for cutaneous carcinomas: Interim results from an ongoing study of INTASYL PH-762. First Author: Mary C. Spellman, MD
Board 61	Abstract 9578: A pooled analysis of clinical outcomes with anti-PD1-based neoadjuvant immunotherapy (NeoIT) in cutaneous squamous cell carcinoma (cSCC). First Author: Ines Esteves Domingues Pires da Silva, MD, PhD	Board 75a	Abstract TPS9592: Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). First Author: Isabella Claudia Glitza, MD, PhD, MSc
Board 62	Abstract 9579: Use of artificial intelligence to identify high risk profiles in early-stage melanoma patients from pathology slides. First Author: Christina Kanaan	Board 75b	Abstract TPS9593: Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY). First Author: Elizabeth M. Burton, PhD, MBA
Board 63	Abstract 9580: Identification of novel RNA biomarkers for the differential diagnosis of cutaneous melanoma and nevi. First Author: Igor Samoylenko, MD, PhD	Board 76a	Abstract TPS9594: A multicenter, randomized, controlled, open-label, phase 2 study of the PD-1/IL-2 α -bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma. First Author: Bin Lian, MD
Board 64	Abstract 9581: Animated patient's guide to melanoma: Assessing patient understanding, shared decision-making, and health outcomes. First Author: Kyleigh Lipira	Board 76b	Abstract TPS9595: NivoReach: Integrated study to demonstrate similarity of JPB898 to reference nivolumab in combination with ipilimumab in patients with advanced melanoma. First Author: Piotr Rutkowski, MD, PhD
Board 65	Abstract 9582: A phase II trial of perioperative oral itraconazole for the management of low-risk basal cell carcinoma. First Author: Rodrigo Perez Pereira, MD	Board 77a	Abstract TPS9596: A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus anti-PD-1 alone in patients with resectable stage III and IV melanoma. First Author: Rodabe Navroze Amaria, MD

- Board 77b **Abstract TPS9597:** A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
First Author: Joseph J. Sacco, PhD, MBChB
- Board 78a **Abstract TPS9598:** The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
First Author: Rashmi Bhakuni, PhD, MSc
- Board 78b **Abstract TPS9599:** A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician's choice in patients with advanced melanoma that has progressed on anti-PD-1 and anti-CTLA-4 therapy (IGNYTE-3).
First Author: Jason J. Luke, MD, FACP, FASCO
- Board 79a **Abstract TPS9600:** A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.
First Author: Jong Chul Park, MD
- Board 79b **Abstract TPS9601:** The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma.
First Author: Zachary Buchwald, MD, PhD
- Board 80a **Abstract TPS9602:** Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel).
First Author: Derrick Law Tao, MD
- Board 80b **Abstract TPS9603:** Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).
First Author: Andrew Scott Brohl, MD
- Board 81a **Abstract TPS9604:** TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.
First Author: Jason J. Luke, MD, FACP, FASCO
- Board 81b **Abstract TPS9605:** A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma.
First Author: Katy K. Tsai, MD
- Board 82a **Abstract TPS9606:** Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck.
First Author: Eric Mastrodonardo
- Board 82b **Abstract TPS9607:** A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.
First Author: Urvashi Mitbander Joshi, MD

- Board 83a **Abstract TPS9608:** Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT).
First Author: Craig L. Slingluff Jr, MD
- Board 83b **Abstract TPS9609:** NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy.
First Author: Milton Jose De Barros E. Silva, MD
- Board 84a **Abstract TPS9610:** A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).
First Author: Maria Gonzalez, BN, BA
- Board 84b **Abstract TPS9611:** A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIb-d resectable melanoma (MEL).
First Author: James Isaacs, MD
- Board 85a **Abstract TPS9612:** Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC).
First Author: Michael Robert Migden, MD
- Board 85b **Abstract TPS9613:** A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).
First Author: Paul D. Nathan, MD, PhD

9:45 AM-11:00 AM Education Session

Challenges and Opportunities for Global Cervical Cancer Elimination: How Can We Build a Model for Other Cancers?

Location: S402

Paolo Giorgi Rossi, PhD

IRCCS

Long-Term Achievements of Cervical Cancer Screening and Early Detection: Where Do We Stand?

Philip E. Castle, PhD, MPH—Chair

National Cancer Institute

Promises and Achievements of Human Papillomavirus Vaccination

Clement Adebamowo, FACS, FWACS, MBChB, ScD

Marlene and Stewart Greenebaum Cancer Center

How Far Are We From Cervical Cancer Eradication? A Global Vision

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Oncology and Suffering: Strategies on Coping With Grief for Health Care Professionals

Location: E450b

Keri Brenner, MD, MPA—Chair

Stanford Medicine

Attending to Suffering When There Is No Cure

Mikolaj Slawkowski-Rode, PhD

Blackfriars Hall

Should We Move On? Spirituality, Suffering, and Grief in Oncology

Abigail Nathanson, DS, MSW

New York University

Practical Tips for Not Being Overwhelmed By the Grief of Those for Whom We Care

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?

Location: E451

Nadia Harbeck, MD, PhD—Chair

University Hospital Munich

Biomarkers for Therapy De-Escalation: Genomic Assays and Beyond

Icro Meattini, MD

Azienda Ospedaliero Universitaria Careggi, University of Florence

How to Integrate Radiotherapy Into Current Treatment Concepts

Elizabeth Rapp Berger, MD, MS

Yale University

How Much Axillary Surgery Is Necessary?

Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

Refining Local Therapies in Central Nervous System Oncology: Hitting the Bullseye

Location: E350

Karisa C. Schreck, MD, PhD—Chair

Johns Hopkins School of Medicine

Nimish Mohile, MD—Chair

University of Rochester Medical Center

9:45 AM Adam Sonabend, MD

Northwestern University

Redefining the Boundaries of Local Therapy

9:57 AM

Abstract 2009: Multicenter trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) with monthly adjuvant temozolomide for patients with high-grade gliomas.

First Author: Graeme Woodworth, MD

10:09 AM

Abstract 2010: Leveraging stimulated Raman histology-based cellularity for random forest prediction of glioblastoma recurrence.

First Author: Sanjeev Herr, MS

10:21 AM

Dieter Henrik Heiland, MD

University Hospital Erlangen University

Discussion of Abstract(s) 2009-2010: Making Sense of Large Data in Surgical Neuro-Oncology

10:33 AM

Abstract 2011: Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.

First Author: Ayal Aizer, MD, MHS

10:45 AM

Iris C. Gibbs, MD

Stanford Cancer Center GI Surgical Oncology

Discussion of Abstract(s) 2011: Radiation for Multiple Central Nervous System Metastases: Is Less More?

10:57 AM

Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

Turning “Cold” Tumors “Hot”

Location: Hall D1

Jarushka Naidoo, MBBCh—Chair

Beaumont RCSI Cancer Centre

9:45 AM

Antoni Ribas, MD, PhD

University of California, Los Angeles

From Resistance to Response: Broadening the Efficacy of Immunotherapy

9:57 AM

Steven Z. Merlin, BS

Pancreatic Cancer Action Network

From the Patient's Perspective: Navigating the Promise of New Immunotherapies

10:09 AM

Abstract 102: A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).

First Author: Stephen Joseph Bagley, MD, MSCE

10:21 AM

Abstract 103: Neoadjuvant biomarker trial of pepinemb to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.

First Author: Conor Ernst Steuer, MD

10:33 AM

Abstract 104: Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer.

First Author: Zhenyu Lin, FASCO

10:45 AM

Elena Garraida, MD, PhD

Vall d'Hebron Institute of Oncology

Discussion of Abstract(s) 102-104: Power Up: Next-Generation Immune Strategies to Fight Cancer

10:57 AM

Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Genitourinary Cancer—Kidney and Bladder

Location: Hall D2

Elizabeth Henry, MD—Chair

Loyola University Medical Center

Manuela Schmidinger, MD—Chair

Comprehensive Cancer Center, Medical University of Vienna

9:45 AM

Abstract 4500: Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.

First Author: Michiel Simon Van Der Heijden, MD, PhD

- 9:57 AM Abstract 4501:** Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.
First Author: Jeannie Hoffman-Censits, MD
- 10:09 AM Abstract 4502:** Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Shilpa Gupta, MD
- 10:21 AM Jacqueline T. Brown, MD**
Emory University School of Medicine
Discussion of Abstract(s) 4500-4502: Breaking the Platinum Ceiling in Advanced Bladder Cancer
- 10:33 AM** Panel Question and Answer
- 10:45 AM Abstract 4503:** Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
First Author: Thomas Powles, MD, PhD, FCRP
- 10:57 AM Abstract LBA4504:** Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomized phase 3 trial (ANZUP 1301).
First Author: Dickon Hayne, MD, FRCS, MBBS
- 11:09 AM John Sfakianos, MD**
Icahn School of Medicine at Mount Sinai
Discussion of Abstract(s) 4503-LBA4504: Can We Adapt Treatment Paradigms in Early Bladder Cancer?
- 11:21 AM** Panel Question and Answer
- 11:33 AM Abstract 4505:** Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
First Author: Toni K. Choueiri, MD, FASCO
- 11:45 AM Abstract 4506:** Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
First Author: Toni K. Choueiri, MD, FASCO
- 11:57 AM Abstract 4507:** Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease-associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.
First Author: Vivek Narayan, MD, MS
- 12:09 PM Abstract 4508:** ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study.
First Author: Samer Ali Srou, MBChB, MS
- 12:21 PM Tian Zhang, MD, MHS**
UT Southwestern Medical Center/Simmons Comprehensive Cancer Center
Discussion of Abstract(s) 4505-4508: From Established Therapies to Emerging Innovations in Renal Cell Carcinoma: Checkpoints, Oxygen, and T Cells
- 12:33 PM** Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Sarcoma

Location: S100a

Alberto S. Pappo, MD—Chair

St. Jude Children's Research Hospital

Elise F. Nassif Haddad, MD, PhD—Chair

The University of Texas MD Anderson Cancer Center

- 9:45 AM Abstract 11500:** Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.
First Author: Xiaohui Niu, MD
- 9:57 AM Abstract 11501:** Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.
First Author: Yuhong Zhou, MD
- 10:09 AM Abstract 11502:** Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers.
First Author: Jie Liu
- 10:21 AM Nicolas Penel, MD, PhD, MBA**
Centre Oscar Lambret
Discussion of Abstract(s) 11500-11502: TIKIN Away: Expanding the Role of Tyrosine Kinase Inhibitors for the Treatment of Sarcomas
- 10:33 AM** Panel Question and Answer
- 10:45 AM Abstract 11503:** Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial.
First Author: Cheng Yang, MD
- 10:57 AM Abstract 11504:** Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.
First Author: Emily K. Slotkin, MD
- 11:09 AM Abstract 11505:** A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.
First Author: Ramya Ramaswami, MBBS, MPH, MRCP
- 11:21 AM Andrew J. Wagner, MD, PhD**
Dana-Farber Cancer Institute, Harvard Medical School
Discussion of Abstract(s) 11503-11505: New Drugs for Rare Sarcomas: Getting Creative
- 11:33 AM** Panel Question and Answer
- 11:45 AM Abstract 11506:** A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
First Author: Robin Lewis Jones, MD, MBBS, BSc, MRCP
- 11:57 AM Abstract 11507:** Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
First Author: Brian Andrew Van Tine, MD, PhD
- 12:09 PM Abstract 11508:** Spatial transcriptomic profiling from over 300 leiomyosarcoma samples.
First Author: Ryan A. Denu, MD, PhD

12:21 PM **Alessandra Maleddu, MD**
University of Colorado School of Medicine
Discussion of Abstract(s) 11506-11508: Targeting Leiomyosarcoma

12:33 PM Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Symptom Science and Palliative Care

Location: S100bc

Carolyn J. Presley, MD, MHS—Chair

The Ohio State University

Tanyanika Phillips, MD, MPH—Chair

City of Hope

9:45 AM **Abstract LBA12000:** PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer.
First Author: Katherine A. Hutcheson

9:57 AM **Abstract 12001:** Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723.
First Author: Meenu Vijayan, MPharm

10:09 AM **Abstract 12002:** Randomized control trial to validate mitigation of chemotherapy-induced peripheral neuropathy by limb-cooling apparatus in breast cancer patients receiving paclitaxel (CECILIA).
First Author: Toshimi Takano, MD, PhD

10:21 AM **Karin Jordan, MD, PhD**
Ernst Von Bergmann Hospital
Discussion of Abstract(s) LBA12000-12002: Tackling Common Challenges in Cancer: Addressing Nutrition, Nausea, and Neuropathy

10:33 AM Panel Question and Answer

10:45 AM **Abstract 12003:** Music therapy versus cognitive behavioral therapy for anxiety in cancer survivors: A telehealth-based randomized clinical trial.
First Author: Kevin T. Liou

10:57 AM **Abstract 12004:** Fear of cancer recurrence in long-term colorectal cancer survivors: A randomized controlled trial of a therapist-guided eHealth intervention.
First Author: Johanne Dam Lyhne

11:09 AM **Abstract 12005:** Results of a multisite randomized trial of Bright IDEAS-Young Adults: Efficacy of problem-solving skills training on distress and health-related quality of life.
First Author: Katie Devine, PhD

11:21 AM **Lara Traeger, PhD**
Massachusetts General Hospital
Discussion of Abstract(s) 12003-12005: Harmony in Healing: Music, Mindfulness, and Mental Health

11:33 AM Panel Question and Answer

11:45 AM **Abstract 12006:** A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.
First Author: Daichi Fujimoto, MD

11:57 AM **Abstract 12007:** Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
First Author: Hanny Al-Samkari, MD

12:09 PM **Abstract 12008:** Carica papaya leaf extract (CPLE) versus placebo to improve chemotherapy induced thrombocytopenia (CIT): Results of a phase III triple blinded, randomized placebo controlled trial (PACT study).
First Author: Vikas Ostwal, MD

12:21 PM **Lauren Chiec, MD**
McGaw Medical Center of Northwestern University
Discussion of Abstract(s) 12006-12008: Mitigating Treatment Toxicity: A Focus on Immune Modulation and Platelet Preservation

12:33 PM Panel Question and Answer

11:15 AM-12:45 PM Rapid Oral Abstract Session

Developmental Therapeutics—Immunotherapy

Location: S406

Daniel Olson, MD—Chair

University of Chicago Comprehensive Cancer Center

Benjamin L. Schlechter, MD—Chair

Dana-Farber Cancer Institute

11:15 AM **Abstract LBA2512:** The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
First Author: Anna Maria Di Giacomo, MD

11:21 AM **Abstract 2513:** Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
First Author: Anup Kasi, MD, MPH

11:27 AM **Abstract 2514:** Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL).
First Author: Zhiming Li, MD

11:33 AM Panel Question and Answer

11:45 AM **Abstract 2515:** An open-label, phase I trial of the SIRPa monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabemlimab in patients with advanced solid tumors.
First Author: Judy S. Wang, MD

11:51 AM **Abstract 2516:** A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR) T-cell therapy.
First Author: Kathryn Ries Tringale, MD, MS

11:57 AM **Abstract 2517:** Role of autoimmune reactivity in neurotoxicities (N-Tox) in melanoma patients treated with immune-checkpoint inhibitors (ICI).
First Author: Agrima Dutt, MS

12:03 PM Panel Question and Answer

- 12:15 PM Abstract 2518:** Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.
First Author: Hirotaka Miyashita, MD
- 12:21 PM Abstract 2519:** Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.
First Author: Darwin Kwok, PhD, MS
- 12:27 PM Abstract 2520:** Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.
First Author: Curtis J. Perry, MD, PhD
- 12:33 PM** Panel Question and Answer

11:30 AM-12:45 PM Education Session

BiTES and Beyond: BiTES, Amivantimab, and the Multidimensional Impact of Toxicity Management

Location: Arie Crown Theater

Jennifer W. Carlisle, MD—Chair

Winship Cancer Institute, Emory University

Striking the Balance: Optimizing Amivantamab Use and Handling Its Adverse Effects in Patients With Lung Cancer

Abdul Rafeh Naqash, MD

Stephenson Cancer Center

Dual-Edged Next-Generation Immunotherapy: The Promise and Perils of Bispecific T-Cell Engagers in Lung Cancer and Beyond

Melinda Laine Hsu, MD, MS

University Hospitals Seidman Cancer Center

Balancing the Price of Progress: Managing Toxicities and Access Challenges in New and Emerging Lung Cancer Treatments

Melissa Lynne Johnson, MD, FASCO

Sarah Cannon Research Institute

Gizmos and Gadgets! How Can Community Oncology Practices Hurdle the Obstacles to Administering Lung Cancer's Newest Therapies

Panel Question and Answer

11:30 AM-12:45 PM Education Session

New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies

Location: E451

Hope S. Rugo, MD, FASCO—Chair

University of California San Francisco

An Oncologist's Approach to Managing Endocrine Toxicities

Neel Pasricha, MD

University of California, San Francisco

Eyes Wide Open: Addressing Ocular Toxicities of Breast Cancer Therapies

Susan Faye Dent, MD

Duke Cancer Institute, Duke University

Navigating Cardiac Risks of Modern Breast Cancer Treatments

Jonathan Leventhal

Yale School of Medicine

Skin Toxicities, Steroids, and Salves: Dermatology for Today's Breast Cancer Oncology

Panel Question and Answer

11:30 AM-12:45 PM Education Session

State of the Art in Utilizing Artificial Intelligence in Neuro-Oncology

Location: E350

Daniel A. Orringer, MD—Chair

NYU Langone Health

Artificial Intelligence and the Future of Brain Tumor Surgery: Transforming Diagnosis and Treatment

Kristin Swanson, PhD

Mayo Clinic

Refining Brain Tumor Imaging With Artificial Intelligence

Jona Ashok Hattangadi-Gluth, MD

University of California San Diego Ideker Laboratory

Artificial Intelligence–Enhanced Radiation Oncology: Precision and Innovation in Brain Tumor Treatment

Panel Question and Answer

11:30 AM-1:00 PM Rapid Oral Abstract Session

Gastrointestinal Cancer—Colorectal and Anal

Location: Hall D1

Kyle Cuneo, MD—Chair

University of Michigan

Valentina Gambardella, MD, PhD—Chair

Hospital Clinico Universitario de Valencia

- 11:30 AM Abstract 3512:** Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.
First Author: Veronica Conca, MD
- 11:36 AM Abstract 3513:** FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
First Author: Lena Weiss, MD
- 11:42 AM Abstract 3514:** Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.
First Author: Yoshinori Kagawa, MD, PhD
- 11:48 AM** Panel Question and Answer
- 12:00 PM Abstract LBA3515:** Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
First Author: Chiara Cremolini, MD, PhD
- 12:06 PM Abstract LBA3516:** JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.
First Author: Jianmin Xu, PhD

- 12:12 PM Abstract 3517:** Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients. First Author: Anwaar Saeed, MD
- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 3518:** Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation. First Author: Aron Bercz, MD
- 12:36 PM Abstract 3519:** Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01). First Author: Feng Tian
- 12:42 PM Abstract 3520:** Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCEP). First Author: Qian Shi, PhD
- 12:48 PM** Panel Question and Answer

11:30 AM-1:00 PM Rapid Oral Abstract Session

Head and Neck Cancer

Location: E450a

Patrick Ha, MD—Chair

University of California San Francisco

Jessica R. Bauman, MD—Chair

Fox Chase Cancer Center

- 11:30 AM Abstract 6012:** Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. First Author: Douglas Adkins, MD
- 11:36 AM Abstract 6013:** Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). First Author: Yungan Tao
- 11:42 AM Abstract 6014:** A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma. First Author: Zhigang Liu, MD, PhD
- 11:48 AM** Panel Question and Answer
- 12:00 PM Abstract 6015:** Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naïve metastatic head and neck squamous cell carcinoma (HNSCC). First Author: Cristina P. Rodriguez, MD
- 12:06 PM Abstract 6016:** Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts). First Author: Christophe Le Tourneau, MD, PhD

- 12:12 PM Abstract 6017:** Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial. First Author: Christine H. Chung, MD

- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 6018:** Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial. First Author: Hongling Wang, MD
- 12:36 PM Abstract 6019:** An open-label, phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma. First Author: Katerin Ingrid Rojas, MD, PhD, MSc
- 12:42 PM Abstract 6020:** Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). First Author: Jérôme Fayette, MD, PhD
- 12:48 PM** Panel Question and Answer

1:00 PM-4:00 PM Plenary Session

Plenary Session

Location: Hall B1

Erika P. Hamilton, MD—Chair

Sarah Cannon Research Institute

Robin Zon, MD, FACP, FASCO—Chair

Cincinnati Cancer Advisors

- 1:00 PM Robin Zon, MD, and Erika P. Hamilton, MD**
Welcome and Opening Remarks
- 1:05 PM Abstract LBA1:** Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). First Author: Frank A. Sinicrope, MD
- 1:17 PM Myriam Chalabi, MD, PhD**
Netherlands Cancer Institute
Discussion of Abstract LBA1
- 1:29 PM** Panel Question and Answer
- 1:37 PM Abstract LBA2:** NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. First Author: Jean Bourhis, MD, PhD
- 1:49 PM Stuart J. Wong, MD**
Medical College of Wisconsin
Discussion of Abstract LBA2
- 2:01 PM** Panel Question and Answer

- 2:09 PM** **Abstract LBA3:** Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV). First Author: Andrew Tucker Kuykendall, MD
- 2:21 PM** **Katherine Walsh, MD, MEd, FACP**
Vanderbilt University Medical Center
Discussion of Abstract LBA3
- 2:33 PM** Panel Question and Answer
- 2:41 PM** **Abstract LBA4:** Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
First Author: Nicholas C. Turner, MD, PhD
- 2:53 PM** **Angela DeMichele, MD, MSCE, FASCO**
University of Pennsylvania
Discussion of Abstract LBA4
- 3:05 PM** Panel Question and Answer
- 3:13 PM** **Abstract LBA5:** Event-free survival (EFS) in MATTERHORN: a randomized, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
First Author: Yelena Y. Janjigian, MD
- 3:25 PM** **Samuel J. Klempner, MD, FASCO**
Massachusetts General Hospital
Discussion of Abstract LBA5
- 3:37 PM** Panel Question and Answer
- 3:45 PM** **Mark Andrew Lewis, MD, FASCO**
Intermountain Health
From Insight to Impact: Driving Plenary Knowledge Into Action This Monday

4:30 PM-5:00 PM Education Session

AI, Improving Cancer Care, and the Future of Collaboration

Location: S100bc

Clifford A. Hudis, MD, FACP, FASCO—Chair
ASCO

Thomas Kurian
Google Cloud

4:30 PM-5:45 PM Education Session

Capturing Unicorns: No Target Is Out of the Realm of Possibility

Location: S100a

Jordi Rodon Ahnert, MD, PhD—Chair
The University of Texas MD Anderson Cancer Center
Can We Target MTAP-Deleted Tumors?

Klas G. Wiman, MD, PhD
Karolinska Institute
p53 Mutations: The Holy Grail of Cancer Targets—What Have We Learned and What Are Innovative Targeted Strategies in Pancreatic Cancer and Other Solid Malignancies?

Karen Cichowski, PhD

Harvard Medical School

The Excitement and Challenges of Targeting RAS Beyond KRAS G12C

Melinda L. Telli, MD, FASCO

Stanford University School of Medicine

New Agents for Triple-Negative Breast Cancer

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Multicancer Detection: Fact and Fiction, Hope and Hype

Location: S102

Hilary A. Robbins, PhD—Chair

International Agency for Research on Cancer

State of the Evidence for the Role of Multicancer Detection in Early Cancer Detection, Successes, Promises, and Failures

Wendy S. Rubinstein, MD, PhD, FACP, FACMG

National Cancer Institute, National Institutes of Health

The U.S. National Cancer Institute's Plans for an Unbiased Evaluation of Multicancer Detections

Kevin Meyer Elias, MD

Brigham and Women's Hospital

Multicancer Detection Versus Organ-Specific Tests? The Case of Gynecologic Cancers

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Neo/Adjuvant Therapy for Soft Tissue Sarcoma: New Developments and Ongoing Unanswered Questions

Location: S406

Leo Mascarenhas, MD, MBBS, MS

Cedars-Sinai Medical Center

Localized Pediatric Soft Tissue Sarcoma: What Have We Learned and What Is Next?

Vinod Ravi, MD—Chair

The University of Texas MD Anderson Cancer Center

Optimizing Regimens in the Neo/Adjuvant Setting for Localized Soft Tissue Sarcoma

Dario Callegaro, MD

Fondazione IRCCS Istituto Nazionale dei Tumori

Applying Prognostic Models to Guide Management of Soft Tissue Sarcoma

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Novel Treatment Paradigms in Nasopharyngeal Carcinoma

Location: E450a

Melvin L.K. Chua, PhD, FRCR, MBBS, FASCO—Chair

National Cancer Centre Singapore

Novel Approaches for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Brigitte Ma, MD

The Chinese University of Hong Kong

Emerging Therapies for Patients With Recurrent/Metastatic Nasopharyngeal Cancer

Anna Spreafico, MD, PhD

Princess Margaret Cancer Centre, University Health Network,
University of Toronto

*Impact of Different Biological Factors and Current and Evolving
Biomarkers in the Management of Nasopharyngeal Carcinoma*

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Real-World Implementation of ASCO SIO Guidelines: Pain, Fatigue, Depression

Location: E350

Kristina Gowin, DO

City of Hope

Integrative Oncology: Defining the Evidence

Eugene R. Ahn, MD

Cancer Treatment Centers of America

Implementing the ASCO-SIO Guidelines

Cherie Sampson, MFA

Society for Integrative Oncology

Implementing the ASCO Guidelines: A Patient Perspective

Ana Maria Lopez, MD, MPH, FASCO—Chair

Sidney Kimmel Cancer Center at Jefferson Health

Communication Strategies When Facing Limited Evidence

Panel Question and Answer

4:30 PM-5:45 PM Education Session

Toxicities of Immunotherapies Including CAR T-Cell Therapy

Location: E451

Michael David Jain, MD, PhD—Chair

Moffitt Cancer Centers

Early Complications of Immunotherapies

Jeremy S. Abramson, MD

Massachusetts General Hospital Cancer Center

Late Complications of Immunotherapies

Stephen M. Ansell, MD, PhD

Mayo Clinic

*Rare Complications of Immunotherapies (Including Secondary
Malignancies)*

Panel Question and Answer

4:30 PM-6:00 PM Clinical Science Symposium

Adjuvant Therapies in Colon Cancer—As Good As a Drug?

Location: Hall B1

Y. Nancy You, MD, MHSc—Chair

The University of Texas MD Anderson Cancer Center

Takayuki Yoshino, MD, PhD—Chair

National Cancer Center Hospital East

4:30 PM Jeffrey A. Meyerhardt, MD, MPH, FASCO

Dana-Farber Cancer Institute, Harvard Medical
School, Harvard University

Can Lifestyle Save Lives in Colorectal Cancer?

4:42 PM Abstract LBA3509: Association between empirical
dietary inflammatory pattern (EDIP) and survival in
patients with stage III colon cancer: Findings from
CALGB/SWOG 80702 (Alliance).
First Author: Sara K. Char, MD

4:54 PM

Abstract LBA3510: A randomized phase III trial
of the impact of a structured exercise program on
disease-free survival (DFS) in stage 3 or high-risk
stage 2 colon cancer: Canadian Cancer Trials
Group (CCTG) CO.21 (CHALLENGE).
First Author: Christopher M. Booth, MD

5:06 PM

Peter T. Campbell, PhD

American Cancer Society - BrightEdge

Diet and Exercise After Colorectal Cancer

Treatment: Challenges and Opportunities

5:18 PM

Abstract LBA3511: Aspirin as secondary
prevention for colorectal cancer liver metastases
(ASAC): A multicenter, randomized, double-blind,
placebo-controlled, phase 3 trial.

First Author: Sheraz Yaqub, MD, PhD

5:30 PM

Jason A. Zell, DO, MPH

University of California, Irvine Medical Center

*Discussion of Abstract(s) LBA3511: Controversies
in Chemoprevention for Colorectal Cancer*

5:42 PM

Panel Question and Answer

4:30 PM-6:00 PM Clinical Science Symposium

The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?

Location: Arie Crown Theater

Jo Chien, MD—Chair

University of California San Francisco

David W. Cescon, MD, PhD, FRCPC—Chair

Princess Margaret Cancer Centre/University Health Network

4:30 PM

Jo Chien, MD

University of California San Francisco Helen Diller
Family Comprehensive Cancer Center

ctDNA in Breast Cancer: It's Here, Are We Ready?

4:42 PM

Abstract 1009: Circulating tumor DNA, pathologic
response after neoadjuvant therapy, and survival:
First results from TBCRC 040 (the PREDICT-DNA
trial).

First Author: Natasha Hunter, MD

4:54 PM

Abstract 1010: Circulating tumor (ct)DNA
monitoring of ER+/HER2- high-risk breast cancer
during adjuvant endocrine therapy.
First Author: Lajos Pusztai, MD, PhD, DPhil,
FASCO

5:06 PM

Abstract 1011: Circulating tumor DNA (ctDNA)
dynamics as a predictor of treatment response in
metastatic breast cancer (mBC).
First Author: Pedram Razavi, MD, PhD

5:18 PM

Abstract 1012: Assessment of ctDNA somatic
homologous recombination deficiency (HRD) in
triple-negative breast cancer (TNBC) from SWOG
S1416 trial.

First Author: Shane R. Stecklein, MD, PhD

5:30 PM

Alexandra Thomas, MD, FACP, FASCO

Duke Cancer Institute

*Discussion of Abstract(s) 1009-1012: To See or Not
to ctDNA?*

5:42 PM

Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Genitourinary Cancer—Prostate, Testicular, and Penile
Location: Hall D2

Karen E. Hoffman, MD, MHSc, MPH—Chair

The University of Texas MD Anderson Cancer Center

Vivek Narayan, MD, MS—Chair

University of Pennsylvania

- 4:30 PM Abstract LBA5012:** An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma.
First Author: Aditya Dhanawat, MD, DM
- 4:36 PM Abstract 5013:** Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs).
First Author: Praful Ravi, MBBChir, MRCP
- 4:42 PM Abstract 5014:** Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
First Author: Eric Huttenlocher Bent, MD, PhD
- 4:48 PM** Panel Question and Answer
- 5:00 PM Abstract 5015:** DB1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
First Author: Andrew Ohyama Parsonson, MBBS, FRACP
- 5:06 PM Abstract 5016:** ¹⁷⁷Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).
First Author: Shahneen Sandhu, MBBS, FRACP
- 5:12 PM Abstract 5017:** Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Capucine Baldini, MD
- 5:18 PM** Panel Question and Answer
- 5:30 PM Abstract 5018:** CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.
First Author: Rikke Lovendahl Eefsen, MD, PhD
- 5:36 PM Abstract 5019:** Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2.
First Author: Stefanie Zschaebitz, MD
- 5:42 PM Abstract 5020:** Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving ¹⁷⁷Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
First Author: Aslı Doğa Munzur, BSc
- 5:48 PM** Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Location: Hall D1

Melina Elpi Marmarelis, MD—Chair

University of Pennsylvania

Patrick M. Forde, MD, PhD—Chair

Trinity St. James's Cancer Institute, Trinity College Dublin

- 4:30 PM Abstract 8009:** Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
First Author: Martin Reck, MD, PhD
- 4:36 PM Abstract LBA8010:** Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T.
First Author: Tina Cascone, MD, PhD
- 4:42 PM Abstract 8011:** ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.
First Author: Henrik Horndalsveen, MD
- 4:48 PM** Panel Question and Answer
- 5:00 PM Abstract 8012:** The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).
First Author: Yu Wang, MD
- 5:06 PM Abstract 8013:** Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
First Author: Santiago Ponce Aix, MD
- 5:12 PM Abstract 8014:** Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).
First Author: David Allen Barbie, MD
- 5:18 PM** Panel Question and Answer
- 5:30 PM Abstract 8015:** Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).
First Author: Alessandro Leonetti
- 5:36 PM Abstract 8016:** Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
First Author: Nicolas Girard, MD, PhD

- 5:42 PM** **Abstract 8017:** Integrin $\alpha_v\beta_3$ -targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIL study).
First Author: Zhaohui Zhu, MD
- 5:48 PM** Panel Question and Answer

4:30 PM-6:00 PM Rapid Oral Abstract Session

Quality Care/Health Services Research

Location: S402

Mina S. Sedrak, MD, MS, FASCO—Chair

David Geffen School of Medicine at UCLA

Monika K. Krzyzanowska, MD, MPH, FRCPC, FASCO—Chair

Odette Cancer Centre, Sunnybrook Health Sciences Centre

- 4:30 PM** **Abstract 11009:** Association between environmental burden and cancer incidence rates across population subgroups in the United States (US).
First Author: Azar Mohammad Abadi Kamarei
- 4:36 PM** **Abstract 11010:** Complex interplay between housing insecurity and forgone care among U.S. cancer survivors.
First Author: Shreya Kondle, MD
- 4:42 PM** **Abstract 11011:** Beyond the clinic: Comprehensive assessment of time burdens in cancer care.
First Author: Rachel I. Vogel, PhD
- 4:48 PM** Panel Question and Answer

- 5:00 PM** **Abstract 11012:** Association of medical debt with cancer incidence rates in the US.
First Author: Jiazhang Xing, MD
- 5:06 PM** **Abstract 11013:** Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer.
First Author: Daniel R. Richardson, MD, MSc, MA
- 5:12 PM** **Abstract 11014:** Utilization and timing of first tumor next-generation sequencing testing (NGS) in patients (pts) with five most common cancers in the USA.
First Author: Chadi Hage Chehade, MD
- 5:18 PM** Panel Question and Answer
- 5:30 PM** **Abstract 11015:** Overall survival and quality of life superiority in modern phase III oncology trials.
First Author: Alexander Dean Sherry, MD
- 5:36 PM** **Abstract 11016:** SWOG S2302, PRAGMATICA-LUNG: A pragmatic trial designed to increase participant representation.
First Author: Karen L. Reckamp, MD, FASCO
- 5:42 PM** **Abstract 11017:** Benefit of adding Cureety remote patient monitoring (RPM) to usual care during injectable anticancer treatment: The OPTIMACURE multicentric French prospective randomized study.
First Author: Audrey Faveyrial, MD
- 5:48 PM** Panel Question and Answer

7:30 AM-8:00 AM Oral Abstract Session

LBA Session: Presentation and Discussion of LBA1008

Location: Hall D1

Gregory Vidal, MD, PhD—Chair

West Cancer Center & Research Institute

7:30 AM Abstract LBA1008: Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2 -positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
First Author: Sara M. Tolaney, MD, MPH, FASCO

7:42 AM To be determined
Discussion of LBA1008

7:52 AM Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

From Localized to Metastatic: Navigating the Renal Cell Carcinoma Treatment Landscape

Location: Hall B1

Benjamin L. Maughan, MD, PharmD—Chair

Huntsman Cancer Institute at the University of Utah
Moderator

Jodi Kathleen Maranchie, MD, FACS

University of Pittsburgh Medical Center
Urologist Perspective

Catherine Fahey, MD, PhD

The University of North Carolina at Chapel Hill
Medical Oncologist Perspective

Scott Capozza, PT, MS

Yale Cancer Center
Patient Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Multidisciplinary Management of Brain Metastases in Breast Cancer

Location: E451

Bethany Marie Anderson, MD—Chair

University of Wisconsin
Moderator

Sasha Beyer, MD, PhD

The Ohio State University
Local Therapy Perspective

Carey K. Anders, MD, FASCO

Duke Cancer Institute
Medical Oncologist Perspective

William Clay Jackson, MD

West Cancer Center
Palliative Care Perspective

Panel Question and Answer

8:00 AM-9:00 AM Case-Based Panel

Multidisciplinary Treatment of Anaplastic Thyroid Cancer

Location: S102

Francis P. Worden, MD—Chair

University of Michigan Health System Comprehensive Cancer Center
Moderator

Caitlin McMullen, MD

Moffitt Cancer Centers
Surgeon Perspective

Nikhil Purushottam Joshi, MD

Cleveland Clinic Foundation
Radiation Oncologist Perspective

Saad A. Khan, MD

Stanford Cancer Center
Medical Oncologist Perspective

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Beyond the Headlines: The Real Impact of Early-Onset Cancers

Location: S100bc

W. Kimryn Rathmell, MD, PhD, FASCO—Chair

The Ohio State University Comprehensive Cancer Center
Chair Remarks

LeeAnn Bailey, MD, PhD

National Institutes of Health
The Rise of Early-Onset Cancer: Navigating Uncharted Territory and Paving a Path Forward

Katie Coleman

Chromophobe and Oncocytic Tumor Alliance
Patient Voice: What Are Patients Experiencing and What Do They Want From Their Team, Oncologist, and the Field?

Andrew T. Chan, MD, MPH

Massachusetts General Hospital, Harvard Medical School
State of the Science: What Do We Know Now About Early-Onset Cancer and Where Do We Need To Go?

Cathy Eng, MD, FACP, FASCO

Vanderbilt-Ingram Cancer Center
Structuring a Clinic: What to Know in Preparing to Offer Care to Younger Patients With Cancer

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Rare Melanoma Subtypes: Where Do We Stand?

Location: E450a

Kari Lynn Kendra, MD, PhD

The Ohio State University
What Is New in Desmosplastic and Acral Melanoma?

Marlana M. Orloff, MD—Chair

Sidney Kimmel Medical College at Thomas Jefferson University
Treatment for Uveal Melanoma: What to Do Now That We Have a Choice

Jun Guo, MD

Beijing Cancer Center
Therapeutic Approaches to Mucosal Melanoma

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Speaking to Power With Power: Advocating for Your Profession

Location: E350

Martin Palmeri, MD, MBA—Chair

Messino Cancer Center

Fighting for Our Profession: A New Breed of Leadership

Jason Westin, MD, MS, FACP, FASCO

The University of Texas MD Anderson Cancer Center

Finding Your Voice: What You Say Matters

Eric McNulty, MA

Harvard T.H. Chan School of Public Health

Negotiating From Power to the Powerful: Know Your Adversaries

Sibel Blau, MD

Northwest Medical Specialties

Reclaiming Medicine: The Advocate Within You

Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

Diving Deeper to Inform Hereditary Cancer Risk and Outcomes

Location: S103

Lisa A. Newman, MD, MPH, FASCO—Chair

Weill Cornell

Heather Hampel, MS—Chair

City of Hope National Medical Center

8:00 AM Payal Deepak Shah, MD

Penn Medicine Abramson Cancer Center

Pathogenic Germline Variants: Clinical Implications and Knowledge Gaps

8:12 AM Abstract 10509: Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.
First Author: Angela Toss, MD, PhD

8:24 AM Abstract 10510: Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer.
First Author: Siddhartha Yadav, MD

8:36 AM Banu Arun, MD, FASCO
The University of Texas MD Anderson Cancer Center
Discussion of Abstract(s) 10509-10510: Leveraging Genetics to Inform Breast Cancer Survival

8:48 AM Abstract 10511: Cancer risk of pathogenic germline variants among 164,774 adult cancers.
First Author: Jie Liu, PhD, MBBS, MPH

9:00 AM Marjanka Schmidt, PhD
Netherlands Cancer Institute
Discussion of Abstract(s) 10511: Expanding the Spectrum of Cancer Risk Among Pathogenic Variant Carriers

9:12 AM Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

Global Cancer Care Delivery: Resiliency in the Face of Conflict and Resource Constraints

Location: S402

Fidel Rubagumya, MD, MMed, MPH—Chair

Rwanda Military Hospital

Manoj Menon, MD—Chair

Fred Hutch Cancer Center

8:00 AM Miriam Claire Mutebi, MD, MMed, MSc, FACS
Aga Khan University Hospital
Overcoming Barriers and Tailoring Cancer Care Delivery for Local Contexts

8:12 AM Abstract 1509: Disparities in pediatric oncology outcomes in the occupied Palestinian territories: A retrospective study from Augusta Victoria Hospital.
First Author: Ru'a Rimawi, MD

8:24 AM Jemma Arakelyan, MD
City University of Hong Kong
Discussion of Abstract(s) 1509: The Hidden Impact of Conflict on Cancer Care

8:36 AM Abstract 1510: Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa.
First Author: Scott Swartz, MD, MS

8:48 AM Abstract 1511: Integrated health system for resolving breast cancer screening actions: Multicenter randomized clinical study—Itaberaí randomized trial, ReBEC, RBR-39vm2nd.
First Author: Ruffo Freitas-Junior, MD, PhD

9:00 AM To be determined
Discussion of Abstract(s) 1510-1511: Rethinking Cancer Care Guidelines and Cancer Screening for Resource-Limited Countries

9:12 AM Panel Question and Answer

8:00 AM-9:30 AM Clinical Science Symposium

Innovative Biomarkers and Vaccines in Pancreatic Cancer

Location: Hall D2

Timothy J. Brown, MD, MSCE—Chair

UT Southwestern Medical Center

Teresa Macarulla, MD, PhD—Chair

Vall d'Hebron University Hospital

8:00 AM Kelsey Klute, MD
University of Nebraska Medical Center
Novel Precision Strategies in Pancreatic Cancer

8:12 AM Abstract 4009: Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
First Author: Anthony Turpin

8:24 AM Abstract 4010: Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.
First Author: Jifang Gong, MD

- 8:36 AM** **Max Miller Wattenberg, MD**
Hospital of the University of Pennsylvania
Discussion of Abstract(s) 4009-4010: T-Cell Tug of War in Pancreatic Cancer
- 8:48 AM** **Abstract 4011:** NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
First Author: Ronan Andrew McLaughlin, MRCPATH, MBBCh
- 9:00 AM** **Peter Joel Hosein, MD**
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Discussion of Abstract(s) 4011: Is Pancreas Subtyping Ready for Prime Time?
- 9:12 AM** Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: S406

Carlos G. M. Ferreira, MD, PhD—Chair
Oncoclinicas Institute

Ki Young Chung, MD—Chair

PRISMA Health Cancer Institute, Institute for Translational Oncology Research

- 8:00 AM** **Abstract 3009:** Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.
First Author: Erika P. Hamilton, MD
- 8:06 AM** **Abstract 3010:** Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)-directed antibody-drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).
First Author: Kartik Sehgal, MD
- 8:12 AM** **Abstract 3011:** BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
First Author: Kathryn C. Arbour, MD
- 8:18 AM** Panel Question and Answer
- 8:30 AM** **Abstract 3012:** Preliminary results from a first-in-human, phase I/II study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava, MD
- 8:36 AM** **Abstract 3013:** A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
First Author: Xinghao Ai
- 8:42 AM** **Abstract 3014:** Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
First Author: Alice P. Chen, MD

8:48 AM Panel Question and Answer

- 9:00 AM** **Abstract 3015:** Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).
First Author: Sarah Shin, MD, MPH
- 9:06 AM** **Abstract 3016:** Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.
First Author: Jonathan Poh, PhD
- 9:12 AM** **Abstract 3017:** Enhancing prognostic precision in bladder cancer: AI-driven tumor microenvironment analysis from H&E images.
First Author: Evelyn Ramberger
- 9:18 AM** Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: E450b

Amandeep Godara, MD, MBBS—Chair
Huntsman Cancer Institute

Ruben Niesvizky, MD—Chair
Weill Cornell Medicine

- 8:00 AM** **Abstract 7509:** Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial.
First Author: Lisa B. Leypoldt, MD
- 8:06 AM** **Abstract 7510:** Linvoseltamab (LINV0) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
First Author: Paula Rodríguez-Otero, MD, PhD
- 8:12 AM** **Abstract 7511:** Heterogeneity in the expression of GPRC5D between patients with multiple myeloma.
First Author: Harsh Parmar
- 8:18 AM** Panel Question and Answer
- 8:30 AM** **Abstract 7512:** Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial.
First Author: Evangelos Terpos, MD, PhD
- 8:36 AM** **Abstract 7513:** Linvoseltamab (LINV0) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
First Author: Salomon Manier, MD, PhD
- 8:42 AM** **Abstract 7514:** Phase 1, first-in-human study of ISB 2001: A BCMAXCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
First Author: Eben I. Lichtman, MD
- 8:48 AM** Panel Question and Answer

- 9:00 AM** **Abstract 7515:** Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVD): Analysis from the DREAMM-8 trial.
First Author: Suzanne Trudel, MD
- 9:06 AM** **Abstract 7516:** Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.
First Author: Thierry Facon, MD
- 9:12 AM** **Abstract 7517:** Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
First Author: Meletios Athanasios Dimopoulos, MD
- 9:18 AM** Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Lung Cancer—Non–Small Cell Metastatic

Location: Arie Crown Theater

Marjorie Glass Zauderer, MD, MS, FACP—Chair

Westchester Medical Center

Toby C. Campbell, MD, MS—Chair

University of Wisconsin

- 8:00 AM** **Abstract 8512:** Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.
First Author: David Ross Camidge, MD, PhD
- 8:06 AM** **Abstract 8513:** Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
First Author: Benjamin Philip Levy, MD, FASCO
- 8:12 AM** **Abstract 8514:** Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
First Author: Yuankai Shi, MD, PhD
- 8:18 AM** Panel Question and Answer
- 8:30 AM** **Abstract 8515:** Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).
First Author: Julia K. Rotow, MD
- 8:36 AM** **Abstract 8516:** Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.
First Author: Yongchang Zhang

- 8:42 AM** **Abstract 8517:** Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.
First Author: Shuang Wei, DrPH
- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 8518:** S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).
First Author: Sukhmani Kaur Padda, MD
- 9:06 AM** **Abstract 8519:** Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.
First Author: Konstantin H. Dragnev, MD
- 9:12 AM** **Abstract 8520:** Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.
First Author: Jia Zhong
- 9:18 AM** Panel Question and Answer

8:00 AM-11:00 AM Oral Abstract Session

Gynecologic Cancer

Location: S100a

Anuja Jhingran, MD—Chair

The University of Texas MD Anderson Cancer Center

Gini F. Fleming, MD, FASCO—Chair

University of Chicago

- 8:00 AM** **Abstract LBA5500:** TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
First Author: Sven Mahner, MD
- 8:12 AM** **Abstract LBA5501:** Sentinel Lymph Node Biopsy versus Pelvic Lymphadenectomy in Cervical Cancer: the PHENIX trial.
First Author: Hua Tu
- 8:24 AM** **Emma Longley Barber, MD**
Northwestern Memorial Hospital
Discussion of Abstract(s) LBA5500-LBA5501: Cuts Both Ways: Surgical Impact in Gynecologic Malignancies
- 8:36 AM** Panel Question and Answer
- 8:48 AM** **Abstract 5502:** Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.
First Author: Jyoti Mayadev, MD
- 9:00 AM** **Abstract 5503:** Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.
First Author: Rebecca Mercieca-Bebber

- 9:12 AM** **Abstract LBA5504:** Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
First Author: Linda R. Duska, MD, MPH, FASCO
- 9:24 AM** **Mark Einstein, MD**
Rutgers New Jersey Medical School
Discussion of Abstract(s) 5502-LBA5504: At Your Cervix: Tailoring Treatment for Locally Advanced Cervical Cancer
- 9:36 AM** Panel Question and Answer
- 9:48 AM** **Abstract LBA5506:** FIRST/ENGOT-OV44: a phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).
First Author: Anne-Claire Hardy-Bessard
- 10:00 AM** **Abstract LBA5507:** ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
First Author: Alexander Olawaiye, MD, FASCO, FACS
- 10:12 AM** **Abstract 5508:** Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.
First Author: Xiaojun Chen
- 10:24 AM** **Debra L. Richardson, MD**
Stephenson Cancer Center at The University of Oklahoma Health Sciences Center
Discussion of Abstract(s) LBA5506-5508: Time for Optimism: Targeted Agents for Gynecologic Malignancies
- 10:36 AM** Panel Question and Answer

8:00 AM-11:00 AM Oral Abstract Session

Pediatric Oncology II

Location: S504

Kavita M. Dhodapkar, MD—Chair

Emory University

Stephanie M. Smith, MD, MPH—Chair

Lucile Packard Children's Hospital, Stanford University

- 8:00 AM** **Abstract 10009:** Promoting Resilience in Stress Management (PRISM): A randomized controlled trial of a psychosocial intervention for adolescents and young adults with advanced cancer.
First Author: Abby R. Rosenberg, MD, MS, MA, FAAP, FAAHPM
- 8:12 AM** **Abstract 10010:** Longitudinal change in cardiac function after doxorubicin and dexrazoxane: A report from COG ALTE11C2.
First Author: Erin Michele Mobley, PhD
- 8:24 AM** **Abstract 10011:** Long-term off-label MAPK inhibitor therapy in children with severe/refractory Langerhans cell histiocytosis: An international observational study of 277 cases.
First Author: Jean Donadieu, MD, PhD

- 8:36 AM** **Lucie Marie Turcotte, MD, MS, MPH**
University of Minnesota
Discussion of Abstract(s) 10009-10011: Navigating the Complexities of Cancer Therapy Impact in Pediatric Patients
- 8:48 AM** Panel Question and Answer
- 9:00 AM** **Abstract 10013:** CCDI-COG molecular characterization initiative: The expanding data on childhood cancer.
First Author: Erin R. Rudzinski, MD
- 9:12 AM** **Abstract 10012:** Understanding the molecular landscape of rare tumors through the CCDI-COG Molecular Characterization Initiative.
First Author: Lauren Marie Vasta, MD
- 9:24 AM** **Abstract 10014:** Genomic newborn screening for cancer risk: A retrospective cohort study.
First Author: Lisa Diller, MD, FASCO
- 9:36 AM** **Adam Shlien, MD**
The Hospital for Sick Children
Discussion of Abstract(s) 10012-10014: Proactive Precision in the Molecular Landscape of Pediatric Oncology
- 9:48 AM** Panel Question and Answer
- 10:00 AM** **Abstract 10015:** The gut microbiome in pediatric diffuse midline gliomas: Correlative study results from the PNOC022 trial.
First Author: Raoull Hoogendijk
- 10:12 AM** **Abstract 10016:** Cognitive outcomes following proton vs. photon radiotherapy for CNS non-germinomatous germ cell tumors: A Children's Oncology Group study.
First Author: David Y. Mak, MD
- 10:24 AM** **Abstract 10017:** Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients.
First Author: Ashley Love Sumrall, MD, FACP, FASCO
- 10:36 AM** **Anuradha Banerjee, MD**
University of California San Francisco
Discussion of Abstract(s) 10015-10017: Preserving Young Minds: Where to Go in Pediatric Neuro-Oncology
- 10:48 AM** Panel Question and Answer

8:30 AM-9:30 AM Highlights of the Day Session

Highlights of the Day II

Location: Hall D1

Thomas William LeBlanc, MD, MHS, MA, FAAHPM, FASCO—Chair

Duke University School of Medicine

- 8:30 AM** **Maryam B. Lustberg, MD, FASCO**
Yale Cancer Center, Yale School of Medicine
Breast Cancer—Metastatic
- 8:45 AM** **Bradley Alexander McGregor, MD**
Dana-Farber Cancer Institute
Genitourinary Cancer—Kidney and Bladder
- 9:00 AM** **Ryan David Nipp, MD, FASCO**
The University of Oklahoma
Symptom Science and Palliative Care

9:15 AM Sarah B. Goldberg, MD
Yale Cancer Center
Lung Cancer—Non–Small Cell Metastatic

9:00 AM-12:00 PM Poster Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall A - Posters and Exhibits

Posters by Topic

Adjuvant Therapy: Board(s) 111-142, 208a-211b

Biologic Correlates: Board(s) 143-164, 212a

DCIS/LCIS/Premalignant Lesions: Board(s) 165, 212b

Local-Regional Therapy: Board(s) 167-179, 213a-214b

Neoadjuvant Therapy: Board(s) 180-206, 215a-216b

Board 111 **Abstract 518:** Impact of chemotherapy on financial toxicity in African-American breast cancer patients: Early findings from the navigator-assisted hypofractionation (NAVAH) phase I clinical trial.
First Author: Maya J. Stephens, MS

Board 112 **Abstract 519:** Out-of-pocket cost modeling of EUROPA trial arms for adjuvant breast cancer therapy: Five days of radiation versus five years of antiestrogen therapy.
First Author: Ena Chinedum Oboh, MS

Board 113 **Abstract 520:** Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial.
First Author: Christine Desmedt, PhD

Board 114 **Abstract 521:** The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy.
First Author: Shawn Michael Doss, BA

Board 115 **Abstract 522:** Practice patterns related to ovarian function suppression in the SWOG S2010 clinical trial of young women with breast cancer.
First Author: Norah Lynn Henry, MD, PhD, FACP, FASCO

Board 116 **Abstract 523:** Beyond the 5-year mark: Adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.
First Author: Jenny Wei, MD

Board 117 **Abstract 524:** Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer.
First Author: Maria Jose Monroy Iglesias, PhD, MSc, MBBS

Board 118 **Abstract 525:** Chemotherapy (CT) declination among patients with early-stage hormone receptor positive breast cancer (BC) and high Oncotype DX recurrence scores (RS).
First Author: Nimfon Jackson, MD, PhD, MPH

Board 119 **Abstract 526:** Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
First Author: Kristina Fanucci, MD

Board 120 **Abstract 527:** Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2– early breast cancer (EBC) eligible for NATALEE.
First Author: Yara Abdou, MD

Board 121 **Abstract 528:** Real-world patterns of Oncotype DX (O-Dx) testing and chemotherapy (CT) use among patients with early-stage, hormone receptor–positive (HR+) breast cancer (BC).
First Author: Marija Sullivan, MD

Board 122 **Abstract 529:** Estrogen receptor expression in residual breast cancer following neoadjuvant chemotherapy.
First Author: Sarah K. Premji, MD

Board 123 **Abstract 530:** Molecular and immune profiling of breast cancer from pregnancy to postpartum: Insights into the tumour-immune landscape during breastfeeding from GEICAM EMBARCAM study.
First Author: Regina Peña-Enriquez, MSc

Board 124 **Abstract 531:** Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study.
First Author: Tara B. Sanft, MD

Board 125 **Abstract 532:** HER2DX prognostic value in older patients with HER2-positive early breast cancer: A correlative analysis from the RESPECT phase III trial.
First Author: Kazuki Nozawa, MD

Board 126 **Abstract 533:** The difference of clinical and molecular characteristics between HR-positive/HER2-positive and HR-negative/HER2-positive early breast cancer: A secondary analysis of 11 clinical trials.
First Author: Hongmei Zheng

Board 127 **Abstract 534:** Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial.
First Author: Ana Elisa Lohmann, MD, PhD

Board 128 **Abstract 535:** Real-world evidence of PARPi-related MDS/AML risk in breast cancer patients: An international collaborative network analysis.
First Author: Michela Palleschi

Board 130 **Abstract 537:** Extended endocrine therapy after 5 years of adjuvant LHRH-agonist in premenopausal patients with node-positive hormone receptor (HR)-positive early breast cancer.
First Author: Carmine Valenza, MD

Board 131 **Abstract 538:** Patterns in male and female breast cancer care: A comparative analysis of stage at presentation, treatment, and survival in the Veterans Health Administration.
First Author: Ariana Naaseh, MD, MSPH

Board 132 **Abstract 539:** Racial differences in the prognostic value of Oncotype (RS) and MammaPrint (MP) in postmenopausal, estrogen receptor (ER)–positive, node-negative (N0) breast cancer (BC) patients with low genomic risk: A National Cancer Database (NCDB) study.
First Author: Prashanth Ashok Kumar, MD, MBBS, FACP

Board 133 **Abstract 540:** The impact of racial and socioeconomic disparities on radiation therapy delays in breast cancer patients: A National Cancer Database analysis.
First Author: Mehmet Murat Zerey, MD

- Board 134 **Abstract 541:** Association between chemotherapy use and clinical outcomes in young BRCA carriers with T1N0 breast cancer: Results from an international cohort study.
First Author: Filipa Lynce, MD, FASCO
- Board 135 **Abstract 542:** Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]).
First Author: Guilherme Nader Marta, MD
- Board 136 **Abstract 543:** Cost-effectiveness of HER2/neu 655 genotyping in managing trastuzumab-induced cardiotoxicity risk in HER2-positive breast cancer patients.
First Author: Isabel Blancas, MD, PhD
- Board 137 **Abstract 544:** Neuromorphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study.
First Author: David Kiesel
- Board 138 **Abstract 545:** Effect of a multidisciplinary intervention based on a supervised training program on cardiovascular risk and quality of life in early-stage breast cancer patients.
First Author: Maria Torrente
- Board 139 **Abstract 546:** Survival impact of adjuvant chemotherapy regimens for small (T1mi/a/b), node-negative (pN0), triple-negative breast cancer (TNBC).
First Author: Kai Conrad Cecil Johnson, MD
- Board 140 **Abstract 547:** Obesity, chemotherapy dosing, and toxicity: Results from the Optimal Breast Cancer Chemotherapy Dosing study.
First Author: Elizabeth Kantor, PhD
- Board 141 **Abstract 548:** Clinical outcomes of patients with stage I triple-negative breast cancer (TNBC) treated with or without chemotherapy: The Mayo Clinic experience.
First Author: Sumeet Kumar Yadav, MD
- Board 142 **Abstract 549:** Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
First Author: Jan Witowski, MD, PhD
- Board 143 **Abstract 550:** Pathologic complete response to neoadjuvant chemotherapy in early-stage male breast cancer across molecular subtypes and racial/ethnic groups.
First Author: Jincong Q. Freeman, MPH, MS
- Board 144 **Abstract 551:** Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41.
First Author: Ilana Schlam, MD, MPH
- Board 145 **Abstract 552:** Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC).
First Author: Luc Cabel, MD, PhD
- Board 146 **Abstract 553:** Association of immune, proliferation gene signatures and stromal tumor infiltrating lymphocytes (sTILs) with outcomes in patients with stage I triple-negative breast cancer (TNBC).
First Author: Paolo Tarantino, MD
- Board 147 **Abstract 554:** Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis.
First Author: Priyanka Sharma, MD
- Board 148 **Abstract 555:** Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early-stage breast cancer (EBC).
First Author: Erin Fidyk, ANP-BC, MBA
- Board 149 **Abstract 556:** Association of genetic predisposition to low-grade systemic inflammation with cancer-related fatigue in women receiving chemotherapy for non-metastatic breast cancer in URCC07012 and URCC10055.
First Author: Ayokunle Olowofela, MD, MS
- Board 150 **Abstract 557:** Assessment of ovarian function suppression (OFS)-containing adjuvant endocrine therapy in premenopausal women by Breast Cancer Index.
First Author: Ruth O'Regan, MD, MRCP, FCRP
- Board 151 **Abstract 558:** Dynamic changes in circulating tumor DNA among Taiwanese early breast cancer patients undergoing upfront surgery: Results from the VGH-TAYLOR study.
First Author: Chi-Cheng Huang, PhD
- Board 152 **Abstract 559:** Impact of germline BRCA status on clinical outcomes of patients with HR+/HER2- early breast cancer.
First Author: Antonio Marra, MD
- Board 153 **Abstract 560:** Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC).
First Author: Marla Lipsyc-Sharf, MD
- Board 154 **Abstract 561:** Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.
First Author: Caterina Sposetti, MD
- Board 155 **Abstract 562:** Association of infiltration of hematopoietic stem cells (HSC) with cell proliferation and patient survival in breast cancer.
First Author: Masanori Oshi, MD, PhD
- Board 156 **Abstract 563:** MRI-based radiomic signature and its association with genomic complexity in breast tumor heterogeneity.
First Author: Joonoh Lim, MD, PhD
- Board 157 **Abstract 564:** Pregnancy-associated breast cancer: Tumor infiltrating lymphocytes TILting the balance?
First Author: Carsten F.J. Bakhuis, BSc
- Board 158 **Abstract 565:** Effect of allostatic load and measures of segregation on cancer detection and false positive rate after screening mammography.
First Author: Niam Abey Siriwardena
- Board 159 **Abstract 566:** Prognostic value of systemic inflammation in early-stage breast cancer in the CANTO cohort (SIM-CANTO).
First Author: Julia Dixon-Douglas, MBBS

- Board 160 **Abstract 567:** Exploring tumor genomics and clinical outcomes in adolescent and young adult (AYA) breast cancer.
First Author: Faris Tamimi, MD
- Board 161 **Abstract 568:** Global trends and regional disparities in young-onset breast cancer: Age-specific patterns from 1990 to 2021.
First Author: Muzamil Khan, MBBS
- Board 162 **Abstract 569:** Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
First Author: Saranya Chumsri, MD
- Board 163 **Abstract 570:** MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
First Author: Yi Liu, PhD, MS
- Board 164 **Abstract 571:** Impact of HER2 low status on pathologic response after neoadjuvant chemotherapy in TNBC: A large scale retrospective cohort study.
First Author: Julia Tchou
- Board 165 **Abstract 572:** Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.
First Author: Thomas O'Keefe
- Board 167 **Abstract 574:** Impact of postmastectomy radiotherapy on health-related quality of life and safety in breast cancer patients undergoing breast reconstruction: A multi-center cross-sectional study (Reborn-02).
First Author: Hirohito Seki, MD, PhD
- Board 168 **Abstract 575:** Development and validation of prediction models for 5-year and 10-year ipsilateral breast tumor recurrence after breast-conserving surgery.
First Author: Yasuaki Sagara, MD, MPH
- Board 169 **Abstract 576:** Regional node recurrence after sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer (second report from SHARE study).
First Author: Shigeru Imoto, MD, PhD
- Board 170 **Abstract 577:** Preoperative axillary US and MRI in early-stage breast cancer: Potential to prevent unnecessary axillary surgery.
First Author: Xin Wang, MD
- Board 171 **Abstract 578:** Use of local estrogen therapy among breast cancer patients in SEER-MHOS database.
First Author: Olivia Mitchel, BS
- Board 172 **Abstract 579:** Efficacy and safety of post-mastectomy radiation therapy for patients with breast cancer after breast reconstruction: A retrospective multicenter cohort study (Reborn-03).
First Author: Wakako Tsuji, MD, PhD
- Board 173 **Abstract 580:** Implications for sentinel lymph node biopsy (SLNB) omission in patients with early-stage node-negative HR+/HER2- breast cancer undergoing mastectomy.
First Author: Jennifer Hechao Chen, MD
- Board 174 **Abstract 581:** Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes.
First Author: Julia Foldi, MD, PhD
- Board 175 **Abstract 582:** TROP2 overexpression as predictor of outcome in patients with early triple-negative breast cancer. Exploratory analysis from the GEICAM_CIBOMA trial.
First Author: Federico Gustavo Rojo Todo
- Board 176 **Abstract 583:** Disparities in demographics and outcomes of breast cancer in females undergoing mastectomy in rural vs. urban teaching centers.
First Author: Harkaran Shergill
- Board 177 **Abstract 584:** Changes in the degree of satisfaction and quality of life in breast cancer patients who are candidates for breast conservation but opted for mastectomy: A single-center prospective study.
First Author: Changhoon Lee
- Board 178 **Abstract 585:** Bilateral mastectomy and breast cancer morality for invasive lobular carcinoma: A SEER-based study.
First Author: Richa Jaiswal, MBBS, DNB, MBBS
- Board 179 **Abstract 586:** Evaluating the outcome of cardiovascular risk factors in breast cancer patients.
First Author: Michelle Koifman, DO
- Board 180 **Abstract 587:** Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.
First Author: Frederick Matthew Howard, MD
- Board 181 **Abstract 588:** Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: A single-arm, open-label, multi-center phase II clinical study (neoTAPPL).
First Author: Wenting Yan
- Board 182 **Abstract 589:** Neoadjuvant low-dose carboplatin and docetaxel in combination with toripalimab for early or locally advanced triple-negative breast cancer (NeoTOP): A single-arm phase 2 trial.
First Author: Jun Tang, PhD
- Board 183 **Abstract 590:** Post-treatment MRI to predict pathological complete response in triple-negative breast cancer following neoadjuvant chemoimmunotherapy.
First Author: Tolsie Ramtohl, MD
- Board 184 **Abstract 591:** Efficacy and safety of neoadjuvant TQB2102 in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, multi-centre phase 2 trial.
First Author: Junjie Li
- Board 185 **Abstract 592:** Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC).
First Author: Clinton Yam, MD

- Board 186 **Abstract 593:** Use of artificial intelligence (AI)-powered spatial analysis to predict pathologic complete response (pCR) in HR+ HER2- breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC).
First Author: Dae-Won Lee, MD
- Board 187 **Abstract 594:** SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer: A single-arm, phase II clinical study.
First Author: Zhenzhen Liu, MD
- Board 188 **Abstract 595:** Computational pathology-informed immune biomarker for trastuzumab benefit in HER2+ breast cancer: Validation in NSABP B-41 clinical trial.
First Author: Satvika Bharadwaj, MS
- Board 189 **Abstract 596:** Exploration of the new classification of hormone receptor-positive breast cancer: Based on the genomic landscape of 2111 early to mid-stage Asian patients.
First Author: Cuiyun Zhang
- Board 190 **Abstract 597:** Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
First Author: Giampaolo Bianchini, MD
- Board 191 **Abstract 598:** Long-term outcomes in triple-negative breast cancers (TNBC) treated with talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
First Author: Hatem Hussein Soliman, MD
- Board 192 **Abstract 599:** Neoadjuvant cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: A single-arm phase II trial (CABIN study).
First Author: Tao Wu
- Board 193 **Abstract 600:** Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial.
First Author: Yunxiang Zhou, MD
- Board 194 **Abstract 601:** Patient outcomes in WSG-ADAPT according to NATALEE and MonarchE risk criteria.
First Author: Oleg Gluz, MD
- Board 195 **Abstract 602:** Racial disparities in clinical outcomes of early-stage triple-negative breast cancer treated with neoadjuvant chemoimmunotherapy: Insights from the NCDB.
First Author: Zunairah Shah, MD
- Board 196 **Abstract 603:** Outcomes of neoadjuvant endocrine therapy (NAET) versus neoadjuvant chemotherapy (NAC) in stage II-III invasive lobular carcinoma (ILC).
First Author: Jason A. Mouabbi, MD
- Board 197 **Abstract 604:** Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
First Author: Jo Chien, MD
- Board 198 **Abstract 605:** Molecular insights into HR+/HER2+ early-stage breast cancer: Neoadjuvant therapy responses by MammaPrint and Blueprint genomic subtypes.
First Author: Laila Samiian, MD, FACS
- Board 199 **Abstract 606:** Results of the prospective randomized controlled trial VOG-01: Neoadjuvant endocrine therapy ribociclib + fulvestrant + GnRH-a versus chemotherapy 4 AC + 4 T for early HR+/HER2-negative breast cancer in premenopausal patients.
First Author: Rashida Orlova, PhD
- Board 200 **Abstract 607:** HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
First Author: Bartomeu Fullana Grimalt, MD
- Board 202 **Abstract 609:** Outcomes of elderly patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.
First Author: Renata Colombo Bonadio, MD
- Board 203 **Abstract 610:** Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
First Author: Amrita Basu, PhD
- Board 204 **Abstract 611:** Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in INFORM (TBCRC 031) patients with low stromal TILs.
First Author: Stuart J. Schnitt
- Board 205 **Abstract 612:** I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
First Author: Mei Wei, MD
- Board 206 **Abstract 613:** Verification of the BREASTEST assay in an Australian population: A novel liquid biopsy assay measuring lipid biomarkers for early-stage breast cancer screening.
First Author: David Speakman
- Board 208a **Abstract TPS615:** A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤ 25 (OFSET): NRG-BR009.
First Author: Eleftherios P. Mamounas, MD
- Board 208b **Abstract TPS616:** A phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician's choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathologic complete response at surgery.
First Author: Heather L. McArthur, MD, MPH, FASCO

- Board 209a **Abstract TPS617:** Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2- early breast cancer (EBC).
First Author: Stephanie L. Graff, MD, FACP, FASCO
- Board 209b **Abstract TPS618:** Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.
First Author: Snehal Patel, MBA, MS
- Board 210a **Abstract TPS619:** ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
First Author: Aditya Bardia, MD, MPH, FASCO
- Board 210b **Abstract TPS620:** EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).
First Author: Michail Ignatiadis, MD, PhD
- Board 211a **Abstract TPS621:** The SURVIVE study: Standard surveillance vs. intensified liquid biopsy-based surveillance in early breast cancer survivors.
First Author: Henning Schäffler
- Board 211b **Abstract TPS622:** The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.
First Author: Kerstin Pfister, MD
- Board 212a **Abstract TPS623:** Short-term pre-operative durvalumab (MEDI 4736) in early small triple-negative breast cancer patients (POP-Durva).
First Author: Joana M. Ribeiro, MD
- Board 212b **Abstract TPS624:** RECAST (Re-Evaluating Conditions for Active Surveillance Suitability as Treatment) for DCIS: Clinical trial in progress.
First Author: Ruolin Lorraine Jiang, BS
- Board 213a **Abstract TPS625:** NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.
First Author: Julia R. White, MD
- Board 214a **Abstract TPS627:** MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET/AGO-B-062, NCT 05559411).
First Author: Maggie Barys-Paluchowski, PhD
- Board 214b **Abstract TPS628:** Radiation omission in patients with clinically node-negative breast cancer undergoing lumpectomy (ROSALIE).
First Author: Elena Parvez, MD, FRCS, MSc

- Board 215a **Abstract TPS629:** HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2- breast cancer.
First Author: Joyce O'Shaughnessy, MD
- Board 215b **Abstract TPS630:** Eliminating breast surgery for triple negative or HR-/HER2+ breast cancer patients with clinical complete response to combined neoadjuvant chemotherapy and neoadjuvant radiotherapy: A multicenter, phase 2 trial (EBCS).
First Author: Zhengjun Yang, MD
- Board 216a **Abstract TPS631:** A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).
First Author: Alexios Matikas, MD, PhD, MSc
- Board 216b **Abstract TPS632:** OPERETTA: A phase II study evaluating neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab for germline BRCA mutated triple negative breast cancer.
First Author: Yuko Takahashi, MD, PhD

9:00 AM-12:00 PM Poster Session

Breast Cancer—Metastatic

Location: Hall A - Posters and Exhibits

Posters by Topic

HER2-Positive: Board(s) 1-19, 99a-100a

Biologic Correlates: Board(s) 20-32

Hormone Receptor-Positive: Board(s) 33-67, 100b-105b

Non-Subtype-Specific Breast Cancer Therapies: Board(s) 68-75, 106a-108a

Triple-Negative: Board(s) 76-94, 108b-110a

Other Breast Cancer Subtypes: Board(s) 95-98, 110b

- Board 1 **Abstract 1022:** Longitudinal tissue analysis and correlation of microenvironmental changes with combined immunotherapy and targeted therapy response in metastatic breast cancer.
First Author: Jieqiong Liu, MD, DBE, DrPH
- Board 2 **Abstract 1023:** Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study.
First Author: David Berz, MD, PhD
- Board 3 **Abstract 1024:** Transcriptomic analysis of HER2 expression in metastatic breast cancer: Insights from a UAE patient cohort.
First Author: Rachel Su Jen Wong, MRCP, MBBS
- Board 4 **Abstract 1025:** Phase I summary of the C406 (CART) efficacy and safety for an HER2-positive breast cancer population.
First Author: Meili Sun, MD, PhD
- Board 5 **Abstract 1026:** Decoding HER2 dynamics: Exploring HER2 expression across a real-world breast cancer cohort.
First Author: Michelle Green, PhD

Board 6	Abstract 1027: A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors. First Author: Shusen Wang, MD	Board 19	Abstract 1040: Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC). First Author: Elias Bou Farhat, MD
Board 7	Abstract 1028: JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies. First Author: Yiqun Du, MD	Board 20	Abstract 1041: Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study. First Author: Samer Alkassis, MD
Board 8	Abstract 1029: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study. First Author: Charlotte Rose Lemech, MBBS, FRACP	Board 21	Abstract 1042: Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer. First Author: Qiang Zhang, PhD
Board 9	Abstract 1030: Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort. First Author: Jean-Sebastien Frenel, MD, PhD	Board 22	Abstract 1043: TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer. First Author: Nicole Casasanta, MD
Board 10	Abstract 1031: Eribulin plus pyrotinib in trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial). First Author: Zhenchuan Song	Board 23	Abstract 1044: Comprehensive results of ESG401, a TROP2-targeting ADC: Updated phase 1 analysis in advanced solid tumors. First Author: Fei Ma
Board 11	Abstract 1032: Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC). First Author: Paolo Tarantino, MD	Board 24	Abstract 1045: Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer. First Author: Nicholas Mai, MD
Board 12	Abstract 1033: Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥ 2 line treatments: Results from a phase 1b/2 study. First Author: Qingyuan Zhang, MD	Board 25	Abstract 1046: Differences in genomic profiles, targeted treatment use, and overall survival in patients with metastatic breast cancer by Area Deprivation Index. First Author: Emily L. Podany, MD
Board 13	Abstract 1034: Association of germline homologous recombination deficiency mutations with HER2 status conversion from negative to positive following neoadjuvant chemotherapy in breast cancer. First Author: Colin P. Bergstrom, MD	Board 26	Abstract 1047: Dissecting primary endocrine resistance through ctDNA profiling of a hybrid real-world and clinical trial dataset in hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). First Author: Lorenzo Gerratana, MD
Board 14	Abstract 1035: Recurrence risk prediction model in HER2-positive early breast cancer after HER2-targeted therapy. First Author: Qingyao Shang, MD, MBBS	Board 27	Abstract 1048: Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC). First Author: Tess A. O'Meara, MD, MHS
Board 16	Abstract 1037: Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer. First Author: Ayse A. Koksoy, PhD	Board 28	Abstract 1049: Macroscale genomic alterations in histomolecular invasive lobular carcinoma compared to other breast cancer subtypes. First Author: Jason A. Mouabbi, MD
Board 18	Abstract 1039: Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: A meta-analysis. First Author: Zouina Sarfraz, MBBS	Board 29	Abstract 1050: Landscape analysis of proteins in the development of breast cancer brain metastasis. First Author: Dongyan Xu
		Board 30	Abstract 1051: Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer. First Author: Robert Hsu, MD, MS
		Board 31	Abstract 1052: Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab. First Author: Antonio Llombart-Cussac, MD, PhD

Board 32 **Abstract 1053:** Antibody drug conjugates treatment response score (ADC TRS) for sequencing trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in advanced breast cancer (aBC).
First Author: Andi Cani, PhD

Board 33 **Abstract 1054:** Estrogen receptor (ER) expression on circulating tumor cells (CTCs) and cell free DNA (cfDNA) mutational landscape in the PACE randomized phase II study.
First Author: Carolina Reduzzi, PhD, MSc

Board 34 **Abstract 1055:** Overall survival in patients with HR+/HER2- advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor: A US Food and Drug Administration pooled analysis.
First Author: Jennifer Gao, MD

Board 35 **Abstract 1056:** Prospective cohort study of palbociclib in HR+/HER2- metastatic breast cancer in Japan.
First Author: Takashi Ishikawa, MD, PhD

Board 36 **Abstract 1057:** Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER2- breast cancer.
First Author: Hyo S. Han, MD

Board 37 **Abstract 1058:** Impact of BMI on CDK4/6 inhibitors efficacy and safety in advanced breast cancer: Results from a propensity score matched study—CAMELIA.
First Author: Min Tian

Board 38 **Abstract 1059:** Clinical utility of [¹⁸F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
First Author: Hannah M. Linden, MD

Board 39 **Abstract 1060:** Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial.
First Author: Joyce O'Shaughnessy, MD

Board 40 **Abstract 1061:** Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2- locally advanced/metastatic breast cancer (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer study.
First Author: Mafalda Oliveira, MD, PhD

Board 41 **Abstract 1062:** Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.
First Author: Seock-Ah Im, MD, PhD

Board 42 **Abstract 1063:** PARPi effectiveness after CDK4/6i in BRCA1- and BRCA2-associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study.
First Author: Emma Zattarin, MD

Board 43 **Abstract 1064:** A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of ecruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.
First Author: Yiqun Du, MD

Board 44 **Abstract 1065:** Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation-negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
First Author: Jing Du, MD, PhD

Board 45 **Abstract 1066:** Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in the GEICAM/2013-02 PEARL trial.
First Author: Angel Guerrero

Board 46 **Abstract 1067:** Prognostic role of estrogen receptor (ER) expression in breast cancer (BC) metastases and its dynamics from primary to metastatic disease: Results from a large multicentric cohort of patients with phenotypically stable ER+(≥10%)/HER2- BC.
First Author: Federica Miglietta, MD, PhD

Board 47 **Abstract 1068:** SIM0270 in combination with palbociclib in patients with ER+/HER2- advanced breast cancer: The phase Ib study.
First Author: Jiong Wu, PhD

Board 48 **Abstract 1069:** First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2- advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.
First Author: Nagi S. El Saghir, MD, FACP, FASCO

Board 49 **Abstract 1070:** Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
First Author: Hope S. Rugo, MD, FASCO

Board 50 **Abstract 1071:** Differential genomic landscape of estrogen receptor (ER)-low versus ER-positive (ER+) and ER-negative (ER-) metastatic breast cancer (MBC).
First Author: Chiara Corti, MD

Board 51 **Abstract 1072:** Molecular and prognostic convergence of HR+/HER2- metastatic breast cancer (MBC) to a TNBC-like profile: Insights from circulating tumor DNA (ctDNA)-based genomic analysis across treatment lines.
First Author: Lorenzo Foffano, MD

Board 52 **Abstract 1073:** Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer.
First Author: Julia Ah-Reum An, MD, MPH

Board 53 **Abstract 1074:** Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.
First Author: Claudio Vernieri, MD, PhD

Board 54	Abstract 1075: Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance. First Author: Pietro De Placido, MD, PhD	Board 66	Abstract 1087: Impact of body weight and body composition on survival and toxicities in patients receiving CDK4/6 inhibitors for ER+/HER2-metastatic breast cancer. First Author: Jorge Avila, MD
Board 55	Abstract 1076: Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC). First Author: George W. Sledge Jr, MD, FASCO	Board 67	Abstract 1088: Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)-positive advanced breast cancer (TBCRC 054). First Author: Neil M. Iyengar, MD
Board 56	Abstract 1077: Steroid receptor expression and overall survival in breast cancer patients with ER+ bone metastasis: A retrospective review. First Author: Anthony Michael Rossi	Board 68	Abstract 1089: Pulmonary toxicities in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic Enterprise Experience, updated. First Author: Jenna Elizabeth Hoppenworth, FNP
Board 57	Abstract 1078: Evaluating accuracy and concordance of pathologists and the utility of AI assistance software for digital HER2 IHC assessment in breast cancer including HER2-ultralow scoring: An international multicenter observational study. First Author: Gabriela Acosta Haab	Board 69	Abstract 1090: Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study. First Author: Shusen Wang, MD
Board 58	Abstract 1079: Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study. First Author: Nancy Chan, MD	Board 70	Abstract 1091: Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer. First Author: Nanuli Gvazava, MD
Board 59	Abstract 1080: Enhancing precision oncology for Haitian breast cancer patients through deep learning-enabled computational pathology tools. First Author: Rebecca Henderson, MD, PhD	Board 71	Abstract 1092: Limited changes in the CNS immune microenvironment in patients with breast cancer metastasis and capturing these changes using machine learning. First Author: Andrew Ip, MD, MS
Board 60	Abstract 1081: Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer. First Author: Ana Christina Garrido-Castro, MD	Board 72	Abstract 1093: A phase II study to evaluate the safety and efficacy of BB-1701 in subjects with HER2 expression locally advanced/metastatic breast cancer previously treated with HER2-ADC containing TOP-I inhibitor. First Author: Xiaoxiang Guan
Board 61	Abstract 1082: Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations. First Author: Jimmitti Teyssir, MD	Board 73	Abstract 1094: Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC). First Author: Priyanka Sharma, MD
Board 62	Abstract 1083: Targeting PARP-1 in ER-positive endocrine-resistant breast cancer. First Author: Azzurra Zicarelli	Board 74	Abstract 1095: Assessing the impact of scalp cooling in patients receiving trastuzumab deruxtecan for metastatic breast cancer. First Author: Elahe Salehi, DNP
Board 63	Abstract 1084: Racial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC). First Author: Catherine Keane, MSN	Board 75	Abstract 1096: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer. First Author: Saranya Chumsri, MD
Board 64	Abstract 1085: Therapeutic impact of novel agents in patients with stage IV de novo HR+ve/Her2-ve breast cancer: Results from a real-world dataset. First Author: Shaheenah S. Dawood, MD, PhD, FACP, FRCP	Board 76	Abstract 1097: First-line durvalumab plus chemotherapy with or without oleclumab for locally advanced or metastatic triple-negative breast cancer: SYNERGY overall survival and circulating tumor DNA analysis. First Author: Elisa Agostinnetto, MD
Board 65	Abstract 1086: Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial. First Author: Sarah L. Sammons, MD	Board 77	Abstract 1098: Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC). First Author: Dan Morgenstern Kaplan, MD, MSc
		Board 78	Abstract 1099: Acute circulating tumor DNA dynamics during and after infusional therapy initiation. First Author: Briana To, PhD, DO

Board 79 **Abstract 1100:** A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.
First Author: Antonio Giordano, MD, PhD

Board 80 **Abstract 1101:** Camrelizumab plus nab-paclitaxel and cisplatin as first-line treatment for metastatic triple-negative breast cancer: A prospective, single-arm, open-label phase II trial.
First Author: Biyun Wang

Board 81 **Abstract 1102:** Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study.
First Author: Fan Wu

Board 82 **Abstract 1103:** SHR-A1811 plus adefrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort.
First Author: Yan Liang

Board 83 **Abstract 1104:** ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.
First Author: Jiayu Wang, MD

Board 84 **Abstract 1105:** Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.
First Author: Ismail Ajjawi

Board 85 **Abstract 1106:** Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC).
First Author: Shipra Gandhi, MD, MS

Board 86 **Abstract 1107:** Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
First Author: Sachin Kumar Deshmukh, PhD

Board 87 **Abstract 1108:** Enhanced efficacy of inavolisib combined with anti-PD-1 or anti-HER2 antibody in treating brain metastases from breast cancer.
First Author: Jian-Li Zhao, MD

Board 88 **Abstract 1109:** Efficacy and safety of RC48-ADC in triple-negative breast cancer subtypes: FUSCC-TNBC-umbrella trial results.
First Author: Yin Liu

Board 89 **Abstract 1110:** Artificial Intelligence-based tumor microenvironment and PD-L1 analysis using digital pathology to predict pembrolizumab response in metastatic triple-negative breast cancer.
First Author: Jee Hung Kim, MD, PhD

Board 90 **Abstract 1111:** Geographic access to triple negative breast cancer (TNBC) clinical trials: Are trials located near Black women?
First Author: Laura Burns Amin, MD

Board 91 **Abstract 1112:** Immunotherapy vs. chemotherapy run-in followed by pembrolizumab plus nab-paclitaxel in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
First Author: Alessandro Leal, MD, PhD

Board 92 **Abstract 1113:** Trop2-targeted PET/CT with ⁶⁸Ga-MY6349 for the diagnosis of primary and metastatic breast cancer and evaluation towards patient stratification in Trop2-targeted ADCs.
First Author: Liang Zhao

Board 93 **Abstract 1114:** Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
First Author: Matias Alberto Bustos, PhD

Board 94 **Abstract 1115:** Concurrent GLP1R-agonist use with chemoimmunotherapy for early-stage triple-negative breast cancer.
First Author: Bethania Santos, MD

Board 95 **Abstract 1116:** HAI-score, an objective HER2 artificial intelligence method for accurate H-score estimation from IHC-stained breast cancer samples.
First Author: Sahar Almahfouz Almahfouz Nasser, PhD

Board 96 **Abstract 1117:** Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC).
First Author: Yutian Zou

Board 97 **Abstract 1118:** Opioid use disorder among females with breast cancer: A comprehensive analysis of prevalence in the United States and associated factors.
First Author: Aneri Sanepara, MBBS

Board 98 **Abstract 1119:** Treatment patterns, genomic characteristics, and outcomes among patients with metastatic lobular breast cancer.
First Author: Sherry Shen, MD

Board 99a **Abstract TPS1120:** A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
First Author: Lior Zvi Braunstein, MD

Board 99b **Abstract TPS1121:** IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.
First Author: David W. Cescon, MD, PhD, FRCPC

Board 100a **Abstract TPS1122:** Phase II study evaluating ⁶⁸Ga-FAPI PET uptake heterogeneity as a predictor of T-DXd treatment response in HER2-positive breast cancer brain metastases.
First Author: Biyun Wang

Board 100b **Abstract TPS1123:** SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.
First Author: Eva Maria Ciruelos, MD, PhD

Board 101a **Abstract TPS1124:** LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.
First Author: Bora Lim, MD

- Board 101b **Abstract TPS1125:** ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.
First Author: Pooja Prem Advani, MBBS
- Board 102a **Abstract TPS1126:** Integrating gene signatures to guide HR+/HER2- MBC therapy in a diverse cohort (INSIGHT).
First Author: Sonya A. Reid, MD, MPH
- Board 102b **Abstract TPS1127:** ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC)—An open-label multicenter phase 2 study.
First Author: Virginia G. Kaklamani, MD
- Board 103a **Abstract TPS1128:** SIMRISE: A randomized phase III trial evaluating SIM0270 in combination with everolimus versus treatment of physician's choice in patients with ER+/HER2- advanced breast cancer, previously treated with CDK4/6 inhibitors.
First Author: Jiong Wu, PhD
- Board 103b **Abstract TPS1129:** ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
First Author: Antonio Llombart-Cussac, MD, PhD
- Board 104a **Abstract TPS1130:** Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.
First Author: Sandra Elaine Dunn, PhD
- Board 104b **Abstract TPS1131:** OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.
First Author: Barbara Pistilli, MD
- Board 105a **Abstract TPS1132:** Immunologic targeting of native and mutated ESR1 receptor for treatment of hormone receptor expressing metastatic breast cancer.
First Author: Aixa Elena Soyano Muller, MD
- Board 105b **Abstract TPS1133:** Adaptive designed eniluracil + capecitabine phase 2 trial in advanced or metastatic breast cancer patients.
First Author: David Young, PhD, MS, PharmD
- Board 106a **Abstract TPS1134:** DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.
First Author: Paolo Tarantino, MD
- Board 106b **Abstract TPS1135:** The efficacy and safety of eutideron, etoposide, and bevacizumab in patients with brain metastases from breast cancer.
First Author: Bishal Tiwari, MD, MBBS

- Board 107a **Abstract TPS1136:** Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer.
First Author: Neal Shiv Chawla, MD
- Board 107b **Abstract TPS1137:** Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
First Author: Laura Ann Huppert, MD
- Board 108a **Abstract TPS1138:** Update on phase III pivotal trial of Bria-IMT + CPI vs physician's choice in advanced metastatic breast cancer (BRIA-ABC).
First Author: Saranya Chumsri, MD
- Board 108b **Abstract TPS1139:** Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study.
First Author: Jiayu Wang, MD
- Board 109a **Abstract TPS1140:** A phase II trial to assess the impact of $\beta 2$ adrenergic receptor ($\beta 2$ -AR) blockade in metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi, MD, MS
- Board 109b **Abstract TPS1141:** Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomerase-1 inhibitor ADC.
First Author: Hyo S. Han, MD
- Board 110a **Abstract TPS1142:** TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
First Author: Tiffany A. Traina, MD, FASCO
- Board 110b **Abstract TPS1143:** AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2-associated metastatic HER2-negative breast cancer (BC).
First Author: Filipa Lynce, MD, FASCO

9:00 AM-12:00 PM Poster Session

Genitourinary Cancer—Kidney and Bladder

Location: Hall A - Posters and Exhibits

Posters by Topic

Kidney Cancer: Board(s) 322-359, 411a-413b

Urothelial Cancer—Advanced/Metastatic Disease: Board(s) 360-376, 414a-416a

Urothelial Cancer—Local-Regional Disease: Board(s) 377-404, 416b-420a

Other GU Kidney and Bladder Cancer: Board(s) 405-410, 420b-421b

- Board 322 **Abstract 4522:** Ipilimumab/nivolumab versus standard of care in non-clear cell renal cancer: Results of the SUNNIFORECAST trial and potential role of the CPS score and tumor nephrectomy.
First Author: Lothar Bergmann, MD

- Board 323 **Abstract 4523:** Efficacy and safety of second-line cabozantinib ± atezolizumab for patients with advanced renal cell carcinoma after progression on immuno-oncology combinations: Subgroup analysis of CONTACT-03.
First Author: Cristina Suárez, MD, PhD
- Board 324 **Abstract 4524:** Comparison of ⁶⁸Ga-NY104 PET/CT with ¹⁸F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, comparative phase II study.
First Author: Wenjia Zhu, MD
- Board 325 **Abstract 4525:** Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II trial.
First Author: Wen-Hao Xu
- Board 326 **Abstract 4526:** Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRRC): Preliminary results from an exploratory prospective multicentre clinical study.
First Author: Pei Dong, PhD
- Board 327 **Abstract 4527:** Investigation of tumor-associated macrophages (TAMs) and therapeutic resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).
First Author: Soki Kashima, MD, PhD
- Board 328 **Abstract 4528:** Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.
First Author: Zachary A. Yochum, MD, PhD
- Board 329 **Abstract 4529:** Phase 1 results of Oncobax-AK in combination with ipilimumab/nivolumab in advanced clear cell renal cell carcinoma (ccRCC; NCT05865730).
First Author: Lisa Derosa, MD, PhD
- Board 330 **Abstract 4530:** Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).
First Author: Ro Malik, BS
- Board 331 **Abstract 4531:** Frailty assessment in patients with advanced/metastatic renal cell carcinoma using routine data collected during treatment with tyrosine kinase inhibitors in the STAR trial.
First Author: Sophie Trotter, MA, MBChir
- Board 332 **Abstract 4532:** International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification and regression tree analysis to characterize objective response rates (ORR) in metastatic renal cell carcinoma (mRCC).
First Author: Martin Zarba, MD, MSc
- Board 334 **Abstract 4534:** Early detection of renal cell carcinoma: A novel cfDNA fragmentomics-based liquid biopsy assay.
First Author: Yulu Peng, PhD

- Board 335 **Abstract 4535:** Efficacy and safety of neoadjuvant toripalimab plus axitinib in renal cell carcinoma with tumor thrombus: A combined analysis of two phase II trials.
First Author: Liangyou Gu, MD
- Board 336 **Abstract 4536:** First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial.
First Author: Xinan Sheng, MD
- Board 337 **Abstract 4537:** Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).
First Author: David A. Braun, MD, PhD
- Board 338 **Abstract 4538:** Genomic and proteomic predictors of sites of metastases in renal cell carcinoma.
First Author: Clara Steiner, MD
- Board 339 **Abstract 4539:** Analysis of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh).
First Author: Bradley Alexander McGregor, MD
- Board 340 **Abstract 4540:** Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.
First Author: Alex Chehraz-Raffle, MD
- Board 341 **Abstract 4541:** Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.
First Author: Shimiao Zhu Sr, MD, PhD
- Board 342 **Abstract 4542:** Clear and non-clear cell renal cell carcinomas and the ability to engage in oxidative phosphorylation.
First Author: Ziad Bakouny, MSc
- Board 343 **Abstract 4543:** HIF family transcription factor expression in a cohort of 4362 patients with renal cell carcinoma (RCC).
First Author: Yu-Wei Chen, MD, MS
- Board 344 **Abstract 4544:** Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.
First Author: Rashad Nawfal, MD
- Board 345 **Abstract 4545:** Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC).
First Author: Paulo Siqueira do Amaral, MD
- Board 346 **Abstract 4546:** Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC.
First Author: Marc Machaalani, MD

- Board 347 **Abstract 4547:** KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype.
First Author: Marie Carlo, MD
- Board 348 **Abstract 4548:** Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.
First Author: David Maj, MBBS, MSc, FRCPC
- Board 349 **Abstract 4549:** Clinical characteristics and determinants of primary refractory metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study.
First Author: Karl Semaan, MD, MSc
- Board 350 **Abstract 4550:** Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.
First Author: Miguel Zugman, MD
- Board 351 **Abstract 4551:** Vasculogenic mimicry as a potential indicator of drug resistance and prognosis in renal cell carcinoma.
First Author: Xingang Cui, MD
- Board 352 **Abstract 4552:** Differences in patient characteristics, treatment patterns, and clinical outcomes of renal cell carcinoma patients in public vs private health care systems in Brazil: Insights from the LACOG 1120 registry.
First Author: Pablo Barrios, MD
- Board 353 **Abstract 4553:** Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.
First Author: Michael Roger Harrison, MD
- Board 354 **Abstract 4554:** Machine learning–derived B-cell epitopes classifiers for early detection of renal cell carcinoma.
First Author: Thomas Campbell, PhD
- Board 355 **Abstract 4555:** Clinical outcomes of patients with primary refractory metastatic renal cell carcinoma receiving second-line (2L) therapies: An International Metastatic Database Consortium (IMDC) study.
First Author: Marc Eid, MD, MSc
- Board 356 **Abstract 4556:** Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Razane El Hajj Chehade, MD
- Board 357 **Abstract 4557:** Identifying key prognostic indicators in Wilms tumor using machine learning techniques.
First Author: Salsabeel Aljawabrah, MD
- Board 358 **Abstract 4558:** Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study.
First Author: Benjamin L. Maughan, MD, PharmD
- Board 359 **Abstract 4559:** The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.
First Author: Mohanad Elchouemi, BS
- Board 360 **Abstract 4560:** Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).
First Author: Kevin R. Reyes, BS
- Board 361 **Abstract 4561:** Avelumab maintenance therapy in patients (pts) with advanced urothelial carcinoma (UC) in Japan: Subgroup analyses by best overall response (BOR) to prior platinum-based chemotherapy (PBC) in a post-marketing surveillance (PMS) population.
First Author: Eiji Kikuchi, PhD
- Board 362 **Abstract 4562:** Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC).
First Author: Martin Kurian, MD
- Board 363 **Abstract 4563:** Final results of a phase 2 study of HDACi chidamide and PD-1 inhibitor for advanced urothelial carcinoma after platinum therapy.
First Author: Zhuowei Liu, MD
- Board 364 **Abstract 4564:** Fibroblast growth factor receptor 3 (FGFR3) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma.
First Author: Shilpa Gupta, MD
- Board 365 **Abstract 4565:** Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC).
First Author: Adanma Ayanambakkam, MD
- Board 366 **Abstract 4566:** Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer.
First Author: Cindy Y. Jiang, MD
- Board 367 **Abstract 4567:** Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenetide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
First Author: Patrizia Giannatempo, MD
- Board 368 **Abstract 4568:** Real-world analysis of 2IR immune response score in histologic subtype urothelial carcinoma (hsUC).
First Author: Jason Robert Brown, MD, PhD
- Board 369 **Abstract 4569:** Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC).
First Author: Samuel Black, MD
- Board 370 **Abstract 4570:** A real-world picture of biomarker testing in metastatic bladder cancer: A comprehensive assessment of 19,979 patients treated in the US and Europe.
First Author: Tiago Costa de Padua, MD, MSc

- Board 371 **Abstract 4571:** EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Jens Bedke, MD
- Board 372 **Abstract 4572:** Profiling treatment-associated evolutionary dynamics in advanced urothelial cancer via deep whole exome sequencing of cell-free DNA.
First Author: Arvind Ravi, MD, PhD
- Board 373 **Abstract 4573:** Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma.
First Author: Michal Sternschuss, MD
- Board 374 **Abstract 4574:** Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.
First Author: Alyssa Arbuio, BS
- Board 375 **Abstract 4575:** Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin/pembrolizumab in advanced metastatic urothelial cancer.
First Author: Aya Abdelnaser
- Board 376 **Abstract 4576:** Assessing treatment outcomes of enfortumab vedotin dose reduction in metastatic bladder cancer.
First Author: Hal Difede Rives, BS
- Board 377 **Abstract 4577:** Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).
First Author: Andrew James Weickhardt, MBBS, FRACP
- Board 378 **Abstract 4578:** Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.
First Author: Brendan Raizenne, MD
- Board 379 **Abstract 4579:** Quantifying patient preferences for bacillus Calmette-Guérin (BCG) and PD-(L)1 inhibitors in high-risk non-muscle invasive bladder cancer (NMIBC): A discrete choice experiment.
First Author: Pam Hallworth, BSc
- Board 380 **Abstract 4580:** Evaluation of surrogate endpoints in muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
First Author: Matthew D. Galsky, MD, FASCO
- Board 381 **Abstract 4581:** MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy.
First Author: Lawrence Howard Schwartz, MD
- Board 382 **Abstract 4582:** Distinct genomic landscape of Lynch syndrome-associated urothelial cancer.
First Author: Jussi Nikkola, MD, PhD

- Board 383 **Abstract 4583:** Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): 3-year efficacy results.
First Author: Nataliya Mar, MD
- Board 384 **Abstract 4584:** Revolutionizing bladder cancer follow-up: Personalized urinary ctDNA analysis for detecting minimal residual disease.
First Author: Xuebin Wan
- Board 385 **Abstract 4585:** An exploratory study of clostridium butyricum combined with neoadjuvant chemioimmunotherapy in urothelial carcinoma.
First Author: Xiao Yang, MD, PhD
- Board 386 **Abstract 4586:** Updated efficacy and safety results from ReBirth, a phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen, MD
- Board 387 **Abstract 4587:** Postoperative assessment using urinary tumor DNA (utDNA) to identify potential candidates for repeat transurethral resection of bladder tumor (re-TURBT) in non-muscle invasive bladder cancer (NMIBC): A retrospective analysis.
First Author: Zihan Xue, MD
- Board 388 **Abstract 4588:** Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104) for HER2-expressing muscle-invasive bladder cancer (MIBC).
First Author: Sujun Han
- Board 389 **Abstract 4589:** Microbiota proteomics profiles in muscle-invasive bladder carcinoma related to response to neoadjuvant chemotherapy.
First Author: Alvaro Pinto, MD, PhD
- Board 390 **Abstract 4590:** Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.
First Author: Shouyong Liu
- Board 391 **Abstract 4591:** First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC).
First Author: Brigida Anna Maiorano, MD
- Board 392 **Abstract 4592:** Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis.
First Author: Shiwang Huang
- Board 393 **Abstract 4593:** Inferring FGFR status from H&E images using digital pathology to identify patients for early-stage bladder cancer targeted therapies.
First Author: Albert Juan Ramon, PhD
- Board 394 **Abstract 4594:** Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Chiara Mercinelli, MD

- Board 395 **Abstract 4595:** Five-year median follow-up update of PURE-01: A phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Valentina Tateo, MD
- Board 396 **Abstract 4596:** A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).
First Author: Joaquim Bellmunt, MD
- Board 397 **Abstract 4597:** Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
First Author: John Sfakianos, MD
- Board 398 **Abstract 4598:** Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.
First Author: Sandip M. Prasad
- Board 399 **Abstract 4599:** Determinants in trimodality therapy for bladder cancer: Overcoming chemoradiotherapy resistance via ferroptosis.
First Author: Takuya Tsujino, MD, PhD
- Board 400 **Abstract 4600:** Survival outcomes of whole pelvic vs. bladder-only radiation in muscle-invasive bladder cancer: A nationwide large-scale study.
First Author: Mohammad Arfat Ganiyani, MBBS
- Board 401 **Abstract 4601:** Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A SEER-Medicare study.
First Author: Yair Lotan, MD
- Board 402 **Abstract 4602:** Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT).
First Author: Ilana Bensussen Epstein, BA
- Board 403 **Abstract 4603:** Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC).
First Author: Tracy L. Rose, MD
- Board 404 **Abstract 4604:** Subsequent treatments and outcomes in bacillus Calmette-Guerin-unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world data analysis.
First Author: Ariel B. Bourla, MD, PhD
- Board 405 **Abstract 4605:** Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.
First Author: Xu Chen
- Board 406 **Abstract 4606:** IL-15R α Fc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.
First Author: Yuke Chen
- Board 407 **Abstract 4607:** Results of BH011 after intravesical administration in patients with CIS and/or papillary non-muscle invasive bladder cancer (NMIBC) after BCG failure: Interim results from a phase I/II clinical trial.
First Author: Dingwei Ye, MD
- Board 408 **Abstract 4608:** AURORA: A single arm, multicentre, phase II clinical trial of atezolizumab immunotherapy for advanced squamous cell carcinoma of the bladder and urinary tract.
First Author: Simon J. Crabb, PhD, MBBS
- Board 409 **Abstract 4609:** Prevalence of histology-agnostic biomarkers in pure squamous cell carcinomas of the genitourinary tract.
First Author: Saad Omar Atiq, MD
- Board 410 **Abstract 4610:** Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naïve in BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.
First Author: Jens Bedke, MD
- Board 411a **Abstract TPS4611:** STARLITE-1: Phase 1b/2 study of combination ^{177}Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.
First Author: Eric Jonasch, MD
- Board 411b **Abstract TPS4612:** STARLITE 2: Phase 2 study of nivolumab plus ^{177}Lu lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (^{177}Lu -girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Darren R. Feldman, MD
- Board 412a **Abstract TPS4613:** A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor $\gamma\delta$ T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC).
First Author: Sumanta Kumar Pal, MD, FASCO
- Board 412b **Abstract TPS4614:** A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
First Author: Neil J. Shah, MD
- Board 413a **Abstract TPS4615:** Transforming kidney cancer treatment through AI-enabled functional precision medicine: The PEAR-TREE2 trial.
First Author: Matthew Williams, FRCR
- Board 413b **Abstract TPS4616:** A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).
First Author: Chinmay Jani, MBBS

- Board 414a **Abstract TPS4617:** Clinical effectiveness of urine DNA for minimal residual disease (MRD) monitoring of urothelial carcinoma in urine: A multicenter, prospective, observational study.
First Author: Xuanjun Guo
- Board 414b **Abstract TPS4618:** A phase 2, open-label, randomized study of livmoniplimab in combination with budigalimab versus chemotherapy in patients with metastatic urothelial carcinoma.
First Author: Terence W. Friedlander, MD
- Board 415a **Abstract TPS4619:** A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2).
First Author: Yohann Loriot, MD, PhD
- Board 415b **Abstract TPS4620:** A randomized phase 2 study of the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with metastatic urothelial carcinoma and oligoprogression on maintenance therapy with avelumab (VOLGA 2).
First Author: Ilya Tsimafeyeu, MD
- Board 416a **Abstract TPS4621:** A phase II trial to evaluate clinical efficacy, pharmacodynamics and exploratory analysis of pemetrexed in relation to MLL4 and UTX alteration status in patients with relapsed/refractory metastatic urothelial carcinoma and other solid tumors.
First Author: Carolyn Moloney, MBChB
- Board 416b **Abstract TPS4622:** Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.
First Author: Nataliya Mar, MD
- Board 417a **Abstract TPS4623:** Neoadjuvant stereotactic radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV).
First Author: Tian Zhang, MD, MHS
- Board 417b **Abstract TPS4624:** PUNCH03: A phase II study of disitamab vedotin combined with tislelizumab and bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
First Author: Zongren Wang
- Board 418a **Abstract TPS4625:** Updates to CORE-008: A phase 2 multi-arm, multi-cohort study to evaluate intravesical cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer.
First Author: Gary D. Steinberg, MD
- Board 418b **Abstract TPS4626:** Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.
First Author: Elena Sevilano, MD
- Board 419a **Abstract TPS4627:** Intravesical sacituzumab tirumotecan in participants with intermediate-risk non-muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.
First Author: Joshua J. Meeks, MD, PhD

- Board 419b **Abstract TPS4628:** SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.
First Author: Guillermo de Velasco, MD, PhD
- Board 420a **Abstract TPS4629:** The uTRACT registry: A single-arm, multicenter, prospective, and retrospective registry study to evaluate the real-world use of UGN-101 in participants with upper tract urothelial carcinoma (UTUC) in the United States.
First Author: Adam Feldman, MD, MPH
- Board 420b **Abstract TPS4630:** ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.
First Author: Siamak Daneshmand, MD
- Board 421a **Abstract TPS4631:** LEGEND: A phase 1/2 study of detalimogene voraplasamid (EG-70), an intravesical monotherapy for patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
First Author: Jen-Jane Liu, MD
- Board 421b **Abstract TPS4632:** ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non-muscle-invasive bladder cancer.
First Author: Neal D. Shore, MD, FACS

9:00 AM-12:00 PM Poster Session

Genitourinary Cancer—Prostate, Testicular, and Penile

Location: Hall A - Posters and Exhibits

Posters by Topic

Epidemiology/Outcomes: Board(s) 220-224

Germ Cell/Testicular Cancer: Board(s) 225-236

Penile Cancer: Board(s) 237-239

Prostate Cancer—Advanced/Castrate-Resistant: Board(s) 240-286, 309a-316b

Prostate Cancer—Advanced/Hormone-Sensitive: Board(s) 287-298, 317a-319a

Prostate Cancer—Local-Regional Disease: Board(s) 299-307, 319b-320a

Other Prostate, Testicular, or Penile Cancer: Board 308

- Board 220 **Abstract 5021:** Association of hormone therapy usage with adverse cardiovascular events in prostate cancer patients of the All of Us Research Program cohort.
First Author: Yuanchu J. Yang

- Board 221 **Abstract 5022:** Comprehensive genomic profiling of Black and non-Hispanic White (NHW) men with prostate cancer (PCa).
First Author: Sharon H. Choi, MD, PhD

- Board 222 **Abstract 5023:** Prognostic impact of brain metastases on survival rates in patients with metastatic testicular cancer: A comprehensive registry-based analysis.
First Author: Rohan Garje, MD

- Board 223 **Abstract 5024:** Use of GIP and GLP-1 receptor agonists in prostate cancer patients.
First Author: Amy L. Shaver, PhD, PharmD, MPH
- Board 224 **Abstract 5025:** Barbados' first next-generation sequencing of a prostate cancer sample.
First Author: Joanne Nicholls
- Board 225 **Abstract 5026:** BEP in intermediate- and poor-risk advanced non-seminomatous germ cell tumor (NSGCT): Standing the test of time.
First Author: Aditya Dhanawat, MD, DM
- Board 226 **Abstract 5027:** Epidemiology, treatment patterns, and survival outcomes of spermatocytic seminoma: A National Cancer Database analysis.
First Author: Nikhil A. Furtado, BS
- Board 227 **Abstract 5028:** Racial and socioeconomic disparities in testicular cancer survival outcomes: A SEER database analysis.
First Author: Charmi Bhanushali, MBBS
- Board 228 **Abstract 5029:** Therapeutic decisions and outcome of patients with stage I testicular germ cell tumor: Single-centre experience.
First Author: Isabella Cavaglià
- Board 229 **Abstract 5030:** Risk factors and causes of early death among patients with germ cell testis tumors (GCTs): An international collaborative study supported by the Global Society of Rare Genitourinary Tumors.
First Author: Michal Mego, MD, PhD
- Board 230 **Abstract 5031:** TROP-2 expression in germ cell tumors (GCT).
First Author: Noah Richardson, MD
- Board 231 **Abstract 5032:** Clinical utility of a tumor-naïve circulating tumor DNA (ctDNA) test to predict outcomes in patients with advanced testicular germ cell tumors.
First Author: Vitor Fiorin de Vasconcellos, MD
- Board 232 **Abstract 5033:** Initiation of high dose chemotherapy at rising tumor markers compared with radiographic progression in patients with relapsed germ-cell tumors (GCT).
First Author: Rebecca Hassoun, MD
- Board 233 **Abstract 5034:** Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience.
First Author: Sara Faouzi, MD, PhD
- Board 234 **Abstract 5035:** Predicting teratoma histology in postchemotherapy residual lesions of non-seminoma testicular cancer (NSTC) patients using integrated CT radiomics and circulating MicroRNAs modelling.
First Author: Guliz Ozgun, MD
- Board 235 **Abstract 5036:** Survival outcomes of patients with mNSGCTs with and without teratoma in the primary tumor: An international retrospective study.
First Author: Manuel Pedregal, MD
- Board 236 **Abstract 5037:** Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers.
First Author: Jamaal Christopher Jackson, MD
- Board 237 **Abstract 5038:** Spatial transcriptional dynamics of CD74⁺ B cells in tertiary lymphoid structures and effects on immune evolution in penile squamous cell carcinoma.
First Author: Zaishang Li
- Board 238 **Abstract 5039:** Long-term outcomes of dynamic sentinel lymph node biopsy in clinically node-negative penile cancer.
First Author: Vivaan Dutt, MS, MBBS, MCh
- Board 239 **Abstract 5040:** Dedicated resources for veteran clinical trial participation: The Prostate Cancer Analysis for Therapy Choice (PATCH) program.
First Author: Julie N. Graff, MD
- Board 240 **Abstract 5041:** Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US).
First Author: Alan Haruo Bryce, MD
- Board 241 **Abstract 5042:** A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Atish Dipankar Choudhury, MD, PhD
- Board 242 **Abstract 5043:** Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.
First Author: Santosh Gupta, PhD, MSc
- Board 243 **Abstract 5044:** Effect of HLA class I expression on the tumor immune microenvironment and prognosis in prostate cancer.
First Author: Pornlada Likasitwatanakul, MD
- Board 244 **Abstract 5045:** Updated prostate cancer risk groups by PSMA-PET PROMISE (PPP2): Results from an international multi-centre registry study.
First Author: Wolfgang Peter Fendler, MD
- Board 245 **Abstract 5046:** Safety and pharmacokinetics of mevorinmetostat (M) in combination with enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Nobuaki Matsubara, MD
- Board 246 **Abstract 5047:** Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
First Author: Xiaojie Bian
- Board 247 **Abstract 5048:** Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.
First Author: Alton Oliver Sartor, MD
- Board 248 **Abstract 5049:** Uptake of targeted therapy in a large cohort of patients with advanced prostate cancer and germline pathogenic variants.
First Author: Hiba M. Khan, MD, MPH
- Board 249 **Abstract 5050:** Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC).
First Author: Rana R. McKay, MD, FASCO

- Board 250 **Abstract 5051:** Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study.
First Author: Lin Shen
- Board 251 **Abstract 5052:** Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Boiarsky, MD
- Board 252 **Abstract 5053:** Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide.
First Author: Matthew Siskin, MD
- Board 253 **Abstract 5054:** 'One button push' fully automated PSMA PET quantification: Correlation with progression free and overall survival in patients undergoing [¹⁷⁷Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer.
First Author: Louise Emmett, MD, MBChB, FRACP
- Board 254 **Abstract 5055:** First-in-human study of ¹⁷⁷Lu-JH020002 in patients with metastatic castration-resistant prostate cancer.
First Author: Fangning Wan
- Board 255 **Abstract 5056:** Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).
First Author: Michael Ong, MD, FRCPC
- Board 256 **Abstract 5057:** Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelimumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).
First Author: Sebastien J. Hotte, MD, FRCPC
- Board 257 **Abstract 5058:** Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)-directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: April A. N. Rose, MD, PhD
- Board 258 **Abstract 5059:** Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).
First Author: Gunhild Von Amsberg, MD
- Board 259 **Abstract 5060:** Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician's choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.
First Author: Simon Chowdhury, MD, PhD

- Board 260 **Abstract 5061:** Prognostic relevance of Aurora kinase A (AURKA) expression in prostate cancer (PCa).
First Author: Maroun Bou Zerdan, MD
- Board 261 **Abstract 5062:** PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.
First Author: Ananya Choudhury, PhD, MA, MRCP, FRCR
- Board 262 **Abstract 5063:** A novel prognostic model to optimize the timing of docetaxel (Doc) following an androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Lola Rodríguez Nogueira, MD
- Board 263 **Abstract 5064:** Additive clinical utility of tissue biomarkers of microsatellite instability (MSI) status and tumor mutational burden (TMB) to predict immune checkpoint inhibitor (ICI) effectiveness for real-world patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Nicolas Sayegh, MD
- Board 264 **Abstract 5065:** Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.
First Author: Elahe A. Mostaghel, MD, PhD
- Board 265 **Abstract 5066:** Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A molecularly selected cooperative group platform study.
First Author: Alexander William Wyatt, PhD
- Board 266 **Abstract 5067:** Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: David R. Wise, MD, PhD
- Board 267 **Abstract 5068:** Survival and hospitalizations with lutetium (Lu)-177 vipivotide tetraxetan in veterans with underlying genomic alterations.
First Author: Sumrah Khan, DO
- Board 268 **Abstract 5069:** A phase I and randomized phase II trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase I results.
First Author: Hiram Alberto Gay, MD
- Board 269 **Abstract 5070:** PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.
First Author: Valentina Marulanda Corzo
- Board 270 **Abstract 5071:** Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alan Haruo Bryce, MD

- Board 271 **Abstract 5072:** Molecular characterization of STEAP1 and -2 in advanced prostate cancer.
First Author: Kevin Kayvan Zarrabi, MD, MS, FACP
- Board 272 **Abstract 5073:** Characterization and impact of B7-H3 (CD276) expression across disease states and racial groups in prostate cancer.
First Author: Justin Hwang, PhD
- Board 273 **Abstract 5074:** Plasma epigenomic profiling to reveal molecular correlates of response and resistance to ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jacob E. Berchuck, MD
- Board 274 **Abstract 5075:** Exploring PSMA heterogeneity and alternative targets expression in PSMA-negative prostate cancer.
First Author: Yelin Mulati
- Board 275 **Abstract 5076:** Comparative effectiveness of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Zeynep Irem Ozay, MD
- Board 276 **Abstract 5077:** Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity.
First Author: Qian Qin, MD
- Board 277 **Abstract LBA5078:** Lower-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer - a multicentric randomized phase III non-inferiority trial.
First Author: Minit Jalan Shah, DM
- Board 278 **Abstract 5079:** Assessment of PSMA PET/CT derived predictive markers for ¹⁷⁷Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.
First Author: Koichiro Kimura
- Board 279 **Abstract 5080:** Molecular correlates of response in patients with metastatic castration-resistant prostate cancer treated with olaparib with or without cediranib (NCI9984).
First Author: Alok Tewari, MD, PhD
- Board 280 **Abstract 5081:** Clinical implications of HER3 overexpression in a diverse patient cohort with prostate cancer.
First Author: Hannah Maluvac
- Board 281 **Abstract 5082:** Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.
First Author: Jennifer A. Freedman, PhD
- Board 282 **Abstract 5083:** Integrated CTC- and EV-based detection of PSMA protein and efficacy of ¹⁷⁷Lu-PSMA-617 radioligand therapy.
First Author: Ali Arafa, MBChB
- Board 283 **Abstract 5084:** Transcriptional profiling to identify a program of enzalutamide extreme non-response in lethal prostate cancer.
First Author: Anbarasu Kumaraswamy, PhD
- Board 284 **Abstract 5085:** Integrated analysis of tissue genomic sequencing and high purity circulating tumor cell RNA sequencing for prostate cancer lineage states as a prognostic factor for survival and resistance to ¹⁷⁷Lu-PSMA-617 in patients with metastatic castrate resistant prostate cancer.
First Author: Marina Nasrin Sharifi, MD, PhD
- Board 285 **Abstract 5086:** Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2.
First Author: Brooke Overstreet
- Board 286 **Abstract 5087:** Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).
First Author: Hedyeh Ebrahimi, MD, MPH
- Board 287 **Abstract 5088:** Triplet versus doublet therapy in older patients with metastatic hormone-sensitive prostate cancer: A network meta-analysis.
First Author: Susu Zhou, MD
- Board 288 **Abstract 5089:** Prognostic validation of six androgen production, uptake, and conversion genes (APUC-6) in the CHAARTED prostate cancer trial.
First Author: Xiaolei Shi, MD, PhD
- Board 289 **Abstract 5090:** 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
First Author: Alison Yan Zhang, PhD, MMed, MBBS, FRACP
- Board 290 **Abstract 5091:** Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
First Author: Zahra Sabahi, MD
- Board 291 **Abstract 5092:** How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castrationsensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data.
First Author: Stephen J. Freedland, MD
- Board 292 **Abstract 5093:** Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).
First Author: Lisa Horvath, PhD, MBBS, FRACP
- Board 293 **Abstract 5094:** Impact of somatic/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume.
First Author: David Olmos, MD, PhD
- Board 294 **Abstract 5095:** ¹⁷⁷Lu-PSMA-617 consolidation therapy post docetaxel in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer: A randomized, phase 2 trial.
First Author: Ashwani Sood, DNB
- Board 295 **Abstract 5096:** Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by PTEN status.
First Author: Dana Rathkopf, MD

- Board 296 **Abstract 5097:** Outcomes of initial vs delayed docetaxel therapy in veterans with metastatic hormone sensitive prostate cancer and high volume of disease.
First Author: Jasnoor Malhotra, BSc
- Board 297 **Abstract 5098:** Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.
First Author: Ravi Amrit Madan, MD
- Board 298 **Abstract 5099:** Evaluation of de novo oligometastatic, oligorecurrent, and oligoprogressive prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
First Author: Sophia C. Kamran, MD
- Board 299 **Abstract 5100:** Assessment of the impact of delays to radiotherapy on prostate cancer mortality in localized prostate cancer.
First Author: Yang Xu, MD
- Board 300 **Abstract 5101:** Five-year outcomes of SABR in intermediate- and high-risk prostate cancer without ADT.
First Author: Nidal Salim, MD, PhD(c)
- Board 301 **Abstract 5102:** COBRA: Assessment of the efficacy of ⁶⁴Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
First Author: Luke Nordquist, MD
- Board 302 **Abstract 5103:** Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.
First Author: Stephen J. Freedland, MD
- Board 303 **Abstract 5104:** Neoadjuvant niraparib in men with DNA repair gene deficient clinically localized prostate cancer: Clinical and molecular results from a phase 2 investigator-initiated trial.
First Author: Marc Dall'Era, MD
- Board 304 **Abstract 5105:** A randomised clinical trial to improve healthy lifestyle adherence in prostate cancer patients undergoing radiotherapy (Microstyle study).
First Author: Sara Gandini, PhD
- Board 305 **Abstract 5106:** External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy.
First Author: Chien-Kuang Cornelia Ding, MD, PhD
- Board 306 **Abstract 5107:** Utility of the PROSTest, a novel blood-based molecular assay, versus PSA for prostate cancer stratification and detection of higher grade disease.
First Author: Pawel Rajwa
- Board 307 **Abstract 5108:** A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa).
First Author: Umair Ayub, PhD, MS

- Board 308 **Abstract 5109:** Insight into the global mortality trends due to prostate cancer among the under-55 population: An analysis of the Global Burden of Disease-2021.
First Author: Amar Lal, MD
- Board 309a **Abstract TPS5110:** Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial).
First Author: John Nikitas, MD
- Board 309b **Abstract TPS5111:** Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.
First Author: Anthony W. Tolcher, MD, FASCO
- Board 310a **Abstract TPS5112:** VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.
First Author: Ruben Raychaudhuri, MD
- Board 310b **Abstract TPS5113:** Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.
First Author: Neeraj Agarwal, MD, FASCO
- Board 311a **Abstract TPS5114:** Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker based study (Alliance A032102).
First Author: Rana R. McKay, MD, FASCO
- Board 311b **Abstract TPS5115:** An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC).
First Author: Katherine J. Kayser-Bricker, PhD
- Board 312a **Abstract TPS5116:** Mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 study.
First Author: Neal D. Shore, MD, FACS
- Board 312b **Abstract TPS5117:** A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrei Iagaru, MD
- Board 313a **Abstract TPS5118:** Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator's choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).
First Author: William Kevin Kelly, DO
- Board 313b **Abstract TPS5119:** A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator's choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).
First Author: Kim N. Chi, MD

- Board 314a **Abstract TPS5120:** The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer. First Author: Steven M. Blinka, MD, PhD
- Board 314b **Abstract TPS5121:** A randomized phase 2 trial of flexible and extended dosing of ¹⁷⁷Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT): Trial in progress update. First Author: Adrien Holzgreve, MD, MHA
- Board 315a **Abstract TPS5122:** A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225. First Author: Michael Paul Kolinsky, MD, FRCPC
- Board 315b **Abstract TPS5123:** A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). First Author: Rahul Raj Aggarwal, MD
- Board 316b **Abstract TPS5125:** SECURE: A dose escalation/expansion study to assess the anti-tumor efficacy of ⁶⁷Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. First Author: Geoffrey Bates Johnson, MD, PhD
- Board 317a **Abstract TPS5126:** A phase 3 study of 177Lu-rosptamab plus standard of care vs. standard of care alone in patients with metastatic castration-resistant prostate cancer (ProstACT Global). First Author: Scott T. Tagawa, MD, FACP, MS, FASCO
- Board 317b **Abstract TPS5127:** PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [¹⁷⁷Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC). First Author: Alton Oliver Sartor, MD
- Board 318a **Abstract TPS5128:** METANOVA: A phase II trial of metastasis-directed radiotherapy for de novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial. First Author: Angela Y. Jia, MD, PhD
- Board 318b **Abstract TPS5129:** TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). First Author: Michael Ong, MD, FRCPC
- Board 319a **Abstract TPS5130:** A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY). First Author: Qian Qin, MD

- Board 319b **Abstract TPS5131:** Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP). First Author: Alicia K. Morgans, MD, MPH, FASCO
- Board 320a **Abstract TPS5132:** Androgen suppression combined with elective nodal irradiation and dose escalated prostate treatment: A non-inferiority, phase III randomized controlled trial of stereotactic body radiation therapy versus brachytherapy boost in patients with unfavourable risk localized prostate cancer (ASCENDE-SBRT; CCTG PR24; NCT06235697). First Author: Andrew Loblaw, MD, FASCO

9:00 AM-12:00 PM Poster Session

Head and Neck Cancer

Location: Hall A - Posters and Exhibits

Posters by Topic

Advanced/Metastatic Disease: Board(s) 429-456, 517a-520a

Biologic Correlates: Board(s) 457-466

Local-Regional Disease: Board(s) 467-500, 520b-524a

Other Head and Neck Cancer (Salivary, Thyroid): Board(s) 501-516, 524b

- Board 429 **Abstract 6021:** Real world utilization of comprehensive genomic profiling (CGP) in head and neck squamous cell carcinoma (SCCHN). First Author: Connie Jiayu Zhou, BS
- Board 430 **Abstract 6022:** Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic nasal cavity and paranasal sinus squamous-cell carcinoma: A prospective phase II study. First Author: Yuquan Qian, MD
- Board 431 **Abstract 6023:** Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC). First Author: Aarti K. Bhatia, MD, MPH
- Board 432 **Abstract 6024:** Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial. First Author: Carla M.L. van Herpen, MD, PhD
- Board 433 **Abstract 6025:** Using longitudinal spatial-omics to demonstrate in-situ Epstein-Barr virus reduction in responders to immunotherapy treated nasopharyngeal cancer. First Author: Yang Wu, PhD, DSc
- Board 434 **Abstract 6026:** Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. First Author: Houyu Ju, MD
- Board 435 **Abstract 6027:** Analysis of gene mutations, TMB, and PD-L1 in relation to ICI response in HNSCC. First Author: Daniel Beau Stamos, MD

- Board 436 **Abstract 6028:** Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM). First Author: Rachel Galot, MD, PhD
- Board 437 **Abstract 6029:** Retlirafusp alfa-a bifunctional anti-PD-L1/TGF- β RIII agent plus nab-paclitaxel and carboplatin in pre-treated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, phase II clinical trial. First Author: Dongmei Ji, MD
- Board 438 **Abstract 6030:** Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial. First Author: Dongmei Ji, MD
- Board 439 **Abstract 6031:** Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study. First Author: Cheng Xu, MD
- Board 440 **Abstract 6032:** The molecular landscape of immunotherapy treatment and advanced disease in head and neck squamous carcinoma (HNSCC). First Author: George Lalotitis, MD, PhD, MHA
- Board 441 **Abstract 6033:** Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC. First Author: Maura L. Gillison, MD, PhD
- Board 442 **Abstract 6034:** A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma. First Author: Yilin He
- Board 443 **Abstract 6035:** Survival for head and neck squamous cell carcinoma treated with versus without neoadjuvant systemic therapy: A national propensity score-matched analysis. First Author: Vanessa Helou, MD
- Board 444 **Abstract 6036:** ctDNA-based clinicogenomic analysis of advanced head and neck cancer patients treated with immune checkpoint inhibitors. First Author: Atul Bhard, PhD
- Board 445 **Abstract 6037:** Versatile-002: Overall survival of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma patients treated with T cell stimulating immunotherapy PDS0101 and pembrolizumab. First Author: Jared Weiss, MD
- Board 446 **Abstract 6038:** Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors. First Author: Pin Wang, PhD
- Board 447 **Abstract 6039:** Two cycles of neoadjuvant therapy with low-dose radiotherapy, PD-1 inhibitor tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): A phase II, open-label, single-arm trial. First Author: Zhigang Liu, MD, PhD
- Board 448 **Abstract 6040:** Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial. First Author: Jingjing Miao, MD, PhD, MSc, MMed, MBBS
- Board 449 **Abstract 6041:** Optimal maintenance therapy strategy for metastatic nasopharyngeal carcinoma: Insights from a cohort study in an endemic region. First Author: Zhuoying Luo
- Board 450 **Abstract 6042:** Major pathological response to neoadjuvant immune-related therapy and influence on long-term survival in patients with locally advanced oral squamous cell carcinoma. First Author: Lai-ping Zhong, MD, PhD, DM
- Board 451 **Abstract 6043:** Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: A randomized, open label, phase II clinical trial. First Author: Lei Liu, MD, PhD
- Board 453 **Abstract 6045:** Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC). First Author: Grégoire Marret, MD, PhD
- Board 454 **Abstract 6046:** Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HNSCC receiving standard of care (SOC). First Author: Omid Haji Maghsoudi, PhD
- Board 455 **Abstract 6047:** ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial. First Author: Filippo Gustavo Dall'Olio, MD, PhD
- Board 456 **Abstract 6048:** Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck. First Author: Douglas Adkins, MD
- Board 457 **Abstract 6049:** Establishment and validation of a dynamic prognostic model using serial circulating tumor DNA (ctDNA) for endemic EBV-related nasopharyngeal carcinoma (NPC): A secondary analysis of EP-SEASON. First Author: Zi-Cheng Zhen, MD
- Board 458 **Abstract 6050:** Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck: A multi-omics IMMUCAN/EORTC analysis. First Author: Athenais van der Elst

- Board 459 **Abstract 6051:** Comprehensive profiling of circulating tumor DNA and microbial landscapes in nasopharyngeal cancer across Asia: NCCH1905/A-TRAIN study.
First Author: Nguyen Huy Thinh, MD
- Board 460 **Abstract 6052:** Characterizing the prevalence and prognostic significance of MTAP loss in endemic nasopharyngeal cancer using immunohistochemistry (IHC) versus fluorescent in situ hybridization (FISH).
First Author: David Johnson
- Board 461 **Abstract 6053:** Tracking circulating tumor DNA through liquid biopsy after radiotherapy for dynamic risk monitoring in cancer patients.
First Author: Renyuan Huang, MD
- Board 462 **Abstract 6054:** Induction chemotherapy followed by chemoradiotherapy with cisplatin or cetuximab for unresectable locally advanced head and neck cancer (TTCC-2007-01 trial): Analysis of genomic biomarkers by next-generation sequencing after long-term outcomes.
First Author: Alejandro Olivares Hernández, MD
- Board 463 **Abstract 6055:** Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
First Author: Jesse M. Zaretsky, MD, PhD
- Board 464 **Abstract 6056:** Survival association of PIK3CA in HPV-driven head and neck squamous cell carcinoma (HNSCC).
First Author: Kelly Bridgham, MD
- Board 465 **Abstract 6057:** Evaluation of plasma methylated DNA markers for detection HPV-positive oropharyngeal squamous cell carcinoma: A case control study.
First Author: Kathryn M. Van Abel, MD
- Board 466 **Abstract 6058:** Evidence of a role for oropharyngeal cancer cells with low HPV gene expression in treatment failure.
First Author: Devraj Basu, MD, PhD
- Board 467 **Abstract 6059:** Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.
First Author: Tomoya Yokota, MD, PhD
- Board 468 **Abstract 6060:** Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
First Author: Chunyan Chen, PhD
- Board 469 **Abstract 6061:** Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a phase 2 window of opportunity trial.
First Author: David M. Routman, MD
- Board 470 **Abstract 6062:** Efficacy of definitive radiotherapy with concurrent and adjuvant immune checkpoint inhibitors in patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC).
First Author: Hazem Aboaid, MD
- Board 471 **Abstract 6063:** Prognostic impact of preoperative imaging-detected extranodal extension in head and neck squamous cell carcinoma treated with postoperative chemoradiotherapy.
First Author: Yuta Hoshi, MD
- Board 472 **Abstract 6064:** Concurrent chemoradiotherapy with or without nimotuzumab in induction chemotherapy resistant locoregionally advanced nasopharyngeal carcinoma: An open-label randomised, controlled, phase 2 trial.
First Author: Li-Ting Liu, MD
- Board 473 **Abstract 6065:** Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Annette May Ling Lim, PhD, MBBS, FRACP
- Board 474 **Abstract 6066:** Osteoradionecrosis as a complication following intensity-modulated radiation therapy or proton therapy in the treatment of oropharyngeal carcinoma.
First Author: Edward Christopher Dee, MD
- Board 475 **Abstract 6067:** Efficacy analysis of neoadjuvant PD-1 inhibitor combined with chemotherapy in various subanatomical sites of locally advanced and recurrent resectable head and neck squamous cell carcinoma: A retrospective real-world study.
First Author: Haolei Tan
- Board 476 **Abstract 6068:** Functional and survival outcomes in HPV positive oropharyngeal squamous cell cancer treated with response-adaptive de-escalation: A pooled analysis.
First Author: Faith Abodunrin, MD
- Board 477 **Abstract 6069:** Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study.
First Author: Zhigong Wei, MD
- Board 478 **Abstract 6070:** Induction pembrolizumab plus cisplatin and 5-FU chemotherapy followed by chemoradiotherapy in locally advanced squamous cell cancer of oropharynx, hypopharynx or larynx: Results of multicenter prospective phase II study.
First Author: Ilya Pokataev, MD
- Board 479 **Abstract 6071:** Primary results from IChoice-02, a phase 2 trial of induction chemoimmunotherapy followed by response-adapted de-escalation of chemoradiation in HPV-associated oropharyngeal cancer.
First Author: Xueguan Lu, MD
- Board 480 **Abstract 6072:** Preoperative steroid for enhancing patients' recovery after head and neck cancer surgery with free tissue transfer reconstruction: Phase III, placebo-controlled, randomized, double-blind study (J-SUPPORT 2022, PreSte-HN Study).
First Author: Kohtaro Eguchi, MD, PhD

- Board 481 **Abstract 6073:** Association of AI-informed biomarkers of spatial organization of tumor-infiltrating lymphocytes with loco-regional recurrence in laryngeal squamous cell cancer. First Author: Sahil Hasit Patel, BS
- Board 482 **Abstract 6074:** Decision analysis of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). First Author: Xiaohong Chen
- Board 483 **Abstract 6075:** Efficacy and safety of Sapylin versus dexamethasone atomized inhalation for CCRT-induced oral mucositis in patients with nasopharyngeal carcinoma: A randomized, parallel design, and non-inferiority clinical trial. First Author: Haiqing Luo, MD
- Board 484 **Abstract 6076:** Use of early EBV DNA clearance to select optimal induction chemotherapy cycles for locoregional advanced nasopharyngeal carcinoma. First Author: Wanping Guo, MD
- Board 485 **Abstract 6077:** Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial. First Author: Kai Hu
- Board 486 **Abstract 6078:** Radiotherapy plus nimotuzumab versus cisplatin in low-risk locoregionally advanced nasopharyngeal carcinoma who had favorable response to induction chemotherapy: A randomised, phase III, non-inferiority trial. First Author: Hai-Qiang Mai, MD, PhD
- Board 487 **Abstract 6079:** 5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial. First Author: Edward S. Sim, MD
- Board 488 **Abstract 6080:** AI-based classification of laryngeal dysplasia and lymphocytic activity quantification from routine histology. First Author: Adam Shephard, PhD
- Board 489 **Abstract 6081:** Examining age-specific trends in the incidence of human papillomavirus-associated oropharyngeal cancer in the United States. First Author: Joshua Elbridge Chan, BS, MS
- Board 490 **Abstract 6082:** AI-driven reflectance confocal microscopy for noninvasive diagnosis and accurate surgical margin assessment intra-operatively in oral cavity squamous cell carcinoma. First Author: Farideh Hosseinzadeh
- Board 491 **Abstract 6083:** Artificial intelligence-powered real-time model for predicting recurrence and survival in head and neck squamous cell carcinoma after curative intent surgery. First Author: Hyun Ae Jung, MD
- Board 492 **Abstract 6084:** Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma. First Author: Richard Bryan Bell, MD
- Board 493 **Abstract 6085:** Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma. First Author: Yuting Wang
- Board 494 **Abstract 6086:** The use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin based chemoradiation: Landmark 3-year survival analysis of a randomized phase III trial (DHANUSH). First Author: Sneha Dhar, DM
- Board 495 **Abstract 6087:** Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial. First Author: Marilene Beth Wang, MD
- Board 496 **Abstract 6088:** Induction chemotherapy (IC) followed by concomitant radiotherapy and weekly cisplatin (CCRT) versus CCRT alone in patients with locally advanced (LA) nasopharyngeal carcinoma (NPC): Twenty-year follow-up of a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. First Author: Amanda Psyrris, MD
- Board 497 **Abstract 6089:** Transoral robotic surgery (TORS) and de-escalated adjuvant therapy for human papillomavirus-related oropharyngeal carcinoma (HPVOPC): Long-term follow up of the Sinai Robotic Surgery (SIRS) trial (NCT02072148). First Author: Marshall R. Posner, MD
- Board 498 **Abstract 6090:** Which systemic regimen to choose in cisplatin-ineligible patients with concurrent radiation therapy for head and neck cancers: carboplatin/5-fluorouracil or carboplatin/paclitaxel? First Author: Parth J. Sampat, MBBS
- Board 499 **Abstract 6091:** Circulating tumor HPV-DNA dynamics and neoadjuvant chemotherapy with or without nivolumab in viral-mediated oropharyngeal cancer. First Author: Maha A.T. Elsebaie, MD, MSc
- Board 500 **Abstract 6092:** Evolving beyond the “unknown primary”: Investigating histopathology after diagnostic transoral robotic surgery for microscopic HPV-associated oropharyngeal carcinoma. First Author: Nikita Bedi
- Board 501 **Abstract 6093:** Dabrafenib and trametinib in the treatment of BRAF-mutated anaplastic thyroid cancers (ATC). First Author: Irini Yacoub
- Board 502 **Abstract 6094:** Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis. First Author: Marcia S. Brose, MD, PhD, FASCO
- Board 503 **Abstract 6095:** Comparative transcriptomic analysis to identify similarities and therapeutic vulnerabilities in olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC). First Author: Elisabetta Xue, MD

- Board 504 **Abstract 6096:** Efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced differentiated thyroid cancer (DTC): A multicenter, single-arm, phase II study.
First Author: Dapeng Li, MD
- Board 505 **Abstract 6097:** Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti-PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
First Author: Dongchen Sun
- Board 506 **Abstract 6098:** Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer.
First Author: Xiangqian Zheng
- Board 507 **Abstract 6099:** BRAF-V600E papillary thyroid cancer: Updated analysis of real-world patient data.
First Author: Martina Chirra, MD
- Board 508 **Abstract 6100:** Anti-TROP2 ADC ESG401 in a master protocol clinical trial for salivary gland cancer based on molecular typing.
First Author: Xiaojuan Zheng
- Board 509 **Abstract 6101:** Amivantamab for recurrent/metastatic adenoid cystic carcinoma: A multicenter, single-arm, phase 2 clinical trial.
First Author: Olga Zamulko, MD
- Board 510 **Abstract 6102:** A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors.
First Author: Ye Guo, MD
- Board 511 **Abstract 6103:** A phase II study of lenvatinib plus pembrolizumab in patients with recurrent/metastatic salivary gland cancers.
First Author: Alan Loh Ho, MD, PhD
- Board 512 **Abstract 6104:** Trop2-targeted PET/CT with ⁶⁸Ga-MY6349 for detecting metastatic lesions in metastatic thyroid cancer: Prospective comparison of diagnostic accuracy with ¹⁸F-FDG PET/CT.
First Author: Hao Fu
- Board 513 **Abstract 6105:** Dual immune checkpoint inhibition in advanced incurable radiiodine-refractory differentiated thyroid carcinoma (RAIR DTC), anaplastic (ATC), and medullary thyroid carcinoma (MTC): Long-term survival results from phase II clinical trial.
First Author: Kartik Sehgal, MD
- Board 514 **Abstract 6106:** A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.
First Author: Katharine Andress Rowe Price, MD
- Board 515 **Abstract 6107:** A multisite randomized trial of an advanced pneumatic compression device vs usual care for head and neck cancer related lymphedema: Short-term results.
First Author: Barbara Murphy, MD
- Board 516 **Abstract 6108:** Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series.
First Author: Mateus Trinconi Cunha, MD
- Board 517a **Abstract TPS6109:** HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥ 20 .
First Author: Jong Chul Park, MD
- Board 517b **Abstract TPS6110:** A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
First Author: Robin Park, MD
- Board 518a **Abstract TPS6111:** VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Katharine Andress Rowe Price, MD
- Board 518b **Abstract TPS6112:** A phase 2 study of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression.
First Author: Danny Rischin, MD
- Board 519a **Abstract TPS6113:** A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.
First Author: Renata Ferrarotto, MD
- Board 519b **Abstract TPS6114:** A phase II study of AK117 combined with cetuximab or AK104 in the treatment of recurrent or metastatic head and neck squamous cell carcinoma after the failure of PD-1 (L1) inhibitors and/or platinum-based therapy.
First Author: Jun Wang
- Board 520a **Abstract TPS6115:** FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman, MD, MPH
- Board 520b **Abstract TPS6116:** Reduction of postoperative radiotherapy in head and neck squamous cell carcinoma: A single-arm, phase II trial (REPORT-HNSCC study).
First Author: Chunyan Chen, PhD
- Board 521a **Abstract TPS6117:** Phase II trial of neoadjuvant chemotherapy (NAC) docetaxel-cisplatin alone (DC) or with anti-human papillomavirus (HPV) gene therapy PRGN-2009 (DCP) followed by surgery in patients (pts) with newly diagnosed HPV-associated oropharyngeal cancer (HPV-OPC).
First Author: Charalampos S. Floudas, MD, DMSc, MS

- Board 521b **Abstract TPS6118:** A phase III randomized controlled trial comparing palliative stereotactic body radiotherapy vs. palliative standard radiotherapy in patients with advanced head and neck cancer (NCT06641791).
First Author: Ian Poon
- Board 522a **Abstract TPS6119:** TRENT-002: A prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of salvage preoperative PD-1 inhibitor combined with chemotherapy neoadjuvant therapy in recurrent laryngeal/hypopharyngeal squamous cell carcinoma (L/HPSCC).
First Author: Xiaohong Chen
- Board 522b **Abstract TPS6120:** A phase II randomized trial of nano-crystalline megestrol acetate for nutritional improvement in postoperative head and neck squamous cell carcinoma undergoing radiotherapy.
First Author: Lei Liu, MD, PhD
- Board 523a **Abstract TPS6121:** A phase 2 clinical trial of preoperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab in resectable locoregionally recurrent head and neck squamous cell carcinoma.
First Author: Kartik Sehgal, MD
- Board 523b **Abstract TPS6122:** A phase 3 randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in locoregional recurrent head and neck squamous cell carcinoma (HNSCC).
First Author: Anastasios Maniakas, MD, PhD
- Board 524a **Abstract TPS6123:** RIBBON-UM: Treatment individualisation by EBV stratification in nasopharyngeal carcinoma (NPC): A phase 2, multi-arm umbrella platform trial.
First Author: Melvin L.K. Chua, PhD, FRCR, MBBS, FASCO
- Board 524b **Abstract TPS6124:** A phase 2 clinical trial of adjuvant ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive salivary gland cancer.
First Author: Glenn J. Hanna, MD

9:45 AM-10:30 AM Award Lecture

The Long Road to Breast Cancer Risk and Genetics-Informed Precision Prevention

Location: S100bc

Fergus Couch, PhD—Chair
Mayo Clinic

Susan M. Domchek, MD, FASCO
Abramson Cancer Center, Penn Medicine
Award Recipient

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Multicancer Early Detection Testing: Are There Cures Without Costs?

Location: S102

Jennifer Keating Litton, MD
The University of Texas MD Anderson Cancer Center
Multicancer Early Detection Research: Which Endpoints Will Justify Widespread Adoption?

A. Mark Fendrick, MD

School of Public Health, University of Michigan
Unintended Consequences of Multicancer Early Detection: The Population Health and Value Perspective

Carmen Guerra, MD, MSCE, FACP—Chair

Perelman School of Medicine, University of Pennsylvania
What Should You Say When Your Patient Asks for the Test?

Panel Question and Answer

9:45 AM-11:00 AM Education Session

New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes

Location: E450b

Valeria Santini, MD, PhD—Chair

Azienda Ospedaliero Universitaria Careggi, University of Florence
Which Novel Treatment Should I Use in Low- and Intermediate-Risk Myelodysplastic Syndromes?

Christine McMahon, MD

University of Colorado School of Medicine
Role of Molecular Testing in Low- and Intermediate-Risk Myelodysplastic Syndromes

Sanjay Ram Mohan, MD

Vanderbilt University
How Do IPSS-R and IPSS-M Affect Treatment Decisions?

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Providing Equitable Cancer Care When Health Care Provision Is Under Threat: Lessons From Sexual Minority Women and Transgender People

Location: S402

Shail Maingi, MD, FASCO—Chair

Dana-Farber Brigham Cancer Center at South Shore Health
Invisible Patients Heard: Barriers to Quality Cancer Care for Sexual Minority Women

Gabrielle Mayer

NYU Langone Health
Inclusive Comprehensive Cancer Care: Fertility Preservation Access, Reproductive Rights, and Sexual Health for Sexual Minority Women

Alison May Berner, PhD, MBBS, MRCP, MSc

Barts Cancer Institute, Queen Mary University of London
Incorporating Best Practices Into Cancer Screening for Sexual and Gender Minorities

Tristan Michael MacKenzie

University of Edinburgh
Isolated in a Sea of Pink: A Transgender Man's Journey Through Breast Cancer Care

Panel Question and Answer

9:45 AM-11:00 AM Education Session

State-of-the-Art Updates in Colorectal Cancer

Location: Hall D2

Anita Turk, MD—Chair

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Advances in Biomarker-Based Management of Metastatic Colorectal Cancer

Sebastian Mondaca, MD
Pontificia Universidad Católica de Chile
Neoadjuvant Management of Colon and Rectal Cancer

Andreana Natalie Holowatyj, PhD, MSCI
Vanderbilt University Medical Center
State of Knowledge on Young-Onset Colorectal Cancer

Panel Question and Answer

9:45 AM-11:00 AM Education Session

Where Are We: Liquid Biopsy and ctDNA for Biomarker-Driven Therapies for Cancer Detection and Treatment
Location: S406

Valsamo Anagnostou, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Precision Medicine and Liquid Biopsy for Cancer Drug Development

Heather A. Wakelee, MD, FASCO
Stanford Hospital & Clinics
ctDNA and Liquid Biopsies for Early and Advanced Lung Cancer

Janice M. Lu, MD, PhD—Chair
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Liquid Biopsy-Guided Therapy for Metastatic Breast Cancer

Christos Vakilavas, MD
Huntsman Cancer Institute at the University of Utah
Novel Clinical Applications of ctDNA Testing

Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

ADC 2.0: Discovering the Targets That Will Change the Game
Location: Hall D1

Jayesh Desai, FRACP, MBBS—Chair
Peter MacCallum Cancer Centre and the University of Melbourne

9:45 AM Patricia LoRusso, PhD, DO, FASCO
Yale Cancer Center
Unlocking the Power of Antibody-Drug Conjugates: From Promise to Practice and Beyond

9:57 AM Jamie LaScala, BS
Are Antibody-Drug Conjugates as Easy as ABC? A Patient Perspective

10:09 AM Abstract 105: Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)—targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.
First Author: Alissa Jamie Cooper, MD

10:21 AM Abstract 106: Phase 1 study of SHR-1826, a c-MET-directed antibody-drug-conjugate (ADC), in advanced solid tumors.
First Author: Yang Zhang, MD

10:33 AM Abstract 107: Phase 1 trial of SHR-A2102, a nectin-4-directed antibody drug conjugate (ADC), in advanced solid tumors.
First Author: Runbo Zhong, MD

10:45 AM Veronique C. Dieras, MD
Eugene Marquis
Discussion of Abstract(s) 105-107: Antibody-Drug Conjugate Targets for Tomorrow

10:57 AM Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Medical Education and Professional Development
Location: E350

Maria Quintos Baggstrom, MD, FACP, FASCO—Chair
Washington University School of Medicine

Raymond Couric Wadlow, MD—Chair
Inova Fairfax Medical Campus

9:45 AM Abstract 9003: Research productivity of international medical graduate (IMG) hematology and oncology fellows in the United States (US).
First Author: Arya Mariam Roy, MD

9:51 AM Abstract 9004: International medical graduates (IMGs) in leadership roles within academic oncology in the United States (US).
First Author: Shipra Gandhi, MD, MS

9:57 AM Abstract 9005: Burnout, professional fulfillment, and associated factors in academic oncology physicians.
First Author: Jennifer A. Ligibel, MD

10:03 AM Panel Question and Answer

10:15 AM Abstract 9006: Who's on the podium? Geographic and career diversity of ASCO Annual Meeting presenters.
First Author: Aysche Stern, MD

10:21 AM Abstract 9007: Board certification and billing practices of international medical graduate hematologists and oncologists.
First Author: Austin Wesevich, MD, MS, MPH

10:27 AM Abstract 9008: Recognizing international medical graduates: Awards and committee membership in ASCO.
First Author: Karun Neupane, MD

10:33 AM Panel Question and Answer

10:45 AM Abstract 9009: Career transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis.
First Author: Jiazhang Xing, MD

10:51 AM Abstract 9010: Productivity of National Cancer Institute K Awardees and their transition to independent funding.
First Author: Mariah Malak Bilalaga, MBBS

10:57 AM Abstract 9011: Trends in racial and gender diversity among adult hemato-oncology trainees over last decade and impact of Covid.
First Author: Ohm Tripathi, BS

11:03 AM Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Melanoma/Skin Cancers
Location: E451

Ravi K. Amaravadi, MD—Chair
University of Pennsylvania

Thach-Giao Truong, MD—Chair
Cleveland Clinic

- 9:45 AM Abstract 9509:** A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.
First Author: Matteo S. Carlino, MBBS, PhD, FRACP
- 9:51 AM Abstract 9510:** A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.
First Author: Janice M. Mehnert, MD
- 9:57 AM Abstract 9511:** Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).
First Author: Yufan Qiu, MD, PhD
- 10:03 AM** Panel Question and Answer
- 10:15 AM Abstract 9512:** Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.
First Author: Lili Mao, MD
- 10:21 AM Abstract 9513:** Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
First Author: Sarah E. Lochrin, MBBSCh
- 10:27 AM Abstract 9514:** A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
First Author: Andrew Scott Brohl, MD
- 10:33 AM** Panel Question and Answer
- 10:45 AM Abstract 9515:** Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
First Author: Theresa Medina, MD
- 10:51 AM Abstract 9516:** Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM).
First Author: Lilit Karapetyan, MD, MSc
- 10:57 AM Abstract 9517:** OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)—resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
First Author: Jason Alan Chesney, MD, PhD
- 11:03 AM** Panel Question and Answer

9:45 AM-11:15 AM Rapid Oral Abstract Session

Symptom Science and Palliative Care

Location: E450a

Nicole Lynn Stout, DPT—Chair
West Virginia University Cancer Institute

Rajiv Agarwal, MD—Chair
Vanderbilt University Medical Center

- 9:45 AM Abstract 12009:** A randomized controlled trial of cognitive behavioral therapy and bright light therapy for insomnia and fatigue during breast cancer treatment: SleepCaRe trial.
First Author: Joshua F. Wiley, PhD
- 9:51 AM Abstract 12010:** Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)—A randomized, double-blind, placebo-controlled phase II study.
First Author: Ellen M. Lavoie Smith, PhD
- 9:57 AM Abstract 12011:** Peri-transplant supportive and palliative care and/or comorbidity management for older, medically infirm, and/or frail recipients of allogeneic hematopoietic cell transplantation (Allo-HCT): Phase II and interim phase III trial analyses.
First Author: Elizabeth Trice Loggers, MD, PhD
- 10:03 AM** Panel Question and Answer
- 10:15 AM Abstract 12012:** Efficacy of treatment with traditional Chinese medicine (Renshen Yangrong Tang granules) for cancer-related fatigue in patients with platinum-based chemotherapy: A randomized, double-blinded, placebo-controlled, multicenter trial.
First Author: Yichen Xu
- 10:21 AM Abstract 12013:** Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC): A randomized clinical trial.
First Author: Christopher Manz, MD, MS
- 10:27 AM Abstract 12014:** Trajectories of patient-reported cognitive function and age-related conditions in a longitudinal observational trial of immune checkpoint inhibitor (ICI) treatment: The DiRECT Cohort.
First Author: Charles Stewart Kamen, PhD, MPH
- 10:33 AM** Panel Question and Answer
- 10:45 AM Abstract 12015:** Severe sarcopenia and symptom burden prior to chemotherapy among older adults (70+) with advanced cancer: A URCC NCORP nationwide study.
First Author: Lindsey Jean Mattick, PhD
- 10:51 AM Abstract 12016:** Effect of incorporating symptom burden with mortality as a composite outcome on accuracy and bias in palliative care identification algorithms in oncology.
First Author: Sophia Shi
- 10:57 AM Abstract 12017:** Precision-calibrated LightGBM machine learning model to predict serious adverse events in oncology patients using FAERS.
First Author: Xiyu Zhao, BS
- 11:03 AM** Panel Question and Answer

11:30 AM-12:45 PM Education Session

Bispecific and Multispecific Antibodies in Hemato-Oncology

Location: S406

Giuseppe Curigliano, MD, PhD—Chair
European Institute of Oncology, IRCCS and University of Milano
Bispecific Antibodies for Dual Receptor Inhibition

Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital
Bispecific Antibodies for Cancer Immunotherapy

Funda Meric-Bernstam, MD, FASCO

The University of Texas MD Anderson Cancer Center
Bispecifics Plus Tyrosine Kinase Inhibition in Combination Strategy

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening on a Global Scale

Location: Arie Crown Theater

Navneet Singh, MD, FRCP, DM, FASCO

Postgraduate Institute of Medical Education and Research
Thinking Globally: Challenges to Implementation of Screening for Lung Cancer in Resource-Limited Settings

Nasser H. Hanna, MD, FASCO

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
End Lung Cancer Now: How to Engage Your Community to Promote Cancer Screening

Florian J. Fintelmann, MD

Massachusetts General Hospital
Needle in the Haystack: Precision Screening for Lung Cancer and Role of Artificial Intelligence

Cheryl M. Czerlanis, MD—Chair

University of Wisconsin Carbone Cancer Center
Widen the Net: Screening for Individuals with Family History and Germline Genetic Alterations

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Changes in Upfront Therapy in Hematologic Malignancies

Location: E450b

Tara L. Lin, MD, MS—Chair

University of Kansas Cancer Center
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia?

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center
Treatment Options for Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Armin Ghobadi, MD

Washington University School of Medicine
Should Bispecifics or CAR T Be Included in Upfront Lymphoma Therapy?

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Let's Talk About Sex: Enhancing Sexual Health for Cancer Survivors Across the Lifespan

Location: E450a

Liz O'Riordan, MD, PhD, FRCS

Royal Marsden Hospital
Patient Perspective on Sexual Health: What I Wish I Knew

Laila Agrawal, MD—Chair

Norton Cancer Institute
Personalized Approach to Sexual Health Assessment for Cancer Survivors

Lawrence Jenkins, MD, FACS, MBA

Tulane University
Addressing Sexual Health and Intimacy Among Older Adults With Cancer

Panel Question and Answer

11:30 AM-12:45 PM Education Session

Leveling Up: Harnessing Cutting-Edge Technology to Enhance Oncology Education and Learning

Location: E350

Caroline Chung, MD, FRCPC

The University of Texas MD Anderson Cancer Center
Artificial Intelligence Empowering Cancer Knowledge: What's Here and What's Coming Soon

Traci Wolbrink, MD, MPH

Boston Children's Hospital
Game On: Motivating Oncology Learning With Data-Driven Gamification

Eleonora Teplinsky, MD—Chair

Valley Health System
Oncology Medical Education in the Era of Digital Media

Panel Question and Answer

11:30 AM-12:45 PM Education Session

State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers

Location: S102

Kathleen N. Moore, MD, MS, FASCO—Chair

Stephenson Cancer Center, Oklahoma University Health
New Targets and New Opportunities in Ovarian Cancer

Joyce F. Liu, MD

Dana-Farber Cancer Institute
Antibody-Drug Conjugates, Immunotherapy, and the Future of Endometrial Cancer Treatment

Domenica Lorusso, MD, PhD

Fondazione Policlinico Universitario a Gemelli IRCCS, and Humanitas San Pio X
New Advances in Cervical Cancer

Panel Question and Answer

11:30 AM-1:00 PM Rapid Oral Abstract Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall D2

Rohan Reddy Katipally, MD—Chair

The University of Chicago, Radiation Oncology

Vanessa Wookey, MD, MD—Chair

Fox Chase Cancer Center

11:30 AM Abstract LBA4012: Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer. First Author: Lin Shen, MD

- 11:36 AM Abstract 4013:** Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.
First Author: Elena Elimova, MD
- 11:42 AM Abstract 4014:** Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.
First Author: Jens Hoepfner, MD, FACHirg
- 11:48 AM** Panel Question and Answer
- 12:00 PM Abstract 4015:** Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.
First Author: Haoxin Peng, PhD
- 12:06 PM Abstract 4016:** Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician's choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase III, randomized, open-label, multicenter trial.
First Author: Jun Zhou, MD, PhD
- 12:12 PM Abstract 4017:** Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.
First Author: Xianjun Yu
- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 4018:** Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
First Author: Robert William Lentz, MD
- 12:36 PM Abstract 4019:** 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.
First Author: Katherine M. Bever, MD
- 12:42 PM Abstract 4020:** Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
First Author: Amylou C. Dueck, PhD
- 12:48 PM** Panel Question and Answer

11:30 AM-1:00 PM Rapid Oral Abstract Session

Sarcoma

Location: S504

Kristen N. Ganjoo, MD—Chair
Stanford Cancer Center

Bruna Bianca Lopes David, MD—Chair
Brazilian National Cancer Institute

- 11:30 AM Abstract 11509:** Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study).
First Author: Jingnan Shen, PhD
- 11:36 AM Abstract 11510:** Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R/DDR2/VEGFR2, in relapsed or refractory osteosarcoma.
First Author: Feng Ye
- 11:42 AM Abstract 11511:** Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS).
First Author: Changsu Lawrence Park, MD
- 11:48 AM** Panel Question and Answer
- 12:00 PM Abstract 11512:** A clinical and genomic landscape analysis of GI stromal tumors.
First Author: Nadeem Bilani, MD
- 12:06 PM Abstract 11513:** Phase II of sunitinib plus nivolumab in extraskelatal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study.
First Author: Nadia Hindi, MD
- 12:12 PM Abstract 11514:** ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS).
First Author: Javier Martin Broto, MD, PhD
- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 11515:** A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713).
First Author: Jason Ballon, BS
- 12:36 PM Abstract 11516:** Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.
First Author: Rashmi Chugh, MD
- 12:42 PM Abstract 11517:** The broad-spectrum KIT inhibitor NB003 and activity in advanced gastrointestinal stromal tumors (GIST): Updated results from a phase 1 study (NCT04936178).
First Author: Ping Chi, MD, PhD
- 12:48 PM** Panel Question and Answer

11:30 AM-2:30 PM Oral Abstract Session

Prevention, Risk Reduction, and Genetics

Location: S100a

Andrea De Censi, MD—Chair
E.O. Ospedali Galliera

Abenaa M. Brewster, MD, MHS, FASCO—Chair
The University of Texas MD Anderson Cancer Center

- 11:30 AM Abstract 10500:** Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.
First Author: Asaf Maoz, MD

- 11:42 AM Abstract 10501:** A prospective study of whole-body MRI (WBMRI) as part of a multimodality screening program for individuals with Li-Fraumeni syndrome (LFS).
First Author: Asaf Maoz, MD
- 11:54 AM Abstract 10502:** The eREACH study: A randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers.
First Author: Angela R. Bradbury, MD
- 12:06 PM Suzette Delaloge, MD, MSc**
Gustave Roussy
Discussion of Abstract(s) 10500-10502: Finding the Unseen: Opportunities for Early Detection
- 12:18 PM** Panel Question and Answer
- 12:30 PM Abstract 10503:** Feasibility of Pap-derived ctDNA for detection of sporadic and Lynch-associated endometrial cancer.
First Author: Alicia Latham, MD, MS
- 12:42 PM Abstract 10504:** Gene-specific outcomes in patients with Lynch syndrome treated by immune checkpoint blockade for advanced cancer.
First Author: Violaine Randrian
- 12:54 PM Abstract 10505:** Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations.
First Author: Susan M. Domchek, MD, FASCO
- 1:06 PM Karen Anne Cadoo, MD**
St James's Hospital & Trinity College Dublin
Discussion of Abstract(s) 10503-10505: Taking It Forward: Novel Avenues to Mitigate Genetic Risk
- 1:18 PM** Panel Question and Answer
- 1:30 PM Abstract 10506:** Menopausal hormone therapy after a diagnosis of breast cancer in women with a BRCA pathogenic variant and risk of death.
First Author: Joanne Kotsopoulos, PhD
- 1:42 PM Abstract 10507:** Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.
First Author: Lucas A. Mavromatis
- 1:54 PM Abstract 10508:** Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.
First Author: Hao Dai, PhD
- 2:06 PM Neil M. Iyengar, MD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 10506-10508: Targeting Modifiable Risks Using Pharmacologic Approaches
- 2:18 PM** Panel Question and Answer

12:00 PM-1:00 PM Annual Business Meeting

ASCO Annual Business Meeting (ASCO Members Only)

Location: S103

1:15 PM-2:15 PM Case-Based Panel

Cancer Predisposition in Pediatric Oncology: When, What, and How?

Location: S504

Chris Porter, MD—Chair

Emory University School of Medicine

Moderator

Kris Ann Pinekenstein Schultz, MD

Children's Hospital & Clinics Minnesota

Oncologist Perspective

Douglas Stewart, MD

National Cancer Institute

Genetics Perspective

Kelly Goddard, RN

National Pediatric Cancer Foundation

Parent/Patient Perspective

Panel Question and Answer

1:15 PM-2:15 PM Case-Based Panel

Navigating Emerging Therapeutic Decisions in the Treatment of Small Cell Lung Cancer: Cases and Considerations

Location: Arie Crown Theater

Sonam Puri, MD—Chair

Moffitt Cancer Center

Moderator

Kevin Lee Min Chua, MBBS, FRCR

National Cancer Centre Singapore

Radiation Oncologist Perspective

Misty Dawn Shields, MD, PhD

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Medical Oncologist Perspective

Raid Aljumaily, MD

Stephenson Cancer Center at The University of Oklahoma Health Sciences Center

Medical Oncologist Perspective

Panel Question and Answer

1:15 PM-2:15 PM Case-Based Panel

Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: What Can We Agree On?

Location: E450a

Alexander M. Menzies, PhD, FRACP, MBBS—Chair

Melanoma Institute Australia

Moderator

Genevieve Marie Boland, MD, PhD

Massachusetts General Hospital

Surgical Oncologist Perspective

Diwakar Davar, MSc, MBBS

UPMC Hillman Cancer Center

Medical Oncologist Perspective

Janis M. Taube, MD

Johns Hopkins University

Pathologist Perspective

Panel Question and Answer

1:15 PM-2:30 PM Education Session

ASCO/ESMO Joint Session: Biomarker-Driven Therapeutics: Translating Innovation Into Practice

Location: S102

Robin Zon, MD, FACP, FASCO—Chair

Cincinnati Cancer Advisors

Welcome and Introductory Remarks From ASCO President

Fabrice Andre, MD, PhD—Chair

Gustave Roussy, INSERM U981, Université Paris-Saclay, IHU-

National PRéclSion Medicine Center in Oncology

Welcome and Introductory Remarks From ESMO President

Benedikt Westphalen, MD

University of Munich

State of the Art: Using Precision Oncology to Guide Care

Arturo Loaiza-Bonilla, MD, FACP, MEd

St. Luke's University Health Network

Advancing Cancer Research and Patient-Centric Pre-Screening

Hubs—Leveraging Digital Technologies

Julie R. Gralow, MD, FACP, FASCO

ASCO

Regulatory Sandboxes: How to Synchronize Safe, Timely

Regulation With Scientific Breakthroughs in Molecular “Niches”

Teresa Amaral, MD, PhD

Skin Cancer Center, Eberhard Karls University of Tübingen

Friendly Partnering of Clinical Trials for Doctors and Patients

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Is Less More? Maximizing Outcomes by Tailoring Treatments to Patients: Oncofertility and Oncomenopause

Location: S100bc

Janice S. Kwon, MD, MPH—Chair

University of British Columbia

A Cut Above: Better Surgery, Better Outcomes

Martha Hickey

Royal Women's Hospital/University of Melbourne

Managing Menopause After Gynecologic Cancer: A

Multidisciplinary Model of Care

Terri Lynn Woodard, MD

The University of Texas MD Anderson Cancer Center

State-of-the-Art Options for Fertility

Joyce Dillon Reinecke, JD

Alliance for Fertility Preservation

Perspectives From a Patient

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Precursors of Hematologic Malignancies: When to Watch and When to Treat

Location: E450b

Omar Nadeem, MD—Chair

Dana-Farber Cancer Institute

Monoclonal Gammopathy of Undetermined Significance to

Multiple Myeloma

Pinkal M. Desai, MD

Weill Medical College of Cornell University/The New York

Presbyterian Hospital

Clonal Hematopoiesis of Indeterminate Potential to Acute Myeloid Leukemia

Jennifer Ann Woyach, MD

The Ohio State University Comprehensive Cancer Center

Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic

Leukemia

Panel Question and Answer

1:15 PM-2:30 PM Education Session

Refining Treatment for Patients With Metastatic Germ-Cell Tumors

Location: Hall D1

Aditya Bagrodia, MD—Chair

UC San Diego Moores Cancer Center

Contemporary Management of Stage II Seminoma

Lawrence H. Einhorn, MD, FASCO

Indiana University Melvin and Bren Simon Comprehensive

Cancer Center

Pitfalls in the Management Metastatic Germ-Cell Tumors

Lucia Nappi, MD, PhD, FRCPC

British Columbia Cancer Agency

Management of Postchemotherapy Residual Masses in

Metastatic Germ Cell Tumors

Hege Sagstuen Haugnes, MD, PhD

University Hospital of North Norway

Survivorship After Germ-Cell Tumor and Health

Panel Question and Answer

1:30 PM-4:30 PM Poster Session

Developmental Therapeutics—Immunotherapy

Location: Hall A - Posters and Exhibits

Posters by Topic

Antibodies: Board(s) 168-178, 315a-317a

Cellular Immunotherapy: Board(s) 179-190, 317b-322a

Circulating Biomarkers: Board(s) 192, 194-212

Immunobiology: Board(s) 213-216

New Targets and New Technologies (IO): Board(s) 217-240,

322b-325a

PD1/PD-L1 Inhibitor Monotherapy: Board(s) 241-250,

325b-326a

PD1/PD-L1 Inhibitor Combinations: Board(s) 251-267,

326b-329b

Tissue-Based Biomarkers: Board(s) 268-284

Vaccines: Board(s) 285-287, 330a-330b

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or

Combination): Board(s) 288-289

Other IO-Related Topics: Board(s) 290-314, 331a-332b

Board 168 **Abstract 2521:** Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis. First Author: Ecaterina Elena Dumbrava, MD

Board 169 **Abstract 2522:** Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial. First Author: Pierluigi Porcu, MD

- Board 170 **Abstract 2523:** Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial.
First Author: Pierluigi Porcu, MD
- Board 171 **Abstract 2524:** Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study.
First Author: Shiraj Sen, MD, PhD
- Board 172 **Abstract 2525:** A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC.
First Author: Min Hee Hong, MD
- Board 173 **Abstract 2526:** Phase 1b dose extension study of a next-generation anti-CD47 monoclonal antibody IMC-002 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC).
First Author: Jung Yong Hong, MD, PhD
- Board 174 **Abstract 2527:** Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.
First Author: Yakun Wang, PhD
- Board 175 **Abstract 2528:** Epigenetic and phenotypic signatures of T-cell response to blinatumomab in pediatric relapsed and refractory B-ALL.
First Author: Tyler G. Bruno, BA
- Board 176 **Abstract 2529:** PD-1 blockade in combination with bevacizumab and nab-paclitaxel for second-line treatment in cancer of unknown primary (Fudan CUP-002): A prospective, single-arm phase II study.
First Author: Zhiguo Luo
- Board 177 **Abstract 2530:** Comprehensive analysis of NSAIDs use and oncological outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
First Author: Yanlin Li, MD
- Board 178 **Abstract 2531:** Preliminary monotherapy efficacy of novel immune checkpoint blockade GV20-0251 (anti-IGSF8) in advanced melanoma patients with primary resistance to anti-PD1.
First Author: Kristopher Wentzel, MD
- Board 179 **Abstract 2532:** Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.
First Author: Xiaoyu Zhu
- Board 180 **Abstract 2533:** Targeting cancer leptomeningeal metastasis with allogeneic chimeric antigen receptor $\gamma\delta$ T-cell therapy.
First Author: Peiwen Ma, MD
- Board 181 **Abstract 2534:** Safety and efficacy of non-viral aPD1-MSLN JL-lightning-CAR-T in advanced malignant mesothelioma in a phase I trial.
First Author: Yan Sun
- Board 182 **Abstract 2535:** Phase I trial of personalized AI-identified TCR-transduced T cell therapy in advanced solid tumors.
First Author: Shuhang Wang, MD, PhD
- Board 183 **Abstract 2536:** Artificial intelligence (XGBoost) in predicting outcomes among CAR-T therapy patients: The impact of malnutrition and comorbidities using the National Inpatient Sample (2020-2022).
First Author: Tong Ren, MD, PhD
- Board 184 **Abstract 2537:** A novel cellular immunotherapy using vaccine generated neoantigen-specific effector T cells.
First Author: Andrew Edward Sloan, MD, FACS
- Board 185 **Abstract 2538:** Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a "cold" ovarian tumor model.
First Author: Sandeep Singh
- Board 186 **Abstract 2539:** Universal solid tumor therapy with CD5-deleted, DSG2-directed CAR-T cells.
First Author: Robert D. Carlson, PhD
- Board 187 **Abstract 2540:** Mayhem under the microscope: T cell cytotoxicity and serial killers captured in situ.
First Author: Greg Sawyer, PhD
- Board 188 **Abstract 2541:** Impact of stromal-targeting antitumor CAR T cells in solid tumors.
First Author: Abdul Khan
- Board 189 **Abstract 2542:** Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer.
First Author: Tara Elisabeth Seery, MD
- Board 190 **Abstract 2543:** Predictors and clinical outcomes of CMV reactivation in CAR-T therapy: A systematic review.
First Author: Faiza Humayun Khan
- Board 192 **Abstract 2545:** Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab.
First Author: Enrique Sanz Garcia, MD, PhD
- Board 194 **Abstract 2547:** Personalized tumor-informed circulating tumor DNA as predictor of progression risk after long-term responses to immunotherapy in advanced non-small-cell lung cancer.
First Author: Fang Wu, MD
- Board 195 **Abstract 2548:** Novel dynamic circulating biomarkers for predicting therapeutic efficacy of PRaG regimen in advanced refractory solid tumors.
First Author: Yuehong Kong
- Board 196 **Abstract 2549:** An exploratory study to predict the efficacy and prognosis of immunotherapy for extensive-stage small cell lung cancer based on peripheral blood dynamic immune profiles.
First Author: Lin Wu, MD
- Board 197 **Abstract 2550:** Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer.
First Author: Blair V. Landon, BS

- Board 198 **Abstract 2551:** Plasma extracellular vesicles as biomarkers of primary versus acquired resistance to immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors.
First Author: Scott Strum, MD, MSc, FRCPC
- Board 199 **Abstract 2552:** Precision medicine research on chemo-immunotherapy combination treatment for locally advanced or metastatic non-small cell lung cancer based on deep plasma proteomics.
First Author: Qiuchi Chen, PhD
- Board 200 **Abstract 2553:** T-cell exhaustion and pre-existing T-cell immunity in circulation as predictive biomarkers for immunotherapy in NSCLC patients.
First Author: Anastasia Xagara, PhD
- Board 201 **Abstract 2554:** Effect of fusobacterium nucleatum on NF- κ B/HIF-1 α /CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma.
First Author: Yu Su
- Board 202 **Abstract 2555:** Monitoring PD-L1 expression in cancer-associated macrophage-like cells as predictor of clinical outcomes in metastatic cancer patients treated with PD-L1 immunotherapies.
First Author: Dimpal M. Kasabwala, BA
- Board 204 **Abstract 2557:** The classification of uncertain histologies based on cfDNA fragmentomic analysis in patients with uncommon cancers screened for NCI-MATCH.
First Author: Chris Alan Karlovich, PhD
- Board 205 **Abstract 2558:** A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors.
First Author: John Guittar, PhD
- Board 206 **Abstract 2559:** Predictive imaging of the immunotherapy and radioimmunotherapy response by immunoPET via a new target (CD103) and innovative protein formats in preclinical NSCLC.
First Author: Léa Zimmermann
- Board 207 **Abstract 2560:** Ultrasensitive ctDNA profiling to identify long-term survivors in phase I immunotherapy trials.
First Author: Oriol Mirallas, MD, MS
- Board 208 **Abstract 2561:** Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer.
First Author: Daisuke Nishizaki, MD, PhD
- Board 209 **Abstract 2562:** Role of pelareorep in activating anti-tumor immunity in PDAC.
First Author: Richard Trauger
- Board 210 **Abstract 2563:** ctDNA features of acquired resistance to immunotherapy in advanced NSCLC.
First Author: Sofiane Taleb, PharmD
- Board 211 **Abstract 2564:** Mutation profiling of appendiceal cancer: Distinguishing tumor grades, comprehensive mutation landscape, and ctDNA as a discovery tool.
First Author: Sefali Patel, DO

- Board 212 **Abstract 2565:** Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC.
First Author: Leeseul Kim, MD
- Board 213 **Abstract 2566:** Identifying peripheral cancer-associated TCR signals for the early-detection of lung cancer.
First Author: Chen Huang, MD
- Board 214 **Abstract 2567:** Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC).
First Author: Edmond Rafie, MD
- Board 215 **Abstract 2568:** The role of lipid-laden Kupffer cells in immunosuppression and immunotherapy response in MASLD-related hepatocellular carcinoma.
First Author: Junzhe Jacky Zhao, PhD
- Board 216 **Abstract 2569:** The economics of cancer immunotherapy: A five-year Medicare B expenditure analysis of checkpoint inhibitors.
First Author: Sharanya Tripathi, MD
- Board 217 **Abstract 2570:** Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors.
First Author: Jian Zhang, MD
- Board 218 **Abstract 2571:** Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer.
First Author: Daniel Saltzman, MD, PhD
- Board 219 **Abstract 2572:** Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.
First Author: Aung Naing, MD, FACP
- Board 220 **Abstract 2573:** SLAMF8 as a potential therapeutic target for modulating tumor-associated macrophages in colorectal cancer.
First Author: Han Xingzhi
- Board 221 **Abstract 2574:** Preclinical development of GNTbm-38, a novel class I histone deacetylase inhibitor, while combined with anti-VEGFR TKI or anti-PD-1 Ab: Assessment of immune activation and immune memory in cancer immunotherapy.
First Author: Jia-Shiong Chen, PhD
- Board 222 **Abstract 2575:** Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study.
First Author: Wen Wee Ma, MBBS
- Board 223 **Abstract 2576:** A generative model for the design of novel inhibitors targeting the PD-1/PD-L1 pathway.
First Author: Juan Velasco, MD
- Board 224 **Abstract 2577:** Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.
First Author: Thomas Urban Marron, MD, PhD

- Board 225 **Abstract 2578:** Deep learning–powered H&E whole-slide image analysis of endothelial cells to characterize tumor vascular environment and correlate treatment outcome to immunotherapy. First Author: Seungeun Lee, MD
- Board 227 **Abstract 2580:** SECN-15: A novel treatment option for patients with checkpoint inhibitor–resistant tumors by targeting Neuropilin-1 with antisense oligonucleotides. First Author: André Maaske, PhD
- Board 228 **Abstract 2581:** Utilizing targeted intra-tumoral hyperthermia as an immunotherapy in immunogenically ‘cold’ tumor models. First Author: Carman Giacomantonio, MD, MSc
- Board 229 **Abstract 2582:** Employing novel pan-cancer targets for immunotherapy in leukemias and solid tumors. First Author: Ashley Varkey, DO
- Board 230 **Abstract 2583:** Prevalence of the HPV, EBV, and TTV viral RNA in the plasma of patients with solid and hematologic neoplasms and the detection of a specific immune signature. First Author: Gustavo Rivero, MD
- Board 231 **Abstract 2584:** Phase 1 trial of HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, in subjects with advanced cancers. First Author: Lucy Yan, MD, PhD
- Board 232 **Abstract 2585:** Role of p57 in cGAS-STING-mediated innate sensing and immunotherapy response in hepatocellular carcinoma. First Author: Shirong Zhang, PhD
- Board 233 **Abstract 2586:** Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. First Author: Jiajian Liu, PhD
- Board 234 **Abstract 2587:** Effect of KROS 101, a small molecule G1TR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity. First Author: John S. Yu, MD
- Board 235 **Abstract 2588:** Machine learning–driven approaches for predicting T-cell–mediated immunity and beyond. First Author: Chongming Jiang
- Board 236 **Abstract 2589:** Phase 1 study of DK2¹⁰ (EGFR), a tumor-targeted IL2 x IL10 dual immunocytokine, in advanced cancer patients: Dose escalation, immune activation, and safety results. First Author: Alexander I. Spira, MD, PhD, FACP, FASCO
- Board 237 **Abstract 2590:** PCT1:CO-STIM TCR T-cells to overcome the hostile tumor micro-environment and target triple-negative breast cancer. First Author: Dora Hammerl
- Board 238 **Abstract 2591:** First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors. First Author: Charlotte Rose Lemech, MBBS, FRACP
- Board 239 **Abstract 2592:** AI-driven biomarker prediction in oncology: Enhancing pathological image analysis with EXAONEPath. First Author: Hyung Kyung Kim, MD, PhD
- Board 240 **Abstract 2593:** Systemic antitumor virotherapy: Pre-clinical evaluation of tumor targeting, efficacy, and safety of lead candidate (CLD-401). First Author: Duong Hoang Nguyen, PhD
- Board 241 **Abstract 2594:** The predictive value of BRCA mutation on survival of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of phase III randomized clinical trials. First Author: Mus’ab Theeb Mustafa
- Board 242 **Abstract 2595:** Monotherapy of envafolelimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial. First Author: Jian Li, PhD, DPhil
- Board 243 **Abstract 2596:** A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. First Author: Ching-Liang Ho, MD
- Board 244 **Abstract 2597:** Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial. First Author: Jun Wang, MD
- Board 245 **Abstract 2598:** Efficacy of low-dose nivolumab in advanced cancers: A retrospective analysis from medical oncology clinic in Eastern India. First Author: Kiran Yidagur Gangadharaiiah Lokesh Sr, DM, DNB, MBBS
- Board 246 **Abstract 2599:** Immune related liver toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers. First Author: Zara Izadi, PhD, MPharm, MS
- Board 247 **Abstract 2600:** Baseline autoimmune diseases and characteristics of solid tumor patients on immune checkpoint inhibitor (ICI) therapy enrolled in a prospective study of immune-related adverse events (irAEs): SWOG S2013 (I-CHECKIT). First Author: Krishna Soujanya Gunturu, MD
- Board 248 **Abstract 2601:** Immune related kidney toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers. First Author: Zara Izadi, PhD, MPharm, MS
- Board 249 **Abstract 2602:** Hepatotoxic adverse events with immune checkpoint inhibitors: Real world pharmacovigilance study using FAERS database. First Author: Panah Parab, MBBS
- Board 250 **Abstract 2603:** Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis. First Author: Moath Albliwi, MD
- Board 251 **Abstract 2604:** Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors. First Author: Keun-Wook Lee, MD
- Board 252 **Abstract 2605:** Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy. First Author: Yu-Fei Zhao, MD

- Board 253 **Abstract 2606:** A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).
First Author: Hong Jae Chon, MD, PhD, PhD(c)
- Board 254 **Abstract 2607:** Outcomes of conversion surgery after immune checkpoint inhibitor-based combination therapy in initially unresectable hepatocellular carcinoma: A retrospective cohort study.
First Author: Mingjian Piao, PhD, MCh
- Board 255 **Abstract 2608:** Phase I/II study of the EP4 antagonist vorbipirant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.
First Author: Filippo Pietrantonio, MD
- Board 256 **Abstract 2609:** Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.
First Author: Hye Ryun Kim, MD, PhD
- Board 257 **Abstract 2610:** Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study.
First Author: Omar Saavedra, MD
- Board 258 **Abstract 2611:** Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer.
First Author: QingLei Gao
- Board 259 **Abstract 2612:** Neoadjuvant serplulimab with concurrent chemoradiotherapy in resectable esophagogastric junction adenocarcinoma: Phase 2 updated results.
First Author: Yuping Ge
- Board 260 **Abstract 2613:** Niraparib plus PD-1 inhibitor for patients previously treated with immune checkpoint inhibitor for solid tumors with homologous recombination repair gene mutation (IMAGENE): A phase II basket study.
First Author: Taigo Kato, MD, PhD
- Board 261 **Abstract 2614:** Stereotactic radiotherapy plus immunotherapy and influence on prognosis in driver-gene-negative non-small cell lung cancer patients with brain oligo-metastases.
First Author: Xiaomei Gong, MD, PhD
- Board 262 **Abstract 2615:** A randomized controlled study of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer and the predictive value of T lymphocyte subsets for efficacy.
First Author: Fang Wu
- Board 263 **Abstract 2616:** PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: A prospective, multicenter clinical trial.
First Author: Pengfei Xing

- Board 264 **Abstract 2617:** Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.
First Author: Jibran Ahmed, MD
- Board 265 **Abstract 2618:** Effect of AdAPT-001 on checkpoint inhibitor resistance in solid tumors.
First Author: Anthony Paul Conley, MD
- Board 266 **Abstract 2619:** Efficacy and toxicity of nivolumab and ipilimumab in rare cancer brain metastases: A multi-center basket trial analysis (NCI/SWOG S1609).
First Author: Manmeet Singh Ahluwalia, MD, MBA, FASCO
- Board 267 **Abstract 2620:** Clinical factors and prognostic outcomes of hyperthyroidism induced by immune checkpoint inhibitor therapy.
First Author: Baqir Jafry, MD
- Board 268 **Abstract 2621:** Quantum mechanics-based multi-tensor AI/ML discovery and validation of actionable and mechanistically interpretable whole-transcriptome predictors of survival in response to immunotherapy from real-world clinical trial data.
First Author: Orly Alter, PhD
- Board 269 **Abstract 2622:** Phase II trial of neoadjuvant nivolumab and SOX in resectable gastric/gastroesophageal junction cancer: Therapeutic response and biomarker correlations.
First Author: Xiangdong Cheng, MD
- Board 270 **Abstract 2623:** Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced non-small-cell lung cancer.
First Author: Yuze Wang
- Board 271 **Abstract 2624:** Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
First Author: Philippe Alexandre Cassier, MD, PhD
- Board 272 **Abstract 2625:** Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.
First Author: Yu Fujiwara, MD
- Board 273 **Abstract 2626:** Impact of Helicobacter pylori infection on molecular alterations and immune dynamics in gastric cancer.
First Author: Daisuke Takayanagi, MD, PhD
- Board 274 **Abstract 2627:** Levels of immune responses in tertiary lymphoid structures of non-small cell lung cancer (NSCLC) and association with survival.
First Author: Jiangping Li, MD, PhD
- Board 276 **Abstract 2629:** Clinical significance of the CGRP pathway gene expression in advanced solid tumors: A sub-analysis of MONSTAR-SCREEN-2.
First Author: Takao Fujisawa, MD

- Board 277 **Abstract 2630:** Predication of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD1 inhibition directly from histopathology slides using inferred transcriptomics.
First Author: Johnathan Arnon
- Board 278 **Abstract 2631:** Evaluation of AI-assisted PD-L1 CPS scoring in immunostained pan-organ tumor whole-slide images.
First Author: Céline Bossard, MD, PhD
- Board 279 **Abstract 2632:** Validation of ENLIGHT, an AI predictor of immune checkpoint blockade (ICB) response and resistance, across the treatment span.
First Author: Scott Strum, MD, MSc, FRCPC
- Board 280 **Abstract 2633:** Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer.
First Author: Borys Hrinchenko, MD, PhD
- Board 281 **Abstract 2634:** Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer.
First Author: Dmitrii Grachev, MSc
- Board 282 **Abstract 2635:** CCR8 positive Tregs and their correlation with immunotherapy response in advanced non-small cell lung cancer (NSCLC).
First Author: Jean Philippe Guégan, PhD
- Board 283 **Abstract 2636:** Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.
First Author: Jean-Philippe Guegan
- Board 284 **Abstract 2637:** The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts).
First Author: Obada Ehab Ababneh, MD
- Board 285 **Abstract 2638:** Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
First Author: Christophe Le Tourneau, MD, PhD
- Board 286 **Abstract 2639:** Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.
First Author: Sebastian Ochsenreither, MD
- Board 287 **Abstract 2640:** An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors: R-ISV-FOLactis trial.
First Author: Ruojing Lv
- Board 288 **Abstract 2641:** First-in-human study of ZGGS15, a dual-specific antibody targeting LAG-3 and TIGIT, as monotherapy in patients with advanced solid tumors.
First Author: Ji Zhu, MD, PhD
- Board 289 **Abstract 2642:** Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/ PD-L1 and CTLA-4 in solid tumors: A meta-analysis.
First Author: Yu Fujiwara, MD
- Board 290 **Abstract 2643:** JAK inhibitor for the treatment of steroid refractory and life-threatening immune-related adverse events secondary to immune checkpoint inhibitors.
First Author: Rami Habib, MDCM
- Board 291 **Abstract 2644:** Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.
First Author: Taha Koray Sahin, MD
- Board 292 **Abstract 2645:** Tumor flare reactions secondary to T-cell engaging immunotherapies: A study from the French REISAMIC registry.
First Author: Alexandre Xu-Vuillard, MD
- Board 293 **Abstract 2646:** Evaluating the role of exercise in modulating immunity and immunotherapy outcomes in cancer: A systematic review.
First Author: Samhitha Gundakaram, MBBS
- Board 294 **Abstract 2647:** Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.
First Author: Michelle Frances Morris, MBBS, FRACP
- Board 295 **Abstract 2648:** Solid tumor-specific patterns of immune-related adverse events due to immune checkpoint inhibitor.
First Author: Shabnam Eghbali, MD
- Board 296 **Abstract 2649:** Impact of immune checkpoint inhibitor (ICI)-associated autoimmune hemolytic anemia (AIHA) on mortality in cancer patients: A retrospective analysis.
First Author: Haris Sohail, MD
- Board 297 **Abstract 2650:** Improved survival with sodium-glucose cotransporter-2 inhibitors and immune checkpoint inhibitors in metastatic solid tumors.
First Author: Sara Young, MD
- Board 298 **Abstract 2651:** Prognostic value of host genetic variants determining Bifidobacterium abundance in the lactose metabolism pathway for immunotherapy efficacy.
First Author: Wenhui Liu Sr, PhD
- Board 299 **Abstract 2652:** Early peripheral Treg expansion after SBRT combined with low-dose radiotherapy to predict subsequent immune checkpoint inhibitor responses in patients with metastatic lung or gastrointestinal cancers.
First Author: Byoung Hyuck Kim, MD, PhD
- Board 300 **Abstract 2653:** The impact of immunotherapy versus chemotherapy on mortality and adverse events in cancer patients hospitalized with septic shock.
First Author: Saad Javaid, MD
- Board 301 **Abstract 2654:** Gut dysbiosis as a potential guide for immunotherapy (dis)continuation after 2 years in non-small cell lung cancer: A mono-institutional, multi-omic assessment.
First Author: Lorenzo Belluomini, MD, PhD
- Board 303 **Abstract 2656:** Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
First Author: Megan Othus, PhD

- Board 304 **Abstract 2657:** PhaseX: Patient tumor avatars for evaluating anticancer therapeutics.
First Author: Kanishka Fernando, PhD, MSc
- Board 305 **Abstract 2658:** Examining the relationship between multi-agent immunosuppressive therapy for immune-related adverse events (irAE) and infectious complications.
First Author: Tristan Lee Lim, MD, MS
- Board 306 **Abstract 2659:** Incidence and outcomes of immune checkpoint inhibitor (ICI) rechallenge after ICI pneumonitis: A single-center retrospective study.
First Author: MacKenzie Adams, MD
- Board 307 **Abstract 2660:** Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
First Author: Jacopo Venturini, MD
- Board 308 **Abstract 2661:** MicroRNA-based signatures of early and late immune-related adverse events to anti-PD1 treatment.
First Author: Joanne B. Weidhaas, MD, PhD
- Board 309 **Abstract 2662:** Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: Results from a large single-centre cohort analysis.
First Author: Tommaso Bosetti, MD
- Board 310 **Abstract 2663:** The impact of lymphocyte count dynamics on the predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitors (ICI) outcomes in patients (pts) with cancer.
First Author: Mustafa Saleh, MD
- Board 311 **Abstract 2664:** Association of intestinal exfoliome and Prevotellaceae with toxicity and clinical outcome during immune-checkpoint blockade.
First Author: Giacomo Vitali, PhD
- Board 312 **Abstract 2665:** A Bayesian population-based framework for detecting hyperprogressive disease on cancer immunotherapies.
First Author: Madison Stoddard, BS
- Board 313 **Abstract 2666:** Safety outcomes of intravenous immunoglobulin (IVIG) in treatment of steroid-refractory immune-checkpoint inhibitor pneumonitis.
First Author: Mary Metkus, MD
- Board 314 **Abstract 2667:** Vedolizumab or infliximab: Treatment option in immune checkpoint inhibitor-induced colitis.
First Author: Shreya Shambhavi, MD
- Board 315a **Abstract TPS2668:** A phase 1, first-in-human study of DS-2243, an HLA-A*02:NY-ESO-directed bispecific T cell engager, in patients with advanced solid tumors.
First Author: Sandra P. D'Angelo, MD
- Board 315b **Abstract TPS2669:** Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.
First Author: Mohamad Adham Salkeni, MD
- Board 316a **Abstract TPS2670:** A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava, MD
- Board 316b **Abstract TPS2671:** ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.
First Author: Prachi Bhawe, MBBS
- Board 317a **Abstract TPS2672:** EGL-121, a first-in-human phase 1/2 trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors.
First Author: Thiziri Nait Achour, PhD
- Board 317b **Abstract TPS2673:** SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma.
First Author: Jason J. Luke, MD, FACP, FASCO
- Board 318a **Abstract TPS2674:** Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial.
First Author: Ning Li, MD
- Board 318b **Abstract TPS2675:** A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
First Author: Rodabe Navroze Amaria, MD
- Board 319a **Abstract TPS2676:** A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma.
First Author: Matthias Schroff, PhD
- Board 319b **Abstract TPS2677:** Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
First Author: Kedar Kirtane, MD
- Board 320a **Abstract TPS2678:** A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.
First Author: Soumit K. Basu, MD, PhD
- Board 320b **Abstract TPS2679:** Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress.
First Author: Samer Ali Srouf, MBChB, MS
- Board 321a **Abstract TPS2680:** QUILT 3.076 phase 1 study of memory-like cytokine-enriched natural killer (M-CENK) cells plus N-803 in locally advanced or metastatic solid tumors.
First Author: Chaitali Singh Nangia, MD

- Board 321b **Abstract TPS2681:** A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies.
First Author: Jacob Randolph Garcia, MD
- Board 322a **Abstract TPS2682:** Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA).
First Author: Robert Michael Wenham, MD
- Board 322b **Abstract TPS2683:** INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.
First Author: Neal Shiv Chawla, MD
- Board 323a **Abstract TPS2684:** An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/ FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC).
First Author: Rachna T. Shroff, MD, FASCO
- Board 323b **Abstract TPS2685:** A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors.
First Author: Roisin Eilish O'Cearbhaill, MD
- Board 324a **Abstract TPS2686:** A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.
First Author: David S. Hong, MD
- Board 324b **Abstract TPS2687:** Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.
First Author: Claire Frances Friedman, MD
- Board 325a **Abstract TPS2688:** A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors.
First Author: Maloy Ghosh, PhD
- Board 325b **Abstract TPS2689:** ELEPHAS-01, ELEPHAS-02 and ELEPHAS-04: Multi-institutional observational prospective clinical trials to assess the accuracy of an ex vivo live tumor fragment platform for predicting immunotherapy response.
First Author: Hincio J. Gierman, PhD, MSC
- Board 326a **Abstract TPS2690:** Phase II basket study to evaluate the tissue-agnostic efficacy of anti-PD1 in patients with advanced rare tumors: The ANTARES trial.
First Author: Camila M. Venchiarutti Moniz, MD, PhD
- Board 326b **Abstract TPS2691:** Phase 2 trial of TU2218, TGFβ-R1, and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with biliary tract cancer and head and neck cancer.
First Author: Do-Youn Oh, MD, PhD
- Board 327a **Abstract TPS2692:** A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.
First Author: Tao Qin
- Board 327b **Abstract TPS2693:** IMMUNORARE⁵: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Anaplastic Thyroid Carcinomas Cohort.
First Author: Hélène Lasolle, MD, PhD
- Board 328a **Abstract TPS2694:** Trial in progress: A first-in-human (FIH) phase I study of PTX-912 in patients with locally advanced or metastatic solid tumors.
First Author: Yan Xing, MD, PhD, MS
- Board 328b **Abstract TPS2695:** Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.
First Author: Mary Frances Wedekind, DO
- Board 329a **Abstract TPS2696:** A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
First Author: Fionnuala Crowley, MBBS
- Board 329b **Abstract TPS2697:** A phase 1 trial of APX-343A, NOX inhibitor targeting CAF-mediated immunosuppression, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Hyesung Shin, RN
- Board 330a **Abstract TPS2698:** A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting.
First Author: Kai-li Liang, MD
- Board 330b **Abstract TPS2699:** A phase I study of a pooled synthetic long peptide mutant KRAS vaccine in patients with pancreatic cystic neoplasms at risk for developing pancreatic cancer.
First Author: Kai-li Liang, MD
- Board 331a **Abstract TPS2700:** A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10.
First Author: Michael Oh, MD
- Board 331b **Abstract TPS2701:** EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
First Author: Iphigenie Korakis, MD
- Board 332a **Abstract TPS2702:** Fecal microbiota transplantation combined with sintilimab and SOX as first-line treatment for advanced gastric cancer (FMT-JSNO-01): A prospective, multicenter, double-blind, randomized placebo-controlled phase II trial.
First Author: Wenyu Zhu, DrPH

Board 332b **Abstract TPS2703:** A first-in-human phase 1 clinical trial of INI-4001, a novel TLR7/8 agonist, in patients with advanced solid tumors.
First Author: Shannon Marilee Miller, PhD

1:30 PM-4:30 PM Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Location: Hall A - Posters and Exhibits

Posters by Topic

Chemotherapy and Antibody-Drug Conjugates: Board(s) 333-358, 472a-477a

Circulating Biomarkers: Board(s) 359-379, 477b

Molecular Diagnostics and Imaging: Board(s) 380-389

New Targets and New Technologies (Non-IO): Board(s) 390-409, 478a-485a

Pharmacology/Pharmacodynamics/Pharmacogenetics: Board(s) 410-412

Radiopharmaceuticals: Board(s) 413-414, 485b

Small Molecules: Board(s) 415-440, 486a

Tissue-Based Biomarkers: Board(s) 441-461, 486b

Other Developmental Therapeutics: Board(s) 462-471, 487a-487b

Board 333 **Abstract 3018:** Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors.
First Author: Alexandra Drakaki, MD, PhD

Board 334 **Abstract 3019:** BC3195, a novel ADC targeting cadherin-3 (CDH3): Updated results of a first-in-human phase I study in patients with advanced solid malignancies.
First Author: Haiyan Tu

Board 335 **Abstract 3020:** A phase 2 basket trial of ado-trastuzumab emtansine for patients with HER2 amplified cancers.
First Author: Jessica Ross, MD

Board 336 **Abstract 3021:** The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study.
First Author: Herui Yao, MD, PhD

Board 337 **Abstract 3022:** A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors.
First Author: Dan Liu, MD

Board 338 **Abstract 3023:** Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FR α), in advanced ovarian cancer and other solid tumors.
First Author: Isabelle Laure Ray-Coquard, MD, PhD

Board 339 **Abstract 3024:** BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.
First Author: Jianli Zhao, MD

Board 340 **Abstract 3025:** A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.
First Author: Jie Wang, MD

Board 341 **Abstract 3026:** First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
First Author: Xiangdong Cheng, MD

Board 342 **Abstract 3027:** Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype (EGFRwt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).
First Author: David Ross Camidge, MD, PhD

Board 343 **Abstract 3028:** First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.
First Author: Javier Torres-Jiménez, MD

Board 344 **Abstract 3029:** A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
First Author: Shuiping Gao, PhD

Board 345 **Abstract 3030:** Efficacy and safety results of a multi-center phase I study of utidelone capsule, a novel oral microtubule inhibitor, in advanced solid tumor patients.
First Author: Judy S. Wang, MD

Board 347 **Abstract 3032:** RC48-ADC combined with radiotherapy and immunotherapy as salvage therapy for advanced solid tumors with HER2 expression: A multicenter, phase II trial.
First Author: Meiling Xu

Board 348 **Abstract 3033:** First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase.
First Author: Cesar Augusto Perez, MD

Board 349 **Abstract 3034:** Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study.
First Author: Jinming Yu, MD, PhD, ABFT

Board 350 **Abstract 3035:** Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors.
First Author: Zhiye Zhang, MHS

Board 351 **Abstract 3036:** Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.
First Author: Ziming Li, MD

Board 352 **Abstract 3037:** First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors.
First Author: Rongbo Lin, MD

- Board 353 **Abstract 3038:** Precectabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.
First Author: Scott Kopetz, MD, PhD, FASCO
- Board 354 **Abstract 3039:** Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.
First Author: Ira Seth Winer, MD, PhD
- Board 355 **Abstract 3040:** EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
First Author: Salman Rafi Puneekar, MD
- Board 356 **Abstract 3041:** ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.
First Author: Manish R. Patel, MD
- Board 357 **Abstract 3042:** First-in-human (FIH) phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
First Author: Manish R. Patel, MD
- Board 358 **Abstract 3043:** Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors.
First Author: Monika L. Burness, MD
- Board 359 **Abstract 3044:** Impact of stereotactic ablative radiotherapy (SABR) on detection of ctDNA in patients with early-stage lung cancer: Interim findings from the prospective SABR-DETECT trial.
First Author: Saurav Verma, MD, DM, MBBS
- Board 360 **Abstract 3045:** Prognostic significance of preoperational circulating tumor DNA detection in early-stage NSCLC using a tissue-free blood test.
First Author: Naixin Liang
- Board 361 **Abstract 3046:** Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction.
First Author: Nensi M. Ruzgar, MD, MHS
- Board 362 **Abstract 3047:** Accurate differentiation of malignant and benign gastric lesions using cell-free DNA biomarkers.
First Author: Hengzhen Li
- Board 363 **Abstract 3048:** Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA.
First Author: John Paul Y.C. Shen, MD
- Board 364 **Abstract 3049:** Prevalence of androgen receptor ligand-binding domain mutations (AR-LBDm) in circulating tumor DNA (ctDNA) versus tissue biopsies in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) and other tumor types.
First Author: Emmanuel S. Antonarakis, MD
- Board 365 **Abstract 3050:** A high-performance blood-based DNA methylation test for early detection of gastrointestinal cancers.
First Author: Xiaosheng He
- Board 366 **Abstract 3051:** A novel magnetic bead-based cfDNA extraction method for advanced ctDNA marker discovery and methylation profiling.
First Author: Zhuoran Jiang
- Board 367 **Abstract 3052:** Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling in patients with advanced or metastatic solid tumors.
First Author: Amna Jamali, MBBS
- Board 368 **Abstract 3053:** Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer.
First Author: Sudhir K. Rawal, DNB, MBBS, MCh, MS
- Board 369 **Abstract 3054:** Molecular profiling of body fluid cfDNA: Advancing diagnostics and therapeutic decisions.
First Author: Aditya V. Shreenivas, MD, MS
- Board 370 **Abstract 3055:** Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
First Author: Tae-Kyung Robyn Yoo, MD, MS
- Board 371 **Abstract 3056:** A plasma proteomics-based model for predicting response to neoadjuvant chemotherapy in ovarian cancer.
First Author: Coren Lahav, MSc
- Board 372 **Abstract 3057:** NeoCircle: Investigating circulating tumor DNA dynamics as a predictor of survival in primary breast cancer.
First Author: Anthony M. George, MSc
- Board 373 **Abstract 3058:** Monitoring populations of tumor-macrophage fusion cells in blood prognosticates PFS and OS in pan-metastatic cancers over 2 years.
First Author: Sonia Muthuraj, BS
- Board 374 **Abstract 3059:** Whole-genome bisulfite sequencing of cell-free DNA to investigate molecular contributors to racial survival differences in advanced-stage triple-negative breast cancer.
First Author: Chun Wang
- Board 375 **Abstract 3060:** Beyond tumor-shed markers: AI driven tumor-educated polymorphonuclear granulocytes monitoring for multi-cancer early detection.
First Author: Rajan Datar
- Board 376 **Abstract 3061:** Next-generation U-Net Encoder: Decoder for accurate, automated CTC detection from images of peripheral blood nucleated cells stained with EPCAM and DAPI.
First Author: Tim Crook, MD, PhD
- Board 377 **Abstract 3062:** Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).
First Author: Richa Dawar, MD

- Board 378 **Abstract 3063:** Microbial metabolic pathways to abrogate immunotherapy toxicity and promote anti-tumor response in metastatic renal cell cancer.
First Author: Shahla Bari, MD
- Board 379 **Abstract 3064:** Tumor-educated platelets as a source of potential biomarkers for colorectal cancer.
First Author: Rodney Macambira, MD, MSc
- Board 380 **Abstract 3065:** Molecular landscape and therapeutic vulnerability of RRAS- and RRAS2-mutant solid tumors.
First Author: Alexander Pfeil, MS
- Board 381 **Abstract 3066:** Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset.
First Author: Alexander E. Drilon, MD
- Board 382 **Abstract 3067:** Non-invasive PD-L1 prediction in NSCLC patients using 3D self-supervised deep learning and radiomics.
First Author: Xavier Rafael-Palou, PhD
- Board 383 **Abstract 3068:** Development and implementation of molecular oncology test e-consult at the VA North Texas Health Care System (VANTHCS).
First Author: Lucas Jiaxue Wang, MD
- Board 384 **Abstract 3069:** Phase 2 multicenter clinical trial to evaluate the safety and efficacy of abenacianine for injection (VGT-309), a tumor-targeted, intraoperative molecular imaging agent, for patients undergoing surgery for cancer in the lung.
First Author: Sunil Singhal, MD
- Board 385 **Abstract 3070:** Analysing the impact of size of NGS panel in defining first line therapeutic strategies in NSCLC.
First Author: Kshitij Joshi
- Board 386 **Abstract 3071:** Evaluation of ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC).
First Author: Daniel Udayan C, MD, DM, MBBS
- Board 387 **Abstract 3072:** Clinical utility of comprehensive transcriptome testing in advanced solid tumors.
First Author: Fei Su, PhD
- Board 388 **Abstract 3073:** Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases.
First Author: Elmira Forouzmand, PhD
- Board 389 **Abstract 3074:** HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay.
First Author: Pegah Safabakhsh
- Board 390 **Abstract 3075:** Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: A systematic review and network meta-analysis.
First Author: Zhang Wengang, MD, PhD
- Board 391 **Abstract 3076:** Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors.
First Author: Toshihiko Doi, MD, PhD
- Board 392 **Abstract 3077:** First report of ROR2 directed therapy with a conditionally active antibody drug conjugate in advanced melanoma.
First Author: Jacob Keeling, MD
- Board 393 **Abstract 3078:** Glutaminase isoform expression in cancer: Implications for metabolic adaptation and therapy.
First Author: Mohammed Osama Ahamd Bader, MBBS
- Board 394 **Abstract 3079:** A phase 1 study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimipitespib) in solid tumors: Dose-expansion results from the NiraPim (EPOC2102) study.
First Author: Yasuyuki Kawamoto, MD, PhD
- Board 395 **Abstract 3080:** Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy.
First Author: Marvin S. Hausman, MD
- Board 396 **Abstract 3081:** Genomic landscape of 5'methylthioadenosine phosphorylase (MTAP) deleted (MTAP loss) non-squamous carcinoma of unknown primary site (nsCUP).
First Author: Parth J. Sampat, MBBS
- Board 397 **Abstract 3082:** Preliminary efficacy results from an ongoing phase I/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced/metastatic solid tumors.
First Author: Jianan Jin, MS
- Board 398 **Abstract 3083:** The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
First Author: Siqing Fu, MD, PhD
- Board 399 **Abstract 3084:** Artificial intelligence (AI)-powered evaluation of protein drug-targetability through subcellular-level expression profiling from immunohistochemistry (IHC) images.
First Author: Sukjun Kim, PhD
- Board 400 **Abstract 3085:** Seizure-related homolog 6 (SEZ6) expression and ctDNA methylation profiles in patients with high-grade neuroendocrine carcinomas (NECs)/neuroendocrine tumors (NETs) from a phase 1 study of ABBV-706 in advanced solid tumors.
First Author: Song Wang, PhD
- Board 401 **Abstract 3086:** EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.
First Author: Ravali Annam Reddy, MD
- Board 402 **Abstract 3087:** A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
First Author: Philippos Apolinario Costa, MD
- Board 403 **Abstract 3088:** The effect of HIFU treatment on liver metastasis of colorectal cancer in mice and its impact on immunity.
First Author: Shasha Wang, PhD
- Board 404 **Abstract 3089:** A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
First Author: Philippos Apolinario Costa, MD

- Board 405 **Abstract 3090:** Effect of extrachromosomal DNA (ecDNA) on MYCN amplified neuroblastoma and patient outcomes.
First Author: Mihika Sonalkar, MS
- Board 406 **Abstract 3091:** AI-driven design of novel PARP inhibitors.
First Author: Juan Velasco, MD
- Board 407 **Abstract 3092:** A first-in-class KIF11 degrader antibody conjugate (DAC) as a potential therapy targeting a broad spectrum of cancers.
First Author: Yan Feng
- Board 408 **Abstract 3093:** Comparative analysis of fibroblast activation protein Inhibitor (FAPI) O4 PET/CT versus fludeoxyglucose (FDG) PET/CT in staging gastrointestinal tumours.
First Author: S.P. Somashekhar, FRCS, MCh
- Board 409 **Abstract 3094:** Role of Lu177 FAPI-09 therapy in combination with chemotherapy or immunotherapy for chemo-resistant progressive cancers: Early clinical experience.
First Author: Prathap H. J., DNB
- Board 410 **Abstract 3095:** Dosing tolerability and adverse events (AEs) in dihydropyrimidine dehydrogenase (DPYD) variant carriers receiving genotyping-guided fluoropyrimidine (FP) dosing.
First Author: Grace Nguyen, PharmD
- Board 411 **Abstract 3096:** Monocentric pilot trial of trametinib in severe extracranial arteriovenous malformations.
First Author: Emmanuel Seront, MD, PhD
- Board 412 **Abstract 3097:** Cost analysis of pre-treatment dihydropyrimidine dehydrogenase (DPYD) genotyping to reduce hospitalizations at a cancer center in the United States (U.S.).
First Author: Sarah Morris
- Board 413 **Abstract 3098:** Predicting immunotherapy response in advanced solid tumors using quantitative imaging features from CD8 PET/CT exams.
First Author: Michael A. Postow, MD
- Board 414 **Abstract 3099:** Interim safety and efficacy data of [²¹²Pb]VMT01 in MC1R expressing melanoma.
First Author: Zachary S. Morris
- Board 415 **Abstract 3100:** SPYK04, a novel RAF-MEK molecular glue: Dose escalation (DE) in first-in-human study for MAPK pathway-altered solid tumors.
First Author: Sarina A. Piha-Paul, MD, MS
- Board 416 **Abstract 3101:** Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from two dose-escalation cohorts of the phase 1b STELLAR 002 study.
First Author: Benjamin Garmez, MD
- Board 417 **Abstract 3102:** Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma or endometrial carcinoma.
First Author: Linda R. Duska, MD, MPH, FASCO
- Board 418 **Abstract 3103:** OMX-0407: A novel spectrum-selective small molecule kinase inhibitor in advanced/metastatic solid tumors.
First Author: Valentina Boni, MD, PhD
- Board 419 **Abstract 3104:** AI molecular search engine paired with RNA sequencing analysis to develop potent and selective VEGFR-3 inhibitors.
First Author: Maxim Sorokin, PhD
- Board 420 **Abstract 3105:** Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003).
First Author: Hitomi Sumiyoshi Okuma, MD, PhD
- Board 421 **Abstract 3106:** Phase 1 study of TT-00973-MS, a highly selective and potent AXL inhibitor, in patients with advanced solid tumors.
First Author: Bo Yang
- Board 422 **Abstract 3107:** A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors.
First Author: Shashank Deoghare, MD, MBBS
- Board 423 **Abstract 3108:** An open-label phase 1 dose-escalation and dose-expansion trial to evaluate the safety, tolerability, and efficacy of TQ-B3234 in adults with neurofibromatosis type 1 (NF1).
First Author: Jun Liu
- Board 424 **Abstract 3109:** A phase 1, multicenter, open-label study of HSK42360, a brain-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.
First Author: Jian Li, PhD, DPhil
- Board 425 **Abstract 3110:** Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in EGFR-mutant lung cancer models.
First Author: Wei Deng, PhD
- Board 426 **Abstract 3111:** Phase II trial of trametinib in patients with advanced solid tumors harboring genomic alterations in the MAPK pathway: Results from the BELIEVE trial (NCCH1901).
First Author: Hideyuki Hayashi, MD, PhD
- Board 427 **Abstract 3112:** Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion-positive (NTRK+) solid tumors.
First Author: Danyun Ruan, MD, PhD
- Board 428 **Abstract 3113:** Discovery of potent degraders of pan-KRAS based on a novel KRAS binder.
First Author: Wei Sun
- Board 429 **Abstract 3114:** Development and validation of a biology-based novel therapeutic agent targeting the LIN28/let-7 pathway in cancer.
First Author: Patrick Sipila, PhD
- Board 430 **Abstract 3115:** A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data.
First Author: Rohit Joshi, MD
- Board 431 **Abstract 3116:** Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Final data from the ARROW trial.
First Author: Vivek Subbiah, MD

- Board 432 **Abstract 3117:** Exploring the efficacy and mechanism of action of combined pan-Raf and MEK inhibition in halting the growth of non-V600 BRAF mutated tumors.
First Author: Islam E. Elkhohi, MD, PhD
- Board 433 **Abstract 3118:** Atropisomeric pyrrolopyrimidine inhibitor as a targeted approach for RET tyrosine kinase in neuroblastoma.
First Author: Ananya Bharathwaj
- Board 434 **Abstract 3119:** Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial).
First Author: Anna Lena Illert, MD
- Board 435 **Abstract 3120:** Safety and efficacy of a small-molecule c-Myc degrader WBC100 in solid tumors: A first-in-human, phase I trial.
First Author: Qi Zhang, MD
- Board 436 **Abstract 3121:** In vitro efficacy of CDK9 inhibitor tambiciclib (SL5009) in ASXL1 mutated colorectal cancer cell lines.
First Author: Dragan Cicic, MD
- Board 437 **Abstract 3122:** Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors.
First Author: Guru P. Sonpavde, MD
- Board 438 **Abstract 3123:** A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01.
First Author: Janine Margaret Lombard, FRACP, MBChB, MMed
- Board 439 **Abstract 3124:** Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors: Results on safety, pharmacokinetics, and anti-tumor activity.
First Author: Apostolia Maria Tsimberidou, MD, PhD, FAAS, FASCO
- Board 440 **Abstract 3125:** Phase I dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway-driven advanced solid tumors.
First Author: Tiago Reis Marques
- Board 441 **Abstract 3126:** Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with ERBB2/3 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: John K. Chan, MD
- Board 442 **Abstract 3127:** Digital spatial profiling of advanced solid tumors and lymphomas from a phase 1 trial of copanlisib and nivolumab.
First Author: Sayak Ghatak, MD, PhD
- Board 443 **Abstract 3128:** Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.
First Author: Michela Bartolini, MD

- Board 444 **Abstract 3129:** Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II INTEGRATE study.
First Author: Florence T.H. Wu, MD, PhD
- Board 445 **Abstract 3130:** Assessment of homologous recombination deficiency and BRCA status in ovarian cancer: Analytical performance and relevance of a decentralized NGS assay for comprehensive genomic profiling.
First Author: Mohit Gupta
- Board 446 **Abstract 3131:** Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.
First Author: Jian Wang, PhD
- Board 447 **Abstract 3132:** Impact of sample characteristics on RNA-based next-generation sequencing (NGS) for fusion gene detection in non-small cell lung cancer (NSCLC).
First Author: Jun Liu Jr
- Board 448 **Abstract 3133:** Effect of irradiation on the killing effect of NK cells in colon cancer through MYB/TIM3 axis.
First Author: Xiuli Guo
- Board 449 **Abstract 3134:** Combined prognostic value of post-surgery circulating tumor DNA and tumor-stroma ratio in patients with stage III colon cancer treated with adjuvant chemotherapy.
First Author: Ingrid Franken, MD, MSc
- Board 450 **Abstract 3135:** Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model.
First Author: Andreas Seeber, MD, PhD
- Board 451 **Abstract 3136:** Relationship between FOLR1 expression and pan-cancer subgroup of tumors with specific transcriptomic profile.
First Author: Andrew Ip, MD, MS
- Board 452 **Abstract 3137:** Multi-omics cohort-based prediction model for early relapse of hepatocellular carcinoma post-surgery.
First Author: Penghong Song
- Board 453 **Abstract 3138:** Comprehensive clinicogenomic profiling of signet ring cell carcinoma across multiple organ sites.
First Author: Lawrence Wen Wu, MD
- Board 454 **Abstract 3139:** Comparative analysis of T-cell subsets and vessel features in matched primary colorectal tumors and corresponding resected liver metastases.
First Author: Pia J. Osterlund, MD, PhD
- Board 455 **Abstract 3140:** Characterisation of ductal carcinoma in situ (DCIS) using mass spectrometry imaging towards near realtime margin assessment.
First Author: Hemali Chauhan
- Board 456 **Abstract 3141:** A minimal comprehensive somatic panel to aid clinical decision making in a low cost setting.
First Author: Urvashi Bahadur, PhD

- Board 457 **Abstract 3142:** Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors.
First Author: Mridula Annette George, MD
- Board 458 **Abstract 3143:** Landscape of genomic alterations in genes implicated in the regulation of hypoxia inducible factor (HIF) signaling: A pooled analysis of two pan-cancer cohorts.
First Author: Wassim Daoud Khatoun, MD
- Board 459 **Abstract 3144:** Analytical validation of EPISEEK, an epigenomic blood-based assay for multicancer detection.
First Author: Thi Hanh Pham, PhD
- Board 460 **Abstract 3145:** Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.
First Author: Francesca Battaglin, MD
- Board 461 **Abstract 3146:** Impact of MGMT methylation on overall survival in solid tumors: A systematic review and meta-analysis.
First Author: Abdulla Alzibdeh, MD
- Board 462 **Abstract 3147:** A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
First Author: Junichi Matsubara, MD, PhD
- Board 463 **Abstract 3148:** Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.
First Author: Rui-Hua Xu, MD, PhD
- Board 464 **Abstract 3149:** Early prediction of prognosis in advanced solid tumor patients using tumor growth rates with g score in early phase clinical trials.
First Author: Kana Kurokawa, MD, PhD
- Board 465 **Abstract 3150:** Picking needles in a haystack: Exploring rare variants of a pan-cancer target in the RET landscape from 229,453 adult cancer patients.
First Author: Niamh Coleman, MD, PhD
- Board 466 **Abstract 3151:** LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.
First Author: Sriram Anbil, MD
- Board 467 **Abstract 3152:** A multicenter, randomized controlled trial of intrapleural drug-loaded vesicle perfusion combined with systemic therapy for malignant pleural effusion.
First Author: Jiani Wang
- Board 468 **Abstract 3153:** The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: Preliminary results from a first-in-human phase 1/2 study.
First Author: Jiongjie Chen, MA
- Board 469 **Abstract 3154:** Effect of biopsy requirement on patient enrollment to phase I trials in cancer.
First Author: Marisa Palmeri
- Board 470 **Abstract 3155:** Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.
First Author: Jibran Ahmed, MD
- Board 471 **Abstract 3156:** Body composition modulations during cyclic fasting-mimicking diet in patients with advanced solid cancers.
First Author: Caterina Sposetti, MD
- Board 472a **Abstract TPS3157:** IDEate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors.
First Author: Takahiro Kogawa, MD, PhD
- Board 472b **Abstract TPS3158:** REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.
First Author: Laurence Albiges, MD, PhD
- Board 473a **Abstract TPS3159:** A phase 1, open-label, multicenter study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors.
First Author: Shiraj Sen, MD, PhD
- Board 473b **Abstract TPS3160:** Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
First Author: Melissa Lynne Johnson, MD, FASCO
- Board 474a **Abstract TPS3161:** A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.
First Author: Charlotte Rose Lemech, MBBS, FRACP
- Board 474b **Abstract TPS3162:** Phase I multicenter, open-label, dose escalation study of T-1201, a small molecule drug conjugate, to assess safety, pharmacokinetics, and antitumor activity in advanced solid tumors.
First Author: Hui-Ching Wang
- Board 475a **Abstract TPS3163:** A phase 1 study to evaluate the safety and tolerability of the antibody-drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors.
First Author: Amita Patnaik, MD, FRCP
- Board 475b **Abstract TPS3164:** TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.
First Author: Shiraj Sen, MD, PhD
- Board 476a **Abstract TPS3165:** PROCEADE PanTumor: A phase 1b/2, multicenter study of precenttabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.
First Author: Zev A. Wainberg, MD
- Board 476b **Abstract TPS3166:** A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors.
First Author: Panpan Zhang, MD
- Board 477a **Abstract TPS3167:** A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
First Author: Michael M. Song, MD, PhD, PharmD

- Board 477b **Abstract TPS3168:** The EQUAL study: Utilizing plasma EGFR cfDNA detection as an accessible screening tool for lung cancer in underserved patients ineligible for routine screening.
First Author: Narjust Florez, MD, FASCO
- Board 478a **Abstract TPS3169:** A phase 1/2 study of FOG-001, a first-in-class direct β -catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors.
First Author: Kyriakos P. Papadopoulos, MD
- Board 478b **Abstract TPS3170:** SCRUM-Japan MONSTAR-SCREEN-3: Comprehensive tumor microenvironment analysis via multi-omics in a large-scale prospective study.
First Author: Mitsuho Imai, MD, PhD
- Board 479a **Abstract TPS3171:** A first-in-human multicenter phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
First Author: Lipika Goyal, MD
- Board 479b **Abstract TPS3172:** Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): The WIN-B study.
First Author: Timothy J. Robinson, MD, PhD
- Board 480a **Abstract TPS3173:** Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
First Author: Anas Gazzah, MD
- Board 480b **Abstract TPS3174:** A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 \pm niraparib in adults with advanced or metastatic solid tumors.
First Author: Vivek Samnotra, MD
- Board 481a **Abstract TPS3175:** A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.
First Author: Nehal J. Lakhani, MD, PhD
- Board 481b **Abstract TPS3176:** First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors.
First Author: Sonia Macia, MD, PhD
- Board 482a **Abstract TPS3177:** IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.
First Author: Jérôme Fayette, MD, PhD
- Board 482b **Abstract TPS3178:** Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations.
First Author: Shiraj Sen, MD, PhD

- Board 483b **Abstract TPS3180:** Phase 1 first-in-human clinical trial of AG01, a recombinant monoclonal antibody to progranulin/glycoprotein 88 (PGRN/GP88), to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor response in subjects with advanced solid tumor malignancies.
First Author: Katherine H. R. Tkaczuk, MD
- Board 484a **Abstract TPS3181:** Trial in progress: First-in-human study of ATX-559, an oral inhibitor of DHX9, in patients with advanced or metastatic solid tumors, and molecularly defined cancers.
First Author: Meredith Pelster, MD, MSc
- Board 484b **Abstract TPS3182:** A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer.
First Author: Nuria Kotecki, MD
- Board 485a **Abstract TPS3183:** A phase I/Ib study of olaparib and ASTX727 in BRCA 1/2- and HRD-mutated tumors.
First Author: Pamela N. Munster, MD
- Board 485b **Abstract TPS3184:** RYZ101 (²²⁵Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study.
First Author: Erica L. Mayer, MD, MPH, FASCO
- Board 486a **Abstract TPS3185:** panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2activating mutations.
First Author: Vivek Subbiah, MD
- Board 486b **Abstract TPS3186:** Molecular residual disease (MRD) in solid tumors.
First Author: Majd T. Ghanim, MD, MSc
- Board 487a **Abstract TPS3187:** Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2-mutated or overexpressed/amplified solid tumors.
First Author: Alison M. Schram, MD
- Board 487b **Abstract TPS3188:** Perfume trial: Phase II trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer.
First Author: Tomoyuki Satake, MD

1:30 PM-4:30 PM Poster Session

Medical Education and Professional Development

Location: Hall A - Posters and Exhibits

Posters by Topic

Clinician Burnout and Wellness: Board(s) 1-5, 35a

Education Research: Board(s) 6-25, 35b

Professionalism and Ethics: Board(s) 26-27

Social Media Research: Board(s) 28-31

Workplace Disparities/Issues: Board(s) 32-34

- Board 1 **Abstract 9012:** A cluster analysis of clinician distress trajectories when caring for seriously ill hospitalized patients.
First Author: Anessa M. Foxwell, PhD

Board 2	Abstract 9013: Oncologists' attitudes and beliefs toward crying with patients and its correlation with burnout. First Author: Hannah Z. Catzen, BA	Board 17	Abstract 9028: Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program. First Author: Rebecca Forman, MD
Board 3	Abstract 9014: The impact of burnout on oncologists and hematologists: Nunc agendum est (now is the time to act). First Author: Rajesh Sharma, MSc, PhD(c), MBA	Board 18	Abstract 9029: Applying learning science principles (LSP) through a simulation session (SIM) for oncology trainees (OT) about fertility preservation (FP) in patients (pts) with cancer and treatment (tx) of pregnant pts (TPP) with cancer. First Author: Tanmayi Pai, MD
Board 4	Abstract 9015: Rethinking future workforce planning by developing novel metrics of complexity in cancer care. First Author: Philip Q. Ding	Board 19	Abstract 9030: Linking comfort levels and knowledge gaps in hematology/oncology (HO) fellowship education: Insights from a multicenter survey. First Author: Ronak Mistry, DO
Board 5	Abstract 9016: Parenting challenges of international medical graduate hematologists-oncologists in the United States. First Author: Vera Kazakova, MD	Board 20	Abstract 9031: Enhancing bereavement education and emotional preparedness: A global survey of oncology residency programs. First Author: Giusti Raffaele, MD
Board 6	Abstract 9017: Communication skills training program for medical staff in cancer genomic testing: A mixed-methods assessment of an educational initiative. First Author: Shuhei Suzuki, MD, PhD	Board 21	Abstract 9032: Evaluation of NCI Designated Cancer Centers medical student education and training initiatives. First Author: Ana I. Velazquez Manana, MD, MSc, FASCO
Board 7	Abstract 9018: Competencies for practicing medical oncology with common sense: A global curricula review. First Author: Haydee Cristina Verduzco-Aguirre, MD	Board 22	Abstract 9033: Advancing gender-responsive cancer control: A mixed methods evaluation of the leadership program for women in oncology. First Author: Meritxell Mallafre-Larrosa, MD, MPH
Board 8	Abstract 9019: Enhancing radiotherapy planning skills through structured deliberate practice and artificial intelligence integration: A pilot study. First Author: Ivy Weishan Ng, MMed, MBBS, FRANZCR, MRCP	Board 23	Abstract 9034: Board certification practices of US hematologists and oncologists. First Author: Austin Wesevich, MD, MS, MPH
Board 9	Abstract 9020: On-shift resident education about hematologic and oncologic emergencies: A needs-based assessment. First Author: Leah Ann Goldberg, MD, MHS	Board 24	Abstract 9035: Exploring DORIS: A cancer-focused AI knowledge platform for diagnosis and treatment information. First Author: Joseph Monforte, PhD
Board 10	Abstract 9021: The hidden toll: Defining impacts of home call on oncology fellows. First Author: Erica Andres, MD	Board 25	Abstract 9036: The value of observerships abroad: Lessons from UA-MED supporting Ukrainian cancer care during the war. First Author: Nataliya Kovalchuk, PhD
Board 11	Abstract 9022: Successful intervention to bridge the knowledge gap in recognizing and managing chemotherapy hypersensitivity reactions among oncology fellows in southeast Michigan. First Author: Jailan Elayoubi, MD	Board 26	Abstract 9037: Dissecting publication timelines: Insights from high-impact oncology journals. First Author: Abdulmalek Aljafari
Board 12	Abstract 9023: Introducing a capacity building model to improve cancer research in MENA. First Author: Sara Ahmad Al-Banna	Board 27	Abstract 9038: The evolving landscape of academic and industry partnerships in gynecologic oncology clinical trials. First Author: Kevin Ji Li, BS
Board 13	Abstract 9024: Enhancing educational experiences through standardization of inpatient hematology curriculums. First Author: Prasanth Lingamaneni, MD	Board 28	Abstract 9039: Addressing gender disparities in oncology and hematology education: Insights from social media engagement analysis. First Author: Viviana Cortiana, BSc
Board 14	Abstract 9025: Leveraging the power of diagnostic metrics to competency based medical education (CBME) implementation in medical oncology (MO) across Canada. First Author: Anna T. Tomiak, MD	Board 29	Abstract 9040: Harnessing social media for cancer prevention and early detection: Challenges, opportunities, and pathways to equity. First Author: Viviana Cortiana, BSc
Board 15	Abstract 9026: Implementation of clinical trial communication skills training for oncology fellows. First Author: Carma Bylund	Board 30	Abstract 9041: Empowering medical oncologists: Exploring the impact and engagement of telegram channels for professional development in Russia. First Author: Anastasia Danilova, MD
Board 16	Abstract 9027: GUIDE-G: An artificial intelligence-powered platform for dynamic NCCN guideline visualization in breast cancer (BC). First Author: Nataly Valeria Torrejon, MD		

- Board 31 **Abstract 9042:** The bubble effect: Impact of ASCO digital promotion on Journal of Clinical Oncology (JCO) download metrics (2023).
First Author: Oyepeju Folashade Abioye, MD, MSc
- Board 32 **Abstract 9043:** Racial, ethnic, sex, and subspecialty demographic composition of initial fellow of the Fellow of the American Society of Clinical Oncology (FASCO) recipients through 2024.
First Author: Victoria Shiqi Wu, MD
- Board 33 **Abstract 9044:** Advancing gender equity in cancer research across north Africa: A comprehensive analysis of women's role and men's supportive efforts—Final findings from the GEORGiNA-1 study.
First Author: Khalid El Bairi, MD
- Board 34 **Abstract 9045:** A multifactorial analysis of first-author retention in ASCO accepted works.
First Author: Taha Huda, MD
- Board 35a **Abstract TPS9046:** A randomized controlled trial of high-fidelity simulation versus mentoring training for residents: ACACIAS 2.
First Author: Elise Deluche, MD, PhD
- Board 35b **Abstract TPS9047:** Evaluating the use of educational videos in a medical oncology sarcoma clinic to improve patient knowledge and satisfaction.
First Author: Fabio Murtas, MD

1:30 PM-4:30 PM Poster Session

Symptom Science and Palliative Care

Location: Hall A - Posters and Exhibits

Posters by Topic

Cardio-Oncology: Board(s) 38-47, 156a

End-of-Life Care: Board(s) 48-52

Late and Long-Term Adverse Effects: Board(s) 53-77, 156b-157a

Palliative Care and Symptom Management: Board(s) 78-118, 157b-159a

Pathobiology of Symptoms: Board 159b

Psychosocial and Communication Research: Board(s) 119-135

Toxicities—Prevention and Management Strategies: Board(s) 136-153, 155, 160a-162b

- Board 38 **Abstract 12018:** Cardiovascular risks associated with aromatase inhibitors versus tamoxifen in breast cancer: A systematic review and meta-analysis.
First Author: Danilo Monteiro Ribeiro
- Board 39 **Abstract 12019:** Effectiveness of the Automated Heart-Health Assessment (AH-HA) tool on cardiovascular health improvements among post-treatment cancer survivors: 12-month results from WF-1804CD.
First Author: Kathryn E. Weaver, PhD, MPH
- Board 40 **Abstract 12020:** Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: A randomized controlled trial.
First Author: Johanne Dam Lyhne
- Board 41 **Abstract 12021:** DNA methylation biomarkers of cardiotoxicity risk in breast cancer patients treated with anthracyclines.
First Author: Mohammed Al-Jumayli, MD

- Board 42 **Abstract 12022:** Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis.
First Author: Sufyan Shahid, MBBS
- Board 43 **Abstract 12023:** Effects of SGLT2i dapagliflozin in primary prevention of cardiotoxicity induced by short-term anthracycline and HER2 blocking agent therapy through inhibition of MyD88 and NLRP-3 pathways.
First Author: Vincenzo Quagliariello, PhD
- Board 44 **Abstract 12024:** Long-term trastuzumab safety in tailored dose-dense anthracycline containing adjuvant chemotherapy in the PANTHER phase III trial.
First Author: Andri Papakonstantinou, MD, PhD
- Board 45 **Abstract 12025:** Does early recognition and treatment of immune-related myositis and myasthenia gravis reduce mortality of immune-related myocarditis?
First Author: Natalie Longino, MD, PhD
- Board 46 **Abstract 12026:** Temporal trends and disparities in cardiovascular mortality among breast cancer patients: A 25-year population analysis of the CDC WONDER database (1999-2023).
First Author: Ibrahim Hassan, MBCh
- Board 47 **Abstract 12027:** Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.
First Author: Omer Ashruf, BS
- Board 48 **Abstract 12028:** Effect of a letter of condolence proposing a post-mortem consultation to the relatives of cancer patients on anxiety, depression and grief: Results of a multicenter randomized study.
First Author: Gwenaëlle Gravis, MD
- Board 49 **Abstract 12029:** Disparities in receipt of palliative treatments among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
First Author: Shriya Garg
- Board 50 **Abstract 12030:** Disparities in place of death in patients with lung cancer.
First Author: Faris Abby Alamin, MD
- Board 51 **Abstract 12031:** Economic impact and mortality outcomes of palliative care integration among cancer patients: Analysis of National Inpatient Sample 2018-2022.
First Author: Shiva Jashwanth Gaddam, MD
- Board 52 **Abstract 12032:** Improving pain management knowledge among hospice family caregivers: A randomized controlled trial.
First Author: Masako Mayahara, PhD
- Board 53 **Abstract 12033:** A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.
First Author: Sabin Goktas Aydin, MD

Board 54	Abstract 12034: Effectiveness of alternating magnetic field therapy on quality of life among cancer survivors with chemotherapy-induced peripheral neuropathy: Insights of SMILE study. First Author: Emi Kubo, MD, PhD	Board 66	Abstract 12046: New-onset osteopenia/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors. First Author: Geoffrey S. Bostany, MD
Board 55	Abstract 12035: Autoimmune conditions and 'breast implant illness' in breast cancer patients with implant-based breast reconstructions. First Author: Jonathan Spoor	Board 67	Abstract 12047: Non-infectious sarcoid-like inflammatory granulomatous conditions (NSIGC) associated with immune checkpoint inhibitors (ICIs) for cancer: Results from the International ICARUS (Immune Checkpoint Associated Rare and Unique Side effects) consortium. First Author: Ayesha Aijaz, MD
Board 56	Abstract 12036: A hierarchical clustering approach to dissect behavioral symptoms in early-stage breast cancer (BC). First Author: Martina Pagliuca, MD	Board 68	Abstract 12048: Identifying genetic susceptibility for severe cardiac events in testicular cancer survivors. First Author: Arkajyoti Bhattacharya, PhD
Board 57	Abstract 12037: Systematic review of prognostic models for cardiomyopathy and heart failure applicable to survivors of adolescent and young adult cancer. First Author: Louise Guolla, MD, FRCPC, MSc, PhD(c)	Board 69	Abstract 12049: Prevalence of sexual dysfunction among men with cancer before the initiation of systemic treatment. First Author: Mario Machado Lopes
Board 58	Abstract 12038: Out of touch: Understanding the frequency and trajectory of chemotherapy-induced neuropathy peripheral (CIPN) in breast cancer survivors. First Author: Savannah Liddell, MD	Board 70	Abstract 12050: A pilot exercise program in breast cancer survivors: Group vs individual training outcomes. First Author: Lindsey Elizabeth Merifield, BS
Board 59	Abstract 12039: Single-cell RNA sequencing atlas of intestinal injury induced by different clinical treatments in colorectal cancer patients. First Author: Luoxi He, BM	Board 71	Abstract 12051: Trajectories of multidimensional worry in survivors of early breast cancer (BC). First Author: Antonio Di Meglio, MD, PhD
Board 60	Abstract 12040: Incidence of ocular toxicities in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin: A systematic review and meta-analysis of phase 3 randomized controlled trials. First Author: Riccesha Hattin, DO	Board 72	Abstract 12052: Prospective observational study on health resource utilization and patterns of care for skeletal-related events in patients with bone metastases secondary to solid tumors. First Author: Mahmoud Abdelsatar Elshenawy, PhD
Board 61	Abstract 12041: Risk of non-breast cancer-related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. First Author: Varsha Gupta, MD	Board 73	Abstract 12053: Hot flashes and night sweats in women with breast cancer: Prevalence and severity of symptoms. First Author: Long Lin
Board 62	Abstract 12042: Incidence of venous thromboembolism (VTE) events in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and combined meta-analysis of phase 3 randomized controlled trials. First Author: Hazem Aboaid, MD	Board 75	Abstract 12055: Cardiovascular risk factor severity and adverse cardiovascular events: A report from the Childhood Cancer Survivor Study (CCSS). First Author: Wendy Bottinor, MD
Board 63	Abstract 12043: Radioimmunotherapy-associated myeloid neoplasms: Real-world multicenter retrospective study using TriNetX database. First Author: Nikhil Vojjala	Board 76	Abstract 12056: Impact of neighborhood disadvantage and residential isolation on cognitive outcomes in cancer survivors. First Author: Noha Sharafeldin, MD, PhD, MBBCh, MSc
Board 64	Abstract 12044: Multisite validation of biomechanical computed tomography for osteoporosis assessment and fracture prediction in patients with high-risk or metastatic prostate cancer. First Author: Samuel L. Washington III, MD	Board 77	Abstract 12057: Pilot study of a muscadine grape extract supplement to decrease fatigue among older cancer survivors. First Author: Heidi D. Klepin, MD, MS, FASCO
Board 65	Abstract 12045: Impact of pembrolizumab on geriatric syndromes in older patients with NSCLC: A propensity-matched retrospective cohort study. First Author: Elvis Obomanu, MBBS	Board 78	Abstract 12058: Trends and disparities in palliative care utilization in advanced head and neck cancer hospitalizations. First Author: Ayobami Gbenga Olafimihan, MD
		Board 79	Abstract 12059: A phase 1b study of SHR-2017, a RANKL/NGF targeted antibody, in patients (pts) with breast cancer bone metastasis. First Author: Xu Liang, MD

- Board 80 **Abstract 12060:** Baseline circulating growth differentiation factor-15 and the cancer phenotype in the PROACC-1 phase 2 study of the efficacy and safety of onsegregomab in patients with cancer cachexia.
First Author: Eric Roeland, MD, FAAHPM, FASCO
- Board 81 **Abstract 12061:** IPElife: Phase III, double-blind trial of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer.
First Author: Danielli Matias, MD
- Board 82 **Abstract 12062:** eHealth disease educational intervention vs. outpatient palliative care as usual among incurable cancer patients cared by family caregivers at home.
First Author: Ying Yu
- Board 83 **Abstract 12063:** Impact of elinzanetant on sleep disturbances and quality of life in women undergoing adjuvant endocrine therapy for breast cancer: Phase 3 OASIS 4 trial.
First Author: Donal J. Brennan
- Board 84 **Abstract 12064:** Nationwide trends and disparities in end-of-life care for acute myeloid leukemia: A 2019–2021 NIS analysis of palliative care utilization and hospitalization costs.
First Author: Nandhini Iyer, MD
- Board 85 **Abstract 12065:** Early palliative care, intensity of end-of-life care, and their impact on overall survival in cancer patients: A real-world study.
First Author: Sebastien Salas, MD, PhD
- Board 86 **Abstract 12066:** Socioeconomic disparities in palliative care utilization among children with late-stage bone and soft tissue sarcomas: A National Cancer Database analysis.
First Author: Paul Phan, BS
- Board 87 **Abstract 12067:** Androgen deprivation therapy and quality of life: A concept map analysis.
First Author: David Lazris, MD
- Board 88 **Abstract 12068:** Care needs and considerations for implementing a community-based palliative care program for women with breast or cervical cancer in three Nigerian states.
First Author: Igoche David Peter, MPH, MBBS
- Board 89 **Abstract 12069:** Granisetron transdermal delivery system for nausea and vomiting prophylaxis in HER2-positive metastatic breast cancer patients receiving pyrotinib and capecitabine: A single-arm phase II study.
First Author: Jun Cao
- Board 90 **Abstract 12070:** Efficacy of Chinese medicine compound Fufang E'jiao Syrup for symptom burden of cancer-related fatigue in patients with advanced cancer: A randomized clinical trial.
First Author: Shanshan Gu, MD
- Board 92 **Abstract 12072:** Single low-dose 5-mg versus 8-mg dexamethasone with NEPA for the 168-h prevention of highly or moderately emetogenic (high-risk patients) chemotherapy-induced nausea/vomiting: An open-label, randomised, controlled, phase 3 trial.
First Author: Xiao Li Xiao, DHSc
- Board 93 **Abstract 12073:** A novel staging system for cancer cachexia.
First Author: Syed Hasan Raza Jafri, MBBS

- Board 94 **Abstract 12074:** Machine learning models to predict skeletal-related events in bone metastasis from advanced cancer.
First Author: Hirohata Miyashita, MD
- Board 95 **Abstract 12075:** Virtual reality for pain and anxiety management during bone marrow biopsy: A systematic review.
First Author: Ronak Patel, MD
- Board 96 **Abstract 12076:** Multidisciplinary and multi-institutional cancer symptom management strategies in the Veterans Affairs: A mixed methods study.
First Author: Johanna Balas, MD
- Board 97 **Abstract 12077:** Comparison of outcomes for patients diagnosed with small cell lung cancer between a university and safety net hospital.
First Author: Ahmad Karkash, MD
- Board 98 **Abstract 12078:** Disparities in receipt of palliative interventions across disaggregated Hispanic subgroups with late-stage colon cancer in the United States.
First Author: Coby Garcia
- Board 99 **Abstract 12079:** A patient advocacy-focused rehabilitation pilot program: Real-life experience in enhancing quality of life for metastatic lung cancer patients.
First Author: Shani Shilo, PhD, DDS
- Board 100 **Abstract 12080:** Muscle mass evaluation among ambulatory cancer patients in China: Comparison of different methods and association with survival.
First Author: Yanfei Wang
- Board 101 **Abstract 12081:** The impact of cannabis use on patient outcomes post immune checkpoint inhibitor (ICI) therapy in a longitudinal observational trial: The DiRECT Cohort.
First Author: Song Yao, MD, PhD
- Board 102 **Abstract 12082:** Outpatient palliative care consultation and end-of-life outcomes among a retrospective cohort of patients treated with immunotherapy for non-small cell lung cancer.
First Author: Chance Bloomer, MD
- Board 103 **Abstract 12083:** Demographic and clinical factors associated with sleep disturbance in breast cancer survivors.
First Author: Paulina S. Marell, MD
- Board 104 **Abstract 12084:** Trends in inpatient palliative care utilization among adolescents and young adults with metastatic cancer.
First Author: Chiamaka Elsie Nwachukwu, MBBS
- Board 105 **Abstract 12085:** Effectiveness and safety of multimodal analgesic management based on the ERAS concept in the perioperative period of TACE for patients with Intermediate and advanced hepatocellular carcinoma.
First Author: Yanqin Wu
- Board 106 **Abstract 12086:** Evaluating palliative care needs of early-phase clinical trial patients.
First Author: Fionnuala Crowley, MBBSCh
- Board 107 **Abstract 12087:** Impact of palliative care on mortality, length of stay, and hospital charges in common cancers.
First Author: Kalaivani Babu, MBBS

- Board 108 **Abstract 12088:** Early supportive and palliative care referral at a comprehensive cancer center: A seven year study.
First Author: Fernando X. Jerves, MD
- Board 109 **Abstract 12089:** Current patterns of care: Referral to palliative care for patients with metastatic gynecologic cancer.
First Author: Lea Tan, BA
- Board 110 **Abstract 12090:** Depression in patients with advanced prostate cancer in SWOG advanced cancer clinical trials.
First Author: Robert S. Krouse, MD
- Board 111 **Abstract 12091:** Intravenous selenium to prevent oral mucositis in patients with lymphoma or myeloma undergoing high-dose therapy followed by autologous hematopoietic cell transplantation: A double-blind randomized trial.
First Author: Corentin Orvain
- Board 112 **Abstract 12092:** The impact of early versus late palliative care referral (PCR) on healthcare utilization in pancreatic cancer patients: A single-center retrospective study.
First Author: Kriti Dhamija, MD
- Board 113 **Abstract 12093:** Differences in supportive care service utilization among long term metastatic breast cancer survivors by rurality.
First Author: Ashley Pariser Davenport, MD
- Board 114 **Abstract 12094:** Race and correlates of cancer cachexia in the Detroit Research on Cancer Survivors cohort.
First Author: Jennifer Lynn Beebe-Dimmer, PhD, MPH
- Board 115 **Abstract 12095:** Barriers to palliative care access in patients with brain metastases: A comprehensive national study.
First Author: Anastasia Amundson
- Board 116 **Abstract 12096:** Age-specific unmet needs among older patients with cancer enrolled in an outpatient palliative care program: A retrospective analysis.
First Author: Sarah Ananda Gomes, MD
- Board 117 **Abstract 12097:** Disparities in cachexia and anorexia in hospitalized female patients with breast cancer: A national population-based study.
First Author: Amro Awad, MD
- Board 118 **Abstract 12098:** Economic outcomes of palliative care in colorectal cancer hospitalizations: A propensity-matched retrospective cohort study on resource utilization.
First Author: Elvis Obomanu, MBBS
- Board 119 **Abstract 12099:** "The telehealth means I get distance from the hospital so I don't feel so much like a patient": A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations.
First Author: Rachel Campbell
- Board 120 **Abstract 12100:** Telemedicine-enabled synchronous medical oncology and home hospice visits.
First Author: Sara Dost, MD
- Board 121 **Abstract 12101:** Evaluating the feasibility of a peer-support group for patients with cancer (presently).
First Author: Brandon Anderson, MD
- Board 122 **Abstract 12102:** Quality of life among oncology patients with distinct spiritual well-being profiles.
First Author: Kayoll G. Gyan, PhD, BSN
- Board 123 **Abstract 12103:** Awareness of gestational surrogacy among female patients treated for cancer: A national survey.
First Author: Alexa Steckler, BA
- Board 124 **Abstract 12104:** Inclusion of gestational surrogacy in oncologist-led fertility counseling at cancer diagnosis: A national survey.
First Author: Alexa Steckler, BA
- Board 125 **Abstract 12105:** Using large language models to assess adherence to ASCO patient-oncologist communication standards.
First Author: Joshua Davis
- Board 126 **Abstract 12106:** The association between emotional distress prior to receiving immune checkpoint inhibitors and overall survival among patients with cancer: A population-based study.
First Author: Luciana Beatriz Mendes Gomes Siqueira, MD
- Board 127 **Abstract 12107:** Effect of a single home visit on distress in cancer patients undergoing chemotherapy: A comparative study.
First Author: Mila Petrova, MD, PhD
- Board 129 **Abstract 12109:** Promoting resilience in stress management within patients with early stage breast cancer.
First Author: Gabrielle Betty Rocque, MD, FASCO
- Board 130 **Abstract 12110:** Systematic screening of perception of curability among patients with advanced cancer: A longitudinal analysis.
First Author: Kayley Ancy, MD
- Board 131 **Abstract 12111:** A longitudinal analysis of social networks and patient-reported outcomes among young adult cancer survivors.
First Author: Katie Darabos, PhD, MS
- Board 132 **Abstract 12112:** Is metastatic cancer curable? A survey of medical oncologists.
First Author: Shalini Subramaniam, FRACP, MMed, MBBS
- Board 133 **Abstract 12113:** Sexual health communication and young-onset cancer (YOC): Healthcare practitioners' attitudes and practices.
First Author: Louise Kelly
- Board 134 **Abstract 12114:** Shared decision-making in follow-up care for lung cancer screening.
First Author: Nihal Mohamed
- Board 135 **Abstract 12115:** Temporal trends of suicide among cancer patients: A SEER database analysis from 2000 to 2021.
First Author: Ahmed Bashir Sukhera, MD
- Board 136 **Abstract 12116:** Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring following therapy.
First Author: Maria Antonia Velez Velez, MD, MS

Board 137 **Abstract 12117:** Equivalence of Ina, an AI-based nutrition platform, to human dietitians for counseling patients with cancer.
First Author: Marissa Buchan, CCRP, RD, MS

Board 138 **Abstract 12118:** Immune profiling to identify predictive biomarkers and highlights the potential efficacy of IL-6R blockade in checkpoint inhibitor-related myocarditis.
First Author: Michel Obeid, MD, PhD

Board 139 **Abstract 12119:** Comparison of two electroacupuncture regimens on symptoms and brain structures in breast cancer survivors: A randomized, controlled trial.
First Author: Alexandre Chan, PharmD, BCOP, FCCP, MPH

Board 140 **Abstract 12120:** MOLGEN: Detecting new DPYD variants for the safer delivery of 5FU and capecitabine.
First Author: Helen Winter

Board 141 **Abstract 12121:** NG11-2 phase-Ib trial to prevent/reduce severe oral mucositis induced by radiotherapy.
First Author: Mary Lei, MD, FRCR, MBBS

Board 142 **Abstract 12122:** Examining the link between p16, an aging biomarker, and a clinically meaningful functional outcome in older adults with early breast cancer.
First Author: Chaipayorn Charles Vatanatham, MD

Board 143 **Abstract 12123:** Effect of IV magnesium supplementation in reducing adverse cisplatin associated kidney outcomes.
First Author: Ekta Panjrolia, DO

Board 144 **Abstract 12124:** Exploring unmet needs in radiation-induced nausea and vomiting after moderately emetogenic treatment.
First Author: Sarah Arn Lowry, DNP

Board 145 **Abstract 12125:** Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates.
First Author: Emre Yekeduz, MD

Board 146 **Abstract 12126:** CDK4/6 inhibitor toxicity in geriatric subgroups: Evidence from the FAERS database.
First Author: Bahadır Köylü

Board 147 **Abstract 12127:** Impact of health literacy in cancer outpatients receiving oral anticancer drugs and followed by the ONCORAL multidisciplinary city-hospital educational follow-up: The LITTORAL study.
First Author: Chloé Herledan, PhD, PharmD

Board 148 **Abstract 12128:** Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy.
First Author: Laura Carpin Kennedy, MD, PhD

Board 149 **Abstract 12129:** Association of IL7 germline variants with immune-related adverse events (irAEs) in cancer patients (pts) treated with immune checkpoint inhibitors (ICIs).
First Author: Eddy Saad, MD, MS

Board 150 **Abstract 12130:** Impact of cancer related fatigue on quality of life of 1,262 patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide phase III RCT.
First Author: Jeremy McGuire, PhD, MS

Board 151 **Abstract 12131:** Virtual yoga (vYOCAS) intervention for psychological distress: A decentralized digital randomized controlled trial with cancer survivors.
First Author: Po-Ju Lin, PhD, RD, MPH

Board 152 **Abstract 12132:** Immune-related endocrinopathy in cancer patients receiving immune checkpoint inhibitor therapy in the nationwide prospective DIRECT cohort.
First Author: Hala Awad, BScPharm, MSc, PharmD, PhD(c), MS

Board 153 **Abstract 12133:** Glucagon-like peptide-1 receptor agonists and the risk of chemotherapy-induced peripheral neuropathy in patients with diabetes: A real-world study.
First Author: Xiaocao Xu, MD

Board 155 **Abstract 12135:** Association between epigenetic clocks and chemotoxicity in older adults with early breast cancer.
First Author: Jingran Ji, MD

Board 156a **Abstract TPS12136:** In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: BREATHS trial.
First Author: Eva Hernandez-Garcia, MPhil, MSc, MSc

Board 156b **Abstract TPS12137:** Social genomic mechanisms of health disparities among adolescent/young adult survivors of Hodgkin and non-Hodgkin lymphoma: ECOG-ACRIN EAQ211.
First Author: Brad J. Zebrack

Board 157a **Abstract TPS12138:** Testosterone replacement therapy for fatigue, sexual dysfunction, and quality of life in older men with cancer (TEMEC).
First Author: Egidio Del Fabbro, MD

Board 157b **Abstract TPS12139:** Randomized trial of a clinical nurse specialist-led enhanced survivorship and early palliative care intervention for patients with metastatic cancer.
First Author: Megha Schmalzle, BS

Board 158a **Abstract TPS12140:** Fecal microbiota transplantation (FMT) for opioid-induced constipation (OIC): A prospective, multicenter, single-arm, phase II clinical study.
First Author: Xiaoying Wang

Board 158b **Abstract TPS12141:** A randomized phase III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for participants with painful non-spine bone metastases (NCT06391242).
First Author: Arjun Sahgal

Board 159a **Abstract TPS12142:** A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.
First Author: Eric Roeland, MD, FAAHPM, FASCO

- Board 159b **Abstract TPS12143:** Supervised home-based exercise in patients with advanced non-small cell lung cancer (NSCLC) on maintenance immune checkpoint inhibitors (ICI).
First Author: Justin Wang Shi, MD
- Board 160a **Abstract TPS12144:** Virtual personalized exercise program for subjects with lung cancer: A feasibility study.
First Author: Melissa Francoise Neumann, MD
- Board 160b **Abstract TPS12145:** An open-label randomized trial of exercise ± creatine supplementation to augment the adaptations of exercise training in cancer survivors.
First Author: Darpan Patel, PhD, MS
- Board 161a **Abstract TPS12146:** A pilot study of the ApricityCare program for early detection and management of treatment-related adverse events in patients with metastatic cancer.
First Author: Lily Chen, MD
- Board 161b **Abstract TPS12147:** ACTIVATE: A pilot randomized activity coaching trial to increase vitality and energy during post-operative pelvic radiation therapy for endometrial cancer.
First Author: Avani Dholakia Rao, MD
- Board 162a **Abstract TPS12148:** A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi).
First Author: Jingran Ji, MD
- Board 162b **Abstract TPS12149:** Epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity treated with topical application of a novel Staphylococcus epidermidis compound.
First Author: Mary C. Spellman, MD

3:00 PM-4:00 PM Case-Based Panel

Endometrial Cancer: A New Staging System

Location: S103

Brittany Anne Davidson, MD—Chair

Duke Cancer Institute

Moderator

David K. Gaffney, MD, PhD

The University of Utah

Radiation Oncologist Perspective

Carol Aghajanian, MD

Memorial Sloan Kettering Cancer Center

Medical Oncologist Perspective

Alison Brand, MD, MMed

Crown Princess Mary Cancer Centre

Gynecologic Oncologist Perspective

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open

Location: E450b

Jason J. Luke, MD, FACP, FASCO

UPMC Hillman Cancer Center and University of Pittsburgh

Novel and Emerging Therapies for Melanoma Progression After Checkpoint Therapy

Evan J. Lipson, MD

Johns Hopkins University

Standard-of-Care Therapies for Melanoma Recurrence After Checkpoint Inhibition

Pauline Funchain, MD—Chair

Stanford Cancer Institute

irAEs and Autoimmune Disease: What to Do When Checkpoint Blockade is Contraindicated

Panel Question and Answer

3:00 PM-4:15 PM Education Session

Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations

Location: E451

Kevin Soares, MD

Memorial Sloan Kettering Cancer Center

Novel Strategies to Stimulate the Immune System to Treat Pancreatic Cancer

Kim Anna Reiss, MD

University of Pennsylvania

Innovations and Challenges in Targeting Treatment for Pancreatic Cancer

Bishal Gyawali, MD, PhD, FASCO—Chair

Queen's University

Enhancing the Generation, Interpretation, and Communication of Evidence About Pancreatic Cancer

Panel Question and Answer

3:00 PM-4:30 PM Clinical Science Symposium

Biomarker-Driven Adaptive Therapy: New Horizons in Head and Neck Cancer

Location: S102

Aarti K. Bhatia, MD, MPH—Chair

Yale School of Medicine

Assuntina G. Sacco, MD—Chair

UC San Diego Moores Cancer Center

3:00 PM Paul Swiecicki, MD

University of Michigan

Redefining Treatment Paradigms in the Era of Biomarker-Driven Risk-Adaptive Cancer Therapy

3:12 PM

Abstract 6009: Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in patients with HPV-positive oropharyngeal cancer (ReACT 1.0).
First Author: Glenn J. Hanna, MD

3:24 PM

Abstract 6010: Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial.
First Author: Ying Sun, PhD

- 3:36 PM** **Jean-Pascal H. Machiels, MD**
Universite Catholique De Louvain
Discussion of Abstract(s) 6009-6010: Smart Blood, Smarter Therapy: Adapting Treatment in Real Time
- 3:48 PM** **Abstract 6011: REMATCH2201: A phase II study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapy.**
First Author: Kunyu Yang
- 4:00 PM** **Anil K. D'Cruz, MS, MBBS, DNB**
Apollo Hospitals
Discussion of Abstract(s) 6011: Cut Less, Cure More: Tailoring Surgery to Response
- 4:12 PM** Panel Question and Answer

3:00 PM-4:30 PM Clinical Science Symposium

New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy

Location: Hall D1

Fatima Karzai, MD—Chair

National Cancer Institute, National Institutes of Health

Emmanuel S. Antonarakis, MD—Chair

University of Minnesota, Masonic Cancer Center

- 3:00 PM** **Jorge A. Garcia, MD, FACP**
Seidman Cancer Center University Hospitals
Radioligand Therapies in Prostate Cancer: Hits, Misses, and Next Steps
- 3:12 PM** **Abstract 5009: Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial).**
First Author: Bastiaan M. Privé, MD, PhD
- 3:24 PM** **Atish Dipankar Choudhury, MD, PhD**
Dana-Farber Cancer Institute
Discussion of Abstract(s) 5009: Radioligand Therapies Unplugged: Is It Time to Break up With Androgen Deprivation Therapy?
- 3:36 PM** **Abstract 5010: First-in-human results of terbium-161 [¹⁶¹Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.**
First Author: James Patrick Buteau, MD
- 3:48 PM** **Abstract 5011: Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [¹⁷⁷Lu] Lu-PSMA-617 (ANZUP1901).**
First Author: Louise Emmett, MD, MBChB, FRACP
- 4:00 PM** **Jeremie Calais, MD, PhD**
University of California, Los Angeles
Discussion of Abstract(s) 5010-5011: Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track
- 4:12 PM** Panel Question and Answer

3:00 PM-4:30 PM Rapid Oral Abstract Session

Pediatric Oncology

Location: S504

Mark A. Applebaum, MD—Chair

University of Chicago

Fariba Navid, MD—Chair

Children's Hospital Los Angeles

- 3:00 PM** **Abstract 10018: Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium's phase 2 study cHOD17 (NCT03755804).**
First Author: Jamie Flerlage
- 3:06 PM** **Abstract 10019: Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children's Oncology Group AHOD1331.**
First Author: Sarah Milgrom
- 3:12 PM** **Abstract 10020: Mortality in survivors of childhood cancer diagnosed with subsequent thyroid cancer: A report from the Childhood Cancer Survivor Study.**
First Author: Dana Barnea, MD
- 3:18 PM** Panel Question and Answer
- 3:30 PM** **Abstract 10021: Social determinants of health (SDOH) and late mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).**
First Author: Cindy Im, PhD
- 3:36 PM** **Abstract 10022: Five-year cardiomyopathy risk prediction in survivors of childhood cancer using electrocardiogram.**
First Author: Luke Patterson, MS
- 3:42 PM** **Abstract 10023: Does early phase study enrollment for pediatric oncology patients have an impact on symptom burden and quality of life (QOL)? A national Canadian study report.**
First Author: Kendra Rodden, BA
- 3:48 PM** Panel Question and Answer
- 4:00 PM** **Abstract 10024: Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I_hIVA) in newly diagnosed very high-risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).**
First Author: Hans Merks, MD, PhD
- 4:06 PM** **Abstract 10025: Integrated molecular characterization of pediatric soft tissue sarcomas: A report from the COG and CCID molecular characterization initiative.**
First Author: Sapna Oberoi, MD
- 4:12 PM** **Abstract 10026: Gut microbiome changes in pediatric AML and association with event free survival.**
First Author: Oren Gordon, MD
- 4:18 PM** Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Breast Cancer—Local/Regional/Adjuvant

Location: Hall B1

Kari Braun Wisinski, MD—Chair

University of Wisconsin Carbone Cancer Center

Oluwadamilola Motunrayo Fayanju, MD—Chair

Perelman School of Medicine, University of Pennsylvania

- 3:00 PM Abstract LBA500:** De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
First Author: Hong-Fei Gao, MD
- 3:12 PM Abstract 501:** Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
First Author: Nadine M. Tung, MD, FASCO
- 3:24 PM Abstract 502:** Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
First Author: Monika Karla Graeser, MD
- 3:36 PM Sara A. Hurvitz, MD, FACP**
Fred Hutch at University of Washington Medical Center
Discussion of Abstract(s) LBA500-502: What Is the Right-Size Treatment for HER2?
- 3:48 PM** Panel Question and Answer
- 4:00 PM Abstract 503:** Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).
First Author: Maggie Banys-Paluchowski, PhD
- 4:12 PM Abstract 504:** Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
First Author: Rita Mukhtar, MD
- 4:24 PM Mediget Teshome, MD, FACS, MPH**
UCLA Health Jonsson Comprehensive Cancer Center
Discussion of Abstract(s) 503-504: Do We "Node" What to Do About the Axilla?
- 4:36 PM** Panel Question and Answer
- 4:48 PM Abstract 505:** 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.
First Author: Prudence A. Francis, MD, FRACP
- 5:00 PM Abstract 506:** Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor-positive breast cancer: Results from the ASTRRA trial.
First Author: Jai Min Ryu
- 5:12 PM Abstract 507:** The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.
First Author: Paola Zagami, MD

- 5:24 PM Abstract 508:** Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.
First Author: Fatima Cardoso, MD
- 5:36 PM Michael Gnant, MD, FACS**
Comprehensive Cancer Center, Medical University of Vienna and Austrian Breast and Colorectal Cancer Study Group
Discussion of Abstract(s) 505-508: Navigating the Long Haul: Enduring Effects of Endocrine Therapy
- 5:48 PM** Panel Question and Answer
-
- 3:00 PM-6:00 PM Oral Abstract Session**
Care Delivery/Models of Care
Location: S100bc
- Dawn L. Hershman, MD, MS, FASCO—Chair**
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
- Nathan Handley, MD, MBA—Chair**
Sidney Kimmel Cancer Center at Jefferson Health
- 3:00 PM Abstract 1500:** Pharmacist-led medication reconciliation televisit (MRT) for phase 1 oncology clinical trials: A telemedicine model.
First Author: Sarah O'Neill, PharmD
- 3:12 PM Abstract 1501:** Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model-enrolled oncology practices.
First Author: Daniel Kendzierski, PharmD, BCOP
- 3:24 PM Abstract 1502:** Video-based genetic counseling to reduce physician workload and enhance counselor understanding: A prospective randomized clinical trial.
First Author: Georg Pfeiler, MD
- 3:36 PM Samyukta Mullangi, MD, MBA**
Thyme Care
Discussion of Abstract(s) 1500-1502: Smarter Cancer Care: Telehealth Solutions in Pharmacy and Genetics
- 3:48 PM** Panel Question and Answer
- 4:00 PM Abstract 1503:** Electronic patient-reported outcome-based weight management versus usual care during induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: A phase II randomized controlled trial.
First Author: Qiu-Yan Chen, MD
- 4:12 PM Abstract 1504:** A novel virtual reality supportive care intervention (BMT-VR) for patients undergoing hematopoietic stem cell transplantation (HSCT): A pilot randomized clinical trial.
First Author: Hermioni L. Amonoo, MD, MPH
- 4:24 PM Abstract 1505:** Geriatric assessment and management with a question prompt list using a web-based application to reduce treatment toxicity in older patients with cancer: A randomized controlled trial (J-SUPPORT 2101 study).
First Author: Ayumu Matsuoka, MD, PhD
- 4:36 PM To be determined**
Discussion of Abstract(s) 1503-1505: Click, Engage, Heal: Digital Innovations to Reduce Cancer Treatment Toxicity

- 4:48 PM** Panel Question and Answer
- 5:00 PM** **Abstract 1506:** A technology-enabled clinical trial program's impact on patient screening and trial enrollment in 2024.
First Author: Samantha Mallahan
- 5:12 PM** **Abstract 1508:** Effect of Human-AI Teams on Oncology Prescreening: Final Analysis of a Randomized Trial.
First Author: Ravi Bharat Parikh, MD, MPP
- 5:24 PM** **Travis Zack, MD, PhD**
UCSF Hematology/Oncology
Discussion of Abstract(s) 1506-1508: Artificial Intelligence Unleashed: Revolutionizing Oncology Trials Through Smart Screening, Precision Metrics, and Human-Artificial Intelligence Synergy
- 5:36 PM** Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant

Location: S100a

Rita Assi, MD—Chair

Indiana University

Mark J. Levis, MD, PhD—Chair

Johns Hopkins University

- 3:00 PM** **Abstract 6500:** Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.
First Author: Ruben A. Mesa, MD
- 3:12 PM** **Abstract 6501:** Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
First Author: Andreas Hochhaus, MD
- 3:24 PM** **Abstract 6502:** Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study.
First Author: Naveen Pemmaraju, MD
- 3:36 PM** **Raajit Rampal, MD, PhD**
Memorial Sloan Kettering Cancer Center
Discussion of Abstract(s) 6500-6502: Advancing Hope: Novel Treatments for Myeloproliferative Neoplasms and Blastic Plasmacytoid Dendritic Cell Neoplasm
- 3:48 PM** Panel Question and Answer
- 4:00 PM** **Abstract 6503:** Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes.
First Author: Guillermo Montalban-Bravo, MD

- 4:12 PM** **Abstract 6504:** An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.
First Author: Amer Methqal Zeidan, MBBS
- 4:24 PM** **Abstract 6505:** Phase 1b/2 study of lisafitoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.
First Author: Michael Francis Leahy, FRACP, FRCP, FRCPATH, MBChB
- 4:36 PM** **Abstract 6506:** Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
First Author: Eunice S. Wang, MD
- 4:48 PM** **To be determined**
Discussion of Abstract(s) 6503-6506: Shaping the Future of Acute Myeloid Leukemia and Myelodysplastic Syndromes Therapy
- 5:00 PM** Panel Question and Answer
- 5:12 PM** **Abstract 6507:** γδ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION.
First Author: Pierre Dumas
- 5:24 PM** **Abstract 6508:** Long-term outcomes of patients surviving beyond 2 years post-allogeneic stem cell transplantation.
First Author: Nihar Desai, MD, DM
- 5:36 PM** **To be determined**
Discussion of Abstract(s) 6507-6508: Immuno- and Cellular Therapy: New and Old
- 5:48 PM** Panel Question and Answer

3:00 PM-6:00 PM Oral Abstract Session

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Arie Crown Theater

Abdul Rafeh Naqash, MD—Chair

Stephenson Cancer Center at The University of Oklahoma Health Sciences Center

C. S. Pramesh, MBBS, MS, FRCS—Chair

Tata Memorial Centre

- 3:00 PM** **Abstract LBA8000:** Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
First Author: Patrick M. Forde, MD, PhD
- 3:12 PM** **Abstract 8001:** Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
First Author: Jamie E. Chaft, MD, FASCO

- 3:24 PM Abstract 8002:** Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.
First Author: Wei Liao, PhD, MS
- 3:36 PM Lizza Hendriks, MD, PhD**
Maastricht University Medical Centre, GROW School for Oncology and Reproduction
Discussion of Abstract(s) LBA8000-8002: The Earlier the Better? From Detection to Treatment of Localized Lung Cancer
- 3:48 PM** Panel Question and Answer
- 4:00 PM Abstract 8003:** SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.
First Author: Charles B. Simone II, MD
- 4:12 PM Abstract LBA8004:** R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.
First Author: Ming Chen, MD, PhD
- 4:24 PM Abstract LBA8005:** Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).
First Author: Bjorn Henning Gronberg, MD, PhD
- 4:36 PM Shankar Siva, PhD**
Peter MacCallum Cancer Centre
Discussion of Abstract(s) 8003-LBA8005: Turning Up the Sparkle: Fresh Radiation Strategies for Lung Cancer
- 4:48 PM** Panel Question and Answer
- 5:00 PM Abstract 8006:** Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
First Author: Luis G. Paz-Ares, MD, PhD
- 5:12 PM Abstract 8007:** A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.
First Author: Xinghao Ai
- 5:24 PM Abstract LBA8008:** Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary Analysis of Ph3 DeLLphi-304.
First Author: Charles M. Rudin, MD, PhD
- 5:36 PM Catherine Belle Meador, MD, PhD**
Massachusetts General Hospital Cancer Center
Discussion of Abstract(s) 8006-LBA8008: Breaking New Ground in Small Cell Lung Cancer: BiTE, TriTE, and Chemoimmunotherapy
- 5:48 PM** Panel Question and Answer

4:30 PM-6:00 PM Clinical Science Symposium

Real-World Immunotherapy: Bridging the Gap Between Trials and Treatment

Location: Hall D2

Kristen Renee Spencer, MPH, DO—Chair
Perlmutter Cancer Center, NYU Langone Health

Elena Elez, MD, PhD—Chair
Vall d'Hebron Institute of Oncology

- 4:30 PM Timothee Olivier, MD**
Hôpitaux Universitaires de Genève
Immunotherapy in Action: Optimizing Delivery of Checkpoint Blockade in the Real World
- 4:42 PM Abstract 2509:** Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India).
First Author: Vanita Noronha, MD
- 4:54 PM Abstract 2510:** Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.
First Author: Francis Albert Lévi, MD, PhD
- 5:06 PM To be determined**
Discussion of Abstract(s) 2509-2510: New Recipes for Success: Adapting the Oncologic Cookbook
- 5:18 PM Abstract 2511:** Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis.
First Author: Muntaser Al Zyoud, MD
- 5:30 PM Elad Sharon, MD, MPH**
Dana-Farber Cancer Institute
Discussion of Abstract(s) 2511: Immunotherapy in Special Populations: Solid Organ Transplant and Beyond
- 5:42 PM** Panel Question and Answer

4:45 PM-6:00 PM Education Session

Implementing Evidence-Based Strategies to Improve On-Therapy Pediatric Oncology Infection Management

Location: S504

Adam J. Esbenshade, MD, MSCI—Chair
Vanderbilt School of Medicine
Creating, Validating, and Implementing Clinical Risk Prediction Models in Pediatric Oncology

Lee Dupuis, PhD
Hospital for Sick Children
Creating and Implementing Clinical Practice Guidelines for Febrile Neutropenia

Venkatraman Radhakrishnan, MD, MSc, DM, MBBS
Cancer Institute (WIA)
Implementing Pediatric Infection Initiatives in Low- and Middle-Income Settings

Panel Question and Answer

4:45 PM-6:00 PM Education Session

Scalable and Sustainable Innovations in Global Oncology Care

Location: S103

Rodrigo Dienstmann, MD

Grupo Oncoclinicas

Innovations in Global Oncology: What Is Working?

Fredrick Chite Asirwa, MD, MBChB, FASCO—Chair

International Cancer Institute

The Future of Global Oncology: What Is Next?

Erika Ruiz-Garcia, MD, MS

Instituto Nacional de Cancerología

Adjusting Global Oncology: Mapping Cancer Care in Low- and Middle-Income Countries

Panel Question and Answer

4:45 PM-6:00 PM Education Session

State of the Art in Care of Hepatobiliary Malignancies

Location: E451

Lipika Goyal, MD

Stanford Cancer Institute

Emerging Treatment Paradigms in Bile Duct Cancer

Robin Kate Kelley, MD

University of California San Francisco

State of the Science in the Management of Hepatocellular Carcinoma

Jennifer Yon-Li Wo, MD—Chair

Massachusetts General Hospital

Local Therapy Options in Hepatobiliary Malignancies

Panel Question and Answer

8:00 AM-9:15 AM Highlights of the Day Session

Highlights of the Day III

Location: Hall D1

Amy Jo Chien, MD—Chair

University of California San Francisco

- 8:00 AM** **Jacqueline Sara Jeruss, MD, PhD**
University of Michigan
Breast Cancer—Local/Regional/Adjuvant
- 8:15 AM** **Cornelia Kolberg-Liedtke, MD, PhD**
University Hospital Essen
Gynecologic Cancer
- 8:30 AM** **Selina M. Luger, MD**
University of Pennsylvania
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft
- 8:45 AM** **Eric Kumar Singhi, MD**
The University of Texas MD Anderson Cancer Center
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

8:00 AM-9:15 AM Education Session

Current and Future Directions in Immunotherapies in Myeloma

Location: S102

Reena Jayani-Kosarzycki, MD—Chair

Vanderbilt University Medical Center

Is There Still a Role for Transplant in Myeloma?

Samer Al Hadidi, MD, MS, FACP

University of Arkansas for Medical Sciences

What Is the Current State of Induction With Four-Drug Therapy?

Attaya Suvannasankha, MD

Indiana University School of Medicine

Is It Time to Include Bispecifics Into Upfront Therapy?

Panel Question and Answer

8:00 AM-9:15 AM Education Session

Genomic Insights in Perioperative Decision-Making in Non–Small Cell Lung Cancer: Navigating *EGFR*, *ALK*, and Emerging Biomarkers

Location: E450a

Charu Aggarwal, MD, MPH, FASCO—Chair

Penn Medicine Abramson Cancer Center

Special Populations: Optimizing Perioperative Management Strategies in Patients With EGFR Mutations

Kaushal Parikh, MD

Mayo Clinic

Special Populations: Optimizing Perioperative Management Strategies in Patients With ALK Mutations

Biagio Ricciuti, MD, PhD

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Expanding Horizons: Exploring Emerging Biomarkers in the Perioperative Management of Non–Small Cell Lung Cancer

Panel Question and Answer

8:00 AM-9:15 AM Education Session

State of the Art: Melanoma 3.0T—Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs

Location: S100a

Susan M. Swetter, MD

Stanford University Medical Center and Cancer Institute

Artificial Intelligence for Melanoma Early Detection and Improving Health Equity

Meredith McKean, MD

Sarah Cannon and HCA Research Institute

Novel Targets in Melanoma Treatment

Donald P. Lawrence, MD—Chair

Massachusetts General Hospital and Dana-Farber Cancer Institute

The Future of T-Cell Therapy

Panel Question and Answer

8:00 AM-9:15 AM Education Session

State of the Art: Personalizing Treatment for Patients With mCRPC in 2025

Location: E451

Wassim Abida, MD, PhD—Chair

Memorial Sloan Kettering Cancer Center

Integrating PARP Inhibitors in the Treatment of Prostate Cancer: Timing, Combination Approaches, and Beyond BRCA1/2

Himisha Beltran, MD, FASCO

Dana-Farber Cancer Institute

Non-Androgen-Receptor-Driven Prostate Cancer: Updates in Biology, Classification, and Management

Ruben Raychaudhuri, MD

University of Washington and Fred Hutchinson Cancer Center

How to Get Lutetium-177 PSMA to Those That Will Most Benefit?

Panel Question and Answer

8:00 AM-9:30 AM Rapid Oral Abstract Session

Gynecologic Cancer

Location: S100bc

Michael Carney, MD—Chair

University of Hawaii

Carolyn Muller, MD—Chair

University of New Mexico Health Sciences Center

- 8:00 AM** **Abstract 5509:** Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16.
First Author: Yang Sun
- 8:06 AM** **Abstract 5510:** Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study.
First Author: Jusheng An, MMedSc
- 8:12 AM** **Abstract 5511:** Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.
First Author: Oladapo O. Yeku, MD, PhD, FACP
- 8:18 AM** Panel Question and Answer

- 8:30 AM Abstract 5512:** Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.
First Author: Shannon Neville Westin, MD, FASCO
- 8:36 AM Abstract 5513:** Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)-positive recurrent endometrial cancer (EC).
First Author: Panagiotis A. Konstantinopoulos, MD, PhD
- 8:42 AM Abstract 5514:** Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC).
First Author: Silvia Damian, MD
- 8:48 AM** Panel Question and Answer
- 9:00 AM Abstract 5515:** A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
First Author: Elizabeth Katherine Lee, MD
- 9:06 AM Abstract 5516:** A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
First Author: Premal H. Thaker, MD
- 9:12 AM Abstract 5517:** Safety and efficacy of BAT8006, a folate receptor α (FR α) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.
First Author: Songling Zhang, MD, PhD
- 9:18 AM** Panel Question and Answer

9:45 AM-11:15 AM Clinical Science Symposium

Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies

Location: E451

Lecia V. Sequist, MD, MPH, FASCO—Chair
Massachusetts General Hospital

Adrian G. Sacher, MD, FRCPC, MMedSc—Chair
Princess Margaret Cancer Centre, University Health Network

- 9:45 AM Hirva Mamdani, MD**
Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine
Bispecific Antibodies in Action: Engineering Immunity to Target Thoracic Malignancies
- 9:57 AM Abstract 8509:** First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).
First Author: Jianya Zhou, MD
- 10:09 AM Abstract 8510:** Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study.
First Author: Lin Shen

- 10:21 AM Abstract 8511:** First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.
First Author: Ying Cheng, MD
- 10:33 AM Lavinia Tan, PhD, MBBS**
Peter MacCallum Cancer Centre
Discussion of Abstract(s) 8509-8511: Teamwork Makes the Dream Work: Bringing the Immune System Together
- 10:45 AM** Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Genitourinary Cancer—Prostate, Testicular, and Penile

Location: Hall D1

Marie Carlo, MD—Chair

Memorial Sloan Kettering Cancer Center

Maria T. Bournon, MD, MSc, FASCO—Chair

Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

- 9:45 AM Abstract 5000:** Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer.
First Author: Theodore L. DeWeese, MD
- 9:57 AM Abstract 5001:** Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
First Author: Charles Thomas Andrew Parker
- 10:09 AM Angela Y Jia, MD, PhD**
University Hospitals Seidman Cancer Center, Case Western Reserve University
Discussion of Abstract(s) 5000-5001: Better Treatments, Better Selection: Improving Patient Outcomes in Localized Prostate Cancer
- 10:21 AM** Panel Question and Answer
- 10:33 AM Abstract 5002:** Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.
First Author: Michael Ong, MD, FRCPC
- 10:45 AM Abstract 5003:** Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials.
First Author: Emily Grist, PhD, MBBS, MRCP
- 10:57 AM Abstract 5004:** Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial.
First Author: Alicia K. Morgans, MD, MPH, FASCO

- 11:09 AM Abstract 5005:** ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Andrew J. Armstrong, MD, MS
- 11:21 AM Rahul Raj Aggarwal, MD**
University of California, San Francisco
Discussion of Abstract(s) 5002-5005: Tailoring Therapy in Castration-Sensitive Prostate Cancer: Do Biomarkers Make the Cut?
- 11:33 AM** Panel Question and Answer
- 11:45 AM Abstract LBA5006:** Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
First Author: Gerhardt Attard, MD, PhD, FRCP
- 11:57 AM Abstract 5007:** A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
First Author: Rana R. McKay, MD, FASCO
- 12:09 PM Abstract 5008:** C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC).
First Author: Ana Aparicio, MD
- 12:21 PM Joaquin Mateo, MD, PhD**
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital
Discussion of Abstract(s) LBA5006-5008: Parp Up the Volume! Combination Strategies in Advanced Prostate Cancer
- 12:33 PM** Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Location: S100bc

Brandon Jamaal Blue, MD—Chair

Moffitt Cancer Centers

Rafat Abonour, MD—Chair

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

- 9:45 AM Abstract 7500:** MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.
First Author: Aurore Perrot, MD, PhD
- 9:57 AM Abstract 7501:** Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.
First Author: Philippe Moreau, MD, PhD

- 10:09 AM Abstract 7502:** Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).
First Author: Francesca Gay, MD, PhD
- 10:21 AM Abstract 7503:** Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
First Author: Carl Ola Landgren, MD, PhD
- 10:33 AM Suzanne Lentzsch, MD, PhD**
Columbia University Irving Medical Center
Discussion of Abstract(s) 7500-7503: Does the Road to Cure Myeloma End with Minimal Residual Disease?
- 10:45 AM** Panel Question and Answer
- 10:57 AM Abstract 7504:** Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1.
First Author: Hang Quach, MD, FRACP, FRCPA
- 11:09 AM Abstract 7505:** First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
First Author: Niels W.C.J. van de Donk, MD, PhD
- 11:21 AM Abstract 7506:** Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
First Author: Sikander Ailawadhi, MD
- 11:33 AM Amrita Y. Krishnan, MD**
City of Hope Comprehensive Cancer Center
Discussion of Abstract(s) 7504-7506: New Roads in Myeloma
- 11:45 AM** Panel Question and Answer
- 11:57 AM Abstract 7507:** Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Peter M. Voorhees, MD
- 12:09 PM Abstract 7508:** Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201.
First Author: Heather Jolie Landau, MD
- 12:21 PM Krina K. Patel, MD, MSc**
The University of Texas MD Anderson Cancer Center
Discussion of Abstract(s) 7507-7508: BCMA-CAR T, One Treatment, Two Diseases
- 12:33 PM** Panel Question and Answer

9:45 AM-12:45 PM Oral Abstract Session

Melanoma/Skin Cancers

Location: S100a

Michael A. Postow, MD—Chair

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College

Teresa M. Petrella, MD, FRCP—Chair

Sunnybrook Health Sciences Centre

- 9:45 AM** **Abstract LBA9500:** Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
First Author: Georgina V. Long, MD, PhD, FRACP
- 9:57 AM** **Abstract LBA9501:** Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
First Author: Alexander Christopher Jonathan van Akkooi, MD, PhD, FRCS
- 10:09 AM** **Abstract 9502:** Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.
First Author: John Miura, MD
- 10:21 AM** **Ana Maria Arance, MD, PhD**
Hospital Clinic Barcelona and IDIBAPS
Discussion of Abstract(s) LBA9500-9502: Treating the Invisible Enemy: Is the Gamble Worth It?
- 10:33 AM** Panel Question and Answer
- 10:45 AM** **Abstract 9503:** NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
First Author: Tina J. Hieken, MD
- 10:57 AM** **Abstract LBA9504:** Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis.
First Author: Meghan Mooradian, MD

- 11:09 AM** **Abstract LBA9505:** A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
First Author: Ahmad A. Tarhini, MD, PhD
- 11:21 AM** **Rodabe Navroze Amaria, MD**
The University of Texas MD Anderson Cancer Center
Discussion of Abstract(s) 9503-LBA9505: Neoadjuvant Survivor: Who Stays on the Island?
- 11:33 AM** Panel Question and Answer
- 11:45 AM** **Abstract 9506:** DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
First Author: Michael B. Atkins, MD, FASCO
- 11:57 AM** **Abstract LBA9507:** A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).
First Author: Zeynep Eroglu, MD
- 12:09 PM** **Abstract LBA9508:** Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.
First Author: Sarah Danson, MBBS, PhD, MSc, FRCP
- 12:21 PM** **Omid Hamid, MD**
The Angeles Clinic and Research Institute
Discussion of Abstract(s) 9506-LBA9508: The Art of Sequencing, Combining, and Cutting Short
- 12:33 PM** Panel Question and Answer